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Multiple pregnancies and the ovarian hyper­
stimulation syndrome (OHSS) are the two most 
important complications of assisted reproduc­
tive technologies (ART). In contrast to multiple 
pregnancies, OHSS has been openly recognized 
as a major problem from the very first years that 
gonadotropins were utilized to induce ovula­
tion. There is a bulk of knowledge about its 
physiopathology, its genetics and its endocrine, 
immunological and epidemiological aspects, 
and many expert clinicians have devised 
approaches to minimize its occurrence or 
reduce its major risk, i.e. thromboembolism. 
Nevertheless, OHSS seems to occur unabated in 
our daily practice. The treacherous thing about 
OHSS is that it appears less of a problem than it 
is. There are two major reasons for this. First, 
lethal cases, although very rare, do occur from 
time to time and are certainly underreported. 
Second, severe OHSS occurs relatively rarely 
(around 1% of all in vitro fertilization (IVF) stim­
ulations) and does not always come to the atten­
tion of the practitioner treating the patient, giv­
ing to the individual physician the impression 
of a rare event indeed. Furthermore, OHSS in 
non-IVF cycles has become very rare because 
stimulations have become less aggressive since 
the 1980s; serious OHSS occurs almost exclu­
sively in IVF treatment cycles.
To date, there is no easy, acceptable and fea­
sible solution to avoid all OHSS, although com­
plete avoidance of human chorionic gonado­
tropin (hCG) as ovulation trigger should and has 
been given serious thought. Replacement of
hCG by other triggers of ovulation, however, is 
in the hands of the industry, not treating 
physicians. Health-economic considerations, 
although favoring less aggressive ovulation- 
triggering methods, seem to weigh less heavily 
on the balance than in the case of, for example, 
prevention of multiples by single embryo trans­
fer. It is likely that for some time to come, and as 
long as we use the existing urinary hCG prepa­
rations as ovulation trigger, we will have to live 
with a risk for OHSS.
The contributions in this book are written by 
senior authors from around the world who have 
made original clinical and/or scientific contribu­
tions to our understanding and management of 
the syndrome. Authors from Europe, America 
and the East synthesize the balance of their 
experience, dictated in part by differences in 
medical culture and cost considerations -  
although, undoubtedly, no cost is too high to 
avoid a young woman dying from an artificial 
and purely iatrogenic disease.
As a rainbow unfolds its many-colored 
splendor, so the subsequent chapters, radiating 
from a common starting point, unfold their dif­
ferent scopes and visions, each highlighting one 
specific aspect of the syndrome. What will 
emerge is the insight that in OHSS there is defi­
nitely more than meets the eye, literally and 
metaphorically: literally, a seemingly innocuous 
hyperstimulation may quickly and unexpect­
edly turn into disaster; metaphorically, OHSS is 
more than just ‘the ovaries reacting a bit more 
like usual’. It is truly a disease state, triggered by
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ovarian hyperstimulation, probably occurring in 
genetically predisposed women, inducing a cas­
cade of disruptions that affect many regulatory 
systems, mainly blood clotting and kidney func­
tion, holding the killing dagger of multiorgan 
failure under its wings.
This book also serves as an indirect plea for 
prospective registration of OHSS, at least of seri­
ous cases, and certainly of lethal cases. This is 
easier said than done. In a world where doctors 
are under great medicolegal pressure, cases tend 
to be minimized. However, starting with regis­
tration on a national basis could be a first step in 
the right direction. Just as many national reg­
istries of deliveries do register the equally sensi­
tive issue of maternal mortality, ART registries 
should ask for patient mortalities, irrespective of 
the cause of death. In the end, this may result 
only in a more robust consolidation of the qual­
ity and safety of our profession.
Short, practical OHSS guidelines for daily 
use on the working floor have been added to 
Chapter 6, and a longer summary of the most 
important aspects of OHSS is provided at the 
end of the book. It will be clear that, as is the 
case for many clinical situations, personal opin­
ions and management strategies differ some­
what. This is richness, not poverty. But clearly, 
the guidelines and the summary should be con­
sidered as a plausible possibility among others 
which may differ slightly.
OHSS represents one of the intensive-care 
aspects of gynecological practice. Giving correct 
pretreatment information to patients is an unat­
tractive option, comparable to a car salesman 
showing his customers the bodies of crash vic­
tims. Yet, this is where the true challenge lies: 
all health-care professionals working in repro­
ductive medicine should be acquainted with the 
theoretical and practical aspects of this syn­
drome, both from a prophylactic point of view 
and once it has developed. OHSS needs to be 
taken seriously, without discrediting the huge 
advantages that our modern reproductive tech­
nologies offer. Therefore, a book focused on the 
clinically relevant aspects of the syndrome 
should be useful for all who take their repro­
ductive job seriously. Decreasing the risk for 
OHSS in the first place, correct recognition of 
the condition and professional management 
avoiding the most serious complications and 
eventually death of the patient will definitely 





Cars collide, trains derail, airplanes crash, big 
ships break and sink, and nuclear as well as 
industrial plants fail and pollute. Humankind 
has always been compelled to pay a heavy trib­
ute to technological advancement. This inex­
orable law applies no less to medical practice, in 
which almost every significant investigative or 
therapeutic progress has entailed untoward 
side-effects and sometimes dramatic conse­
quences. Strictly speaking, this paradox is in 
opposition with the old Hippocratic aphorism: 
primum non nocere. The ovarian hyperstimula­
tion syndrome (OHSS) appears as the utmost 
stereotype of this contradiction. This explains 
why this iatrogenic entity has -  rather amaz­
ingly to the outside observer -  become the object 
of as much thorough investigation and care as 
the infertile situations from which it originates 
indirectly.
In the middle of the last century, gonado­
tropins already being on the market, OHSS was 
a rare but much feared complication of anovula­
tion treatment. Its physiopathological mecha­
nism remained a mystery and, all too often, seri­
ous forms of this syndrome resulted in bilateral 
ovariectomy and pregnancy loss. By strongly 
boosting the ovarian response, assisted repro­
ductive technologies (ART) have vastly 
increased the numbers of OHSS cases. As ART 
are not vital to the physical health of patients, it 
was thus imperative that the most dangerous 
and sometimes life-threatening complication of 
this treatment should be prevented at all costs. 
Therefore, it its hardly surprising that the search
for prevention and treatment of OHSS should 
have rapidly evolved in several directions. Clin­
ical, pharmacological, molecular, genetic and 
even economic areas relevant to this syndrome 
have all been tackled and are currently 
explored.
Artificial transformation of the mono­
ovulatory human female into the equivalent of a 
polytocous species entails a cataclysmic rupture 
of the subtle neuroendocrine and para-autocrine 
balance which enables the human ovary to 
release generally no more than one egg per 
cycle.
As explained in certain chapters of the pres­
ent book, it is fascinating to learn that the homeo­
static conditions prevailing in women with 
stimulated ovaries depend on a delicate equilib­
rium existing between antagonistic types of 
receptors for VEGF (vascular epithelial growth 
factor) and between divergent actions of ovarian 
and renal RAS (renin-angiotensin systems).
A vast array of prevention modes and of 
therapeutic attack angles for the OHSS has like­
wise emerged from a host of clinical studies, 
which are thoroughly analyzed in the present 
volume. However, prospective and well-planned 
multicentric studies are still needed to ensure 
proper assessment of the results. Hopefully, 
future genetic investigations will also help in 
understanding why some patients develop 
OHSS while others, although showing similar 
basic conditions as well as an equally high 
estrogenic response, do not. These are only a 
few examples of the many new insights offered
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by the various experts who have contributed to 
this book.
From the ethical point of view, the OHSS sit­
uation remains a most problematic one. This is 
especially true in the presence of a so-called 
‘critical case’, when the physician will feel that 
he is treading the razor’s edge, asking himself if 
he should put an end to an ongoing pregnancy 
or pursue a very risky gamble indeed. Under 
such conditions, the extreme solution of preg­
nancy termination obviously represents a cata­
strophic failure of treatment threatening to
entail indelible psychological sequelae. A series 
of excellent guidelines are offered here that will 
enable practicing fertility specialists to avoid 
becoming entrapped in such hair-raising dilem­
mas and to prevent high-risk situations for their 
patients.
Finally, it is to be hoped that the pharma­
ceutical industry will be able to resume investi­
gations into recombinant gonadotropins in order 
to produce an efficient ovulatory molecule not 
burdened with a long half-life such as that of 
hCG.
Fernand Leroy 
Honorary Professor of 
Obstetrics and Gynecology 
Free University Brussels (ULB)
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CHAPTER 1
General definition of the 
ovarian hyperstimulation syndrome
Annick Delvigne
Ovarian hyperstimulation syndrome (OHSS) is 
a potentially fatal iatrogenic complication of the 
luteal phase in ovulation stimulation. This syn­
drome is characterized by an increased size of 
the ovaries due to multiple cysts, and by an 
increase in the vascular permeability causing 
ascites, pleural effusion and sometimes even 
pericardial effusion. Severe forms are also 
accompanied by electrolyte disturbances and 
cardiopulmonary, hepatic, renal and hemody­
namic disturbances associated with increased 
thromboembolic risk.
There is currently no specific treatment for 
OHSS.
The prevalence of the severe form of OHSS 
is fortunately small, varying according to the lit­
erature between 0.5 and 5%. Nevertheless, since 
this is an iatrogenic complication of a non-vital 
treatment with a potential fatal outcome, the 
syndrome remains a serious problem for spe­
cialists dealing with infertility, leading to impor­
tant clinical questions:
(1) Is it possible to identify patients at risk?
(2) Which are the most adequate stimulation 
schemes and follow-up methods for 
patients with an identified risk (primary 
prevention)?
(3) Which preventive method should be 
applied when an exaggerated ovarian 
response occurs (secondary prevention)?
(4) Which symptoms are pathognomonic and 
which are rare but essential to be accu­
rately identified?
(5) What is the physiopathology of this 
syndrome?
(6) Which is the most adequate treatment 
according to the severity of OHSS?
HISTORICAL PERSPECTIVE
The ovarian hyperstimulation syndrome is a 
rare iatrogenic complication of ovarian stimula­
tion occurring during the luteal phase or during 
early pregnancy. This syndrome has been 
known since gonadotropins (gonadotropic 
preparations made from the serum of pregnant 
mares or extracts of sheeps’ pituitary glands and 
the urine of pregnant women) were first used to 
induce ovulation in 19431)2. The first fatal cases 
were described in 1951 by Gotzsche3 and in 
1958 by Figueroa-Casas4. In 1957, Le Dali5 
described this syndrome in his thesis. This 
author reported acute cases necessitating a
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laparotomy and unilateral or bilateral ovariec­
tomy, or puncture and suture of ruptured cysts. 
Further subacute situations are also mentioned, 
characterized by pain and healing in 58% of the 
cases after bedrest and antispasmodic treatment. 
Oliguria and renal failure were the principal 
complications leading to death at that time.
Later on, OHSS appeared to be a possible 
complication of the induction of ovulation by 
almost every agent used for this purpose. The 
presentation and severity of this clinical syn­
drome have evolved with time in relation to 
stimulation protocols. For instance, the develop­
ment of in vitro fertilization (IVF) and other 
techniques such as cryopreservation has led to 
more and more aggressive treatment schemes 
aimed at obtaining sufficient numbers of 
oocytes and embryos, but consequently leading 
to an increased risk of OHSS.
Thus, historical descriptions of OHSS diag­
nosed using elevated urinary estradiol excretion 
are now obsolete, since new techniques aim at 
obtaining hyperstimulation per se.
DEFINITION
Nowadays, it is the loss of control over hyper­
stimulation that constitutes the ‘ovarian hyper­
stimulation syndrome’.
The most common form  occurs a few days 
after follicular rupture or puncture, when follic­
ular growth has been medically induced utiliz­
ing either clomiphene citrate or gonadotropins, 
sometimes in conjunction with gonadotropin- 
releasing hormone (GnRH) agonists or antago­
nists and following final follicular maturation 
and luteinization achieved by the administra­
tion of human chorionic gonadotropin (hCG).
Some other particular forms of OHSS have 
also been reported: spontaneous OHSS, some­
times occurring repeatedly in the same patient 
or family6-17; or OHSS subsequent to a flare-up 
effect of a GnRH agonist, whether or not in con­
junction with gonadotropins18-22.
Apart from these rare events, OHSS gener­
ally happens only after ovarian stimulation and 
exposure to hCG.
This iatrogenic complication is very particu­
lar, because it is not the consequence of a 
treatment that is vital or mandatory for the 
patient’s health. However, it can be fatal: the 
OHSS mortality rate has been estimated at 
1/45 000-500 000, with a morbidity even higher 
but not accurately quantified23.
CLINICAL DESCRIPTION
In the initial form, the increase in size of the 
ovaries is accompanied by abdominal discom­
fort. In a more advanced form, the ovaries 
become cystic, and this will often result in 
abdominal distension and pain, nausea, vomit­
ing and sometimes diarrhea.
These digestive symptoms may be present as 
soon as 48 h after hCG administration, but they 
become most severe between days 7 and 10 after 
hCG.
The following clinical signs are likely to 
result from a circulatory dysfunction correspon­
ding to increased vascular permeability and 
marked arterial dilatation24. The first sign of 
OHSS is the formation of a small amount of 
ascites, which is sometimes only visualized 
through vaginal ultrasound. It is difficult to dis­
tinguish this from the frequent bleeding occur­
ring after oocyte pick-up (Figure 1). In more 
severe forms, ascites is echographically obvious 
(Figure 2) and clinically identifiable, but is very 
uncommon before day 7 after hCG administra­
tion. The cystic ovaries are enlarged, sometimes 
reaching a size even greater than 12 cm. Cases of 
rupture and/or hemorrhage of ovarian cysts 
have been observed, sometimes masking an 
ectopic pregnancy.
Compression by enlarged ovaries can induce 
hydroureter. A series of other complications 
may occur, some of them ending in complex 
end-organ failure.
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Ascites fluid is characterized by a high con­
centration in proteins (4.8 g/100 ml), a low 
leukocyte count and the presence of relatively 
high numbers of red blood cells.
The extravascular protein-rich exudate accu­
mulated in the peritoneum, in the pleura 
(hydrothorax) (Figure 3) and even in the peri­
cardiac space is associated with intravascular 
volume depletion and hemoconcentration, acti­
vation of vasoconstrictor and antinatriuretic fac­
tors, severe hypoalbuminemia and sometimes
Figure 1 Thin line of ascites hardly discernible 
from usual discrete intra-abdominal bleeding as 
the result of ovarian puncture
Figure 2 Uterus floating in echographically 
obvious large quantity of ascites
vulvar or generalized edema (anasarca). The 
cardiovascular effects include arterial hypo­
tension, reduced fluid volume, low central 
venous pressure, tachycardia, increased cardiac 
output, low peripheral resistance, increased 
vascular stasis, hemoconcentration and hyper­
coagulation.
The associated hypovolemia can induce olig­
uria and electrolyte imbalance. Oliguria exists 
in about 30% of cases, and renal failure second­
ary to hypoperfusion or to compressive obstruc­
tion occurs in about 1.4% of the severe forms of 
OHSS21,25. Decreased renal perfusion induces 
stimulation of renal tubules and resorption of 
sodium and water, resulting in clinical manifes­
tations of oliguria and sodium retention. Elec­
trolyte imbalance is then observed, typically 
hyponatremia and hyperkalemia.
Figure 3 Hydrothorax (usually right-sided)
3
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Figure 4 Two severely enlarged ovaries in 
OHSS patient undergoing laparotomy. Courtesy 
Dr G I Serour, Egypt
Together with ascites, the associated para­
lytic ileus can impair diaphragmatic movement 
to such an extent that respiratory problems 
ensue. If pleural effusion also develops, lung 
function may be seriously affected, leading to 
adult respiratory distress syndrome (ARDS).
Pleural effusion can complicate massive 
ascites or exist as an isolated manifestation of 
OHSS without peritoneal fluid accumulation. 
Liver dysfunction can also occur. Thromboem­
bolic phenomena constitute the ultimate com­
plication of OHSS and are capable, despite 
appropriate treatment, of killing the patient26.
Such an array of potential severity of side- 
effects is rarely encountered, especially for a 
treatment applied for non-lethal pathology. The 
challenge for assisted reproductive technologies 
in the future is certainly an improvement of the 
baby take-home rate without impairment of 
women’s health and their long- or short-term 
quality of life.
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CHAPTER 2
Epidemiology and primary risk factors for 
ovarian hyperstimulation syndrome
Peter van Dop
In this chapter, risk factors for ovarian hyper- 
stimulation syndrome (OHSS) are restricted to 
so-called controlled ovarian hyperstimulation 
(COH). The primary risks for OHSS in ovulation 
induction (01) are not dealt with, since the aim 
of 01 (preferably obtaining one follicle) is differ­
ent from that of COH (obtaining multiple folli­
cles), and a low number of follicles excludes 
OHSS.
Epidemiology is a science that deals with the 
incidence, distribution and control of disease in 
a population. Incidence is the rate of occurrence 
of new cases of a particular disease in a popula­
tion being studied [Webster’s Unabridged Dictio­
nary, 1976). To avoid semantic hair-splitting in 
this area, we keep only to the incidence of 
OHSS.
DIFFICULTIES IN DEFINITION OF 
OHSS
OHSS is an iatrogenic condition characterized 
by cystic enlargement of the ovaries and a fluid 
shift from the intravascular to the third space 
following increased capillary permeability1. 
Hence, the main features of OHSS are cystic 
enlargement of the ovaries and a fluid shift. 
Both the size of the ovaries and the amount of
fluid may (independently) vary in a quantitative 
way. These variations -  and other features -  are 
the basic concepts of grading (the severity of) 
OHSS. The grading of OHSS is extensively dis­
cussed in a subsequent chapter.
Difficulties in analysis of the quantitative 
parts of the definition of OHSS (ovarian enlarge­
ment and amount of peritoneal fluid) still exist. 
Measurement of the size to which ovaries can 
develop is much more exact than measurement 
of the amount of peritoneal fluid. Owing to its 
sharply recognizable borders, ovarian size can 
be measured by ultrasound in an exact and 
reproducible way. Owing to the nature of the 
fluid and its dispersion between other intraperi- 
toneal organs, this is not true for the ultrasound 
measurement of peritoneal fluid. Precision in 
ultrasound measurement of the amount of peri­
toneal fluid has not been assessed. Intra- and 
interobserver errors of the ultrasound measure­
ment of peritoneal fluid in OHSS are not known. 
The accumulation of peritoneal fluid in larger 
(more than 1 litre) quantities may be assessed 
most accurately by weighing every luteal day on 
the same weighing scale under the same condi­
tions. Weighing should be performed every 




FLUID SHIFT, OVARIAN SIZE AND  
OHSS
In the natural monofollicular ovulatory cycle, 
the occurrence of a certain amount of peritoneal 
fluid is a normal phenomenon2. At present, no 
reliable prospective data on ultrasound meas­
urement of the size of ovaries during COH and 
its relationship to the risk of ovarian hyperstim­
ulation as a syndrome are available. No studies 
are available addressing the question of whether 
the degree of ovarian enlargement without con­
siderable fluid shift in the intraperitoneal space 
has any relation to the incidence of OHSS. Even 
the quantitative relationship between ovarian 
size and the amount of peritoneal fluid has not 
been studied in depth. However, in daily prac­
tice two facts are clear: a substantial enlarge­
ment of the ovaries during COH is possible 
without signs of OHSS, and OHSS is not likely 
without a substantial fluid shift to the peritoneal 
space. In this latter situation enlargement of 
the ovaries is present, but may be seen as an 
epiphenomenon.
INCIDENCE OF OHSS
The main classifications of OHHS are by Golan 
et a l 3 and by Navot and co-workers4. The inci­
dence of OHSS varies with the degree or the 
grade of OHSS. The incidence of mild OHSS 
may vary between 8 and 23% and may be of lit­
tle clinical relevance; the incidence lies between 
< 1 and 7% for moderate grades and the severe 
form is reported to vary between < 1 and 10%. A 
report from Israel5 suggests an increase in the 
severe form over the years. The main character­
istic of the incidence of OHSS is its large varia­
tion. It may be concluded that OHSS from a 
quantitative point of view is an ill-defined con­
dition, and this impairs reliable epidemiological 
studies on the incidence of the disease.
PRIMARY RISK FACTORS
Within the scope of this chapter, a primary risk 
factor is defined as a factor that entails a greater 
risk for developing OHSS apart from the risk 
caused by controlled ovarian hyperstimulation. 
In the November 2003 issue of Fertility and 
Sterility, the Practice Committee of the Ameri­
can Society for Reproductive Medicine (ASRM) 
discussed a guideline on OHSS6. The following 
risk factors were enumerated: young age, low 
body weight, polycystic ovarian syndrome 
(PCOS), higher doses of exogenous gonado­
tropins, high absolute or rapidly rising estradiol 
levels and previous episodes of OHSS. The first 
three features can be considered as primary risk 
factors and are discussed in this chapter, 
whereas other risks of OHSS are reviewed by 
other authors.
Assessing clinical risks
To assess risks in clinical practice, tools used in 
evidence-based medicine (EBM) are helpful. 
Already in 1985, Sackett, Haynes and Tugwell7 
described the principles and tools to assess risks 
for a target disorder, which in the context of this 
chapter is OHSS. The sensitivity and specificity 
of a test are calculated from the well-known 
2x2 table of a target disorder (OHSS) being 
present or absent versus a positive or negative 
test. Receiver operating characteristic (ROC) 
curves show the interrelation between sensitiv­
ity and specificity. Odds ratios may be used to 
compare incidences due to risk factors. To deter­
mine the power of diagnostic tools for assessing 
the risk of OHSS, a likelihood ratio (LR) is best 
used in EBM. The LR =  the post-test odds/the 
pre-test odds for the target disorder. A cut-off 
point for the test (e.g. a certain age for the risk of 
OHSS) and a ‘gold standard’ to assess the dis­
ease are indispensable, but not available. Stol- 
wijk and co-workers8 used other sophisticated 
tools for prediction of the outcome of in vitro fer­
tilization (IVF). This group9 also dealt with the
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issue of external validation of factors predicting 
IVF outcome. External validation of primary risk 
factors for OHSS has not been performed.
Young age as a primary risk factor
In the above-mentioned OHSS guideline of the 
ASRM, five references to the literature concern­
ing the subject of primary risks are given. Nei­
ther the ASRM paper, nor any of these refer­
ences, presents quantitative data on age, let 
alone an EBM analysis to assess the risk of age. 
In a retrospective Belgian study10 including 128 
cases of OHSS and 256 controls, the mean age of 
OHSS patients was 30.2 ±  3.5 years versus 
32.0 ± 4.5 years in controls. This small differ­
ence between the means combined with the 
wide spread expressed by relatively large stan­
dard deviations permits the concern that a 
usable cut-off point for age as a risk factor is not 
available. Similar small differences with a wide 
variation in age have been shown in two 
prospective studies10’11. Finding differences for 
a possible risk factor between different groups of 
patients does not necessarily mean that these 
risk factors can be used to predict the risk for a 
certain disease.
Proper tools used in EBM are necessary for 
risk assessment in clinical practice. Internal and 
external validations of a possible risk factor are 
a necessary next step to validate its clinical 
value. So, the conclusion can be that young age 
as a risk factor for developing OHSS is men­
tioned in many papers, book chapters and pre­
sentations, but has not been evaluated in a 
robust, scientifically sound way. Moreover, the 
fact that older patients have a greater risk of 
being poor responders during COH, and hence 
have a lower risk for OHSS, does not necessarily 
imply that patients with a young age are at 
greater risk.
Low body weight as a risk factor
Low weight is an obsolete notion, since it does 
not consider height. A better and more useful
concept is the body mass index (BMI), since 
with BMI weight is related to height. IVF stimu­
lation protocols do not usually correct the dose 
of gonadotropins for BMI or weight. This means 
that patients with a low BMI or weight receive 
relatively higher doses of gonadotropins. Merely 
due to a relatively higher dose, a higher risk of 
OHSS is likely, but has not been proved.
A recent Medline search performed by the 
author utilizing OHSS and weight or body mass 
as the search terms yielded 11 hits, from which 
only two hits were usable, since they had body 
weight or mass in the title of the study. Lashen 
et al.12 studied extreme body mass, which is not 
relevant to this chapter. Enskog et al.11 and 
Delvigne et al.10 found no correlation between 
lean body mass and OHSS, whereas only the 
study of Navot and co-workers13 described a 
positive correlation. Danninger and co­
workers14 found a lower body weight in women 
developing OHSS during COH in IVF. Unfortu­
nately they presented their data only as the p  
value (p =  0.011) of the difference.
The conclusion can be that, at present, a low 
body mass index is not a scientifically sound 
proven risk factor for developing OHSS.
PCOS as a risk factor for OHSS
PCOS is notorious not only in 01 but also in 
COH for its narrow therapeutic range. In the 
study of Delvigne et al.10, 37% of their OHSS 
patients suffered from PCOS versus 15% in the 
controls. PCOS-like ovarian ultrasound features 
(more than ten follicles) are a predictive factor 
for OHSS in IVF15.
Delvigne and co-workers16, as well as Bodis 
et al.17, showed an increased risk for OHSS in 
patients with a luteinizing hormone/follicle 
stimulating hormone (LH/FSH) ratio of more 
than 2. The same was shown17 for patients with 




PCOS seems to be a risk factor to develop 
OHSS, but quantitative analysis of the risk must 
be improved by tools used in EBM.
Ovarian volume as a risk factor for 
OHSS
Danninger and co-workers14 measured baseline 
ovarian volume in patients who underwent IVF 
with COH using three-dimensional ultrasound. 
This volume was significantly greater (11.3 ml 
vs. 8.9 ml) in patients who subsequently devel­
oped OHSS. They did not elaborate their data. 
The cut-off was ‘roughly estimated’ to be 10 ml. 
In patients with an ovarian volume <10m l, 
10% had OHSS, whereas, of patients with an 
ovarian volume >10m l, 23.5% developed the 
syndrome. They did not mention the cut-off 
value for ovarian volume for which no or very 
few patients showed OHSS. Hence, their data 
are not applicable to the individual patient.
Other primary risk factors
Patients who have suffered previous severe 
OHSS, patients with a high initial antral follicle 
count and patients with an allergic disposition 
(see Chapter 12) may also be considered at an 
increased primary risk to develop severe OHSS.
CONCLUSIONS
OHSS is an iatrogenic condition and may be 
life-threatening. When applying so-called con­
trolled ovarian hyperstimulation, OHSS is a 
condition that is difficult to avoid, since the eti­
ology and risk factors for patients are not suffi­
ciently known. Due to lack of insight into the 
etiology, no therapy, but only management, is 
available for OHSS. The early recognition of 
patients at risk is mandatory, but a scientifically 
sound risk assessment is still lacking, despite 
the fact that young age and low weight are often 
mentioned as primary risk factors. PCOS as a 
primary risk factor is better described from a
quantitative point of view, but needs further 
analysis with EBM tools. For a robust risk analy­
sis, tools employed in EBM must be used.
At present it is incomprehensible why not all 
patients undergoing COH and showing com­
pletely non-physiological numbers of follicles 
develop OHSS. Even under these non- 
physiological circumstances the incidence of 
severe OHSS can be considered as low, but nev­
ertheless it remains dangerous. Thus, it might 
be helpful to identify patients at risk. Unfortu­
nately this is currently not possible utilizing pri­
mary risk factors such as young age and low 
body weight or BMI, despite that these factors 
are mentioned in many publications. Low BMI 
and young age need robust scientific analysis 
before they can be assigned the status of primary 
risk factors for OHSS.
Every patient undergoing COH should be 
considered at (primary) risk for OHSS. All co- 
workers, medical and non-medical, in an IVF 
team should be taught to recognize OHSS. This 
must be evident in protocols relating to both 
patients and those working in an IVF setting.
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CHAPTER 3
Secondary risk factors for 
ovarian hyperstimulation syndrome 
during stimulation
Annick Delvigne, Rina Agrawal and Gautam Allahbadia
INTRODUCTION
The ovarian hyperstimulation syndrome 
(OHSS) is a serious and potentially life-threat­
ening iatrogenic complication, typically 
encountered in patients who undergo so-called 
controlled ovarian hyperstimulation (COH). The 
syndrome is usually associated with regimens of 
exogenous gonadotropins, but can also be seen, 
albeit rarely, during the administration of 
clomiphene citrate for ovulation induction, and, 
moreover, exceptional spontaneous OHSS may 
also occur. Although the full clinical manifesta­
tion of the syndrome occurs in the postovula­
tory (or post-oocyte retrieval) phase of a stimu­
lated cycle, signs and symptoms predictive of 
OHSS can be observed earlier in the stimulation 
phase of the treatment cycle. At this stage of our 
knowledge of the etiology of OHSS, we have to 
base our decisions about preventive strategies 
on the identification of risk factors that have 
been associated with OHSS and are thought to 
have predictive value, as there is currently no 
specific treatment for the condition.
The scope of this chapter is to discuss the 
secondary risk factors for OHSS.
Secondary risk factors are by definition 
those that come to the surface once controlled 
ovarian stimulation has started1.
ESTRADIOL
Many investigators have shown that an elevated 
serum estrogen concentration at the day o f  
human chorionic gonadotropin (hCG) adminis­
tration constitutes a (secondary) risk factor for 
OHSS2*3. Already in 1970, a correlation was 
demonstrated between preovulatory urinary 
estrogen and the incidence of severe OHSS4, 
while in a series of 70 ovulation induction 
cycles with menotropins, the serum estradiol 
(E2) level was found to be the only predictive 
factor for OHSS5. Others attempted to identify a 
high-risk group among 637 in vitro fertilization 
(IVF) patients, with six (0.94%) suffering from 
severe OHSS6. In this group, none of the 
patients with serum E2 levels <  3500pg/ml 
developed OHSS, while 1.5% of those with E2 
levels of 3500 ±  5999 pg/ml and 38% with serum 
E2 levels >6000 pg/ml developed OHSS. These 
authors identified a sensitivity of 83% and a 
specificity of 99%, but the positive predictive 
value was only 38%. Another group discussed 
the predictive value of E2, and found only 8.8% 
of OHSS cases among patients with E2 levels of 
over 6000 pg/ml (n =  34)7. This rather low inci­
dence was probably due to the mixed popula­
tion studied, which also included oocyte 
donors. When a more homogeneous group of
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IVF cycles with embryo transfer was considered, 
the incidence was 17% (n =  18). An additional 
group, using a cohort of 78 early- and late-OHSS 
patients, determined the oocyte number and 
peak E2 level that best discriminated cycles with 
and without OHSS8. These authors calculated 
the sensitivity and specificity for different cut­
off limits: only a moderately significant positive 
likelihood ratio (LR; 6.37) was obtained for an E2 
level >  2642 pg/ml, while a moderately signifi­
cant negative LR (0.13) was obtained for an E2 
level <  1847 pg/ml.
Although mean serum E2 levels are signifi­
cantly higher in patients who develop OHSS 
compared with controls, serum E2 alone is not a 
sufficiently predictive factor. Indeed, an exten­
sive overlap of serum E2 values was found 
between controls and OHSS patients in two 
series of 54 OHSS patients2 and 128 patients9 
(Figure 1).
Some authors studied the predictive value of 
measuring the early cycle serum E2 level to esti­
mate cycle outcome in IVF. E2 was measured in
the mid-follicular phase (day 9) during COH 
(long gonadotropin-releasing hormone (GnRH) 
agonist and human menopausal gonadotropin 
(hMG) started on day 3), and excessive ovarian 
responsiveness was defined by E2 > 4000 pg/ml 
on the day of hCG administration or the neces­
sity for coasting based on E2 > 3000 pg/ml before 
the day of hCG injection. With a serum E2 level 
> 800  pg/ml on cycle day 9, 55.8% of patients 
fulfilled the criteria for excessive ovarian 
responsiveness, but none of the patients with a 
serum E2 level <  300 pg/ml met the criteria. 
According to these previous data, the authors 
recommended decreasing the hMG dose on day 
9 in order to tailor the ovarian response10.
D’Angelo et al. studied the predictive value 
of different serum E2 cut-off levels on days 11 
and 8 of COH in a retrospective case-control 
study of 80 patients11. A serum E2 of 3354 pg/ml 
on day 11 of COH gave a sensitivity and speci­
ficity of 85% for the detection of women at risk 
for OHSS (only mild and moderate OHSS were 
recorded in the studied patients). Moreover,
Figure 1 Overlap of estradiol values between OHSS and control patients9
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they found that all women who developed 
OHSS had elevated E2 on day 11 but only 60% 
had a high E2 level on day 8. The authors rec­
ommended using E2 level on day 11 as an ‘early 
warning’ sign to apply subsequent preventive 
measures11.
The rate o f E2 increase during stimulation is 
also a (secondary) risk factor, as has been shown 
in a multicentric study evaluating 128 OHSS 
cases9. The discriminant analysis selects the 
increase in E2 expressed semi-logarithmically 
for the mathematical model ((3) (Tables 1 and 2 ). 
Some authors also take this measure into 
consideration when deciding on preventive 
measures12’13.
Severe OHSS has been observed in patients 
with very low serum E2 levels of 475 and 
29pg/ml14-16; likewise, five atypical cases of 
severe OHSS characterized by a mean serum E2 
level of only 2138pg/ml have been reported17. 
Severe OHSS was also reported for patients with 
partial 17,20-desmolase deficiency with very 
low E218. These observations underscore the 
inadequacy of serum E2 as the sole predictive 
factor.
The role of elevated serum E2 levels to pre­
dict OHSS remains somewhat controversial, but 
lowering the serum E2 level by coasting helps to 
prevent OHSS19,20. Moreover, monitoring serum 
E2 was found to be effective in reducing the
Table 1 Discriminant analysis by progressive introduction of data for all ovarian hyperstimulation 
syndrome (OHSS) cases: post-oocyte retrieval conditions
Variables
studied






(%)OHSS Controls Positive Negative
Log estradiol, pa, hMGb, ORc 96 200 22.0 19.8 78.7
+  age (years) 96 198 21.7 21.9 78.2
+ log estradiol md 33h 95h 24.2 30.3 74.2
+ ooc. me 33h 97h 21.6 30.3 76.1
+  endocrinopathy 96 199 21.1 22.9 78.3
+ LH/FSH > 2f 94 199 23.1 18.1 78.5
+ necklace sign8 86 172 20.3 22.1 79.1
+  hyperandrogenism 96 200 22.5 20.8 78.0
+ anovulation 94 200 22.5 19.1 78.6
aSlope of estradiol increment; bno. of human menopausal gonadotropin (hMG) ampoules administered; cno. of 
oocytes retrieved; logarithm of mean estradiol concentrations of previous trials; emean no. of oocytes retrieved 
during previous trials; fLH/FSH, luteinizing hormone/follicle stimulating hormone ratio; 8polycystic ovaries at 
ultrasound examination; hlow numbers of cases
Predictive formula for post-oocyte retrieval conditions
The best prediction for post-oocyte retrieval conditions obtained false-negative value 18.1% and prediction rate 
78.5%
(LH/FSH ratio with score of 1 if LH/FSH >  2 and 0 if LH/FSH <  2)
A =  (2.89 x log estradiol) +  (0.32 x P) -  (0.77 x 10"2 x hMG dose) +  (0.07 x number of oocytes retrieved) +  
(0.23 x LH/FSH)-1 0 .8 6
A >  0.26 in OHSS cases
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Table 2 Discriminant analysis by progressive introduction of data for all ovarian hyperstimulation 
syndrome (OHSS) cases: preovulation-triggering conditions
Variables
studied






(%)OHSS Controls Positive Negative
Log estradiol, pa 96 200 27.0 18.8 75.7
+ age (years) 96 198 28.8 18.8 74.5
+  log estradiol mb 33f 95 26.3 24.2 74.2
+ ooc. mc 33f 97 26.8 24.2 73.8
+  endocrinopathy 96 199 25.6 19.8 76.3
+  LH/FSH >  2d 94 199 26.6 18.1 76.1
+ necklace signe 86 172 26.2 19.8 76.0
+ hyperandrogenism 96 200 27.0 19.8 75.3
+ anovulation 94 200 27.0 19.1 75.5
a-eSee Table 1; flow numbers of cases
Predictive formula under preovulation-triggering conditions
The best prediction for preovulation-triggering conditions obtained prediction rate 76.1% and false-negative rate 
18.1%
A =  (4.44 x log estradiol) +  (1.38 x p) +  (0.09 x LH/FSH) -1 5 .5 4  
A >  0.24 in OHSS cases
incidence of OHSS3,21. The reasons why coast­
ing is effective in preventing OHSS are specula­
tive, and are elaborated in more depth in 
Chapters 22 and 23. Tortoriello et al.22 hypo­
thesized that coasting may diminish the func­
tional granulosa cell cohort, resulting in the 
gradual decline in circulating levels of serum E2, 
and of the chemical mediators or precursors of 
fluid extravasation. The size of the granulosa 
cell population available for luteinization fol­
lowing hCG determines both the incidence and 
the severity of OHSS20. Moreover, the findings 
of Tozer et al. suggest that coasting has an effect 
on the functional capacity of the granulosa cells 
and the duration of their function23. The E2 level 
can be considered as a good marker of the gran­
ulosa cell population available to produce this 
vasoactive mediator.
The threshold of serum E2 level above which 
there is a considerable risk of OHSS varies 
widely among different investigators. Most stud­
ies selected a serum E2 of 3000pg/ml as a safe 
value for hCG administration20 (Figure 2).
A recent prospective cohort study evaluated 
the predictive value of E2 in antagonist cycles24. 
None of the E2 thresholds could predict severe, 
late or early OHSS in this type of COH24.
In conclusion, it is believed that, irrespective 
of the debatable role of E2 itself in the pathogen­
esis of OHSS, there is a general agreement that 
serial serum E2 assays are an important marker 
for detecting the majority of patients at risk for 
OHSS and deciding whether to apply a preven­
tive method such as coasting, for example19.
FOLLICLE NUMBER AND SIZE 
DURING STIMULATION AND  
OOCYTES COLLECTED
Most studies have found that a large number 
of preovulatory follicles during stimulation
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Figure 2 Frequency histogram of estradiol (E2) value (pg/ml) which was chosen by physicians 
(27 =  141) as value for administration of human chorionic gonadotropin (hCG) when applying coast­
ing as preventive measure
constitute a risk factor for OHSS. Moreover, 
according to different authors, the size of folli­
cles which should be considered a threshold 
value for risk is variable. Blankstein et al.25 in 
1987 evaluated a cohort of 65 patients treated 
with COH and found that patients with OHSS 
had significantly more follicles at the time of 
hCG than did patients without OHSS. In moder­
ate to severe OHSS, 95% of the preovulatory fol­
licles were < 16 mm and 55% < 9 mm; in con­
trast, in mild OHSS, 69% were follicles of 
intermediate size (9-15 mm). Although this 
study is often cited as a reference, its results 
should be distinguished from those of other 
reports, because the stimulation conditions 
were quite different. For example, hCG was 
administered to all patients when their 24-h 
urinary excretion of E2 was between 80 and 
180 ng, independent of any maturation criteria 
assessed by ultrasound.
A significant correlation was found between 
the presence of multiple (> 4.2) secondary folli­
cles of size 14-16 mm and severe OHSS26, while 
others2,27 found that during ovarian induction 
and IVF cycles, respectively, follicles of 
12-14 mm or <  18 mm were associated with an 
increased risk of OHSS.
Finally, it was observed that, during IVF, 
OHSS patients had more follicles >15m m  in 
size15.
The discussion regarding follicular size may 
be obsolete, because stimulation criteria are 
totally different according to whether ovarian 
induction or IVF is applied. Furthermore, the 
error in follicle measurement and counting is 
related to their number6. Hence, the risk of 
OHSS is often related to the total number of 
developing follicles and to the number of col­
lected oocytes (90% of follicles seen)6. In the lat­
ter study, no patient developed severe OHSS
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when < 2 0  oocytes were collected, whereas 
1.4% of patients with 20 ± 29 oocytes and 22.7% 
with > 30 oocytes developed this complication. 
Retrieval of > 30 oocytes was associated with a 
sensitivity of 83%, a specificity of 67% and a 
positive predictive value of only 23%. Another 
group evaluated the incidence of OHSS among 
oocyte donors and classical IVF patients who 
yielded > 30 oocytes7. Only 6.5% of OHSS cases 
were in the combined group of oocyte donors 
and classical IVF, and 14% if only classical IVF 
was considered.
If we consider cycles in which GnRH antag­
onists are used, > 1 3  follicles with a diameter 
above 11 mm on the day of hCG administration 
predict all OHSS cases with a sensitivity of 
100%, a specificity of 70% and a highly signifi­
cant negative likelihood ratio of 0.0124.
COMBINATION OF DATA TO PREDICT 
OHSS
Serum E2 level and number of follicles and/or 
oocytes collected are often used together to pre­
dict OHSS occurrence: according to one group, 
for patients with a serum E2 level >  6000 pg/ml 
and > 3 0  oocytes collected, the incidence of 
severe OHSS was 80%6.
Morris et aL7 in 1995 reported an incidence 
of 20% of cases of OHSS when they considered 
only classical IVF and excluded oocyte donors. 
Once more, markedly elevated serum estradiol 
concentrations and/or numerous oocytes may 
predispose to, but are not sufficient for the 
development of, OHSS. Some oocyte donors did 
not develop OHSS even in the presence of high 
serum levels of E2 (maximum 9590 pg/ml) and 
when large numbers of oocytes (maximum 58) 
were collected.
According to one investigation, early OHSS 
is predicted by E2 and the number of oocytes 
retrieved, while late OHSS is related to the num­
ber of gestational sacs seen at ultrasound28.
These contradictory data may be due to a 
mixture of early- and late-OHSS cases in most 
studies. Although such a distinction is theoreti­
cally possible, in clinical practice, many cases 
evolve from one situation to the other.
The considerable overlap of the distribution 
of values for different parameters between con­
trol and OHSS populations makes any single 
variable inefficient for risk prediction (Figures 1 
and 3). Combinations of variables were studied 
in a discriminant function in order to increase 
predictivity and decrease the false-negative rate. 
Progressive introduction and automated step­
wise selection of variables were applied to IVF 
patients, all OHSS cases [n =  128). The best pre­
diction (78.5%) was obtained in OHSS cases 
under post-retrieval conditions using log E2, 
slope of log E2 increment, hMG dosage, number 
of oocytes retrieved and ratio of luteinizing hor- 
mone/follicle stimulating hormone (LH/FSH) in 
the formula, with a corresponding false-negative 
rate of 18.1% (Table 1). However, effective pre­
vention of OHSS implies the ability to withhold 
hCG injection. Therefore, a formula for pre­
oocyte retrieval conditions was established 
yielding a prediction rate of 76.1%, with a false­
negative rate of 18.1% (Table 2). To be validated, 
such formulae would have to be applied to 
another population of IVF cases used as a 
‘testing-set’29.
OVARIAN VOLUME
Total ovarian volume on transvaginal sonogra­
phy before hCG administration was found to be 
higher in women who develop moderate or 
severe OHSS compared with controls, and may 
therefore be used as an additional parameter in 
the preventive strategy for ovarian hyperstimu­
lation syndrome30. Using ovarian volume meas­
urement, one group found a significant correla­
tion between baseline ovarian volume 
(measured by three-dimensional ultrasonogra­
phy) and the development of OHSS in 101
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Figure 3 Overlap of number of oocytes retrieved between OHSS and control patients20
patients who underwent IVF31. In addition, a 
significant correlation was found between the 
baseline number of follicles, the number of 
oocytes retrieved and OHSS.
Some investigators furthermore evaluated 
the intraovarian blood flow, and identified a 
close correlation between OHSS severity and 
lowered resistance to blood flow in the stimu­
lated ovaries32. However, the predictive value of 
these data should be validated in larger series. 
Agrawal et al. suggested that within ovarian and 
uterine blood vessels, blood flow velocities were 
higher in the early follicular phase and on the 
day of hCG administration in women with poly­
cystic ovaries/polycystic ovarian syndrome 
(PCO/PCOS)33. A positive correlation was 
observed between serum vascular endothelial 
growth factor (VEGF) and E2 concentrations on 
the days of hCG administration and oocyte 
retrieval, and between serum VEGF concentra­
tion and Doppler blood flow velocities through­
out the IVF cycle33. Quantification of the 
Doppler signal in PCOS using three-dimensional 
power Doppler ultrasonography was recently 
published by Pan et al.34. These authors found 
that mean ovarian volume was significantly 
higher (p < 0.05) in women with PCOS com­
pared with women with normal ovaries. The 
vascularization flow index (VFI), flow index (FI) 
and vascularization index (VI) were signifi­
cantly higher (p < 0.05) in women with PCOS 
compared with women with normal ovaries. 
The authors concluded that this observation 
may help to explain the excessive response often 
seen during gonadotropin administration in 
women with PCOS34. However, other investiga­
tors have concluded that polycystic ovaries are 
not associated with an inherent disturbance in 
blood flow dynamics of the uterine and ovarian 
arteries, as measured by color Doppler, and that 
an increased sensitivity of polycystic ovaries to
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stimulation with gonadotropins cannot be 
explained in this way35.
OTHER RISK FACTORS 
Inhibins
A common element in most theories of OHSS 
has been endothelial activation by ovarian prod­
ucts and an increase in capillary permeability 
leading to fluid shifting to third spaces36. Sev­
eral such products have been studied as puta­
tive predictors of OHSS, including inhibins A 
and B37. These were evaluated in 15 patients 
with severe OHSS and 15 controls matched for 
age and number of follicles. Inhibin A and B lev­
els were followed from the start of ovarian stim­
ulation until at least 3 days post-embryo trans­
fer. Inhibin A, in the OHSS group, showed a 
continuous increase during stimulation to 
embryo transfer, but this elevation was signifi­
cantly higher than in the controls only at the 
point where OHSS had developed. Inhibin B 
levels also rose from the start of the stimulation, 
with peak values 3 days prior to oocyte retrieval, 
and then declined. This elevation was signifi­
cantly higher in OHSS patients as well as on the 
day of oocyte retrieval. The authors suggest that 
inhibin levels may serve as indicators of OHSS 
risk, but threshold levels have still to be 
defined37.
Vascular endothelial growth factor
Serum VEGF levels are higher in women at risk 
for OHSS, and correlate with the clinical course 
of the syndrome38. In addition, anti-VEGF anti­
bodies neutralize the vascular permeability 
activity of follicular fluids and of ascitic fluid 
obtained in women with OHSS39. In contrast to 
the natural cycle, COH cycles are associated 
with an exaggerated ovarian production of 
VEGF that results in an increase in circulating 
levels of free VEGF during the early luteal phase 
in women at risk for OHSS. Why some women
develop OHSS during COH cycles and others do 
not is incompletely understood. It is interesting 
to speculate that early-onset OHSS occurs when 
exaggerated ovarian VEGF production during 
the early luteal phase greatly exceeds the capac­
ity of neutralizing VEGF binding proteins and/or 
soluble receptors8. In support of this idea are 
studies that demonstrate higher VEGF levels at 
the time of embryo transfer in women who 
develop OHSS40, and that VEGF levels continue 
to rise during the luteal phase in women who 
develop severe OHSS, but not in women with­
out OHSS41. These data suggest that, in most 
COH cycles, physiological concentrations of 
binding proteins and soluble receptors can 
accommodate rising levels of ovarian-derived 
VEGF during the luteal phase, but that OHSS 
may occur when free/total VEGF ratios are dra­
matically altered. Whether other angiogenic fac­
tors contribute or modify VEGF actions in the 
pathogenesis of OHSS is currently unknown, 
but represents an important area of future 
investigation.
Today, VEGF measurement is not recom­
mended to predict OHSS in individual patients 
even if its role in the etiopathology of OHSS 
seems more and more accepted.
Rising FSH levels
Agrawal et a7.41 found that FSH stimulated 
VEGF production to a similar degree, compared 
with hCG. This emphasizes the importance of 
circulating FSH levels in the pathogenesis of 
OHSS and correlates nicely with results of a 
study showing that circulating FSH levels were 
much higher during the days before hCG in 
anovulatory women treated with FSH who had 
marked enlargement of the ovaries after hCG42. 
It was not clear whether those increased circu­
lating levels of FSH were due to increased 
endogenous release, to decreased clearance of 
FSH or both. It has been empirically observed 
that tapering of the FSH dose later in the course 
of ovarian stimulation for IVF reduces the risk of
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OHSS despite a higher starting dose of stimula­
tion. This approach may also be more physio­
logical and has been empirically associated with 
a better IVF outcome. Reduction of circulating 
FSH may be the mechanism through which 
coasting reduces the incidence of OHSS. Al- 
Shawaf et a/.43 showed that circulating FSH fell 
to the normal range over this period of time. The 
adverse effects of FSH may also indicate that 
recombinant LH is a better approach as a surro­
gate LH surge than use of a GnRH agonist, which 
releases large amounts of both FSH and LH.
Erythrocyte aggregation
Increased capillary leak brought about by the 
elevation of erythrocyte aggregation could be a 
newly discovered mediator in the pathophysiol­
ogy of OHSS and an independent risk factor44. 
An increase in erythrocyte aggregation is associ­
ated with unfavorable hemorrheological effects 
in terms of microcirculatory slow flow, tissue 
hypoxemia and microcirculatory occlusions45. 
These changes alter the peripheral resistance, 
reduce capillary perfusion and oxygen transfer 
to tissues and bring about a degeneration of the 
vascular wall, leading to capillary leak46. A 
recent study clearly showed that enhanced ery­
throcyte aggregation can be detected in the 
peripheral blood of women following 
gonadotropin administration. This phenomenon 
of erythrocyte aggregability can have a deleteri­
ous effect on the microcirculatory flow46,47. 
Levin et al. believe that increased erythrocyte 
aggregation in patients with COH and OHSS 
after the administration of gonadotropins is 
brought about by hyperfibrinogenemia44. It has 
been shown that fibrinogen has a major role in 
the induction and/or maintenance of increased 
erythrocyte aggregation in the peripheral 
blood47. The enhanced synthesis of this macro­
molecule is probably a result of the presence of 
enhanced interleukin-6 (IL-6) concentrations in 
the peripheral blood48.
C-reactive protein
C-reactive protein (CRP) is a biological marker 
of systemic inflammation, produced by the liver. 
It was recently demonstrated to have a strong 
prognostic value for cardiovascular events49. 
CRP levels have no diurnal variation, are stable 
over long periods50 and increase after estrogen 
administration51. Orvieto et al. observed a 60% 
increase in CRP levels from the initial day of 
stimulation to the day of hCG administration, 
which is in accordance with the positive effect 
of the serum E2 level on the CRP level52. The 
finding in a recent study of an observed increase 
in serum CRP, which reflects a state of systemic 
inflammatory response, may further substanti­
ate the role of systemic inflammation in the 
pathophysiology of OHSS and may designate 
increasing levels of CRP as a risk factor for 
OHSS during ovarian stimulation53.
CONCLUSIONS
The most frequently used and studied predic­
tive factors reflect the amplitude of the ovarian 
response to COH (E2 level and number of folli­
cles). This is based on the fact that most women 
who develop OHSS also have an exaggerated 
response to stimulation. Different threshold lev­
els and a combination of these predictive factors 
have been proposed, but no optimal prediction 
currently exists. Indeed, these parameters do 
not reflect the physiopathology of OHSS.
Therefore, other parameters linked to the eti­
ology and pathology of the syndrome are evalu­
ated (VEGF, erythrocyte aggregation, CRP) but 
have not yet been validated in clinical use.
In clinical practice, in the mean time, 
absolute serum E2 level and the rate of its 
increase, and the number of follicles or the 
number of oocytes collected, remain the factors 
that should be used to monitor COH and initiate 
preventive measures (Table 3).
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f igure 4 (aj Thickened endometrium during ovarian stimulation, (b, c) Multifollicular ovarian 
development in left and right ovaries accompanied by small quantities of free abdominal fluid. 
Courtesy Dr D Navot and Dr Z Levine, USA
Table 3 Secondary risk factors predicting 
OHSS
Serum estradiol >  3000pg/ml at hCG injection
Serum estradiol >  800 pg/ml at day 9
Serum estradiol >  3354 pg/ml at day 11
> 2 0  follicles at the end of the follicular phase 
of COH with GnRH agonist
> 1 3  follicles at the end of the follicular phase 
of COH with GnRH antagonist
> 1 5  oocytes retrieved
hCG, human chorionic gonadotropin; COH, controlled 
ovarian hyperstimulation; GnRH, gonadotropin­
releasing hormone
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CHAPTER 4
Clinical manifestations of 
ovarian hyperstimulation syndrome
Gamal Serour
Ovarian hyperstimulation syndrome (OHSS) is 
mostly an iatrogenic complication of ovarian 
stimulation. It has been observed over the past 
60 years, since gonadotropins were first used to 
induce ovulation in infertile patients. OHSS is 
the consequence of an exaggerated response to 
ovulation induction therapy. Ideally, ovulation 
induction should stimulate the ovaries to obtain 
the desired level of ovulation, i.e. monofollicu- 
lar development. However, the narrow range 
between no response at all and an exaggerated 
response to ovulation induction agents com­
bined with the unpredictable patient response 
makes prevention of OHSS virtually impossible, 
and prediction unlikely1. Some degree of ovar­
ian hyperstimulation occurs in all women who 
respond to ovulation induction, but this should 
be distinguished from the clinical entity of 
OHSS. OHSS may also be encountered in clini­
cal practice in some rare conditions not related 
to the intake of ovulation-inducing drugs 
(Table 1).
OVARIAN HYPERSTIMULATION NOT 
RELATED TO INTAKE OF OVULATION- 
INDUCING DRUGS
OHSS may be encountered in patients not 
receiving ovulation-inducing drugs. Physicians
should be aware of these conditions, to be able 
to diagnose them and avoid unnecessary harm­
ful management because of misdiagnosis. These 
clinical entities include the following.
Ovarian hyperstimulation in 
intrauterine life
Fetal ovarian hyperstimulation in a pregnancy of 
35 weeks was reported by Berezowski et al.2. 
Two large cystic septate ovaries without internal 
vegetations were observed in the fetal abdomen 
by ultrasonography. There was significant eleva­
tion of maternal serum (3-human chorionic 
gonadotropin (hCG) levels. Spontaneous regres­
sion of fetal ovarian volume and of maternal 
serum (3-hCG occurred after delivery. The failure 
to diagnose this condition may result in unnec­
essary termination of pregnancy and/or neonatal 
surgery which may lead to castration of the 
female child.
Ovarian hyperstimulation in preterm 
infants
Ovarian cysts are a relatively frequent finding in 
neonates. In preterm infants, the simultaneous 
occurrence of estradiol-producing ovarian cysts 
and edematous swelling of the vulva, the thighs 
and the lower abdominal wall has been 
described. Vochem reported four cases of
25
OVARIAN HYPERSTIMULATION SYNDROME
Table 1 Various forms of ovarian hyperstimulation (OHS) encountered in clinical practice
Form o f OHS Diagnostic criteria
Spontaneous OHS
OHS in intrauterine life and in 
preterm infants
35-39 weeks of pregnancy, large cystic ovaries, stimulation 
of external and internal genitalia, elevated maternal 
p-hCG, fetal E2
OHS with gonadotroph adenoma Ovarian enlargement, headache, galactorrhea, elevated E2, 
FSH and (3-LH, CT scan and MRI
OHS in spontaneous pregnancy Usually associated with hypothyroidism, PCO, MP or
hydatidiform mole
May be recurrent and familial
Develops between 8 and 14 weeks of pregnancy
Serial color and pulsed Doppler ultrasonography, elevated hCG,
VEGF and TSH
Iatrogenic OHS
OHS in IVF/ICSI cycles Abdominal discomfort, nausea, vomiting, abdominal distension 
Large cystic ovaries, with > 2 5  small and intermediate-sized 
follicles
E2 > 4000 pg/ml (> 14 500 mol/1)
OHS in ovulation induction/ 
ovulation enhancement
History of intake of hMG, FSH or CC 
Large cystic ovaries and elevated E2 level
IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; hCG, human chorionic gonadotropin; E2, estra­
diol; FSH, follicle stimulating hormone; LH, luteinizing hormone; CT, computerized tomography; MRI, magnetic 
resonance imaging; PCO, polycystic ovaries; MP, multiple pregnancy; VEGF, vascular endothelial growth factor; 
TSH, thyroid-stimulating hormone; hMG, human menopausal gonadropin; CC, clompiphene citrate
extremely low-birth-weight infants with ovarian 
cysts, and stimulation of the external and inter­
nal genitalia beginning at 35-39 weeks3. Serum 
estradiol was elevated. The findings receded 
during the first 5-9 weeks of neonatal life. The 
physiologically high concentration of gonado­
tropins in preterm infants stimulates the ovaries 
to produce ovarian cysts as well as to secrete 
high amounts of estradiol, which induce tran­
sient stimulation of the external and internal 
genitalia. The condition subsides spontaneously 
within a few weeks and does not need any sur­
gical interference.
Spontaneous and severe ovarian 
hyperstimulation due to gonadotroph 
adenoma
Spontaneous and severe ovarian hyperstimula­
tion due to gonadotroph adenoma has been 
reported4,5. Patients present with ovarian 
enlargement simulating hyperstimulation, 
headache, galactorrhea, a dramatic rise in 
plasma estradiol, elevated levels of follicle stim­
ulating hormone (FSH) and marginally elevated 
levels of (3-luteinizing hormone (LH). Com­
puterized tomography and pituitary magnetic
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resonance imaging reveal a huge pituitary ade­
noma. Transvaginal ultrasound shows enlarged 
ovaries resembling a hyperstimulation-like pat­
tern. Although the estradiol level is extremely 
high in these patients, they do not present with 
ascites, suggesting that chronically elevated 
estradiol does not play a crucial role in OHSS. 
The condition subsides after trans-sphenoidal 
surgery.
OHSS in spontaneous pregnancy
The rare condition of OHSS during spontaneous 
pregnancy has been reported. The overproduc­
tion of endogenous chorionic gonadotropin 
during pregnancy has been associated with 
spontaneous OHSS (also termed hyperreactio- 
luteinalis of the first trimester), as well as hyper- 
emesis gravidarum and transient gestational 
thyrotoxicosis6-10. OHSS in spontaneous preg­
nancy is particularly associated with primary 
hypothyroidism, polycystic ovaries, multiple 
gestations or hydatidiform mole, known to be 
associated with abnormally high levels of 
hCG6,11-16. In OHSS associated with hypothy­
roidism it has been suggested that the high level 
of thyroid-stimulating hormone (TSH) could 
stimulate the ovaries14. Familial recurrent gesta­
tional spontaneous OHSS has also been 
reported17-20. The follicular recruitment occurs 
later through stimulation of the FSH receptor by 
pregnancy-derived hCG. Massive luteinization 
of enlarged stimulated ovaries induces the 
release of vasoactive mediators, resulting in the 
development of OHSS21.
Severe spontaneous OHSS during pregnancy 
with normal levels of chorionic gonadotropin 
was explained by Smits et al. and by Vasseur et 
al. to be due to a chorionic gonadotropin- 
sensitive mutation in the follicle-stimulating 
hormone receptor22 23. This is treated in more 
detail in Chapter 13.
Spontaneous forms of OHSS have generally 
been reported to develop between 8 and 14 
weeks of amenorrhea. The initial corpus luteum
related to the pregnancy is not responsible for 
the development of OHSS. The formation of sec­
ondary multiple corpora lutea, or at least of a 
critical mass of luteinized granulosa cells, could 
induce a massive release of vasoactive sub­
stances resulting in the development of OHSS21.
Spontaneous OHSS is often misdiagnosed as 
an ovarian carcinoma with consequent laparo­
tomy and castration, or severe complications 
such as renal insufficiency may develop 
because the diagnosis and treatment of OHSS 
are delayed. Serial color and pulsed Doppler 
ultrasonographic imaging and hCG, vascular 
endothelial growth factor (VEGF), TSH, free tri­
iodothyronine and free thyroxine levels estima­
tion can help in the diagnosis of spontaneous 
OHSS and evaluation of the patient, and permit 
conservative therapy.
OVARIAN HYPERSTIMULATION 
RELATED TO INTAKE OF OVULATION- 
INDUCING DRUGS (IATROGENIC 
OHSS)
In iatrogenic OHSS, follicular recruitment and 
enlargement occur during ovarian stimulation 
with exogenous FSH, or rarely with clomiphene 
citrate followed by the administration of 
gonadotropin-releasing hormone (GnRH)24.
OHSS in in vitro fertilization programs
With the currently widespread use of GnRH 
agonists (GnRHa) for pituitary desensitization in 
combination with exogenous gonadotropin 
administration in in vitro fertilization (IVF) pro­
grams, up to 10% of IVF cycles result in OHSS, 
with severe OHSS observed in 0.5-2% of IVF 
cycles25. Considering the large number of IVF 
cycles performed annually around the world, 
OHSS is not a rare clinical problem. In a center 
performing 1000 IVF and intracytoplasmic 
sperm injection (ICSI) cycles/year, between 5 
and 20 patients will become seriously ill from
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OHSS every year. Moreover, we are dealing here 
with a condition that can result in thromboem­
bolism, requires hospitalization and may even 
cause the death of a young, healthy woman who 
may not have been the primary source of the 
infertility for which she had received treatment.
OHSS in ovulation induction/ovulation 
enhancement
It has been reported that OHSS occurs in < 4% 
of cycles of ovulation induction1. It is difficult to 
obtain an accurate incidence of OHSS attributa­
ble to ovulation induction/ovulation enhance­
ment (OI/OE) procedures as there is no system 
for recording the use of ovulation-inducing 
drugs not in association with IVF programs. The 
syndrome is becoming more common as the 
number of women receiving ovulation induc­
tion with gonadotropins for OI/OE, apart from 
IVF, is increasing. It is rarely seen in conjunction 
with clomiphene citrate or GnRH usage24. How­
ever, there are a few reports in the literature con­
cerning the occurrence of OHSS in patients 
receiving clomiphene citrate for OI/OE26, espe­
cially with repeated use over 3 consecutive 
months27. The failure to recognize and diagnose 
the possibility of OHSS with clomiphene citrate 
could result in unnecessary oophorectomy.
Patients at risk of iatrogenic OHSS
Patients who are at risk of OHSS should be iden­
tified before scheduling them for ovarian stimu­
lation, whether for IVF/ICSI cycles or OI/OE, 
during ovarian stimulation and after oocyte 
pick-up (Table 2). According to the European 
Society of Human Reproduction and Embryol­
ogy (ESHRE) special interest group (SIG) on 
safety and quality, these include: polycystic 
ovarian syndrome (PCOS) patients, and those 
with incomplete forms of PCOS, a high number 
of resting follicles, i.e. ^ 10 in each ovary, a 
LH/FSH ratio z2, hyperandrogenism and a pre­
vious history of OHSS28. Also, young age (< 35 
years), lean bodily habitus, allergies and using
Table 2 Patients at risk of iatrogenic ovarian hyperstimulation syndrome (OHSS)
Before stimulation During stimulation After stim ula tion
PCOS patients Patients requiring high dose of OPU > 2 5  oocytes
Incomplete forms of PCOS gonadotropin Exogenous hCG for luteal
^ 10 resting follicles in each Rapidly rising E2 level
phase support
ovary E2 > 4000 pg/ml Pregnancy particularly
LH/FSH s> 2 
Hyperandrogenism 
Previous OHSS 
Young age < 3 5  years 
Lean bodily habitus 
GnRHa down-regulation
> 2 5  small and intermediate 
follicles
Exogenous hCG for ovulation 
induction
multiple pregnancy
PCOS, polycystic ovarian syndrome; LH, luteinizing hormone; FSH, follicle stimulating hormone; GnRHa, 
gonadotropin-releasing hormone agonist; E2, estradiol; hCG, human chorionic gonadotropin; OPU, oocyte 
pick-up
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GnRHa for down-regulation are reported to be 
possible risk factors28-33.
During stimulation, patients who are more 
likely to develop OHSS include those requiring 
higher doses of exogenous gonadotropins or those 
with a high absolute or rapidly rising serum 
estradiol level (>4000pg/ml; >  14 500mol/l) 
(with no clear cut-off value); other factors are 
the occurrence of >  25 small and intermediate- 
sized follicles, and the use of exogenous hCG for 
ovulation induction and luteal phase sup­
port34,35.
Women at increased risk of OHSS should be 
on the lowest possible dose of gonadotropins 
with the aim of reducing the granulosa/luteal 
cell mass36. Patients who yield a large number of 
oocytes (> 25 oocytes) and those who become 
pregnant, particularly with a multiple preg­
nancy, are more likely to develop OHSS. Preg­
nancy increases the likelihood, duration and 
severity of OHSS.
OHSS may occur early or late, with two dif­
ferent risk factors. Luteinization is mandatory 
for the manifestation of OHSS. An early form of 
OHSS presents 3-7 days following hCG admin­
istration, is usually severe and reflects the 
degree of ovarian stimulation. Late OHSS pres­
ents about 12-17 days after hCG administration, 
is due to a pregnancy-related rise in hCG, is usu­
ally mild and is more prolonged. It is related 
more to pregnancy and to the number of gesta­
tional sacs seen on ultrasound 4 weeks after 
ovulatory hCG injections. However, a prospec­
tive observational study by Mathur et a l 37 com­
paring patient and cycle characteristics among 
three study groups -  early OHSS, late OHSS and 
non-OHSS -  showed that late OHSS was more 
likely than early OHSS to be severe, and is only 
poorly related to preovulatory events.
Clinical manifestations of iatrogenic OHSS
OHSS has a broad spectrum of clinical manifes­
tations, from mild illness, which is usually self- 
limiting and requires no active therapy apart 
from careful observation, to moderate and
severe disease which is life-threatening, and 
requires hospitalization, intensive-care monitor­
ing and expert management. OHSS has tradi­
tionally been classified into three categories: 
mild, moderate and severe, and into six grades 
of increasing severity. Probably the most com­
monly used classification is the Golan classifi­
cation38. Mild OHSS occurs in 23-33% of 
gonadotropin-stimulated IVF treatment cycles, 
moderate OHSS in 3-6% and severe OHSS in
0.2-1.9%32,35,39.
The clinical symptoms and signs of OHSS 
exhibit a continuum of scope and severity that 
defies attempts at specific classification or stag­
ing. Unless the treating physician is aware of 
and predicts OHSS from the beginning, the 
moderate form passes on easily to the severe 
form in a short period of time. The guidelines of 
the ESHRE SIG for quality and safety in assisted 
reproductive technologies (ART) describe clini­
cal manifestations of OHSS collectively as clini­
cal symptoms, paraclinical signs and biological 
findings28. The Practice Committee of the Amer­
ican Society for Reproductive Medicine have 
classified clinical manifestations of OHSS into 
mild and severe types24.
Clinical manifestations of mild OHSS Clini­
cal manifestations of mild OHSS include: tran­
sient lower abdominal discomfort, mild nausea, 
vomiting, diarrhea and abdominal distension, 
which is observed in up to a third of superovu­
lation cycles. The onset of symptoms typically 
occurs soon after ovulation (in superovulation 
cycles) or after oocyte retrieval in ART cycles, 
but it may be delayed. Progression of illness is 
recognized when the symptoms persist, worsen 
or include ascites that may be demonstrated by 
increasing abdominal girth or ultrasound evalu­
ation (Table 3).
Clinical manifestations of severe O HSS
Severe illness exists when pain is accompanied 
by one or more of the following symptoms and 
signs: rapid weight gain, tense ascites, hemo­
dynamic instability (orthostatic hypotension,
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Table 3 Clinical manifestations of iatrogenic OHSS
Mild OHSS Progression o f illness Severe OHSS
Observed in up to a third of 
superovulation cycles
Transient lower abdominal 
discomfort




Symptoms persist or worsen
Ovarian enlargement
Ascites demonstrated 
clinically or by ultrasound 
evaluation
Occurs in 0.5-2% of 
superovulation cycles
Lower abdominal pain
Intractable nausea and 
vomiting











tachycardia), respiratory difficulty (tachypnea), 
progressive oliguria and laboratory abnormali­
ties. The symptoms and signs of severe OHSS 
can be grouped under the following items 
depending on the severity of the condition and 
the time the diagnosis is made. Physicians 
should not wait until all these symptoms and 
signs appear before diagnosing severe OHSS. 
Any group of these symptoms and signs com­
bined with ovarian enlargement, abdominal 
pain and distension would qualify for the diag­
nosis of severe OHSS in a patient receiving 
drugs for induction of ovulation:
(1) Intractable nausea and vomiting that pre­
vent ingestion of food and adequate fluids;
(2) Hypovolemia and hemoconcentration as a 
result of extravasation of protein-rich fluid 
from the vascular compartment to the 
third space, which in turn results in con­
traction of the vascular volume and low­
ered blood pressure and central venous 
pressure;
(3) Oliguria or anuria because of reduced 
renal perfusion due to decreased vascular 
volume and/or tense ascites; when not cor­
rected the decreased renal perfusion stim­
ulates the renal tubules to increase salt 
and water resorption in the proximal 
tubules, producing oliguria and low uri­
nary sodium excretion; with less sodium 
being delivered to the distal tubules there
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is a decrease in exchange of hydrogen and 
potassium for sodium, resulting in hyper- 
kalemic acidosis;
(4) Rapid weight gain, because of salt and 
water retention;
(5) Dyspnea due to pulmonary compromise 
from an elevated diaphragm and/or 
hydrothorax;
(6) Ascites, pleural effusion and pericardial 
effusion; pleural effusion is usually sec­
ondary to ascites and possibly similar in 
pathogenesis to Meig’s syndrome40; as the 
ascitic fluid is an exudate and, therefore, 
protein-rich fluid, serum albumin levels 
decrease markedly, producing hypoalbu- 
minemia;
(7) Hypercoagulability with thromboembolic 
sequelae; this results from hemoconcen- 
tration, immobilization due to abdominal 
distension and pain, mechanical compres­
sion of venous blood flow in the pelvic 
brim and lower limb, high estradiol levels 
and endothelial cell damage due to stress- 
induced leukocytosis41; Arterial and 
venous thromboses occur in various sites, 
including upper and lower limbs as well 
as intracerebrally42;
(8) Adult respiratory distress syndrome 
(ARDS), due to pulmonary edema and 
restricted lung movement, may occur.
If OHSS is not quickly managed and hemody­
namics restored, multiple organ dysfunction 
syndrome and death may occur. Brinsden et al. 
believe that death is rare following OHSS, and 
occurs in approximately 1:500 000 stimulated 
cycles1. This seems to be an underestimation of 
this complication. There have been few, iso­
lated, published reports of women who died 
from OHSS. Serour et al. in a series of 3500 
IVF/ICSI cycles reported one death due to hepa­
torenal failure that occurred in a patient with 
moderate OHSS, who was retrospectively found
to have an unrevealed history of hepatitis C with 
impairment of liver function39. Semba et al. 
reported a patient who died suddenly of rapid 
respiratory insufficiency. Autopsy examination 
revealed massive pulmonary edema, intra- 
alveolar hemorrhage and pleural effusion with­
out any evidence of pulmonary thrombo­
embolism. Histopathology of the ovary showed 
a picture consistent with OHSS43. Death may 
also occur due to acute respiratory failure, lactic 
acidosis, shock, massive cerebral infarction, 
myocardial infarction, supraventricular tachy­
cardia or massive thromboembolic manifesta­
tions. Mortality due to OHSS is underreported 
in the literature. The author is aware of many 
cases in different parts of the world which were 
never published. Many of these patients, when 
seriously ill, end up in emergency and intensive 
care or the neurosurgery unit, and may never 
report to the IVF center.
Laboratory findings
Laboratory findings in women with severe 
OHSS comprise: hemoconcentration (hemato­
crit >45% ) due to an increase in capillary per­
meability and leakage of protein-rich fluid from 
the intravascular space; leukocytosis (white 
blood cell count > 15 000) due to hemoconcent­
ration and generalized stress reaction; electrolyte 
imbalances (hyponatremia: sodium < 135mEq/l; 
hyperkalemia: potassium >5.0mEq/l); elevated 
liver enzymes; decreased creatinine clearance 
(serum creatinine > 1.2mg/dl; creatinine clear­
ance <50ml/min), and low serum albumin 
level <  30 g/1.
CLINICAL MANIFESTATIONS OF 
COMPLICATIONS OF OHSS
Not uncommonly, the reproductive medicine 
physician is not the one who is consulted when 
patients are admitted to hospital with complica­
tions of OHSS. Many of these patients end up in 
the surgical, vascular, neurosurgery, neurology,
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chest or critical-care units. Furthermore, a large 
number of publications on the complications of 
OHSS appear in the medical journals of vascular 
surgery, neurosurgery, neurology, chest medi­
cine, intensive care units and others. Conse­
quently, many reproductive medicine physi­
cians are unfortunately not fully aware of the 
frequency of occurrence of these complications, 
or familiar with their clinical manifestations. 
Reciprocally, the attendant physicians in these 
different subspecialty units should be aware of 
clinical manifestations of the complications of 
OHSS. This is essential for early diagnosis and 
proper management of this potentially fatal syn­
drome. It necessitates a continuous dialog 
between reproductive medicine physicians and 
their colleagues in other subspecialties relating 
to this newly emerging set of complications due 
to the widespread use of ovulation-induction 
drugs for OI/OE or in IVF programs. A history of 
the recent intake of these drugs should be 
included in the admission sheets of all women 
of reproductive age admitted to these units.
The diagnosis of some complications of 
OHSS may be masked by the pain, distension 
and ascites associated with OHSS. Sometimes, 
one or another of these complications may be 
the first presenting manifestation of OHSS 
(Table 4). The complications of OHSS include 
the following.
Ovarian torsion
While the overall risk of ovarian torsion is about 
1 per 5000 stimulations, it is greater in the pres­
ence of OHSS. Mashiach et al. noted torsion in 
16% of pregnant patients with OHSS compared 
with 2.3% in non-pregnant patients44. The risk 
of torsion increases with an increase in ovarian 
size and with ligamentous softening, which 
explains the increased susceptibility in early 
pregnancy after ovarian hyperstimulation40.
The characteristic symptoms include sud­
den, extreme abdominal pain accompanied by 
nausea. If undiagnosed and neglected this may
result in ovarian necrosis. The risk of torsion 
may even persist beyond the treatment cycle, 
and it may be precipitated by exercise or strenu­
ous activity if regression to normal ovarian size 
has not been achieved45.
Ovarian hemorrhage
Ovarian hemorrhage may occur in OHSS due to 
ovarian rupture or, rarely, intraovarian hemor­
rhage. Ovarian rupture may be precipitated by 
abdominal trauma, strenuous activity or biman­
ual examination. It is manifested by severe 
abdominal pain, distension, hypotension, severe 
pallor and free fluid in the peritoneal cavity. 
Pain and ascites associated with severe OHSS 
can easily mask ovarian rupture.
Hemorrhage inside the ovarian follicles may 
also occur, and lead to a picture similar to inter­
nal hemorrhage. The ovaries become large, 
tense and edematous with multiple cystic struc­
tures filled with blood. Ultrasonography and 
repeat hemoglobin level assessment will help to 
diagnose these conditions.
Thromboembolism
This is a rare but extremely serious complica­
tion of OHSS. Most cases of thrombosis are late 
complications of OHSS, and may or may not be 
associated with hereditary hypercoagulability. It 
may occur in patients with mild, moderate or 
severe OHSS39’42-46"60.
The clinical manifestations and mecha­
nisms61-64 underlying thromboembolic compli­
cations are treated in further detail in Chapter 5.
Venous compression due to enlarged ovaries 
and ascites, in addition to the immobility due to 
pain and distension, and all the above transient 
changes in coagulation factors, are the main eti­
ological factors in the increased incidence of 
thromboembolic complications in OHSS. 
Thromboembolism of the internal jugular veins 
presents with pain and swelling in the neck and 
dyspnea, or it may present with pulmonary 
embolism. Thrombosis of the middle cerebral
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Table 4 Diagnostic criteria of complications of iatrogenic OHSS
Complication Diagnostic criteria
Torsion Exercise or strenuous activity followed by extreme 
abdominal pain and nausea
Ovarian hemorrhage Abdominal trauma or strenuous activity followed by 
severe abdominal pain, distension, hypotension, severe 
pallor, low Hb level and ultrasound scan
Thromboembolism which may be 
arterial or venous in various sites 
including upper and lower limbs, 
neck and intracerebral vessels
A possible positive family history of thrombosis and/or 
thrombophilias, signs depend upon site of 
thromboembolism
Usually presents between 7 and 10 weeks’ gestation. 
Positive specific tests for blood hypercoagulability 
MRI and MRA
Hepatocellular and cholestatic disorders Usually in third trimester
Impaired renal function and anuria
Mild to moderate increase in AST and ALT 
May persist for >  2 months
Oliguria or anuria 
Serum creatinine > 1.2mg/dl 
Creatinine clearance < 5 0  ml/min 
Sodium <  135mEq/l 
Potassium >  5.0mEq/l 
Hyperkalemic acidosis
Temporary failure of transplanted 
kidney
Anuria
Bilateral or unilateral hydrothorax Chest tightness, dry cough and dyspnea 
Chest ultrasonography or chest X-ray
ARDS Rapid respiratory insufficiency 
Chest X-ray or ultrasonography 
Blood gases assessment 
Lung function tests 
MRI and MRA
Pulmonary embolism Fever, dyspnea, wheeze and hemoptysis 
Chest X-ray, MRI and MRA
Pericardial effusion Supraventricular arrhythmia 
Echocardiography
ARDS, adult respiratory distress syndrome; Hb, hemoglobin; MRI, magnetic resonance imaging; MRA, magnetic 
resonance angiography; AST, aspartate aminotransferase; ALT, alanine aminotransferase
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artery presents with a picture of cerebral infarct. 
Deep vein thrombosis presents with pain and 
swelling of the leg.
Duplex Doppler ultrasonographic examina­
tion and magnetic resonance angiography of 
suspected occluded vessels based on the clinical 
manifestations will help in the diagnosis and 
initiation of treatment before the onset of seri­
ous complications.
Liver dysfunction
Liver dysfunction is a rare complication of 
severe OHSS. More recently it has been reported 
even in moderate OHSS39,65. Both hepatocellu­
lar and cholestatic disorders were reported. 
Abnormal hepatic function has been increas­
ingly recognized as a complication of severe 
OHSS that may persist for more than 2 months. 
Liver biopsy shows significant morphological 
abnormalities only at the ultrastructural level.
Midgley et a l,66 describe a case of recurrent 
cholestasis following OHSS during a twin preg­
nancy. On the first occasion cholestasis devel­
oped unusually in the first trimester, and on the 
second occasion it developed in the third 
trimester as usual. In a large prospective longi­
tudinal study of 50 consecutive patients with 
ascites due to severe OHSS, Fabregues et al.67 
showed that 15 patients (30%) had abnormal 
liver tests characterized by a mild to moderate 
increase in aspartate aminotransferase (AST) 
(mean 103 ± 17.1 IU/1 and alanine aminotrans­
ferase (ALT) (76 ±  8.3 IU/1), which was associ­
ated in some cases with an increase in y-glu- 
tamyl transpeptidase or alkaline phosphatase. 
All abnormalities reverted to normal after reso­
lution of the syndrome. The death of a patient, 
with an unrevealed history of hepatitis C, from 
hepatorenal failure following moderate OHSS 
has been reported by Serour et al.39. Davis et 
a l,68 describe a case of severe OHSS with
Figure 1 Severe abdominal distension in a patient with severe OHSS. Picture taken on day 16 after 
embryo transfer. The patient was pregnant with twins. Courtesy Dr J Gerris, Belgium
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Figure 2 Vulvar edema in a patient with OHSS. Courtesy Dr J J Amy, Belgium
Figure 3 Three subsequent images of thorax X-ray in the same patient, showing severe resolving and 
resolved hydrothorax. Courtesy Dr J Gerris, Belgium
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malnutrition, severe hypoalbuminemia with 
gross edema and progressively worsening liver 
function.
Gastrointestinal complications
Gastrointestinal symptoms such as nausea and 
vomiting may be initial presentations of OHSS. 
Failing to suspect such a condition may result in 
later presentation of these patients with cere­
brovascular accidents. These symptoms are usu­
ally due to a high level of estradiol, ovarian 
enlargement and abdominal distension. Uhler et 
a7.69 reported a perforated posterior duodenal 
ulcer associated with OHSS. Stress associated 
with invasive monitoring, multiple medical 
therapies in the intensive-care unit and Heli­
cobacter pylori infection appear to be the most 
probable causative factors of the ulcer. Prompt 
recognition of this complication and an emer­
gency exploratory laparotomy will help to save 
the life of these patients.
Renal complications
Tension ascites can impair renal function, and 
in severely hypovolemic cases, prerenal failure 
will be heralded by oliguria, raised blood urea 
and creatinine, followed by anuria, hyper­
kalemia and uremia30,40. Temporary failure of a 
transplanted pelvic kidney has also been 
reported, due to pressure on the transplanted 
kidney by enlarged ovaries70.
Respiratory complications
OHSS usually causes ascites and occasionally 
hydrothorax. When ascites is lacking an isolated 
pleural effusion in a pregnant or non-pregnant 
patient can be mistaken for pulmonary 
embolism. Several workers have reported this 
not so uncommon sole presentation of 
OHSS71-74. The isolated hydrothorax may result 
from a combination of positive intra-abdominal 
pressure, negative intrathoracic pressure and 
diaphragmatic defects that promote the transfer
of intra-abdominal fluid into the pleural fluid, 
resulting in hydrothorax in the absence of 
abdominal fluid. The preferential location of 
hydrothorax on the right side in most cases 
might be explained by a capillary leak and exu­
dation into the pleural space due to the 
decreased right lymphatic drainage as compared 
with the left side, in addition to the defect in the 
diaphragm being more common in its right por­
tion. Clinically, hydrothorax manifests with 
chest tightness, dry cough and dyspnea. There is 
a negative history of fever, wheeze, hemoptysis 
or leg swelling. The diagnosis can be confirmed 
with chest ultrasonography or X-ray. Early 
recognition and diagnosis of the condition 
should allow for appropriate therapeutic 
management.
Bibasilar partial atelectasis or ARDS may 
occur. This may be attributable to lung move­
ment restriction because of pain, tense ascites or 
large ovarian cysts and transudation of fluid 
from pulmonary capillaries into the alveoli. The 
condition can be diagnosed by chest X-ray, ultra­
sonography and assessment of blood gases and 
lung function. Other diagnostic procedures such 
as magnetic resonance imaging (MRI) and mag­
netic resonance angiography (MRA) can help to 
differentiate the condition from pulmonary 
embolism.
Pulmonary embolism may also occur as a 
result of a shower of emboli from different sites 
of thrombosis. The patient develops fever, dysp­
nea, wheeze and hemoptysis. The diagnosis can 
be confirmed with chest X-ray, MRI and MRA.
Cardiac complications
Pericardial effusion may present with supraven­
tricular arrhythmia. Pericardial effusion and car­
diac tamponade is a rare and potentially fatal 
event, and once the diagnosis is made by 
echocardiography, drainage of the fluid by a car­
diologist is necessary. Massive myocardiac 
infarction may also occur, and results in sudden 
death.
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Ventriculoperitoneal shunt failure
Ventriculoperitoneal shunt dysfunction has 
been reported by Lee et al.75. Shunt dysfunction 
is attributed to intra-abdominal hypertension as 
a consequence of ascites and enlarged ovaries. 
Neurosurgeons should be alerted to this possi­
bility with the increasing number of patients 
developing OHSS.
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CHAPTER 5
Thromboembolic complications of 
ovarian hyperstimulation syndrome
Jane Stewart
Ovarian hyperstimulation syndrome (OHSS) is 
a complex phenomenon which has not yet been 
fully elucidated. Whilst rare cases of sponta­
neous OHSS can occur for example in molar 
pregnancy1 or as a result of gonadotropin recep­
tor abnormalities2, it is primarily an iatrogenic 
condition. It is incumbent therefore upon the 
practitioner supervising the risk-causing treat­
ment to ensure that the recipient is fully 
informed of those risks and that they are kept to 
a minimum.
Mild cases of OHSS may be uncomfortable, 
inconvenient and time-consuming; however, it 
should not be forgotten that serious complica­
tions can arise and may result in significant 
morbidity both acutely and in the longer term. 
There is a risk of mortality if severe or unrecog­
nized, and there are implications for future 
health and well-being even if appropriate treat­
ment is given. One such complication is throm­
boembolism. The aim of this chapter is to dis­
cuss the nature of thromboembolic disease and 
put it in the context of the woman of reproduc­
tive age and indeed of women undergoing 
assisted reproductive treatment. OHSS is con­
sidered as a specific risk factor. The prevention, 
diagnosis and treatment of thromboembolism in 
relation to ovarian stimulation and OHSS are 
discussed.
THROMBOEMBOLISM IN WOMEN OF 
REPRODUCTIVE AGE
Venous thromboembolic disease (VTE) is widely 
experienced and much highlighted in the public 
forum. It is a significant cause of peroperative 
morbidity3, and is still a feared risk in the use of 
the combined oral contraceptive pill (COCP)4 
and hormone replacement treatment (HRT)5. It 
has been drawn again and most recently to pub­
lic attention as a silent risk of long-haul air 
travel6. It is broadly understood, therefore, in 
the lay population that it results from some form 
of intervention and is preventable. Increasing 
awareness has led to a drive to consider more 
formally the risk of venous thromboembolism 
(VTE) in hospital in-patients other than the 
postoperative population.
Whilst there is an increased risk of VTE in 
the elderly population, and hence the concerns 
regarding medical in-patients and long-haul 
flights in this group in particular, in a woman of 
reproductive age the risk of VTE occurring is 
said to be 5-21/100 000 women/year7. This risk 
increases to 15-25/100 000 women/year in users 
of the combined oral contraceptive pill (COCP) 
and increases to 60/100 000 women/year during 
pregnancy8. Despite this awareness, the risk 
associated with an otherwise uncomplicated
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pregnancy is probably unknown to most women 
and may not be generally discussed as part of 
normal antenatal care unless there are other 
associated risk factors, and even then not always 
appropriately: 30 cases of direct maternal death 
from thromboembolic disease were reported in 
the UK from 2000 to 2002, representing an inci­
dence of 1.5/100 000 maternities, over half of 
which were considered to have received subop- 
timal care9.
There are numerous additional risk factors 
that play a role in the incidence of this disorder 
in an otherwise healthy population (Table 1).
THROMBOEMBOLISM
Intravascular thrombosis is the inappropriate 
formation of clots within vessels, and embolism 
results from the movement of these clots or por­
tions of them, to lodge downstream in smaller 
vessels. The result of these episodes is develop­
ment of symptoms related to poor blood flow in 
the affected, occluded vessels and also in down­
stream organs or tissues. Thrombosis can occur 
in both arteries and veins, and, peculiarly, arte­
rial thromboembolism is associated with ovar­
ian stimulation and OHSS10.
Virchow’s triad describes the combination of 
features which allows clots to form: stasis, 
endothelial damage and hypercoagulability (Fig­
ure 1). The natural process of clot formation 
works to reduce bleeding at the site of injury 
and promote the healing process. Intravascular 
thrombosis results from the inappropriate trig­
gering of this process by one of a number of fac­
tors. If Virchow’s triad is considered, then 
numerous mechanisms can be derived (Table 2). 
These various factors may be invoked as a basis 
for considering the nature of thrombosis and in 
particular for the etiology when associated with 
OHSS.
PREGNANCY AND THROMBOSIS
The effects of pregnancy on the hemostatic 
mechanism are well known and take effect from 
early on in the process. Pregnancy induces a 
hypercoagulable state by virtue of changes in 
numerous clotting and thrombolytic factors. An 
increase in the von Willebrand factor 
(VIIIR.vWf), factor VIII, factor V and fibrinogen, 
an acquired resistance to activated protein C 
and a reduction of protein S with associated 
increases in plasminogen activator inhibitors 1
Table 1 General risk of thromboembolism in women of reproductive age
Background risk factors Addition ol risk fa  dors
Age > 3 5  years COCP, HRT
Obesity Pregnancy
Mobility problems Cancer
Significant family history of thrombosis Surgery
Thrombophilia -  inherited or acquired Immobility including bedrest and long-haul travel
Previous thrombosis
Varicose veins
COCP, combined oral contraceptive pill; HRT, hormone replacement treatment
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Figure 1 Virchow’s triad
Table 2 Virchow’s triad and venous thromboembolism








obstructive mass, e.g. tumor, 
pregnancy
Reduced intravascular volume 























Hematological disorders, e.g. 
polycythemia
Atrial fibrillation
COCP, combined oral contraceptive pill; HRT, hormone replacement treatment
and 2 induce a relative thrombophilia11. The 
process of placental invasion results in signifi­
cant local vascular changes, and it is possible 
that such local changes are reflected in the
endothelium throughout the vasculature, 
adding to hypercoagulability. As pregnancy pro­
gresses, generalized venous stasis occurs as a 
result of reduced vascular resistance and also
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the effect of the growing uterus reducing venous 
return from the lower limbs. Pregnancy itself 
thus encompasses several risk factors for throm­
bosis, although in reality thrombosis is probably 
uncommon without any additional features9. 
Obesity and intercurrent disease are additive 
factors, and multiple pregnancy and operative 
delivery simply increase these risks further9.
The hormone changes of pregnancy are 
responsible for many of the early and late 
changes that occur, and both estrogen and prog­
esterone are implicated in development of the 
hypercoagulable state.
OHSS AND THROMBOSIS
In OHSS, as in pregnancy, there are physical 
features that make the increased risk of throm­
bosis entirely explicable. The physical presence 
of greatly enlarged ovaries and potentially tense 
ascites will result in a degree of obstruction to 
venous drainage from the lower limbs, resulting 
in reduced blood flow. Women experiencing 
OHSS are nearly always nauseated and may 
have recurrent vomiting, and are therefore 
potentially dehydrated as well as being laid up 
in bed with general malaise, both being further 
contributors to their risk of thromboembolism at 
least in the lower limbs. There are features of 
this phenomenon in association with OHSS, 
however, which are less easy to understand.
In 1997 we summarized the worldwide 
reports available at that time of thromboembolic 
disease associated with a variety of fertility 
treatments, all but one involving ovarian stimu­
lation10. Fifty-four cases had been reported then 
since 196412-47. Most interesting about these 
reports, however, was that they were not all the 
lower-limb venous thromboses that might have 
been expected. The 54 cases comprised 25% 
arterial thrombosis, and, of the venous throm­
boses reported, 60% were sited in the upper 
limb or neck. It is possible that this idiosyn­
cratic distribution is the result of under­
reporting of common lower-limb deep venous 
thrombosis (DVT) as unremarkable and perhaps 
not unexpected, compared with thrombosis at 
other sites, which are reported as novel cases. It 
could be argued that women do not report a 
problem back to the treatment center, and this 
may well be true in some units where follow-up 
is not an automatic feature; however, this unit, 
based in the National Health Service in the UK, 
has always carefully followed up cases of OHSS 
and sees virtually every couple treated, back for 
review 6-8 weeks after completion of that treat­
ment. In addition, there is a telephone advice 
service for first-line contact by couples in the 
event of acute problems, and open access to the 
unit is encouraged. Finally, since most couples 
live in the region, admission with complications 
and/or delivery if pregnant, if not to the unit’s 
parent hospital, would be to one of the local dis­
trict general hospitals. It is unlikely that a sig­
nificant complication, therefore, would go unre­
ported at base. In our experience, however, in 
over 15 years, although a number of women 
have undergone tests to exclude the possibility, 
where five cases of thromboembolism have 
occurred, we have never seen a traditional DVT 
following assisted conception treatment47.
Since 1997 there have been a further 30 
cases of thromboembolic disease reported in 
association with OHSS, the majority reviewed 
by Delvigne and Rozenberg48: two cases of pul­
monary embolism49; ten cases of internal jugu­
lar venous and/or subclavian vein thrombosis 
(two bilateral and one including the superior 
vena cava)50-58; one superior sagittal sinus 
thrombosis59 and one cortical vein thrombosis 
(with second site inferior vena cava extending to 
both iliac veins)60; two carotid artery throm­
boses, one resulting in a stroke61,62; a brainstem 
infarction from intracranial thrombosis63 and 
seven further intracranial arterial complica­
tions49,64-69, including one central retinal artery 
thrombosis69; two upper-limb arterial throm­
boses70,71; and, finally, coronary artery and 
intracardiac thromboses72,73. A single iliofemoral
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thrombosis has been reported74, but there have 
been no reports of series of lower-limb DVT oth­
erwise. There are at least two further reports of 
thrombosis associated with ovarian stimulation 
where OHSS was not implicated75’76.
Whilst these cases do not represent a huge 
number in relation to the number of cases of 
ovarian stimulation performed internationally 
per year, they do represent important morbidity 
and occasional mortality, and it is clear that 
reported cases will not represent the full pic­
ture. Reporting bias results in skewing towards 
more ‘interesting’ and less ‘routine’ cases, and in 
addition some cases may indeed remain un­
noted simply because the woman reports else­
where than the fertility clinic and the link may 
not be made.
OHSS is not always the key factor, although 
present in the majority of these cases. The inter­
pretation of this association remains problem­
atic, however, due to the enormous differences 
both across international boundaries and over 
time in making the diagnosis.
Upper-limb thrombosis is a relative rarity, 
representing about 4% of all VTE in the general 
population77. Specific risk factors include long- 
line intravenous catheterization and obstructive 
lesions in the chest, whether tumors or bony 
abnormalities78. Arterial thrombosis is also rare 
in young healthy adults, occurring as a result of 
specific trauma, including arterial canalization, 
or in the elderly in the form of strokes. There are 
no specific features of assisted conception treat­
ment which can account for this peculiar distri­
bution of cases except the generation of a hyper- 
coagulable state.
Importantly, in around 80% of the OHSS- 
associated cases, pregnancy was also a feature. 
Since severe OHSS is associated with high preg­
nancy rates it is not unreasonable that these fac­
tors should go hand in hand, but it is of interest 
to note that the timing of occurrence of the 
reported thrombosis does not generally coincide 
with the probable peak of OHSS severity. The 
mean period from treatment to diagnosis of
venous thrombosis was about 34 days (upper 
limb, head and neck; range 14-50) and 20 days 
(lower limb and pulmonary embolism; range 
11-24). That of arterial thrombosis was shorter 
at 13 (range 1-36 days)10. It is likely that there is 
a cumulative effect of the two conditions on 
risk, and whilst the hypercoagulability induced 
by pregnancy has been discussed above in gen­
eral terms, the fact that thrombosis can occur 
with OHSS unaffected by pregnancy means that 
this must represent an independent risk factor, 
and numerous hypotheses have been put for­
ward to explain this phenomenon.
THE HYPERCOAGULABLE STATE IN 
OHSS
As described above, there are a number of fea­
tures of OHSS which contribute to the general­
ized increased risk of thrombosis. It is likely that 
the influence of hyperestrogenemia has a role to 
play in its pathogenesis. Working on the hypoth­
esis that women undergoing ovarian stimulation 
may behave like pregnant women, Wfamsby et 
al.79 have considered acquired activated protein 
C (APC) resistance. They assessed 20 women 
undergoing in vitro fertilization (IVF) treatment, 
all of whom were confirmed non-carriers of the 
factor V Leiden mutation, and compared these 
with women tested during their normal men­
strual cycles. They showed that, unlike preg­
nant women, there was no change in APC resist­
ance during stimulation, and that it did not 
differ from that of unstimulated women who 
similarly showed no cyclical differences. 
Although a dose-dependent role has been con­
firmed in exogenous estrogen administration80, 
the same effect of endogenous estrogen is less 
clear, although Kodama et al.61 were able to 
show sequential changes, in particular thrombo- 
philic features (D-dimer, plasmin-a2-antiplasmin 
complex and thrombin-antithrombin III (ATIII) 
complex), which were more marked in women 
who generated high rather than low endogenous
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serum estradiol concentrations during treat­
ment, and more so again where significant 
OHSS intervened. Of these changes, the throm- 
bin-ATIII complex denotes activation of the 
coagulation pathway, and the plasmin-a2- 
antiplasmin complex and D-dimer are associ­
ated with activation of the fibrinolytic pathway. 
The changes rapidly returned to normal if no 
pregnancy ensued, but persisted for several 
weeks when pregnancy occurred, a finding that 
fits with the observations regarding the combi­
nation of OHSS, pregnancy and the different 
timings of thrombosis. They were also able to 
show that changes in D-dimer and plasmin-a2- 
antiplasmin were more marked and preceded 
the development of thrombosis in the one 
woman of age 22 with OHSS who developed the 
condition43.
Kim et a l 82 described an increase in fibrino­
gen concentration in the blood of women under­
going ovulation induction which correlated 
with estrogen concentration. They also showed 
an increase in VIIIR.vWF and a reduction in 
ATIII. However, no difference in prothrombin 
time (PT) or activated partial thromboplastin 
time (APTT) was demonstrated. Other studies 
have suggested increased fibrinogen and 
reduced ATIII concentrations in association 
with an increase in clot lysis time83, a thrombo- 
protective reduction in factor VII and an 
increase in free protein C concentrations84 and 
significant changes in PT and APTT, but within 
the normal ranges, thus negating the importance 
of the change85. Although these changes were 
related to ovarian stimulation, they were not 
studied in the context of OHSS.
Other studies specifically examining hema­
tological changes in cycles affected by OHSS 
have been of limited use because they have not 
provided follow-up data of sufficient duration to 
include the period of risk, which appears to be 
some weeks after human chorionic gonado­
tropin (hCG) administration10. Philips et a l 86 
reported increased concentrations of factor V, 
fibrinogen, profibrinolysin, fibrinolytic inhibi­
tors and platelets in two women experiencing 
severe OHSS, and both Kaaja et a l 87 and 
Todorow et a l 88 suggested that changes in von 
Willebrand factor behavior could predict the 
onset of OHSS. Delvigne et a l 89 examined a 
number of clotting parameters in women suffer­
ing from OHSS, and showed no abnormality in 
PTR, APTT, ATIII or APC resistance. There was 
a slightly higher fibrinogen concentration in 
women with OHSS. Unfortunately, sampling 
was not done until after resolution of the OHSS 
symptoms and was done only once, so that any 
dynamics of these parameters throughout stim­
ulation, OHSS and its resolution would not be 
seen.
It does, however, seem likely that there are 
changes in various factors associated with the 
thrombolytic and fibrinolytic pathways which 
may promote a thrombophilic state, but the 
combined studies are inconclusive, and whilst 
estrogen concentrations are implicated, the 
mechanism is uncertain.
Hemoconcentration is a cardinal feature of 
significant OHSS, and increases the risk of 
thrombosis because of increased blood viscosity 
and, potentially, also an increased concentration 
of circulating coagulation factors. Levin et al. 
suggested that increased erythrocyte aggregation 
detected in OHSS compared with unaffected 
controls may have a role in its pathogenesis90. It 
is not clear how this finding relates to the 
expected hemoconcentration, however. Hemo­
concentration may also allow more prolonged 
exposure of circulating factors to the endothelial 
surface, thus increasing the effect of any local 
damage. There is evidence, for instance, that tis­
sue factor in the coagulation pathway is 
increased and tissue factor pathway inhibitor 
decreased in severe OHSS91. Circulating factors 
may in themselves have effects on the endothe­
lial surface, making it more prone to stimulate 
thrombus formation. Balasch et a l 92 suggested a 
role in thrombogenesis of tissue factors pro­
duced by monocytes in women with severe 
OHSS, and endothelial damage by stress-
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induced leukocytes has also been hypothe­
sized44. Finally, Foong et a l.93 have hypothesized 
that a change in arteriolar reactivity observed in 
women with OHSS may predispose to its patho­
genesis, but by changes in local blood flow this 
may also have a role in promotion of the pro- 
thrombotic state in these women.
There has been some discussion that predis­
position to subfertility, the need for treatment 
and OHSS may be secondary to an associated 
thrombophilia. Dulitsky et a7.49 found that 17 
out of 20 women experiencing severe OHSS 
compared with 11 of 41 controls had at least one 
thrombophilic marker, albeit that some were 
acquired. Of these women, three had some form 
of thromboembolic disorder. Each of these had a 
combination of at least two thrombophilic mark­
ers. Importantly, Grandone et a l .94 examined 
305 women undertaking a total of 747 cycles of 
IVF. They were able to show that the risk of 
thromboembolic disease corresponded to 
1.6/100 000 cycles/woman (4/747 cycles were 
thus complicated), and that age over 39 years 
was a specific risk factor. Following testing for 
both inherited and acquired thrombophilias 
they also showed that mild hyperhomocysteine- 
mia was strongly associated with the throm­
boembolic disorders that occurred. Whilst 
admitting that the study was not powered to do
so, Delvigne et al.89 showed no increased inci­
dence in a full range of thrombophilias (includ­
ing antiphospholipid syndrome) in women who 
developed OHSS, compared with matched con­
trols. Similarly, Fabregues et a l 95 considered the 
prevalence of thrombophilias, both inherited 
and acquired, in women with severe OHSS and 
found no excess compared with unaffected 
controls.
These most recent papers are significant in 
that they highlight a change in knowledge that 
has occurred over recent years, with the recog­
nition of thrombophilias and their clinical 
importance7 (Table 3). When many of the cases 
of ovarian stimulation-associated thromboem­
bolic disease were being reported, few consid­
ered these disorders, and many of the women 
whose problems were reported were not 
screened either before, in the case of known risk 
factors, or necessarily afterwards to make the 
diagnosis. It is likely, therefore, that in a number 
of those cases where this possibility was not 
considered mainly for historical reasons, there 
would have been an underlying thrombophilia. 
It is also likely, however, that thrombophilia rep­
resents an additional risk factor rather than a 
cause to explain fully the phenomenon of 
thrombosis in OHSS.
Table 3 The thrombophilias
Inherited thrombophilia Acquired thrombophilia
Factor V Leiden Antiphospholipid syndrome





Prothrombin gene G20210A variant
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It is clear on reviewing the literature that 
there is as yet no firm pathogenetic link between 
the development of OHSS and its associated 
complication of thromboembolism. In the rest of 
this chapter a more pragmatic view is taken with 
regard to prophylaxis, diagnosis and treatment 
of thromboembolism in association with fertility 
treatment and OHSS.
PREVENTION OF THROMBOEMBOLIC 
DISEASE IN WOMEN UNDERGOING  
OVARIAN STIMULATION
The basis for prevention of thrombosis is first 
and foremost to recognize the risk. It is common 
in peroperative patients or hospital in-patients 
to assess formally that risk on the basis of age, 
weight, mobility, underlying disorder (including 
operation to be undergone), previous personal 
history or family history of thromboembolism 
and other intercurrent risk factors. A scoring 
system is often employed to determine the type 
of thromboprophylaxis relevant to their situa­
tion, whether it be simply early mobilization, 
the use of graduated stockings, prophylactic 
doses of heparin or full anticoagulation3. Most 
women undergoing assisted conception treat­
ment are healthy individuals where the calcu­
lated risk is low, and no specific measures need 
to be taken. Regarding operative risk, oocyte 
retrieval under sedation does not constitute a 
high risk, although a lengthy procedure per­
formed under general anesthesia probably war­
rants antiembolism stockings at least. There is, 
however, a need to maintain awareness of the 
changing nature of that risk as treatment pro­
gresses, particularly where there are other fac­
tors such as obesity to take into account. The 
development of OHSS requires reassessment of 
that risk. One such scoring system for ovarian 
stimulation is proposed in Table 4.
ADDITIONAL RISK FACTORS
It is of course true that if the process of ovarian 
stimulation increases the risk of thromboem­
bolism then, as with pregnancy, this will be sig­
nificantly enhanced by any other coincidental 
thrombophilic disorder or a previous history of 
thromboembolic disease, and in several of the 
case reports discussed above a thrombophilia 
was implicated along with other risk fac- 
tors19,42,45’50’73’75. These must be taken into 
account when considering the appropriateness 
of fertility treatment and the type of treatment 
considered. Discussion of these risks must come 
into the process of information counseling of the 
couple undergoing treatment, and serious con­
sideration given to thromboprophylaxis, not just 
for the ensuing treatment but also for any con­
sequent pregnancy. This includes a considera­
tion of multiple pregnancy and potential mode 
of delivery.
Table 4 Risk of thromboembolism in associa­
tion with ovarian stimulation: proposed scoring 
system
Risk factor Score*
Age > 3 5  years 1
Obesity 1
Poor mobility 1





Admission with OHSS or 3 or more days 
in absence of OHSS
2
* Score of 3 or more warrants thromboprophylaxis; 
VTE, venous thromboembolism
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SCREENING
Screening for thrombophilia would allow for 
further risk assessment; however, thrombophil­
ias are relatively rare: up to 1 in 20 are carriers 
for the commonest -  factor V Leiden96 -  but 
homozygosity is much rarer. The clinical and 
cost-effectiveness of screening is therefore 
debatable. Fabregues et a l 95 concluded that 
even screening for the commonest inherited 
thrombophilias (factor V Leiden and prothrom­
bin G20210A variant) is not cost-effective in this 
population, with a cost of nearly $500 000 esti­
mated to prevent one thrombotic episode asso­
ciated with factor V Leiden. The screening issue 
was thoroughly discussed in the debate around 
factor V Leiden and oral contraceptive use. The 
conclusion was, in that setting, where the risk 
was not high, that screening for thrombophilia
Table 5 Risks of anticoagulant treatment
was not worthwhile97. In addition, it was not 
clear how significant heterozygosity was, and it 
was possible that many women would be denied 
the use of the COCP spuriously as a result of 
testing. The relative risk of thromboembolism 
associated with fertility treatment, although dif­
ficult to assess in absolute terms, appears to be 
significantly lower than that with use of the 
COCP and certainly lower than that with preg­
nancy. Long duration of prophylactic doses of 
anticoagulants can in themselves be harmful 
(Table 5). It seems unreasonable to presume, 
therefore, that the benefits of screening may out­
weigh the risks in an otherwise low-risk popula­
tion. Where there is a history suggestive of 
thrombophilia, however, such screening is 
almost certainly warranted, since for example a 
significant family history and positive screen 


























Breast-feeding Safe Safe Safe
Monitoring required Yes Yes In pregnancy




Antiphospholipid syndrome is a condition char­
acterized by both arterial and venous thrombo­
sis. Whilst in this severe form it is rare, it can be 
manifest in young women by recurrent poor 
obstetric outcome, and is the only treatable 
cause of recurrent miscarriage98. Whilst the role 
of otherwise asymptomatic antiphospholipid 
syndrome in subfertility is more controversial, 
there may be an association. Women with the 
syndrome who have had successive pregnancy 
problems are treated in subsequent pregnancy 
with low-dose aspirin and heparin99, which can 
have a significant impact on the outcome of 
pregnancy. It is not clear what, if any role, 
asymptomatic and unrecognized antiphospho­
lipid syndrome may have on the risk of throm­
bosis in fertility treatment. It is possible that 
such a condition could be responsible for the 
arterial thromboses experienced in this popula­
tion. Thus, consideration of antiphospholipid 
syndrome constitutes part of standard throm­
bophilia screening when this is warranted, as 
well as in screening for recurrent pregnancy 
loss.
PROPHYLAXIS
Whilst short-term thromboprophylaxis is used 
to cover a particular risk period, as a general 
rule, if thromboprophylaxis for the period of fer­
tility treatment is considered, then extension 
into subsequent pregnancy is likely to be 
required. Similarly, if prophylaxis is required 
for pregnancy, then its commencement as early 
as possible is warranted, and that is likely to 
include preceding ovarian stimulation treatment.
Low-risk prophylaxis
Aside from the above, OHSS and pregnancy 
combined appear to constitute the greatest risk 
of thromboembolism to women undergoing 
assisted conception treatment. Pregnancy alone
does not require intervention, but the develop­
ment of OHSS necessitates further assessment. 
Our practice is to manage OHSS on an out­
patient basis as far as possible, admitting 
women to hospital if intravenous therapy is 
required, if there is significant ascites warrant­
ing paracentesis or if the woman simply is not 
coping. In these situations, women are probably 
spending large periods of time resting, and are 
therefore accumulating significant risk factors 
for thrombosis. All women with a diagnosis of 
OHSS who require admission to hospital there­
fore receive a prophylactic dose of subcuta­
neous heparin throughout their admission, and 
treatment is discontinued usually on discharge. 
If they are clinically improved but retain a sig­
nificant degree of abdominal distension by fluid 
and are pregnant then this may be continued 
after discharge until the OHSS, prolonged by 
pregnancy, has resolved.
Prophylaxis for high risk
Where a woman has a personal history of 
venous thrombosis, then it is incumbent upon 
the practitioner to ensure that appropriate meas­
ures are taken to avoid recurrence. In this situa­
tion, unless there was an obvious provocative 
and temporary risk factor, the decision is proba­
bly clear-cut, and for any woman undergoing 
superovulation, prophylactic doses of heparin 
should be considered for the duration of treat­
ment and into pregnancy100,101. Where there has 
been a specific episode contributing to the pre­
vious thrombosis, prophylaxis for pregnancy 
may be withheld and thus is probably not nec­
essary preceding fertility treatment unless there 
are other risk factors. The development of OHSS 
during such treatment warrants review of that 
decision.
Prophylaxis for thrombophilia
The consideration of thromboprophylaxis is 
more complicated when there is a known 
thrombophilia, since, as has been discussed,
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screening for the condition is not advocated in 
otherwise asymptomatic women without a per­
sonal or significant family history. It is difficult, 
therefore, in this situation to recommend pro­
phylaxis for all women who incidentally test 
positive but have no other risk factors except 
planned fertility treatment and anticipated preg­
nancy102. The need for pretreatment prophy­
laxis then depends on the type of throm­
bophilia, and, if inherited, the zygosity, as it 
would in pregnancy.
The risk of thrombosis is greatest in women 
who are homozygous for an inherited disorder, 
are heterozygous for more than one throm­
bophilia or have ATIII deficiency11. In these sit­
uations thromboprophylaxis would usually be 
offered for pregnancy, and should probably 
therefore also be offered for ovarian stimulation. 
In lower-risk situations, for example heterozy­
gosity for factor V Leiden, thromboprophylaxis 
would perhaps be offered only in the presence 
of other significant risk factors such as a family 
history, and considered in older or obese 
women100-102.
Other measures
Whilst the value of graduated stockings in 
thromboprophylaxis is uncertain, it is our prac­
tice to provide these to women admitted to hos­
pital with OHSS.
DIAGNOSIS OF THROMBOEMBOLISM
Thromboembolism may of course present as a 
cause of sudden death. A large pulmonary 
embolus or significant intracranial arterial 
thrombosis may be the first sign of the condi­
tion. A high index of suspicion should be main­
tained in any sudden collapse of a young 
woman undergoing fertility treatment, since 
only by prompt treatment in that situation in an 
intensive-care setting may the outcome be 
improved. Where the presentation is less sud­
den, a suspicion of thromboembolism is raised 
initially by unusual symptoms in such women. 
The woman may complain of unilateral limb 
pain or swelling, or, in the case of neck throm­
bosis, neck stiffness. In arterial thrombosis there 
may be symptoms associated with ischemia, 
although if intra-abdominal this may be difficult 
to elucidate. In the case of intracranial thrombo­
sis neurological sequelae may be present. Where 
there is a suspicion of venous thrombosis, exam­
ination may reveal swelling, skin discoloration 
and limb warmth and tenderness. Some form of 
imaging is generally necessary to confirm and 
assess the thrombosis. First-line for venous 
thrombosis is ultrasonography, including occlu­
sion ultrasound and Doppler studies. The inter­
pretation of negative results depends upon the 
history and considered likelihood of DVT103 
(Table 6). If the likelihood of thrombosis is high, 
further imaging may be of benefit -  venography 
remains the gold standard for diagnosis of 
venous thrombosis -  and ventilation with or 
without perfusion scan is used for confirmation 
of pulmonary embolism, but may not be consid­
ered necessary in a woman with positive ultra­
sound results and chest symptoms. Computer­
ized tomography (CT) scanning and magnetic 
resonance imaging (MRI) have a role in evaluat­
ing more complex situations, for example to 
confirm vena cava involvement, or arteriogra­
phy for arterial thromboses. Where ultrasonog­
raphy is negative and suspicion of thrombosis is 
low, no further action need necessarily be taken; 
however, if symptoms persist, a repeat assess­
ment is of value a few days later100. This strategy 
is recommended for pregnant women with a 
suspicion for thrombosis, and is easily transfer­
able to the fertility patient100. The assessment of 
blood D-dimer (fibrinogen breakdown product) 
concentration has been lauded as a useful 
adjunct to initial ultrasound assessment and 
even as a screening test prior to undertaking 
imaging procedures104. The concentration of 
D-dimer rises physiologically in pregnancy, 
however, and this appears to be paralleled in
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Table 6 Clinical probability of diagnosis of venous thrombosis based on reference 103
Risk fa  ctor Score  *
Prior history of DVT 1
OHSS and/or pregnancy 1
Paralysis, paresis (recent plaster or immobilization of lower limb) 1
Localized tenderness 1
Entire limb swollen 1
Calf swelling > 3 cm compared with contralateral limb 1
Pitting edema 1
Collateral superficial veins 1
Alternative diagnosis as likely or greater than DVT -2
* Score of -2  to 1 =  low risk, 2 or more =  high risk; DVT, deep venous thrombosis
OHSS81. A raised concentration, whilst other­
wise indicative of pathology, cannot therefore be 
interpreted as such in these situations. D-dimer 
in the normal range, however, effectively rules 
out significant thrombus formation even in 
pregnancy11.
TREATMENT
As has been discussed, the occurrence of throm­
boembolism in fertility treatment is rare. When 
diagnosed, however, it requires rapid and expert 
intervention. The mainstay of treatment is of 
course anticoagulation to prevent extension of 
the primary clot, reduce the risk of embolism 
and facilitate its organization such that recanal­
ization of the affected vessel can occur. With 
appropriate imaging techniques the extent of the 
thrombus can be assessed, which allows for 
symptoms to be accounted for, and the possible 
risks and effects of embolism to be considered. 
Where this risk is significant, operative inter­
vention may be considered by means of 
thrombectomy, as may be necessary in arterial
thrombosis, or insertion of an upstream 
‘umbrella’ in the case of inferior vena cava 
thrombosis105. Thus, the diagnosis and treat­
ment of thromboembolism requires a multidis­
ciplinary decision-making approach including 
the radiologist and potentially also the vascular 
surgeon.
In the case of otherwise uncomplicated 
venous thrombosis, standard treatment would 
involve anticoagulation with heparin, initially 
intravenously and followed by subcutaneous 
administration of a maintenance dose of either 
unfractionated heparin monitored using APTT 
or, more conveniently, an appropriate therapeu­
tic dose of one of the low-molecular-weight 
(LMW) heparins. Conversion to a therapeutic 
dose of warfarin, monitored by International 
Normalized Ratio (INR) assessment, is an alter­
native suitable for women where there is no 
associated pregnancy. A therapeutic dose is con­
tinued for 6 months and consideration then 
given to its cessation105.
In the event of pregnancy heparin is used, 
since there are significant potential adverse 
effects of warfarin to the fetus100. LMW heparin
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is the preferred choice for maintenance therapy 
in pregnancy, and is considered to be as safe as 
unfractionated heparin in this setting. The 
advantage of LMW heparin is that it can be 
given as a standard dose in relation to the 
woman’s weight, and does not require such rig­
orous monitoring. As with heparin the thera­
peutic dose is continued for about 6 months, but 
should be extended into the postpartum period. 
It can be readily reduced for delivery and rein­
stated immediately after delivery. Conversion to 
warfarin maintenance may be considered fol­
lowing delivery, and either drug is considered 
safe to the breast-feeding infant100.
Graduated compression stockings should be 
worn by all women undergoing treatment for 
DVT, as there is evidence that they may reduce 
the risk of prolonged symptoms106. The effect of 
some form of similar compression on the long­
term symptomatology associated with upper- 
limb thrombosis is unknown107.
LONG-TERM OUTLOOK
The morbidity associated with thromboem­
bolism depends on its site, severity and treat­
ment. In the case of intracerebral arterial throm­
bosis, whilst in the long term recovery may be 
good, the process of rehabilitation may be pro­
longed, and the woman may well be left with 
some form of disability or weakness as a result 
of the stroke. Successful treatment of venous 
thrombosis does not necessarily exclude the 
possibility of long-term problems. Post- 
thrombotic syndrome refers to the residual 
effects of vascular occlusion, and includes 
altered sensation, heaviness and reduced mobil­
ity in the limb. It occurs in both lower- and to a 
lesser extent upper-limb venous thromboses107 
and can be progressive (at least in the first 2 
years), prolonged and debilitating, culminating, 
for example, in some cases in venous ulceration.
Finally, of course, upon completion of thera­
peutic treatment for thrombosis, consideration
needs to be given to the risk of recurrence and 
long-term prophylaxis. Whilst it may be consid­
ered that OHSS with or without pregnancy is 
explanation enough for thrombosis occurring, it 
is necessary to assess the woman’s risk in more 
detail. However, if there are other obvious fac­
tors such as obesity these should be addressed 
in this situation. Whilst it will not affect man­
agement of the primary thrombosis, it is neces­
sary to ensure that such women have had 
thrombophilia screening performed. A positive 
result not only allows a fuller assessment of her 
ongoing risk, but will affect the recommenda­
tions made regarding prophylactic treatment in 
either similar or different circumstances in the 
future. A significant result (for example confir­
mation of homozygosity where the risk is high) 
may also have an effect on her decision to pur­
sue further fertility treatment and indeed preg­
nancy. A positive result for inherited throm­
bophilia also has implications for other 
members of her family, which needs to be dis­
cussed.
CONCLUSION
There is a small but important risk of venous or 
arterial thrombosis in women undergoing ovar­
ian stimulation for fertility treatment, which is 
heightened by both OHSS and pregnancy. 
Whilst most women are at low risk of throm­
boembolic disease at the outset of treatment, 
this risk needs to be considered and reviewed as 
clinical conditions change. Women who have 
known risk factors for thromboembolism should 
be assessed for thromboprophylaxis, and, if con­
sidered appropriate, it should be instituted at 
the start of treatment and probably maintained 
throughout the subsequent pregnancy. OHSS 
brings with it a number of factors which 
increase the likelihood of thromboembolism, 
and whilst the pathogenetic links have yet to be 
fully determined, when women are hospitalized 
with this condition consideration should be
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given to appropriate thromboprophylaxis even 
in the absence of other risk factors.
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CHAPTER 6
Anonymous reports of lethal cases of 
ovarian hyperstimulation syndrome
Didi Braat, Rob Bernardus and Jan Gerris
INTRODUCTION
Severe ovarian hyperstimulation syndrome 
(OHSS) in patients undergoing hormonal treat­
ment for multiple follicular recruitment prior to 
in vitro fertilization (IVF) has been discussed 
extensively in the literature. Iatrogenic lethal 
outcome of these elective treatment modalities, 
however, is sparsely found: is this due to the 
very low incidence or due to (for obvious rea­
sons) unwillingness to report it? It goes without 
saying that the impact of this most serious com­
plication is devastating to the partners and fam­
ilies, as well as to the medical professionals con­
cerned. Should we not learn from each other? 
Do we have to wait a generation before long­
term observational studies may become avail­
able, and should we, medical professionals, 
remain blind and/or deaf to reports that appear 
meanwhile in the lay literature?
When trying to write this chapter, the aim 
was to identify lethal cases for which as many 
objective data as possible could be collected. 
This has proved difficult. Questionnaires were 
sent to Dutch and Flemish gynecologists asking 
for anonymous information regarding lethal 
cases of OHSS. A letter asking for information 
was published in Human Reproduction1. The 
primary aim was to obtain information as to
what had been the primary cause of death in 
these cases, and whether some intervention 
could have prevented the patient from dying. 
Reactions to these requests were scant and 
mostly negative.
In total, 11 published cases could be identi­
fied, three in The Netherlands, two in Belgium 
and six cases in other countries, published over 
recent decades; four more cases have been pub­
lished in the lay literature.
Between 1992 and 1997, three lethal cases 
occurred in IVF treatments in The Netherlands 
that can be attributed to the stimulatory phase. 
In an effort to initiate transparency by sharing 
these shocking experiences, as well as possible 
measures to prevent recurrence, we report these 
lethal cases. The same holds for the two cases in 
Belgium and for the six previously published 
cases.
LETHAL CASES ORIGINATING IN THE 
NETHERLANDS
Patient 1 (1992)
The patient was 28 years old and had primary 
infertility because of polycystic ovarian syn­
drome (PCOS). Eventually, IVF was initiated
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owing to the extreme difficulty in obtaining 
mono-ovulatory induction of ovulation. The 
patient was treated with a combination of 
gonadotropin-releasing hormone (GnRH) analogs 
and gonadotropins. There was a discrepancy 
between the number of follicles and the number 
of oocytes retrieved. Two days after egg collec­
tion the patient was admitted to hospital 
because of dyspnea, nausea and general malaise. 
Because of the risk of OHSS all embryos were 
frozen. One day later she was transferred to the 
intensive-care unit because of adult respiratory 
distress syndrome (ARDS), oliguria and 
hydrothorax. Unfortunately, she developed mul­
tiorgan failure and died 29 days after oocyte 
pick-up (OPU).
Patient 2 (1994)
This was a 35-year-old patient who had been 
suffering from primary infertility for 9 years. 
She had PCOS. She had undergone ovulation 
induction for many cycles, some of which had 
been ovulatory and some anovulatory. After 12 
ovulatory cycles, of which the last 6 cycles were 
combined with intrauterine insemination (IUI), 
IVF was initiated. The woman had a normal 
body mass index (BMI) (24.2).
Ovarian hyperstimulation was combined 
with GnRH analogs. She started with 225IU of 
gonadotropins for 7 days. This dosage was 
changed to 150 IU from day 8 onwards, because 
of the growth of many follicles. Four days later 
the dominant follicle reached 19 mm, and the 
next day 10 000IU of human chorionic gonado­
tropin (hCG) was administered. No serum estro­
gen levels were measured. Follicular aspiration 
was technically difficult because of many small 
follicles. Seventeen oocytes were obtained. The 
day following egg collection the patient com­
plained of abdominal pain. Ultrasonography 
revealed multicystic ovaries (6 cm in diameter) 
and a small amount of fluid. The next day she 
was admitted to hospital because of an aggrava­
tion of complaints and symptoms. The ovaries
were 7 cm in diameter and there was a large 
amount of ascites. She became dyspneic and 
was transferred to the intensive-care unit. No 
embryo transfer was performed, and all (16) 
embryos were frozen. She developed ARDS and 
artificial respiration was applied. Two days later 
electrolytes and kidney function tests were nor­
mal; antibiotics were started because of suspi­
cion of a lung infection. One day later, however, 
kidney function deteriorated and the patient 
was transferred to a tertiary center, where she 
died because of multiple organ failure. Her 
decease was 25 days after egg collection. 
Autopsy revealed 11 of ascitic fluid, no pleural 
effusion and ovaries of size less than 10 cm in 
diameter.
Patient 3 (1997)
This patient was 40 years of age. She had had 
primary infertility for 3 years due to a tubal fac­
tor, for which IVF was indicated. She started her 
first IVF cycle with a short GnRH analog proto­
col combined with gonadotropins. She was 
given 200 IU for 7 days from cycle day 3 
onwards, followed by 150 IU for 4 days, and 
subsequently 50 IU for 1 day. That same 
evening, 5000 IU hCG was administered. At 
oocyte collection, 29 follicles (of which 17 were 
> 16 mm) were aspirated, resulting in 11 
oocytes. Serum estradiol levels were 2.1, 7.7 and 
21.9nmol/ml (656, 2406 and 6844pg/ml) on 
cycle days 10, 12 and 14, respectively.
One day later the patient complained of 
abdominal pain. Ultrasonography revealed mul­
ticystic ovaries (8.8 x 8 x 7 cm and 8 x 7 x 5  cm in 
diameter) and a small amount of peritoneal 
fluid. Because of threatening OHSS, daily visits 
were arranged. However, the next morning she 
was admitted to hospital because she felt worse. 
According to her husband, she sometimes acted 
confused. There were no complaints of 
headache, nor of an increase of abdominal pain. 
Blood pressure was 130/90 mmHg, pulse rate 
100, temperature 36.7°C. No signs of an acute
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abdomen were found. Prophylactic heparin 
treatment was started. Three hours later the 
patient lapsed into a coma. Angiography 
revealed occlusion of the A. vertebralis dextra, 
A. basilaris and Aa. cerebri posteriores. Selec­
tive streptokinase was administered, but 
although this resulted in passage of the A. basi­
laris, the Aa. cerebri posteriores remained 
obstructed. The patient died on the third day 
after OPU. Autopsy was refused. A family his­
tory of thromboembolic disease was negative; 
retrospective analysis of thrombophilia factors 
turned out negative for factor V (Leiden), pro­
teins C and S and antithrombin III.
LETHAL CASES ORIGINATING IN 
BELGIUM
Patient 1 (1995)
The report regarding this patient is constructed 
on the basis of personal remembrance of one of 
the physicians who was working in the treating 
center, called here center B. The patient died in 
another hospital in another city (called here 
center A), and the reporting physician learnt of 
the patient’s death by pure accident a long time 
after the events took place. Notwithstanding, 
several efforts at obtaining a written report of 
what went wrong, and direct telephone contact 
with the physicians who treated the patient after 
she was admitted to their hospital, did not until 
now result in any manner of formal report. The 
patient was a Caucasian GiPa who was 41 years 
of age at the time she consulted center A for sec­
ondary infertility. She had been trying to con­
ceive since 1992 (3 years). She had already been 
treated by ovulation hyperstimulation and with 
one IVF cycle, in which no fertilization had 
occurred. Routine sperm characteristics were 
within normal values. In center B, intracyto- 
plasmic sperm injection (ICSI) was proposed, 
accepted and performed, and led to a pregnancy 
ending in clinical miscarriage at 8 weeks of
amenorrhea and the patient’s demise. The fatal 
cycle was her second treatment cycle. It was car­
ried out with the classical long protocol, using 
buserelin for 3 weeks followed by stimulation 
with 300IU of human menopausal gonado­
tropin (hMG). On the day of hCG administra­
tion, serum estradiol was 3921pg/ml, and the 
day after hCG it rose to 7200pg/ml. On the sub­
sequent day of oocyte collection, serum estra­
diol dropped to 2331pg/ml and a total of 26 
oocytes were collected, of which 20 were in 
metaphase II. Fourteen of these were normally 
fertilized after ICSI; four embryos were trans­
ferred and another eight could be cryopre- 
served. Eight days after transfer, serum hCG was 
13 mlU/ml with an estradiol level of 3115 pg/ml. 
Nothing more was heard from the patient, and it 
was not until much later that the physicians at 
center B learned that the patient had died. 
According to indirect and anonymous informa­
tion obtained at center A, the patient had been 
admitted at 6 weeks of pregnancy with severe 
OHSS. The ovaries both had a diameter of 
> 1 0  cm and there was much ascites. She was 
treated by doctors from the department of inter­
nal medicine who administered diuretics. 
Transabdominal ascites puncture was per­
formed by a gynecologist. During the puncture, 
the patient developed hypovolemic shock, from 
which she did not recover. Via another source of 
information, we learned that as much as 41 of 
ascitic fluid had been collected over a short 
period of time (1 h).
Patient 2
The same center B has in its records one other 
lethal case of which, however, nothing is known 
apart from the fact that the patient died. She was 
a foreign patient who died in her country of ori­
gin. Taken together, and for what it is worth, two 
patients from this center died in a cohort of 
>  55 000 IVF/ICSI cycles spanning an activity 
period of 22 years (incidence 1:27 500).
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CASE REPORTS FROM THE 
LITERATURE
To our knowledge, in the literature only six 
other cases of lethal OHSS are reported, with 
four additional case reports available in the lay 
literature.
The first mortal case was published by 
Gotzsche in 1951 (cited by Esteban-Altirriba2). 
The patient was a 28-year-old woman with sec­
ondary amenorrhea who was treated with uri­
nary menopausal gonadotropins and human 
chorionic gonadotropins according to the then 
prevailing scheme proposed by Rydberg, who 
was also the first, in 1942, to attract attention to 
the existence of what was the called massive 
hyperluteinization o f the ovaries (cited by Este­
ban-Altirriba2). Six days after administration of 
hCG, the now well-known acute abdominal dis­
tension syndrome developed and became so 
pronounced that a surgical intervention was 
performed. Both ovaries were enlarged to the 
size of the fist of a man and appeared necrotic. 
There was a large quantity of serosanguinolent 
fluid in the abdominal cavity. Colic adhesions 
had formed around several large blood clots. 
The ‘cysts’ were partially  removed but the 
patient died soon afterwards.
The second mortal case was published by 
Figueroa-Casas in 19583. This was a patient 
who, after three failed treatment cycles, 
received huge doses of hMG (a total dose of 
15 000IU) and hCG (45 000IU). She developed 
the typical OHSS syndrome, showing abdomi­
nal distension compatible with a pregnancy of 
20 weeks’ amenorrhea. Put to rest with antispas- 
modic and antibiotic treatment, the patient 
remained stable. Further stimulation was con­
ducted during another 11 days, when the situa­
tion quickly became critical (nausea, tachycar­
dia, biliary vomiting, severe oliguria). It was 
decided to operate on the patient (under local 
anesthesia): 3.51 of a foul fluid were removed, as 
well as two hugely cystically enlarged ovaries;
the uterus was left in place. The patient died the 
next day of anuria.
A third dramatic case with death in the end 
was published by Mozes et a l 4. This patient 
died as the result of thrombosis of the carotid 
arteries leading to a deep coma.
Much later, another case of lethal OHSS was 
published relating to a 39-year-old woman who 
initially developed moderate OHSS5. After OPU 
she was drowsy, and she never regained full 
consciousness. She deteriorated quickly over a 
10-day period and died of hepatorenal failure. 
Retrospective review of her medical records 
revealed a history of hepatitis C with residual 
impairment of liver function.
Another recent case relates to a patient who 
died 11 days after OPU because of severe OHSS 
with cerebral infarction6.
The last published case report describes a 
28-year-old Japanese woman with PCOS7. 
Because of primary infertility she had under­
gone ovulation induction with 150IU hMG for 6 
days, followed by 5000 IU hCG. No evidence of 
ovulation was detected. Twelve days after the 
start of treatment she was admitted because of 
abdominal pain, possibly due to the enlarge­
ment of her ovaries. On ultrasound scan the 
right ovary measured 8.5 cm and the left ovary 
8.1 cm in diameter. Her blood analysis suggested 
moderate OHSS (hemoglobin 15.0 g/dl, hemat­
ocrit 43.9%). She was treated with dopamine, 
after which her condition improved. However, 
16 days after the start of hMG she suddenly 
developed respiratory arrest and she died of res­
piratory failure. On autopsy, 500 ml ascites and 
550 ml (right) and 320 ml (left) pleural effusion 
was found. There was massive pulmonary 
edema and intra-alveolar hemorrhage, without 
any evidence of pulmonary thromboembolism.
Four other unpublished cases are mentioned 
on the Internet on a commercial website called 
LifeSite, describing itself as ‘a web portal dedi­
cated to issues of culture, life, and family.’ It has 
Catholic inspiration. At http://www.lifesite.net/ 
ldn/2005/apr/05041408.html, the four cases are
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mentioned to the lay public. A professional 
report on these cases could not be tracked.
They include one woman who died in 1996 
in the USA and whose death was reported by 
the Centers for Disease Control (CDC). She died 
from intracranial hemorrhage supposedly due to 
IVF-induced OHSS. Another woman seems to 
have died in 1995 in New Zealand as the result 
of an OHSS-triggered cerebral embolism. 
Another 32-year-old Irish woman died in 2004 
as the result of adult respiratory distress syn­
drome arising as a complication of OHSS. Most 
recently, a 33-year-old UK woman collapsed at a 
bus-stop, and was disconnected from life sup­
port 5 days later after reportedly suffering a mas­
sive heart attack. Although it is difficult to see 
how this could have been typical OHSS, the 
woman’s death seems nevertheless related to 
thrombophilic complications elicited by hor­
monal treatment.
For the sake of completeness, it should be 
mentioned that in an Australian survey of mor­
tality in a cohort of IVF patients, Venn et al. con­
cluded that there were no more deaths than 
among women not treated with IVF8. In particu­
lar, no death in the cohort studied could be 
linked to OHSS.
WHAT CAN WE LEARN FROM THESE 
CASE REPORTS?
Dutch cases and the literature
All three Dutch women were hyperstimulated in 
an IVF setting, and they all had an early (3-7 
days after hCG) onset of OHSS, with rapid 
aggravation of symptoms. Two of the three 
patients in our report suffered from PCOS, as 
well as the Japanese woman from the literature. 
This is also probably true for the very early 
cases published in the 1950s. In both PCOS 
women there was a discrepancy between the 
number of follicles and the amount of oocytes. 
This may indicate that the real number of small
(and intermediate) follicles was higher than 
measured, and/or that not all follicles had been 
aspirated. It is known that especially the num­
ber of intermediate (10-14 mm in diameter) fol­
licles is important for the prediction of OHSS9. 
Monitoring of estradiol is lacking in our first two 
cases. Although monitoring with ultrasound is 
sufficient in most IVF patients, it may be helpful 
to predict OHSS in the case of high-risk women. 
Young (< 35 years), lean women and women 
with polycystic ovaries, as well as women who 
have had previous OHSS, are prone to develop 
OHSS. At the Capri European Society of Human 
Reproduction and Embryology (ESHRE) consen­
sus meeting it was concluded that individuals at 
high risk for developing the syndrome have 
estradiol levels >12.8nm ol/l (4000pg/ml) 
and/or > 3 5  follicles at the time of induced ovu­
lation10. The woman in case 3 did not have 
PCOS. Furthermore, she was 40 years old. How­
ever, the level of estradiol in case 3 had strongly 
increased from cycle day 12 to cycle day 14.
Based on the existing literature on severe 
OHSS, primary measures should involve knowl­
edge of risk factors in the individual patient, 
before treatment starts. In those PCOS patients 
who are difficult to stimulate with gonado­
tropins, other treatment modalities such as 
laparoscopic electrocautery of the ovaries11 or 
metformin as a (co)treatment should be consid­
ered, before converting to IVF. If there is an indi­
cation for IVF, the unpredictive nature of the 
ovarian response in PCOS patients must warrant 
an individually tailored, slow step-up (or even 
step-down) protocol of gonadotropin stimula­
tion. Monitoring of estradiol production on a 
routine basis is debatable, but may be advanta­
geous as an early warning sign. As there is no 
advantage of a higher dose of hCG for final fol­
licular maturation, a standard dose of 5000IU 
should be administered. In the case of threaten­
ing OHSS, discontinuation of the cycle should 
be considered by not providing hCG. Embryo 
transfer can be postponed in cases at risk, by 
freezing all embryos. A 7/7 days and 24/24 h
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availability of the clinic does not guarantee a 
good outcome, but will prevent further delay in 
diagnosing patients at risk.
Further to the recognition of risk factors 
associated with the OHSS, an awareness of the 
change in hyperstimulated patients into a 
hypercoagulable state12’13, most probably due to 
the hyperestrogenic condition, should always be 
present. Extreme vigilance for signs and symp­
toms of developing thromboembolism (venous 
or arterial) may change the course of events, 
when dealt with timely and properly. Patient 
number 3 acted confused; in retrospect, this 
phenomenon could have served as an early 
warning sign, which could have led to more 
diagnostic measures. A quest for familial throm­
boembolism in the patient’s history and for 
thrombophilia factors, when indicated, can lead 
to prophylactic measures.
Severe OHSS, if managed well, is ‘a self- 
limiting’ disease. However, the course of events 
in the presented cases detiorated rapidly and 
resulted in (multiple) organ failure, most proba­
bly due to the hypercoagulable state. Until the 
underlying pathophysiology in OHSS and 
thromboembolism is found and leads eventually 
to possibilities to identify women at risk, 
extreme suspicion of possible complications is 
mandatory in patients who undergo assisted 
reproductive treatments.
The reported cases have been discussed 
extensively by the Dutch Society of Obstetrics 
and Gynecology (NVOG). Although there is yet 
no reliable national complication register, it is 
agreed by all IVF specialists that all serious com­
plications are to be reported to the IVF working 
party of the NVOG. Since 1998 there has been a 
national guideline, ‘OHSS’12.
Today, we are more aware of the risks of 
ovarian hyperstimulation, especially in women 
with PCOS. To our best knowledge, since 1997, 
no lethal cases of OHSS have occurred in The 
Netherlands.
Belgian cases
If anything can be learned, it is that other doc­
tors apart from those working in an IVF unit 
should be aware of the existence and the poten­
tial severity of OHSS. It is the conviction of the 
authors of this chapter that in severe cases, it is 
mandatory to refer the patient to the center 
where the patient was primarily treated for her 
infertility, or at least to a hospital where such a 
center and the expertise with OHSS exist. Per­
haps it can also be underlined that ascitic fluid 
should not be evacuated too quickly. Patients 
usually experience a marked subjective relief 
even after the removal of a small quantity of 
fluid, and there is no need for quickly losing 
large volumes.
Recently, a guideline on OHSS was issued by 
the Reproductive Working Group of Flanders. It 
can be surmised that, in most countries, such 
guidelines exist and can often be found on the 
Internet. The short form of the planned OHSS 
guideline of the ESHRE is given in the Appendix 
to this chapter.
THE IMPORTANCE OF REGISTRIES
It is understandable but remains to be deplored 
that lethal cases of OHSS are almost never 
reported. It is impossible that the 11 cases 
which have been (summarily) identified should 
be the only ones that have occurred in recent 
decades. If three cases occur over a 10-year 
period in The Netherlands, i.e. over an esti­
mated 100 000 cycles, the incidence can be esti­
mated at 0.003%. Given an annual number of 
IVF/ICSI cycles worldwide of — 500 000, i.e. 
over a period of 10 years a total number of 
cycles of —5 000 000, this would mean —150 
lethal cases in the world over the past 10 years. 
This is only a very rough estimate, because the 
number of annual cycles has been rising 
steadily. This would come to one case in 33 333 
cycles. Brinsden et a7.14 estimate the incidence
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to be 1/500 000. In reality, the true incidence 
could be significantly higher.
The only way to obtain a better idea of the 
true incidence is to strive towards prospective 
registration of all fertility treatments (ovulation 
induction, IUI, IVF/ICSI), as well as of their 
most important complications. This chapter 
aspires no more than to create the awareness 
that, in the long term, such registries are 
unavoidable. It is unacceptable that young 
women should die while being treated for a 
problem that, in one case out of two, is not 
theirs.
For the issue of multiple pregnancy, centers 
worldwide have come a long way in registering 
the incidence of this most frequent complica­
tion. Expressing the efficacy of a center by an 
indicator called CUSIDERA (cumulative single- 
ton delivery rate) and its safety by another indi­
cator called CUTWIDERA (cumulative twin 
delivery rate) could be one way of reporting 
multiples, as suggested by Germond et a/.15.
In contrast, few countries ask their centers to 
report the incidence of OHSS, and if they do, 
lethal cases are not reported. Such reports could 
help in understanding the direct mechanisms of 
death as well as help in suggesting measures to 
prevent the death of these patients.
Moreover, before such a register of complica­
tions could have any usefulness (apart from cre­
ating unwanted reactions from an incompletely 
informed public), there must be unity of defini­
tion of OHSS, when it is mild, moderate and 
serious, and a guarantee of anonymity to avoid 
under-reporting. National and supranational 
registries, such as the American Society for 
Reproductive Medicine (ASRM), the European 
IVF Monitoring (EIM) program and the World 
Registry on assisted reproductive technologies 
(ART) should ask their accredited members to 
report all cases of severe OHSS and all cases of 
maternal mortality, whatever the cause of death.
Figure 1 Thrombi (arrowheads) in right arteria 
basilaris of patient who died of thromboembolic 
complications of OHSS. Courtesy of Dr R 
Bernardus, The Netherlands
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F Olivennes, J Gerris, A Delvigne and K Nygren
Primary risk factors before treatment
• Polycystic ovarian syndrome;
• Incomplete forms of PCOS:
High number of resting follicles: ^ 10 follicles of 4-10 mm in each ovary; 
Luteinizing hormone/follicle stimulating hormone (LH/FSH) ratio > 2; 
Hyperandrogenism;
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• Previous history of OHSS;
• Young age*;
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• Low body weight*;
• Allergies*.
• Scientific evidence to confirm these factors is weak.
Criteria for defining a patient as being at risk of OHSS during stimulation for IVF
• Serum estradiol value > 3000/4000 pg/ml:
No clear cut-off value;
Poor predictive value (8-73%);
Not a mediator as OHSS possible with low estradiol;
The slope of the estradiol rise is the main risk factor and of more importance than the 
maximum estradiol value;
• Follicle numbers > 20-25 in both ovaries:
No clear cut-off value (10-35);
Variation due to operator and technique;
• Other predictors not used as routine:
Vascular endothelial growth factor (VEGF) > 200 pg/ml.
Clinical diagnosis and staging
Most common symptoms and signs.
Clinical symptoms
• Lower abdominal discomfort;










• Pleural effusion (right > left);







• Hemoconcentration (increased hematocrit);
• Leukocytose (related to hemoconcentration);
• Low creatinine clearance;
• Low blood pressure;





3-7 days after hCG;
Related to the intensity of ovarian response;
More severe form.
Late forms:
12-17 days after hCG;
Related to fetal hCG secretion;
Milder but more prolonged.
Clinical classification:
Mild OHSS
Abdominal distension and discomfort (grade 1);
Grade 1 plus nausea, vomiting and/or diarrhea, ovaries 5-12 cm.
Moderate OHSS
Grade 2 and ultrasonic evidence of ascites (grade 3).
Severe OHSS
Moderate OHSS plus clinical evidence of ascites and/or hydrothorax or dyspnea (grade 4);




Any sign of severe OHSS.
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Follow-up of abdominal circumference;
Instruction to consult at any sign of complication;





Sonographic examination: ascites volume, ovarian size;
Thorax X-ray (if dyspnea);
ECG (to exclude pericardiac effusion);
Red and white blood cell count, electrolytes, renal function tests, liver function tests (mainly 




Intravenous administration of Ringer’s lactate solution;
First 24 h: 1500-3000 ml;
Subsequent days: amount of fluid amount depending on fluid balance;
Combination of Ringer’s lactate + dextrose 5% solution or sodium chloride 0.9% (saline) +  dextrose 
5% (standard) solution.
Plasma expanders
HES: hydroxyethyl starch 6% solution in isotonic sodium chloride solution;
Maximum daily dose: 33ml/kg in 250-500 ml per day, dropwise, slow administration to avoid lung 
congestion.
Albumin administration
Should be kept for a later stage, once hypoalbuminemia is proven, because of risk of hepatitis, exces­
sive albumin overload, renal function impairment and potential vial contamination. Administration 
is mainly important during drainage of ascites.
Daily dose: 25-75 g (100-300 ml) per day according to the severity of hypoalbuminemia and the total 
volume of ascitic fluid drained.
Anticoagulants





Hypercoagulability or thromboembolic history;
Uncorrected hemoconcentration after 48 h of the usual intravenous treatment.
Low-dose aspirin
For prevention of thromboembolic complication;
Patients who are immobilized because of obesity (not recommended if ascites drainage).
Ascites drainage 
Abdominally or vaginally;
Proposed if patient discomfort is important, or systematically, or when biological anomalies are not 
corrected by the usual intravenous treatment (persistent hemoconcentration and/or renal failure). 




Modern classification of the 
ovarian hyperstimulation syndrome
Zalman Levine and Daniel Navot
INTRODUCTION
Ovarian hyperstimulation syndrome (OHSS) is 
the gravest complication of so-called controlled 
(far too often uncontrolled) ovarian hyperstimu­
lation (COH)1. From a perspective of priorities in 
reproductive medicine in general, and assisted 
reproductive technologies in particular, OHSS is 
second only to high-order multiple birth on the 
list of adverse outcomes which need to be mini­
mized or completely eliminated.
NEED FOR CLASSIFICATION
Like many other diseases, OHSS exists in a clin­
ical spectrum. Some patients, at one end of the 
spectrum, exhibit only mild signs and symp­
toms of the disease; others, at the other extreme, 
require intensive management and may even be 
at risk for death from the disease2-6. Diseases 
that can manifest in a range of severity need 
classification systems for two reasons. First, if 
clinicians are to evaluate and treat patients with 
the disease, parameters must exist which can be 
applied to each patient to assess the extent of 
disease and to plan an appropriate management 
strategy. Just as congestive heart failure is clas­
sified based on the level of functional ability to
help clinicians determine whether the patient 
can be managed medically or should be placed 
on a heart-transplant list, so must OHSS be clas­
sified to help clinicians determine whether the 
patient should be managed supportively or 
intensively, medically or surgically, at home or 
in hospital.
Second, if clinical researchers are to study 
disease epidemiology and investigate various 
strategies for treatment and prevention, a uni­
form classification scheme will ensure consis­
tency by allowing researchers to speak in a com­
mon language about the disease and by enabling 
clinicians to apply the results of these studies to 
individual patients. Just as the revised Ameri­
can Fertility Society classification system for 
endometriosis enables standardized research 
into the disease and ensures the relevance of 
clinical trials for clinical practice, so must 
OHSS be classified to ensure uniform defini­
tions in clinical research and to maximize appli­
cation of the research to everyday clinical care.
CLASSIFICATION SCHEMES BY 
DISEASE SEVERITY
Over the past 25 years, several classification sys­
tems have been suggested to categorize OHSS
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better and disseminate uniform guidelines for 
prevention and treatment. Most of these classifi­
cation systems are based on the severity of the 
disease, which is in turn based on a combina­
tion of the severity of the patient’s symptoms as 
well as severity of the physical, laboratory and 
radiological signs of the disease (Table 1). Five 
major schemes have been suggested to classify 
OHSS.
Rabau (1967)
Although pregnant mare serum gonadotropin 
was used clinically as early as the 1930s to 
induce ovulation, the results of these early trials 
were disappointing. Gonadotropin treatments 
began to enter the clinical armamentarium in
1958, when a combination of follicle stimulating 
hormone derived from cadaveric human pitu­
itary glands and human chorionic gonadotropin 
(hCG) successfully induced ovulation and preg­
nancy7. With the use of these agents, and with 
the later introduction of clomiphene citrate8 and 
human menopausal gonadotropins9, experience 
with the spectrum of ovarian hyperstimulation 
syndrome unfortunately grew.
The original classification, suggested by 
Rabau et al. in 196710, categorizes the syndrome 
into six grades by levels of increasing severity. 
Grade 1 disease is defined by the presence of 
supraphysiological levels of estradiol and preg- 
nanediol, as measured by 24-h urinary excretion 
greater than 150 ng and 10 \ig, respectively.
Table 1 Classification of OHSS
Mild Moderate Severe Critical
Bloating Vomiting Massive ascites Tense ascites
Nausea Abdominal pain Hydrothorax Hypoxemia
Abdominal distension US evidence of ascites Hct >  45% Pericardial effusion
Ovaries ^ 5 cm Hct > 41% WBC > 15 000/mm3 Hct > 55%
WBC > 10 000/mm3 Oliguria WBC > 2 5  000/mm3
Ovaries >  5 cm Creatinine Oliguria or anuria
1-1.5 mg/dl Creatinine
Creatinine clearance > 1.5 mg/dl
^ 50 ml/min Creatinine clearance







US, ultrasound; Hct, hematocrit; WBC, white blood cell count; ARDS, adult respiratory distress syndrome
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Grade 2 adds to these laboratory measurements 
the presence of enlarged ovaries and, question­
ably, palpable cysts. Interestingly, Rabau did not 
define grades 1 and 2 as OHSS at all, and felt 
that these grades were expected by-products of 
ovarian stimulation and required no attention or 
treatment.
In the Rabau classification system, grade 3 
disease adds the presence of abdominal disten­
sion and definitively palpable ovarian cysts, and 
grade 4 includes vomiting and possibly diar­
rhea. To Rabau, patients with grades 3 and 4 
OHSS are at possible risk for future worsening 
and complications, and require observation but 
no intervention. Grades 5 and 6, in this system, 
require hospitalization with aggressive observa­
tion and intervention. Grade 5 is defined by 
fluid shifts and third spacing leading to ascites 
and hydrothorax, and grade 6 is defined by 
hematological changes in blood volume, blood 
viscosity and coagulation time.
Schenker (1978)
Schenker and Weinstein11 modified the Rabau 
classification system to group the grades into a 
less cumbersome mild/moderate/severe termi­
nology, but maintained the grading system as 
well. In the Schenker scheme, grades 1 and 2 are 
termed mild OHSS, and include the same defi­
nitions: urinary excretion of estradiol and preg- 
nanediol for grade 1, and enlarged ovaries with 
small cysts for grade 2. Grades 3 and 4 are 
termed moderate OHSS, and include abdominal 
distension for grade 3, and nausea, vomiting 
and/or diarrhea for grade 4. Grades 5 and 6 are 
defined as severe disease, including large ovar­
ian cysts and ascites and/or hydrothorax for 
grade 5, and hemoconcentration, increased 
blood viscosity and coagulation changes for 
grade 6.
Golan (1989)
While the Rabau and Schenker classification 
systems seemed at the time to be comprehen­
sive, they suffer from several drawbacks. First, 
they focus more on ovarian response, particu­
larly in the lower grades of the disease, than on 
the clinical syndrome. Second, they are difficult 
to incorporate into the clinical setting, as 24-h 
urinary hormones are not routinely measured. 
Third, they incorporate unnecessarily cumber­
some subdivisions; simple classification as 
mild, moderate and severe OHSS would be ade­
quately descriptive and more clinically useful. 
Finally, these schemes were developed through 
observation of women undergoing ovulation 
induction. More recently, with the evolution of 
assisted reproductive technologies (ART) and 
routine use of controlled ovarian hyperstimula­
tion (COH) in ART patients, the laboratory and 
clinical findings in the lower grades of the 
Rabau and Schenker classifications are rou­
tinely observed and may reflect not a syndrome 
but an acknowledgment that COH has indeed 
been achieved. Therefore, there was a need for a 
simpler, more clinically useful and more rele­
vant system.
Golan et al. in 198912 attempted such a revi­
sion of these older systems by classifying OHSS 
into mild, moderate and severe, eliminating hor­
mone measurements from the system, and 
including in the mild category clinical symp­
toms previously classified as moderate disease 
prior to the days of routine COH for ART. Golan 
maintains a grading scheme, defining grades 1 
and 2 as mild OHSS, grade 3 as moderate OHSS 
and grades 4 and 5 as severe OHSS. In the mild 
category, grade 1 includes abdominal discomfort 
and distension, and grade 2 adds enlarged 
ovaries to 5-12 cm and nausea, vomiting and/or 
diarrhea. For moderate OHSS, Golan introduces 
the use of ultrasound, defining ultrasound evi­
dence of ascites as grade 3, even if the degree of 
ascites is not detectable clinically. Severe OHSS 
features respiratory symptoms such as dyspnea 
and tachypnea and clinical evidence of ascites 
and/or hydro thorax as grade 4, and hemocon­
centration, oliguria, increased blood viscosity, 
coagulation abnormalities, hypotension and
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renal hypoperfusion as grade 5. Perhaps one of 
the most important innovations of the Golan 
system is the introduction of ultrasound as a 
tool in classifying OHSS, encouraging the use of 
this technology, already in widespread use in 
the monitoring of ovarian response, for the eval­
uation and monitoring of OHSS as well. The 
moderate form of OHSS includes significant 
ovarian enlargement (5-12 cm), and accompany­
ing symptoms such as abdominal pain, signifi­
cant bloating, nausea and diarrhea.
Navot (1992)
The major deficiency of the Golan classification 
scheme is the absence of a distinction between 
forms of the disease that are severe but not life- 
threatening, and forms that are critical and 
potentially fatal. If one of the major purposes of 
the classification scheme is to aid the clinician 
in appropriately managing the patient with 
OHSS, such a distinction would be of great clin­
ical import. Additionally, clinicians routinely 
assess the severity and course of OHSS with lab­
oratory measurements of hematological parame­
ters, electrolytes and renal function, yet the clas­
sification system does not address these widely 
used measurements in a quantitative way.
To correct these deficiencies, Navot et a l,13 
subdivided the ‘severe’ category into ‘severe 
OHSS’ and ‘critical OHSS’. According to the 
Navot scheme, patients with severe OHSS have 
variably enlarged ovaries, massive ascites with 
or without hydrothorax, a hematocrit greater 
than 45%, a leukocyte count greater than 15 000, 
clinically measured oliguria, serum creatinine 
1.0-1.5, creatinine clearance at least 50ml/min, 
laboratory evidence of hepatic dysfunction and 
anasarca. Patients with critical, life-threatening 
OHSS have a critically contracted blood volume 
and multiorgan failure. They exhibit more 
extreme forms of the same parameters, includ­
ing a hematocrit greater than 55%, a leukocyte 
count greater than 25 000, serum creatinine at 
least 1.6, creatinine clearance 50ml/min or less,
prerenal azotemia, thromboembolic phenomena 
and adult respiratory distress syndrome (ARDS).
Of note, unlike the earlier schema, the Navot 
system minimizes the significance of ovarian 
enlargement. In the past, ovulation induction 
was the primary cause of OHSS, and ovarian 
size may have been an important parameter in 
assessing the disease. However, now that much 
OHSS results from COH for ART, follicular aspi­
ration and iatrogenic follicular trauma during 
oocyte retrieval may minimize ovarian size even 
in the face of severe OHSS. With COH, anasarca 
can frequently coexist with relatively minor 
ovarian enlargement. Therefore, the Navot 
scheme downplays ovarian enlargement, relying 
more on the general clinical picture and on com­
mon laboratory parameters.
Rizk (1999)
In an attempt to subdivide further Golan’s 
severe category, Rizk and Aboulghar14 defined 
three grades of severe OHSS. Grade A severe 
OHSS features dyspnea, oliguria, nausea, vomit­
ing, diarrhea, abdominal pain, clinical or ultra­
sound evidence of ascites, hydrothorax and 
enlarged ovaries on ultrasound. Patients with 
grade A disease have a normal biochemical pro­
file. Grade B severe OHSS adds massive ascites, 
markedly enlarged ovaries, severe dyspnea, 
severe oliguria, increased hematocrit, hepatic 
dysfunction and elevated serum creatinine. 
Grade C OHSS, which features complications 
that Rizk feels can also occur in the setting of 
moderate disease, resembles Navot’s ‘critical’ 
category, with end-organ complications such as 
renal failure, venous thrombosis and ARDS.
Over the past decade, this Navot modifica­
tion of the prior classification systems has 
become the most widely used scheme in clinical 
practice and in research settings. It is compre­
hensive and logical, and we advocate it to be 
universally adopted for clinical evaluation as 
well as for academic investigation.
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CLASSIFICATION BY DISEASE ONSET: 
EARLY AND LATE OHSS
Since 1994, investigators15-17 have recognized 
that what is commonly called OHSS actually 
includes two distinct disease entities: OHSS 
that occurs 3-7 days after hCG triggering, and 
OHSS that occurs more than 10 days after hCG 
triggering. As a disease, OHSS seems to include 
these two distinct forms based on the timing of 
its onset, and can consequently be classified 
into early OHSS and late OHSS. Both forms of 
OHSS share a common pathophysiology; in 
both, hCG triggers granulosa cells to produce 
vasoactive substances which induce the capil­
lary permeability that yields the clinical seque­
lae of OHSS. What distinguishes the early and 
late forms of the disease is the source of the 
hCG. In early OHSS, the exogenously injected 
hCG drives the granulosa directly to secrete suf­
ficient vasoactive substances to produce the 
syndrome within 3-7 days, while in late OHSS, 
early pregnancy is responsible for the granulosa 
cell activity, as the implanting trophoblast pro­
duces increasing levels of endogenous hCG.
Clinically, these two entities ought to be dis­
tinguished, because they are distinct. Early 
OHSS, but not late OHSS, is dependent on ovar­
ian stimulation; higher peak estradiol levels and 
greater gonadotropin doses are correlated with 
an increased incidence of early OHSS, but not of 
late OHSS. Therefore, criteria related to ovarian 
response can be used to predict early OHSS, but 
not late OHSS. Early OHSS can occur in any 
stimulated cycle, while late OHSS occurs only 
in the setting of a pregnancy. Late OHSS is more 
likely to be severe; in fact, late OHSS may 
account for almost 70% of all cases of severe 
OHSS. Late OHSS can occur with either a sin­
gleton or multiple pregnancy. While some 
authors have suggested that multiple pregnancy 
has a stronger association with late OHSS than 
singleton pregnancy by virtue of higher tro­
phoblastic hCG production, a recent report
found an equal association of singleton and 
multiple pregnancies with late OHSS18.
Of interest, OHSS has recently been reported 
in several women with spontaneous pregnan­
cies19-21, and the cause of this OHSS seems to be 
a familial mutation in the follicle stimulating 
hormone (FSH) receptor, increasing its sensitiv­
ity to trophoblastic hCG. The mutation allows 
for constitutive stimulation of the FSH receptor 
by hCG, triggering the ovarian cascade responsi­
ble for OHSS. This form of OHSS clearly illus­
trates the distinction between early and late 
OHSS; these women did not have stimulated 
ovaries and did not have hCG triggering, yet 
developed OHSS due to endogenous production 
of hCG by the developing pregnancy. This spon­
taneous late OHSS in at least one report was 
severe, requiring hospitalization and intensive 
management. Whether FSH receptor mutations, 
or polymorphisms, play a role in the onset or 
severity of iatrogenic OHSS will require further 
research (see also Chapter 13).
SUMMARY
OHSS can be classified in various ways based 
on its severity and based on the timing of its 
onset. Any and all of these systems can be of 
both clinical and academic utility, helping to 
establish uniform standards for clinical research 
into the epidemiology, prevention and manage­
ment of OHSS and for the clinical care of a 
patient with OHSS.
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CHAPTER 8
Ovarian hyperstimulation syndrome 
in singleton and twin pregnancies
Diane De Neubourg and Jan Gerris
INTRODUCTION
The most important adverse effect of in vitro 
fertilization/intracytoplasmic sperm injection 
(IVF/ICSI) is the occurrence of multiple preg­
nancies. Due to the scale of this problem and the 
seriousness of the obstetric and neonatal com­
plications, multiple pregnancies remain the 
number-one complication of assisted reproduc­
tive technologies (ART). Although ovarian 
hyperstimulation syndrome (OHSS) is less fre­
quent, it is a potentially life-threatening condi­
tion for a young woman undergoing ART.
Ovarian hyperstimulation syndrome is an 
iatrogenic complication of the use of 
gonadotropins. The pathophysiology of the dis­
ease is poorly understood, but the condition and 
disease are related to estrogens, vascular 
endothelial growth factor (VEGF) and the luteal 
phase induced by luteinizing hormone (LH) or 
human chorionic gonadotropin (hCG). The syn­
drome is caused by a change in vascular perme­
ability by factors such as VEGF. This leads to a 
shift of fluid from the intravascular compart­
ment to the third space, causing ascites and 
pleural effusion. The consequences of this shift 
are hypovolemia, hypoproteinemia and hemo- 
concentration leading to hypercoagulability,
increased liver enzymes, elevated leukocytes, 
disturbance of electrolytes and renal failure.
It is well known that the development of 
ovarian hyperstimulation syndrome is related to 
the presence of hCG. The administration of hCG 
for ovulation induction in IVF/ICSI procedures 
can trigger ‘early-onset’ OHSS, whereas hCG 
from a developing pregnancy causes ‘late-onsef 
OHSS. This was first described by Lyons et al.1. 
These authors also suggested that in the case of 
late-onset OHSS, the risk of developing OHSS 
and the severity of the syndrome were related to 
the occurrence of multiple pregnancy1. The pro­
file and early pregnancy outcome of early and 
late OHSS have most recently been described by 
Papanikolaou et al.2. They describe a higher risk 
of preclinical miscarriage in the early OHSS pat­
tern, and a close association of late OHSS with 
conception cycles, especially multiple pregnan­
cies, when compared with non-OHSS cycles. 
However, it should be stressed that a median of 
two embryos were transferred in all analyzed 
subgroups.
The question of whether the transfer of only 
one embryo in a larger number of cycles might 
decrease the incidence of OHSS cases, through 
avoiding a number of twins, has never been 
investigated. Some authors have supposed that 
this would be the case, but data to show this to
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be effectively true are lacking. We actually 
investigated whether the introduction of single 
embryo transfer (SET) with its subsequent 
decline in twin pregnancies would result in a 
lower incidence of OHSS. It is helpful to realize 
that the population at risk for OHSS we are thus 
considering remains the same, i.e. the young 
woman with a good or even exaggerated ovarian 
response who previously received double 
embryo transfer and conceived with a high 
chance of twin pregnancy and who is now 
advised to have single embryo transfer.
DOES SINGLE EMBRYO TRANSFER 
RESULT IN LESS OHSS THAN DOUBLE 
EMBRYO TRANSFER?
Clinical research data with respect to 
the occurrence of OHSS in singleton 
and twin pregnancies in a program 
introducing elective SET
We analyzed the incidence of OHSS over a 7- 
year period (January 1998 until December 
2004), during which we gradually introduced 
SET into our IVF/ICSI program. The percentage 
of single embryo transfer increased from 13% in 
1998 to 63% in 2004; coincidentally, the mean 
number of embryos per transfer declined from 
2.26 to 1.41. The overall pregnancy rate 
remained stable at a mean of 31.3%, while the 
multiple pregnancy rate declined from 33.6 to 
9.2% (11.9% when monozygous pregnancies are 
included)3,4.
Patients were treated with the long 
gonadotropin-releasing hormone (GnRH) ago­
nist desensitization protocol, starting in the 
mid-luteal phase, with 6 x 100 jig of buserelin 
(Suprefact®; Aventis, Frankfurt, Germany) given 
intranasally for a period of 3 weeks. Ovarian 
stimulation was initiated using 150IU of 
Metrodin HP® (Serono, Geneva, Switzerland), 
Menopur® (Ferring, Copenhagen, Denmark), 
Gonal-F® (Serono) or Puregon® (Organon, Oss,
The Netherlands) given subcutaneously, except 
in patients with known poor response, where 
the starting dose was augmented to 225 IU. The 
criterion for hCG administration was the pres­
ence of at least three mature follicles with a 
diameter of 18 mm. Ten thousand IU of hCG 
(Profasi®, Serono, or Pregnyl®, Organon) were 
given intramuscularly exactly 37 h prior to 
oocyte pick-up. The IVF/ICSI procedure, 
embryo quality assessment and embryo transfer 
technique were performed as previously 
described5.
In brief, oocyte pick-up was performed vagi- 
nally under ultrasound guidance. Approxi­
mately 16-19 h after insemination/injection, 
normal fertilization was checked. On day 2, 
every embryo was scored for the total number of 
cells, the presence of anuclear fragments and 
multinucleated blastomeres. On day 3, embryo 
quality was again evaluated. Selection for 
embryo replacement was made according to 
embryo characteristics as elaborated previously 
by our team6. All transfers were performed on 
an out-patient basis using a Wallace embryo 
transfer catheter (Sims Portex Ltd, Hythe, Kent, 
UK), consisting of an inner catheter and an outer 
catheter.
In all cycles, the luteal phase was supported 
by vaginally administered micronized natural 
progesterone (200 mg three times a day, Utroges- 
tan®; Besins, Belgium). When pregnant, the 
patient continued the treatment until the first 
ultrasound scan. hCG was never administered 
in the luteal phase. When a patient was identi­
fied as being at risk for OHSS, in general two 
types of preventive measures were taken. When 
the serum estradiol level was s>4000pg/ml on 
the day of hCG administration, a reduced 
amount of 5000 IU hCG was administered rather 
than the usual 10 000IU. On the other hand, 
coasting was performed when serum estradiol 
levels were rapidly increasing and reaching a 
level of ^ 5000 pg/ml before a sufficient number 
of dominant follicles (;>18 mm) were present. 
Gonadotropin injections were withdrawn until
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serum estradiol levels dropped to <;3000pg/ml 
and follicles with a diameter s>18 mm were 
present7,8.
We used the criteria of Golan et al. to classify 
OHSS9. According to these criteria, patients 
with moderate to severe OHSS requiring bedrest 
or admission to hospital were marked in our 
database.
Student’s t test was used to evaluate statisti­
cal differences between continuous variables. A 
p  value <; 0.05 was considered significant. Confi­
dence interval analysis was performed to com­
pare the incidence of OHSS in singleton versus 
twin conception cycles.
Evolution of pregnancy rate, multiple 
pregnancy rate and incidence of 
OHSS
Over this 7-year period, 44 cases of OHSS 
occurred in 2882 cycles (1.52%). The incidence 
of ovarian hyperstimulation syndrome was
fairly stable over this period, varying between
0.5 and 2.4% with an average of 1.52% per 
cycle. The effect of the evolution of implemen­
tation of SET on the ongoing pregnancy rate, the 
multiple pregnancy rate and the incidence of 
OHSS is shown in Figure 1. Of the 44 cases of 
OHSS, eight cases occurred in a non-conception 
cycle during the first week after oocyte retrieval. 
Thirty-six cases of OHSS occurred in 906 con­
ception cycles (4.0%). There were 30 cases in 
727 singleton conception cycles (4.1%) and six 
cases in 157 twin pregnancy cycles (3.8%) (odds 
ratio 1.08, 95% confidence interval 0.44-2.64).
Analysis of cycle-related variables
We analyzed cycle-related variables in non­
conception cycles (early OHSS) and conception 
cycles (late OHSS). In the latter group a com­
parison was made between singleton and twin 
pregnancies. A total of 48 cases were analyzed 
(four cases from 2005 were also included).
Figure 1 Evolution of pregnancy rate, multiple pregnancy rate and incidence of OHSS
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These data showed no significant difference 
between the number of oocytes retrieved and 
the level of serum estradiol at the day of hCG 
administration (Table 1). However, the rank of 
the cycle in which OHSS occurred in twin preg­
nancies was significantly higher (cycle 3) than 
in singleton pregnancies (cycle 1.45)(p = 0.001). 
Also, the level of hCG on day 12 after day-3 
embryo transfer was significantly higher in con­
ception cycles leading to a twin pregnancy 
(247 ± 5 1 IU/1) compared with cycles resulting in 
a singleton pregnancy (154 ± 68 IU/1) (p =  0.002).
DISCUSSION
Over the 7-year period during which we regis­
tered the occurrence of OHSS, we did not detect 
any change in its incidence. The overall inci­
dence of OHSS is 1.5% per cycle with egg 
retrieval and 4% in conception cycles. We did 
not find a significant difference in the incidence 
of OHSS between singleton and twin pregnan­
cies. However, a significant difference could be 
detected in the serum levels of hCG on the 12th 
day after day-3 embryo transfer between single- 
ton and twin pregnancies, leading to the conclu­
sion that it is merely the presence of hCG rather 
than its level per se which is responsible for the 
development of OHSS. This is in contrast to 
publications that stated that late-onset OHSS is 
related not only to conceptions but to multiple
pregnancies1’2. Therefore, one cannot conclude 
that prevention of multiple pregnancies is an 
adequate measure to prevent OHSS, as sug­
gested by Orvieto10, nor that single embryo 
transfer can, at present, be considered a preven­
tion of OHSS. Cases of OHSS are, perhaps 
unfortunately, as frequent in pregnancies result­
ing from single embryo transfer as from two- 
embryo transfer.
There are no differences in cycle character­
istics for number of oocytes and serum estradiol 
levels between conception and non-conception 
cycles, either between singleton and twin preg­
nancies.
However, the rank of the cycle in which 
OHSS occurred was higher for twin than for sin­
gleton pregnancies, reflecting the change in 
embryo transfer policy where double embryo 
transfer with a risk for twin pregnancies occurs 
in cycles with a higher rank. This observation 
stands in line with the transfer policy in Bel­
gium, where a large proportion of first and sec­
ond IVF/ICSI cycles are single embryo transfer 
cycles, resulting in a predictable ‘shift’ of twin 
pregnancies from first cycles a couple of years 
ago towards third and higher-rank cycles at the 
present time.
This analysis of incidence of OHSS and 
cycle characteristics shows that the population 
at risk for OHSS has not changed. In general, 
these are patients with a good to even exagger­
ated ovarian response in their first cycles, with
Table 1 Characteristics of cycles with OHSS. Values are expressed as mean ± SD
Number o f 
OHSS cases
Rank 
o f the 
cycle







at day 12 
post-transfer
No conception 10 1.7 ±  1.1 4771 ± 2432 18.0 ±6 .7 0
Singleton pregnancy 31 1.4 ± 0 .9 ** 3592 ± 1769 15.3 ±  7.3 154 ± 6 8 *
Twin pregnancy 7 3 ± 1 .7 ** 3519± 1790 14.1 ±6 .6 247 ± 5 1 *
*p =  0.002, **p =  0.001, singleton vs. twin pregnancy; hCG, human chorionic gonadotropin
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a high chance of conception. These patients are 
offered single embryo transfer and, as previ­
ously shown by our group, the chance of con­
ception is not affected through this embryo 
transfer policy3,4. Therefore, it could be antici­
pated that the incidence of OHSS will not be 
affected if the occurrence of OHSS is not related 
to the development of multiple pregnancy.
As it is clear that the late form of OHSS is 
induced by the presence of hCG originating 
from the early pregnancy, it appears that merely 
the presence of hCG rather than its level is 
responsible for the occurrence of late OHSS11. 
Therefore, to reduce the incidence of OHSS, 
measures other than those mentioned here 
should be considered. Embryo transfer can be 
postponed until the blastocyst stage, to evaluate 
the symptoms in a patient with early presenta­
tion of OHSS12. Another possibility is to pro­
ceed with hCG administration and oocyte 
retrieval but to cancel the embryo transfer and 
freeze all the embryos13. The success of this pol­
icy largely depends on the results of the cryop- 
reservation program of the center.14 Recently, 
the introduction of GnRH antagonists seems to 
offer a good perspective for prevention of 
OHSS15. An important advantage of the use of 
GnRH antagonists is the possibility of using 
GnRH agonists for ovulation induction in the 
prevention of OHSS16.
This inevitably brings us to the considera­
tion of ‘friendly IVF’, providing that lower num­
bers of oocytes and embryos do not decrease the 
chance to present an embryo with a high 
implantation potential, thus maintaining the 
high pregnancy rates for SET. Some of the 
investigated protocols appear to be very 
promising17,18.
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The ovarian hyperstimulation syndrome 
(OHSS) is characterized by an increase in size of 
the ovaries, with the appearance of multiple 
cysts, and by an increase in the vascular perme­
ability of ovarian vessels causing ascites, pleural 
effusion and sometimes pericardiac effusion. 
The severe form is also accompanied by elec­
trolyte disturbances, as well as by cardio­
pulmonary, hepatic, renal and hemodynamic 
disturbances, leading to an increased thrombo­
embolic risk. The dominant finding is bilateral 
multicystic enlargement of the ovaries. Morpho­
logical examination of these ovaries reveals 
multiple corpora lutea, follicle cysts and mas­
sive edema of the ovarian stroma. It has been 
suggested that formation of the cysts is a direct 
reaction to stimulation with gonadotropins, 
since similar ovarian observations exist in other 
conditions associated with high levels of 
endogenous gonadotropins such as hyda- 
tidiform mole, choriocarcinoma and multiple 
pregnancy.
Animal experiments have shown that the 
main pathological feature of OHSS is an 
increase in capillary permeability, as demon­
strated in a rabbit experimental model using 
intravenous dyes1. Furthermore, angiogenesis is
also enhanced in OHSS. It has been demon­
strated in animals that the amount of fluid shift­
ing from the intravascular space into the abdom­
inal cavity depends on the presence of the 
ovaries. The latter, however, do not have to be in 
the peritoneal cavity2. Neither estrogen nor a 
progestin in excessive amounts caused ascites in 
female rabbits1. Moreover, OHSS cannot be 
induced in male animals or in men treated with 
large doses of gonadotropins.
Consequently, the following principles can 
be considered as established: first, the presence 
of an ovary is a compulsory condition for OHSS; 
second, a vasoactive mediator secreted by the 
ovaries plays a major role in the development of 
OHSS, after ovarian stimulation. This factor is 
probably secreted into the peritoneal cavity and 
liberated in the systemic circulation where it 
can exert its action.
Some investigators have hypothesized that 
ascites in women with OHSS contains this 
chemical ovarian product responsible for OHSS. 
This hypothesis has been confirmed by in vitro 
permeability experiments, using follicular fluid 
and ascites of patients suffering from OHSS3.
Subsequently, much research has been 
directed toward identifying this mediator either 
in the blood or in the ascites of patients with
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Estrogens, prolactin and 
prostaglandins
Estrogen is a marker of ovarian response but is 
not the causative agent of OHSS, since the 
administration of estradiol does not induce 
OHSS. Some authors have suggested other 
causal candidates such as prolactin and 
prostaglandins, but no evidence of a directly 
causative role of these substances has been 
demonstrated so far4.
Activation of the ovarian 
prorenin-renin-angiotensin system
There is a proven contribution of the prorenin- 
renin-angiotensin system (RAS) to the process 
of OHSS. It has been established that some fac­
tors of the RAS are secreted by the ovary, and 
that the RAS process can be influenced by some 
well-known risk factors associated with OHSS 
such as human chorionic gonadotropin (hCG). 
The systemic activation of the RAS during 
hemodynamic perturbations related to OHSS 
has also been documented. What remains to be 
established is whether an imbalance in the RAS 
is a ‘primum movens’ in the pathogenesis of 
OHSS or whether it is a catalyst of the hemody­
namic degradation that occurs in OHSS. Alter­
natively, the activation of RAS may be a homeo­
static response to hypovolemia during OHSS.
Cytokines
Studies of cytokines produce contradictory 
results, even in apparently similar populations, 
affected by OHSS for different reasons.
These low-molecular-weight proteins are 
active in extremely low concentrations, and can
exert their influence in an autocrine, paracrine 
or endocrine fashion. Cytokine activity is influ­
enced by the functional status of cytokine recep­
tors, and the presence of cytokine inhibitors, 
soluble receptors and binding proteins. Never­
theless, most data converge to show that posi­
tive modulators of the early phase of inflamma­
tion (interleukins (IL) IL-1, IL-2, IL-6, IL-8, IL-18, 
tumor necrosis factor (TNF) and vascular 
endothelial growth factor (VEGF) are increased 
during the early stage of OHSS, and that 
immunosuppressive and anti-inflammatory 
cytokines (IL-10) tend to be lower in OHSS 
patients before treatment. One may hypothesize 
that patients with OHSS suffer from an intrinsic 
deficiency in their immune response, and that 
this differentiates them from those at high risk 
for OHSS who do not develop the condition.
Allergy cytokines and histamine
Because the pathophysiological changes during 
OHSS resemble an excessive inflammatory 
response, the possibility of hyperreactivity of 
ovarian mast cells in patients suffering from 
OHSS has been suggested. With regard to 
allergy, histamine and histamine blockade have 
been studied: histamine blocking has been 
shown to prevent the occurrence of OHSS in the 
rabbit model. However, OHSS in these rabbits 
did not involve antigen-antibody complexes, 
suggesting that antihistamine blocking of OHSS 
could take place directly at the ovarian level. 
Another rabbit study showed no difference in 
either histamine levels or ovarian mast-cell con­
tents between OHSS and controls. Conflicting 
results were obtained for the inhibition of 
ascitic fluid formation and ovarian enlargement 
using H-l receptor blockers4.
Vascular endothelial growth factor
Vascular permeability and the subsequent 
development of ascitic fluid are thought to be 
induced by follicular fluid. The ovarian produc­
tion of VEGF is demonstrated by the fact that, in
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most studies, higher concentrations are found in 
the follicular fluid than in the serum. Most, but 
not all, observations report an increase in 
plasma or serum VEGF concentrations in OHSS 
patients at the time of ovulation. In addition, 
hCG administration enhances the mRNA 
expression of VEGF by luteinized granulosa 
cells in a dose-dependent manner, explaining 
why the use of hCG in in vitro fertilization (IVF) 
protocols is often a critical step in the develop­
ment of OHSS. The increased expression of 
VEGF mRNA has been described in women with 
polycystic ovarian syndrome (PCOS) who are at 
high risk of developing OHSS.
Nevertheless, many questions about the 
ovarian production and action of VEGF remain 
unanswered, and certain observations are con­
tradictory. These conflicting results can be at 
least partially attributed to the method of VEGF 
assessment:
(1) VEGF can be measured in plasma or in 
serum, but the clotting process increases 
VEGF levels in serum 8-10-fold, and 
degranulation or hemoconcentration 
occurring in OHSS may entail misinter­
pretation of true levels of free active VEGF;
(2) OHSS ovarian-derived VEGF could be 
trapped in ascitic fluid or large cystic cor­
pora lutea;
(3) Immunoassays cannot differentiate the 
four isoforms of VEGF;
(4) The biologically active isoform of VEGF in 
the circulation has not been determined;
(5) The relationship between soluble VEGF 
receptors and VEGF in the follicular fluid 
may influence the biological activity of 
VEGF, and different biological affinities of 
VEGF for receptors may exist4.
The studied populations are heterogeneous, and 
the control group may influence the results; in 
particular, whether OHSS and control patients
are matched for number of follicles is of para­
mount importance.
VEGF is thus certainly a mediator of the 
OHSS cascade, but it remains unknown 
whether disruption of the normal controlled fol­
licular expression of VEGF constitutes a ‘pri- 
mum movens’ of OHSS.
Miscellaneous substances that may 
play a role in OHSS4
Angiogenin has been found at significantly 
higher levels in the blood and ascitic fluid of 
OHSS patients, suggesting that angiogenin may 
be associated with neovascularization in OHSS.
The kinin-kallikrein system has been stud­
ied in the rat model. The results suggest that the 
kinin-kallikrein system plays an intermediate 
role in capillary permeability during OHSS.
Soluble vascular cell adhesion molecule-1 
(sVCAM-1) and soluble intercellular adhesion 
molecule-1 (sICAM-1), which belong to the 
immunoglobulin superfamily, are major media­
tors of white blood cell adhesion, interaction 
and extravasation during inflammatory and 
immune reactions. A case-control study of peri­
toneal fluid and plasma levels of sVCAM-1 and 
sICAM-1 suggested that soluble cell adhesion 
molecules may play a role in the pathogenesis 
and evolution of OHSS5.
The serum and ascites concentrations of 
sICAM-1 and of soluble E-selectin, another 
endothelial cell adhesion molecule, were fol­
lowed in a controlled study6. Higher levels of 
sIC AM-1 and lower levels of E-selectin were 
observed in serum and ascitic fluid. More stud­
ies are needed to understand the kinetics and 
the cause-effect relationship between OHSS 
and these adhesion molecules. However, they 
seem to be implicated in the pathophysiological 
process leading to capillary hyperpermeability 
in severe OHSS.
The von Willebrand factor (vWF) is consid­
ered to be a marker of endothelial cell activa­
tion, and excessive endothelial cell VEGF
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production enhances vWF concentrations. The 
increased vWF on the day of embryo transfer 
has been shown to be related to the severity of 
OHSS, and an elevation of vWF precedes the 
clinical manifestations in severe OHSS7. This 
increase has not been observed in follicular 
fluid, suggesting that vWF is not produced by 
the ovary. vWF may be of endothelial origin and 
influenced by vasoactive ovarian factors. Higher 
plasma levels of vWF in OHSS patients com­
pared with high responders on the day preced­
ing oocyte retrieval lasted until after embryo 
transfer and were maintained well into the late 
luteal phase8. In high responders without 
OHSS, the levels of vWF also increased during 
the pre-ovulatory phase, but decreased from the 
day of oocyte retrieval onward. Subsiding levels 
of vWF in patients with severe OHSS indicate 
improvement of the disease. This test might 
become clinically useful as an additional ‘dis­
criminating parameter’ or ‘prognostic marker’. It 
is likely that vWF plays a role in the cascade 
that leads to OHSS, but rather as a consequence 
of the activation of endothelial cells by a factor 
of ovarian origin than as its causal factor.
Endothelin-1, another vasoconstrictor that 
increases capillary permeability, was found to 
be 100-300-fold higher in follicular fluid than in 
plasma. In OHSS patients, serum endothelin-1 
level is elevated but in parallel with other neu- 
rohormonal vasoactive factors, and without cor­
relation with the OHSS grading, suggesting a 
homeostatic response rather than an initiating 
role in OHSS9.
Contribution of neurohormonal and 
hemodynamic changes to arteriolar 
vasodilatation
Balasch et al. evaluated systemic, endogenous 
vasoactive neurohormonal factors in severe 
OHSS during the appearance of the syndrome 
for a period of 4-5 weeks9. The authors recorded 
increased hematocrit, decreased mean arterial 
pressure, increased cardiac output and reduced
peripheral vascular resistance. This was accom­
panied by marked increases in plasma renin, 
norepinephrine, antidiuretic hormone (ADH) 
and atrial natriuretic peptide levels. The authors 
compared previous results in women with and 
without hemoconcentration: similar values 
were observed except for renin, norepinephrine 
and ADH, which were found to be higher in 
OHSS patients. These observations suggest that 
OHSS is associated with arteriolar vasodilata­
tion. Indeed, if circulatory dysfunction were to 
be due solely to an extravascular shift, contrac­
tion of the circulating blood volume should 
induce a reduction in cardiac output, an 
increase in peripheral vascular resistance and a 
decrease in atrial natriuretic peptide. In con­
trast, cardiac output and atrial natriuretic pep­
tide are increased and peripheral vascular resist­
ance is markedly reduced, indicating a marked 
peripheral arteriolar vasodilatation. The simul­
taneous occurrence of these disorders leads to 
hyperdynamic circulatory dysfunction, with 
marked stimulation of the sympathetic nervous 
system, renin-angiotensin system and ADH.
Evbuomwan et al. observed an alteration of 
osmoregulation during OHSS, with an osmotic 
threshold for arginine vasopressin secretion that 
is reset to lower plasma osmolality during 
superovulation10. This new, lower, body tonicity 
is maintained in OHSS patients until at least 10 
days after the administration of hCG. These 
authors suggest that a decrease in plasma osmo­
lality and plasma sodium levels is due to altered 
osmoregulation rather than to electrolyte losses.
CONCLUSION (Figure 1)
The main hypothesis concerning the develop­
ment of OHSS is that regulation of the inflam­
mation-like ovulation process is disturbed. This 
leads to overproduction of local proinflamma- 
tory factors in the ovary. In turn, this results in 
secondarily increased capillary leakage and 
transmission of inflammatory mediators to other
86
PATHOPHYSIOLOGY OF THE OHSS
Figure 1 Pathophysiology of OHSS. TNF, tumor necrosis factor; VEGF, vascular endothelial growth 
factor; VEGFR-1, VEGF receptor-1; RAS, prorenin-renin-angiotensin system; vWF, von Willebrand 
factor
Figure 2 (a) Images of cut surface of ovary of OHSS patient and (b) edema of the alveoli of the lungs 
of same patient. Reproduced from reference 11, with permission
compartments. In the most severe form of 
OHSS, this process also leads to systemic mani­
festations.
In addition to the shift of fluid to extravas- 
cular spaces, OHSS is consistently associated 
with marked arteriolar vasodilatation.
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The site and mechanism of arterial vasodi­
latation and increased permeability are not elu­
cidated. A link between arterial vasodilatation 
and capillary leakage may exist because arterio­
lar dilatation induces the formation of intersti­
tial edema by increasing the capillary surface 
area and capillary hydrostatic pressure.
Various authors have performed renowned 
and fascinating studies to document these hypo­
theses; Chapter 10 details these observations.
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CHAPTER 10
Role of vascular endothelial growth factor 




The main symptom of ovarian hyperstimulation 
syndrome (OHSS) is third-space fluid sequestra­
tion due to generalized capillary leakage1. The 
loss of serum causes hemoconcentration and 
kidney failure from hypovolemic shock2. Symp­
toms of OHSS are aggravated by an increase in 
von Willebrand factor, resulting in thrombosis 
in atypical parts of the body or in embolism of 
the lung or brain3’4. Human chorionic 
gonadotropin (hCG) exacerbates all symptoms5. 
This severe condition after controlled ovarian 
stimulation (COS) results from substances 
which are obviously produced by the ovaries6. 
Bilateral ovariectomy will immediately resolve 
this critical situation7.
CHARACTERISTICS OF VASCULAR 
ENDOTHELIAL GROWTH FACTOR
In 1979, Dvorak et al. described a factor from 
hepatocarcinoma cell lines which increased vas­
cular permeability8. This factor was designated 
as vascular permeability factor (VPF)9. Ferrara 
and Henzel isolated from follicular stellate cells
of the pituitary gland a highly specific endothe­
lial cell mitogen which they named vascular 
endothelial growth factor (VEGF)10. Eventually, 
it became apparent that VPF and VEGF were dif­
ferent names for the same protein11. VEGF is 
now the mainly accepted label for this growth 
factor. Recently, specific forms of VEGF from 
different gene loci have been found. The origi­
nal VEGF is therefore also dubbed VEGF-A.
VEGF comprises a family of proteins of 
about 45 000 Da which originate from a single 
gene located on chromosome 6p21.312. The 
human VEGF gene is organized into eight exons, 
separated by seven introns. From this gene a 
variety of five different proteins are processed 
by alternative splicing. These proteins are 
labeled VEGFi21, VEGF145, VEGFi65, VEGFi89 
and VEGF2o6> according to their respective num­
bers of amino acids. VEGF12i and VEGF165 are 
the most prominent forms. VEGF121 is freely 
secreted. It lacks residues from exons 6 and 7, 
and is strongly acidic in the way it reacts. 
VEGFies is partially secreted, reacts basically 
and possesses a heparin binding site. It lacks the 
residue from exon 613. VEGFi45 is predominantly 
produced in the endometrium. It contains 
residues from exons 1-6 and 814. The larger
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VEGF forms, 189 and 206, react highly basically 
and remain cell-associated within the extracel­
lular matrix15.
The expression of VEGF is strongly induced 
by hypoxia16’17. Furthermore, VEGF expression 
can be up-regulated by a series of cytokines 
including other growth factors, e.g. epidermal 
growth factor (EGF) or keratinocyte growth fac­
tor (KGF)18. Even heterozygous VEGF gene- 
deficient mice do not survive the 1 2  th day in 
utero, indicating that there is no substitute for 
the angiogenic effects of VEGF19.
Two VEGF receptor tyrosine kinases have 
been identified. Both represent transmembra- 
nous phosphokinase receptors with seven anti­
body-like loops as extracellular domains. Fms- 
like tyrosine receptor (flt-1 ) is associated with 
VEGF receptor- 1 (VEGFR-1 ). Kinase domain- 
inserted receptor (KDR) corresponds to VEGF 
receptor-2  (VEGFR-2 ). Both receptors are con­
fined to endothelial cells20. VEGFR-1  exhibits a 
dissociation constant [Kb ] for VEGFi 65 of 
2 0 pmol/l21, and VEGFR-2  a KD for VEGF165 of 
1 0 0 pmol/l22. Mice embryos knocked out for one 
of the two receptor types die in utero between 
days 8.5 and 9.523,24. Signal transduction 
through the VEGFR-2  leads to mitogenic activity 
in endothelial cells and enhances vascular per­
meability within minutes25,26. In adults, no such 
immediate effects can be observed after the acti­
vation of VEGFR-1 27. VEGFR-1  regulates 
endothelial cell morphology and tissue factor 
production in endothelial cells, as well as mono­
cyte attraction by these cells. Fibroblast growth 
factor (FGF) expression28 or asphyxia29 causes 
an increased expression of both receptor 
types30.
A third specific receptor is confined to lym­
phatic endothelial cells. It is designated as flt-4 
or VEGFR-331. This receptor can also be stimu­
lated with VEGF. However, the specific ligand 
seems to be VEGF-C32.
THE VEGF SUPERFAMILY
VEGF belongs to the superfamily of platelet 
derived growth factor (PDGF) together with fur­
ther growth factors which all have some com­
mon genetic symmetry33.
Placental growth factor (P1GF) is produced in 
villous trophoblast cells, and occurs in two 
forms arising from alternative splicing34. The 
gene is localized on chromosome 14q2 435. Its 
biological function is unknown. P1GF knock-out 
mice develop normally36. It exhibits only a spe­
cific binding affinity to VEGFR-1  and cannot 
activate any other VEGF receptors.
In the attempt to determine the gene for 
MEN-1 , VEGF-B was found37, and localized to 
chromosome l lq l3 38. Again, it occurs in two 
isoforms arising from alternative splicing. 
VEGF-B has a high affinity to VEGFR-1 , but 
lacks any affinity for VEGFR-2  or -3.
As a specific ligand for VEGFR-3, VEGF-C is 
described. It possesses only about 30% homol­
ogy with VEGF165. The Kb for VEGFR-3 is 
135pmol/l, whereas the affinity to VEGFR-2  
occurs at about 410pmol/l39. Its gene is found 
on chromosome 4q3438. It promotes the growth 
of lymphatic endothelial cells. By activation of 
VEGFR-2  it can also induce vascular permeabil­
ity in blood vessels as well as in lymphatic 
vessels40.
Closely related to VEGF-C is VEGF-D. Due to 
its structural similarity it also binds and acti­
vates VEGFR-341.
THE VEGF/VEGFR COMPLEX
Usually, VEGFs occur as dimers. Dimerization 
can happen between different forms of VEGF. 
Therefore, the receptor specificity may vary in 
in vivo experiments. To obtain a maximum bio­
logical response, i.e. proliferation of endothelial 
cells, receptors also develop into dimers, with 
optimal results from the dimerization of 
VEGFR-1  and VEGFR-2 . However, VEGF tends
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to leave the receptor fairly rapidly. To obtain 
optimal activation, the VEGF/VEGFR complex 
has to be stabilized by neuropilins on the cell 
surface42. Neuropilins themselves do not show 
any specific intracellular effects after binding 
the VEGF/VEGFR complex.
IMPORTANCE OF VEGF ACTIVITIES
The physiological task of VEGF is the induction 
of endothelial cell proliferation. This occurs 
normally during wound-healing processes43. In 
the adult organism, there are only two organs 
where angiogenesis can be observed regularly: 
in the cyclic endometrium and in the ovary dur­
ing follicular development and corpus luteum 
formation44. VEGF enables fenestration of the 
endothelial barrier in small venules and capil­
laries45. In some organs, VEGF is obviously 
needed for specific endothelial maintenance, 
e.g. lung or kidney46.
In some pathological conditions, VEGF 
expression is elevated. This can be observed in 
retinopathy47 or rheumatic arthritis48. The most 
dramatic growth induction of endothelial cells 
can be observed in malignant tumors. Here, 
VEGF expression is usually extremely high43. 
Therefore, many attempts are made to block 
angiogenesis in tumors.
VEGF EFFECTS IN VIVO ASSOCIATED 
WITH OHSS
VEGF can induce all the processes which are 
typical of clinical symptoms of OHSS. A major 
effect is the fenestration of vessels, increasing 
vascular permeability49, von Willebrand factor 
production in endothelial cells can be increased 
by VEGF50. Therefore, the idea that VEGF may 
elicit OHSS is challenging.
The hypothesis could be strengthened if the 
source of VEGF in the ovaries is determined. 
Analyzing the clinical course of OHSS, it
becomes clear that a risk exists only after ovula­
tion and during corpus luteum formation51. 
Before ovulation, patients may complain of dis­
comfort due to enlarged cystic ovaries, but there 
is no generalized capillary leakage producing 
ascites or pleural effusion.
VEGF EFFECTS IN VITRO
In 1993, luteinized granulosa cells became the 
most interesting suspects. It could be demon­
strated that VEGF mRNA was expressed in this 
cell population in vitro52. Granulosa cells 
expressed VEGF121 and VEGF16553. Moreover, 
hCG could be confirmed to induce the mRNA 
expression rate dose-dependently. The hCG- 
dependent secretion of VEGF from granulosa 
cells in vitro could also be validated54. Recent 
data indicate that progesterone is able to sup­
port hCG-dependent VEGF production55. Granu­
losa cells of patients with polycystic ovarian 
syndrome exhibit a greater capacity to express 
and secrete VEGF, explaining the higher risk for 
these individuals to develop OHSS after COS56.
VEGF CONCENTRATIONS IN URINE, 
ASCITES, SERUM AND FOLLICULAR 
FLUID
In vivo data showed that ascites from OHSS 
patients contained large amounts of VEGF57. 
The urinary excretion of VEGF was higher in 
patients suffering from OHSS than in healthy 
women undergoing COS58. Quantification of 
VEGF in follicular fluid suggested higher con­
centrations in patients at risk for OHSS59. Also, 
serum contents of VEGF were elevated60.
Unfortunately, this simple hypothesis did 
not endure for long. It became feasible that after 
COS, with comparable results in ovarian per­
formance, granulosa cells from these individual 
patients exhibited a wide range of VEGF expres­
sion. There was no straight correlation between
91
OVARIAN HYPERSTIMULATION SYNDROME
symptoms of OHSS and the intensity of VEGF 
expression53. VEGF quantification in blood 
serum was compromised by thrombocyte contri­
butions which could not be exactly calculated61. 
Improved systems to measure VEGF produced 
conflicting results regarding VEGF concentra­
tions in follicular fluid and serum62,63.
VEGF RECEPTORS
Finally, other substances were identified which 
interfere with the biological effects of VEGF. The 
VEGF-VEGFR system exemplifies a paracrine 
organization in the ovary64. VEGF produced by 
the growing follicle or in the corpus luteum acti­
vates endothelial cell growth in the vicinity of 
the maturing follicle. A dense capillary network 
provides sufficient nutrient supply for the 
oocyte. Endocrine signals from the follicle or 
corpus luteum are transported into the circula­
tion. However, VEGFR-1 poses a very important 
capacity.
SOLUBLE VEGF RECEPTOR-1
Endothelial cells can produce a soluble, freely 
secreted form of VEGFR-1 by alternative splic­
ing of the common VEGFR-1 mRNA65. This sol­
uble receptor (sVEGFR-1) acts as a natural VEGF 
antagonist66-69. The situation is comparable to 
that of growth hormone and its receptor.
sVEGFR-1 AS VEGF ANTAGONIST
It was demonstrated that sVEGFR-1 can effec­
tively inhibit corpus luteum formation in pri­
mates70. Soluble VEGFR-1 was detected in fol­
licular fluid. Results demonstrated that high 
amounts of sVEGFR-1 in follicular fluid corre­
sponded to a poor responder, whereas low
sVEGFR-1 concentrations coincided with high 
ovarian response and elevated risk for OHSS53. 
Only the concentration of free VEGF was linked 
to clinical OHSS71. In rats, the use of luteinizing 
hormone (LH) instead of hCG for ovulation 
induction could prevent vascular permeability 
by reducing VEGF production72. Similar results 
could be obtained by GnRH-agonist ovulation 
induction73, accounting for lower biologically 
active VEGF concentrations. Coasting during 
COS also reduced the amount of total and free 
VEGF in the peripheral blood74,75.
REGULATION OF sVEGFR-1 
SECRETION
Substances which regulate the production of 
sVEGFR-1 are unknown. From in vitro experi­
ments it became clear that follicular fluid or 
granulosa cell-conditioned media could reduce 
the production of sVEGFR-1 in human umbilical 
venous endothelial cells (HUVEC). Messenger 
RNA expression of VEGFR-1 or sVEGFR-1 
remained unchanged, indicating that this effect 
is related to post-transcriptional processes. This 
observation suggested that granulosa cells 
enhance VEGF effects by down-regulating 
sVEGFR-1 production in endothelial cells. The 
paracrine signal by which granulosa cells can 
influence sVEGFR-1 production remains to be 
identified76.
CONCLUSIONS
VEGF remains the main suspect in the patho­
physiology of OHSS. However, it is obvious that 
other substances produced by endothelial cells 
and granulosa cells affect the clinical course of 
this condition. From this interesting research on 
OHSS, profound knowledge about the regula­
tion of angiogenesis can be expected.
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CHAPTER 11
The renin-angiotensin system 
in the pathophysiology of 
ovarian hyperstimulation syndrome
Maria Jose Teruel and Isabel Hernandez Garda
INTRODUCTION
Ovarian hyperstimulation syndrome (OHSS) 
normally manifests itself as a serious complica­
tion of ovulation induction treatments, although 
there have also been reports of spontaneous and 
familial OHSS, associated with pregnancy1,2. 
The pathogenesis of this syndrome has not been 
fully clarified, although the description of two 
spontaneous cases with familial association sug­
gests that a certain genetic predisposition may 
prove necessary to induce the disorder. Human 
chorionic gonadotropin (hCG) probably stimu­
lates the ovarian secretion of vasoactive factors 
that in turn increase vascular permeability and 
contribute to third-compartment fluid accumu­
lation, these being characteristic physiopatho- 
logical features of OHSS. Many substances have 
been suggested as possible mediators of the syn­
drome, including serotonin, histamine, pro­
lactin, estrogens and prostaglandins, although 
the renin-angiotensin system (RAS) and certain 
cytokines (interleukin-2 and -8) produced by the 
ovaries have been proposed as the main factors 
implicated in OHSS physiopathology. Thus, the 
renin-angiotensin system (RAS) is one of the 
mechanisms presumed to participate in ovarian 
hyperstimulation syndrome.
In the mid-1980s, Haning et al. suggested 
that OHSS results from excessive secretion of 
the hormone in charge of regulating peritoneal 
fluid during the normal menstrual cycle. They 
found the syndrome to be characterized by an 
increase in serum aldosterone associated with 
an increase in plasma renin activity. Initially, it 
was considered that intravascular fluid dis­
placement to the peritoneum stimulated renin 
and aldosterone production, secondary to the 
hypotension implied by the loss of plasma vol­
ume. As a result, the increases in these hor­
mones would simply constitute a reaction to 
ascites3.
Subsequently, Navot et al. suggested partici­
pation of the RAS based on their studies in 
women with OHSS, in which a direct relation­
ship was found between plasma renin activity 
and the severity of ovarian hyperstimulation 
syndrome4.
An increase in plasma renin concentration 
has also been observed in one of the docu­
mented cases of recurrent and familial OHSS5.
RENIN-ANGIOTENSIN SYSTEM: 
MECHANISM OF ACTION
The main function of the RAS in maintaining 
arterial pressure seems to be regulation of the 
balance between ingestion and excretion of salt.
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Renin acts upon angiotensinogen (a plasma 
protein synthesized in the liver), converting it to 
angiotensin I (a scantly active molecule) which, 
at small vessel level, is converted to angiotensin
II. This conversion is mediated by angiotensin- 
converting enzyme (ACE) located mainly in the 
pulmonary capillaries.
The principal effects of angiotensin com­
prise arteriolar vasoconstriction (resulting in an 
increase in total peripheral resistance) and 
venous constriction (thus increasing venous 
return), a reduction in the renal elimination of 
sodium and water, and stimulation of aldos­
terone by the adrenal glands (Figure 1).
The RAS is stimulated by different mecha­
nisms. Thus, an increase in central venous pres­
sure has been shown to reduce both renin and 
angiotensin levels, while sympathetic stimula­
tion exerts the opposite effect. In turn, the RAS 
exerts a response independent of the central 
nervous system, characterized by direct vaso­
constrictive action affording compensation for 
arterial pressure reductions of up to 65%.
Angiotensin II is a potent vasoconstrictor 
that acts directly upon the tubular resorption of 
sodium, and indirectly by modifying the hydro­
static and oncotic forces. In experimental ani­
mals it has been shown that angiotensin II, at
physiological concentrations, increases fluid 
resorption in the proximal renal tubuli, while at 
high concentrations it inhibits sodium excre­
tion. Angiotensin therefore seems to reduce 
renal blood flow through vasoconstriction, or 
possibly by modifying the glomerular filtration 
coefficient. In this context, it reduces the 
glomerular filtration rate by approximately 20%. 
This effect, and the increase in sodium resorp­
tion, modifies the pressure-natriuresis balance. 
Such action is a consequence of renal cortical 
vasoconstriction, while medullary flow does not 
seem to be modified. In this way, angiotensin 
modifies the pressure-diuresis curve, shifting it 
to the right. This in turn implies that a higher 
arterial pressure is needed to excrete the same 
amount of water and sodium. Aldosterone in 
turn increases net sodium resorption in the dis­
tal tubuli, thereby increasing the extracellular 
volume and therefore arterial pressure.
The mechanisms described for pressure con­
trol are decisive for long-term control, although 
short-term arterial pressure adjustments are 
principally mediated by the nervous system, 
which modifies total peripheral resistance and 
cardiac output.
Figure 1 Cardiovascular and renal effects of the renin-angiotensin system. ACE, angiotensin- 
converting enzyme
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On the other hand, recent studies6,7 have 
demonstrated that angiotensin II increases vas­
cular permeability that may be mediated by vas­
cular endothelial growth factor (VEGF). In cul­
tured human aortic smooth muscle cells, it was 
shown that angiotensin II induces expression of 
the messenger RNA (mRNA) encoding for a gly­
coprotein known as vascular permeability factor 
or VEGF (see also Chapters 10 and 14). In this 
same study it was also found that selective 
losartan-induced inhibition of angiotensin type
I (ATi) receptors prevents increases in angio­
tensin II and expression of mRNA encoding 
VEGF. Likewise, Hernandez et al. have recently 
published a study in rats in which ATa receptor 
block with losartan attenuates the increase in 
vascular permeability induced by the inhibition 
of nitric oxide (NO) synthesis via the adminis­
tration of JV^-nitro-L-arginine methyl ester (L- 
NAME). All these data suggest that angiotensin
II may play an important role in regulating vas­
cular permeability under different pathophysio­
logical conditions6.
THE OVARIAN RENIN-ANGIOTENSIN  
SYSTEM
Since the mid-20th century it has been known 
that plasma renin activity (PRA) varies in the 
course of the normal ovarian cycle8. Later, the 
existence of an ovarian RAS was demonstrated. 
This system is activated by gonadotropins and is 
independent from the renal RAS9. In the course 
of an ovarian cycle, an increase in angiotensin II 
has been observed in the follicular fluid of the 
preovulatory follicle10. In 1990, Blankenstijn et 
a l., after studying the RAS in nephrectomized 
women, confirmed that prorenin (the inactive 
precursor of renin) is secreted by the ovary in 
response to luteinizing hormone (LH) and 
hCG11. On the other hand, since the studies of in 
vitro fertilization (IVF) cycles, it has been known 
that prorenin is found in concentrations 12-fold 
greater in follicular fluid than in plasma, and
that hCG administration increases the plasma 
concentration of prorenin12. Later still, Morris 
and Paulson found that in addition to synthesiz­
ing prorenin, the ovaries also contain the entire 
enzyme system needed to transform prorenin 
into angiotensin II. The studies of this research 
group also suggested that angiotensin may mod­
ulate steroid synthesis, oocyte maturation, ovu­
lation and formation of the luteal body13.
Different studies have confirmed the exis­
tence of specific angiotensin II receptors in ovar­
ian follicles10,12-17, thereby defining the func­
tionality of the ovarian RAS. Thus, studies in 
rabbit ovaries have revealed the presence of ATi 
receptors in the granulosa and theca of preovu­
latory follicles18. On the other hand, AT2 recep­
tors have been identified in atretic rat follicles, 
the induction of apoptosis being attributed to 
stimulation of these receptors19. The various 
studies conducted to date have shown the 
ovaries to contain a complete and intrinsic RAS, 
as well as receptors for angiotensin II. These ele­
ments and other ovarian modulators contribute 
to establish ovarian function. This ovarian RAS 
participates fundamentally in atresia, formation 
of the dominant follicle, and ovulation -  
although the underlying intrinsic mechanisms 
are not known.
RENIN-ANGIOTENSIN SYSTEM AND  
OHSS
At present it is known that during ovarian 
hyperstimulation syndrome both the ovarian 
and plasma RAS are activated (Figure 2). Del- 
baere et al. found that women who develop 
OHSS have significantly greater concentrations 
of renin and prorenin in ascitic fluid than in 
plasma, while the aldosterone levels were 
higher in plasma than in ascitic fluid. These 
authors therefore suggested that the greater 
renin and prorenin levels in ascitic fluid imply 
activation of the ovarian RAS, while the high
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Figure 2 Postulated mechanisms of the renin-angiotensin system (RAS) implication in pathophysi­
ology of ovarian hyperstimulation syndrome. ACE, angiotensin-converting enzyme; Ang, angiotensin; 
VEGF, vascular endothelial growth factor
serum levels of active renin and aldosterone 
reflect activation of the renal RAS20.
Other studies have shown increases in the 
plasma concentrations of prorenin, renin and 
aldosterone in women with severe OHSS21’22, as 
well as increments in renin and angiotensin 
activity in both plasma and ascitic fluid 
obtained from women with OHSS23-27. There 
have also been reports of an increase in 
angiotensin-converting enzyme (ACE) activity 
in another woman with this same syndrome23. 
According to these data, OHSS appears to be 
characterized by stimulation of all RAS compo­
nents.
The results of studies conducted with ACE 
inhibitors (ACEIs) in experimental models of 
OHSS reveal participation of the RAS in the 
pathophysiology of the syndrome, and more 
specifically in the production of ascites. Thus, 
the administration of enalapril (an ACEI) 
reduced ascites by 40% in female rabbits treated 
with gonadotropins28. Gul et al. found that rab­
bits treated with enalapril showed a significant
reduction in aldosterone concentration, with no 
significant differences in relation to the volume 
of ascitic fluid28. In the same way, Teruel et al. 
found that treatment with captopril (another 
ACEI) did not modify ovarian size in rabbits, 
although it did reduce the percentage of animals 
with ascites (80% vs. 50%) and also the volume 
of ascitic fluid in those animals that presented 
ascites29.
When OHSS manifests itself, the affected 
patients show both ovarian and renal RAS acti­
vation, with elevated prorenin, renin activity, 
active renin and angiotensin II values. These 
values in turn are even higher in ascitic and 
pleural fluid than in plasma -  thus reflecting 
activation of the ovarian RAS20,23’25. Plasma 
renin activity normalizes after the acute phase 
of the syndrome, in coincidence with patient 
clinical normalization. In this way, in a docu­
mented case of OHSS with internal jugular vein 
thrombosis, increased plasma renin activity was 
seen to decrease in parallel with resolution of 
the thrombus30.
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CLINICAL CHARACTERISTICS
Modifications associated with OHSS
Increased vascular permeability
Different authors attribute the observed increase 
in vascular permeability to the substances 
secreted by the corpus luteum after the admin­
istration of hCG31,32.
Studies in experimental animal models have 
shown that ascites is produced by a generalized 
increase in vascular permeability, and does not 
originate in the ovary33. The authors reached 
this conclusion after exteriorizing the ovaries 
from the peritoneum of rabbits that subse­
quently underwent ovulation induction with 
gonadotropins. Both the production of ascites 
and the plasma hormone levels were found to be 
no different in these animals compared with the 
non-operated controls.
Nevertheless, according to Goldsman et al., 
some substances produced by the ovaries play a 
fundamental role in the induction of OHSS34. 
The application of follicular and peritoneal fluid 
obtained from women treated with gonado­
tropins during an IVF cycle to the endothelium 
of bovine aorta induced vascular permeability in 
vitro. Likewise, a correlation was found between 
the increase in vascular permeability and the 
susceptibility of the donating women to the 
development of OHSS, determined as the stim­
ulation of over 25 follicles34. Other authors have 
studied the modifications in Starling pressure, 
which determines transcapillary exchange, dur­
ing ovarian stimulation with gonadotropins. 
They observed a progressive reduction of 
plasma colloidosmotic pressure, together with 
an increase in interstitial colloidosmotic pres­
sure, thus implying a gradual reduction of the 
transcapillary colloidosmotic gradient (i.e. the 
difference between plasma colloidosmotic pres­
sure and interstitial colloidosmotic pressure), 
and therefore an increase in vascular perm­
eability to proteins during increasing ovarian 
stimulation35.
The studies conducted in experimental mod­
els have corroborated the hypothesis that 
angiotensin participates as a mediator in 
increasing vascular permeability, since ACEI 
administration reduces the incidence and sever­
ity of the syndrome35,36. The administration of 
captopril during ovarian hyperstimulation with 
gonadotropins reduces both the appearance of 
ascites and the vascular permeability index, as 
determined by the extravasation of albumin 
dyed with Evans blue stain.
Hemodynamic alterations
On the other hand, according to Balasch et al., 
women who develop OHSS present circulatory 
alterations characterized by hypotension, tachy­
cardia, an increased cardiac output and a reduc­
tion in peripheral resistance37. These authors 
consider that in addition to the increase in vas­
cular permeability, some other factor is respon­
sible for the hemodynamic alterations. This is 
because the increase in vascular permeability 
would give rise to hypovolemia, which in turn 
would lead to a decrease in cardiac output and 
hypotension. As a response to hypotension, the 
sympathetic nervous system would attempt to 
increase cardiac output, elevating heart rate and 
peripheral resistance in an attempt to restore 
arterial pressure. However, in the studies of 
women with severe ovarian hyperstimulation, 
Balasch et al. found a decrease in total periph­
eral resistance, and an increase in cardiac out­
put with hypotension. These authors therefore 
consider that the observed circulatory disorders 
are secondary to peripheral vasodilatation, with 
the association of increased vascular permeabil­
ity. This hyperdynamic circulatory situation is 
comparable to that observed after the formation 
of edemas and ascites secondary to liver fail­
ure37. On the other hand, in a study published 
by Manau et al. in women subjected to ovula­
tion induction and who did not develop OHSS, 
the increase in plasma estradiol concentrations 
was associated with a decrease in arterial pres­
sure and peripheral vascular resistance, together
101
OVARIAN HYPERSTIMULATION SYNDROME
with a rise in cardiac output. It was also seen 
that changes in plasma renin activity paralleled 
plasma estradiol concentration, and aldosterone 
increased only at the end of the luteal phase. On 
the basis of these observations, the authors sug­
gested that circulatory dysfunction develops 
during ovarian stimulation, affecting all 
patients, and that OHSS represents the extreme 
expression of such dysfunction38.
Other authors, however, have reported 
hypotension with a decrease in cardiac output, 
systolic stroke volume and cardiac index39, 
together with a drop in central venous pres­
sure40,41, thus supporting the classical idea 
(defended by Schenker and Elchalal) whereby 
diminished intravascular volume secondary to 
massive displacement towards the third com­
partment, due to a sudden increase in perme­
ability, leads to hypovolemia which in turn 
gives rise to hypovolemic shock42 (Figure 2).
Alterations in renal function
Renal dysfunction is another of the clinical fea­
tures of severe OHSS, and may even culminate 
in acute renal failure. As shown by Balasch et 
al., the most frequent renal alterations are olig­
uria and sodium retention43-45, along with a 
minor reduction in glomerular filtration rate. 
The same authors reported a significant increase 
in serum creatinine levels in women with OHSS 
compared with the creatinine levels recorded 
following patient normalization. They therefore 
suggested that the glomerular filtration rate 
decreases in the course of the syndrome46. On 
the other hand, different authors have reported 
decreases in sodium excretion in urine in 
women with this syndrome, with some pub­
lished cases of undetectable urine sodium lev­
els47. As a result, these authors suggest that the 
hyperstimulation syndrome involves sodium 
retention47.
Altered kidney function is indicative of 
marked disease severity in women with OHSS. 
Accordingly, in previous classifications of the 
syndrome, serum creatinine > 1.5mg/ml, or cre­
atinine clearance <  50 ml/min, was used to 
define critical OHSS48.
This modification associated with ovarian 
hyperstimulation syndrome can also be due in 
part to RAS activation, since both glomerular fil­
tration and sodium resorption are modified by 
high angiotensin II levels (Figure 1). On the 
other hand, studies in rabbits have reported a 
right shift of the pressure-natriuresis curve in 
animals with OHSS, thus indicating a tendency 
toward sodium retention. In this case, ACEI 
therapy (captopril) normalizes the curve, sug­
gesting that angiotensin II may play an impor­
tant role in the pathophysiology of OHSS.
RENIN-ANGIOTENSIN AND  
VASCULAR ENDOTHELIAL GROWTH 
FACTOR
Another mediator in the development of OHSS 
is vascular endothelial growth factor (VEGF), a 
protein belonging to the family of heparin lig­
ands, which acts directly upon the endothelial 
cells, inducing angiogenesis and increased vas­
cular permeability49-55.
The implication and possible association of 
RAS and VEGF in the pathophysiology of OHSS 
appears to have been confirmed by the different 
studies conducted to date. Not only do the two 
mediators increase angiogenesis and vascular 
permeability, but the production of both is 
moreover interrelated. Angiotensin II affords 
potent stimulation of VEGF production in 
smooth muscle cells, myocardium, retinal 
epithelium and mesenchymal cells56. It has also 
been shown that angiotensin II induces VEGF 
expression in endometrial cancer cells57 and in 
cervical cancer cells58. Angiotensin II is related 
to VEGF production associated with angiogene­
sis59, as a result of which some investigators 
have proposed administering an ACEI as co­
treatment in oncological processes60. In the kid­
ney, this relationship between the two media­
tors has also been observed, with angiotensin
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regulating VEGF expression61. However, other 
authors, on providing treatment with an ACEI 
(enalapril) in rats subjected to OHSS induction, 
have reported no reduction in VEGF expression 
at the ovarian level62. Since angiotensin II exerts 
multiple effects via specific receptor interaction, 
and moreover shares many functions with 
VEGF, both substances may possibly mediate 
the pathophysiology of OHSS either directly or 
indirectly.
CONTROVERSIES
The ovarian or renal origin of the high plasma 
concentration of total renin and renin activity 
during severe OHSS has been a matter of debate 
for a long time. Haning et a l 3 first suggested that 
the markedly elevated plasma renin activity was 
secondary to the hypovolemia accompanying 
the syndrome. However, hyperstimulated 
ovaries have been considered as the main source 
of hyperreninism in OHSS since a direct corre­
lation between plasma renin activity and the 
severity of the syndrome was observed4. Further 
investigations, performed on the ascites from 
patients with OHSS, showing total renin and 
prorenin and angiotensin II concentrations 
much higher in the ascites than in the plasma, 
reinforced the hypothesis of a marked stimula­
tion of ovarian RAS in the syndrome23-25. On the 
other hand, the severe forms of the syndrome 
were shown to be consistently associated with a 
marked arteriolar vasodilatation and fall in 
blood pressure46. This hemodynamic state leads 
to a neurohormonal compensatory response that 
involves rapid activation of the RAS and sympa­
thetic nervous system and non-osmotic release 
of antidiuretic hormone. In view of the above 
data, the possibility that stimulation of the ovar­
ian RAS is a primary phenomenon, related to a 
direct effect of gonadotropin, has to be taken 
seriously, while, on the other hand, the intense 
stimulation of the renal RAS is secondary to the
hemodynamic changes occurring during the 
syndrome.
TREATMENT
As has already been mentioned in the course of 
this chapter, the RAS is implicated in the devel­
opment of OHSS, and different authors using an 
ACEI have been able to reduce both the inci­
dence of the syndrome and its severity. All such 
work has been done in experimental rabbit 
models28,36,63 and in women.
Morris et al. administered captopril (ACEI) 
to patients who developed ovarian hyperstimu­
lation syndrome and were oocyte donors27. 
These women showed an increase in plasma 
estradiol levels and a decrease in progesterone 
concentration. These results suggest that ovar­
ian angiotensin II may exert a stimulating effect 
on cytochrome P450 and an inhibitory effect on 
ovarian aromatase -  thus raising the possibility 
that angiotensin II may tonically inhibit estra­
diol secretion and increase progesterone secre­
tion. In view of this, Morris et al. speculated on 
the possibility of administering an ACEI as pre­
ventive treatment, immediately after ovula­
tion27. However, considering the teratogenic 
potential of the ACEIs (e.g. enalapril produces 
renal defects when administered in the second 
and third trimesters of pregnancy), such ACEI 
therapy cannot be advised -  unless the cycle 
involves no gestation. Nevertheless, it is impor­
tant to know the pathophysiological particulars 
of the syndrome and identify the intervening 
mediators, since this opens the way for exerting 
action at different therapeutic levels.
CONCLUSION
The renin-angiotensin system (RAS) plays a 
very important role in ovarian physiology, and 
angiotensin II intervenes in the modulation of 
steroid synthesis and in follicle production and
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maturation, ovulation and follicular atresia. 
Ovarian hyperstimulation syndrome (OHSS) is 
secondary to an excessive ovarian response, and 
simply represents a pathological hyperresponse 
to ovarian stimulation with gonadotropins. In 
this context, both the ovarian and systemic 
renin-angiotensin systems contribute to the 
syndrome, together with other modulators of 
ovarian origin.
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Immunological aspects of 
ovarian hyperstimulation syndrome
Anders Enskog and Mats Brannstrom
INTRODUCTION
The main pathophysiological mechanism of 
ovarian hyperstimulation syndrome (OHSS) is 
increased vascular leakage from the ovaries as 
well as within the peritoneal lining of the 
abdominal and thoracic sinuses. This pro­
nounced plasma leakage to the third compart­
ment induces hypovolemia, and because of sec­
ondary tissue hypoperfusion, the syndrome may 
escalate to multiple organ failure. There may 
also be activation of the coagulation cascade, 
with the development of thrombosis in large 
vessels.
The increased permeability is also a hall­
mark of inflammation, and it has been suggested 
that there is a major role of inflammatory events 
during the development and establishment of 
OHSS. The risk factors for OHSS that also have 
a strong association with inflammation are poly­
cystic ovarian syndrome (PCOS)1,2, allergy3 and 
suppressed interleukin (IL)-IO production4. 
Their proposed mechanisms of action in OHSS 
pathophysiology are discussed in detail in this 
chapter. Moreover, the possible roles of inflam­
mation-associated regulatory T cells (TR) and 
local glucocorticoid activation in the pathophys­
iology of OHSS are mentioned.
In our large cohort study, more than 400 
patients in one in vitro fertilization (IVF) pro­
gram were prospectively followed, with blood 
samples taken throughout gonadotropin stimu­
lation3. Eighteen patients (about 3%) developed 
severe OHSS. Matched (for age, number of folli­
cles and pregnancy) controls from the study 
group were selected and compared with cases 
with severe OHSS. There was an increased 
prevalence of hypersensitivity (allergy) in the 
OHSS group, suggesting a link between an over- 
active immune response and the increased 
inflammatory events during the development of 
OHSS3. Moreover, the OHSS group had lower 
levels of the immunosuppressive cytokine IL-10 
at the early stages of gonadotropin stimulation, 
with a negative correlation between the num­
bers of follicles and IL-10 levels at the time of 
oocyte aspiration, seen only in the OHSS 
patients4. The OHSS patients showed increased 
IL-10 levels at later stages of gonadotropin stim­
ulation, indicating a natural immune response 
to counteract and thereby control the increasing 
inflammatory events.
Taking the above results into consideration, 
it seems as if immunological dysregulation is 
central in the events occurring in the ovary dur­
ing OHSS development, and this dysregulation 
may be present during the follicular phases
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(folliculogenesis, ovulation/luteinization). This 
imbalance may cause enhanced inflammatory 
changes in the ovary, thereby increasing the risk 
for OHSS.
This review is based on our current hypoth­
esis that women with inherent dysregulation of 
the immune system are more prone to develop 
OHSS during gonadotropin stimulation. Dysreg­
ulation can take the form of increased proin- 
flammatory activation, decreased anti-inflam­
matory activity or a combination of both. The 
increased inflammatory response can be exem­
plified by hypersensitivity/allergy and the 
decreased anti-inflammatory response by an 
altered IL-10 response.
INFLAMMATION AND  
HYPERSENSITIVITY
Since inflammation is a central event in the 
pathophysiology of OHSS, and also because 
inflammation is an integral part of the cycle- 
dependent ovarian phases, a brief overview of 
the general mechanisms of inflammation is 
given below. The clinical hallmarks of inflam­
mation are swelling (tumor), redness (rubor), 
heat (calor), pain (dolor) and loss of function of 
the affected area. These are the obvious signs of 
tissue protection, modulation and remodulation 
upon stimulation. Today we have considerable 
knowledge about the cellular and biochemical 
changes that explain these gross changes, and 
they can generally be described in terms of the 
non-specific as well as the specific inflamma­
tory response.
Non-specific inflammatory response
Cells of phagocytic lineage (macrophages/mono- 
cytes, Langerhans cells, dendritic cells, neu­
trophils) are important components of the non­
specific immune response, since they have a 
general capacity to ingest and destroy cells or 
threatening organisms. Other active cells, such 
as basophils, eosinophils and mast cells, release
opsonins, which enhance phagocytosis, as well 
as cytotoxic factors that kill cells or bacteria. 
The natural killer (NK) cell acts on altered mem­
branes of abnormal cells, and destroys the target 
cell by puncture of the cell membrane.
In inflammation, granulocytes and mono­
cytes play the initiating roles. A general early 
inflammatory phenomenon is that the endothe­
lial cells of the capillaries around the inflamma­
tory site are induced to express adhesion mole­
cules, enabling transmigration of leukocytes 
through the vascular wall to the affected site. By 
this mechanism, polymorphonucleated (PMN) 
leukocytes accumulate during the first 
30-60 min at the site, using their capacity to 
phagocytose damaged cells or intruders, along 
with release of lysosomal enzymes. The activa­
tion of macrophages starts soon after PMN acti­
vation. Activated macrophages release large 
quantities of tissue-remodeling enzymes, 
eicosanoids and cytokines. The cytokines typi­
cally act in a cytokine network to induce spe­
cific responses. The release of IL-1, IL-6 and 
tumor necrosis factor-a (TNFa) induces further 
extravasation and activation of neutrophils, 
monocytes and lymphocytes by up-regulation of 
adhesion molecules, and also increases perme­
ability directly by the release of vasoactive 
agents. The result is massive accumulation of 
activated leukocytes and edema. Macrophages 
also produce tissue factor, the counterpart of 
activated coagulation factor VII, to induce coag­
ulation through the extrinsic pathway. Today, 
this pathway is known to be the most important 
way to induce the coagulation cascade in vivo.
The cytokines that are released from 
macrophages also induce the production of 
locally and systemically acting acute-phase pro­
teins. The local response is in part generated by 
activation of the coagulation, kinin-forming and 
fibrinolytic pathways. Acute-phase proteins also 
increase vascular permeability and the expres­
sion of adhesion molecules, with the ability to 
induce contraction of vascular endothelial 
cells5.
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Specific inflammatory response
This response is induced after the initial non­
specific response. Cellular processing to activate 
humoral (B cells) and cell-mediated (T cells) 
lymphocytes depends on specific antigen- 
presenting cells (APCs). APCs are dendritic 
cells, Langerhans cells, monocytes, macro­
phages and, in some cases, B cells. The APCs 
carry human leukocyte antigen (HLA) class II on 
their surfaces. HLA class I molecules are 
expressed on all nucleated cells, in contrast to 
HLA class II. T lymphocytes, that express CD3, 
are subdivided into T helper (Th) cells express­
ing CD4, which recognize HLA class II, and T 
cytotoxic (Tc) cells expressing CD8, which rec­
ognize cells expressing HLA class I together 
with the antigen expressed on their surface. 
APCs have the capacity, after ingestion of mate­
rial, to expose an antigen, together with HLA 
class II on their cell membranes, to Th cells. 
This activation of Th (CD4+) cells results in the 
production of specific combinations of 
cytokines to drive the immune response in cer­
tain directions. This entire process takes place 
in the lymph node, where APCs enter to find a 
specific Th cell that responds to the specific 
antigen.
When activated, Th cells divide to enhance 
the production of cytokines that activate other 
cells such as monocytes/macrophages, Tc 
(CD8+) cells that are involved in cytotoxic 
events and B cells that proliferate and differen­
tiate into antibody-producing plasma cells, rec­
ognizing the same specific antigen. When B 
cells differentiate into plasma cells, the organi­
zation of the cytokine milieu will determine the 
type of antibodies that are produced.
ThI and Th2
There exist principally two subgroups of TH 
cells arising from naive (ThO) cells, dependent 
on their specific cytokine profile produced6, 
which can be more cytotoxic (ThI) or a more 
immunoglobulin E (IgE)-mediated (Th2)
response. Recent data also indicate other popu­
lations of Th cells with a regulating function 
(Tr). In development of the polarization of TH 
cells, which takes place in the lymph node7, the 
pivotal cytokines that stimulate TH1 production 
are IL-12 and interferon-y (IFNy). The important 
cytokine concerning Th2 development is IL-4.
The ThI cytokines IFNy and IL-12 signal 
through different cellular pathways, activating 
the transcription factors (tf) STAT 1 and STAT 4, 
respectively. As a result of activating STAT 1 
there will be a production of the master tf T-bet, 
which together with STAT 4 activation, 
increases the production of IFNy. In contrast, 
activation of the IL-4 receptor in Th2 develop­
ment induces tf STAT 6, with production of the 
master tf GATA-3, and this results in increased 
production of IL-4 and IL-57. Together, this indi­
cates a delicate balance between TH1 and TH2 
T-lymphocytes with their different cytokine 
profiles.
The result of the specific TH1 cytokine 
response is activation of Tc cells, NK cells and 
macrophages involved in cell-mediated effects, 
but also switching of B cell activity towards 
some subgroups of IgG production. The Th2 
cells produce cytokines that trigger B cells to 
switch to IgE production and that also activate 
eosinophils.
A central cytokine in the activation of T cells 
is IL-2, which is mostly produced by TH1 and Tc 
cells8. IL-2 is a proliferation factor for activated 
T cells, and stimulates the development of a 
subgroup of regulatory T cells. The IL-2 receptor 
exists as low-, intermediate- and high-affinity 
receptor subtypes. The high-affinity receptor 
(100-fold increased affinity compared with the 
low-affinity subtype) is expressed shortly after 
stimulation of the T cell receptor, with the 
resulting production of IL-2.
Hypersensitivity
Hypersensitivity, or an allergic reaction, differs 
from the protective immune response in that it 
is inappropriate to the host. The reaction
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includes activation of the humoral and/or cell- 
mediated immune response.
Hypersensitivity reactions are divided into 
four different types. Classification into types I, II 
and III depends on the specific type of antibody 
that reacts with the antigen challenge. The type 
I reaction is a Tr2-dependent reaction, which 
includes activation via IgE antibodies of mast 
cells and basophils and a release of histamine 
and other mediators. Activation of eosinophils 
causes airway inflammation and asthmatic 
hyperresponsiveness9. Other forms of type I 
hypersensitivity reactions are rhinitis and 
atopic dermatitis. The switch to IgE production 
and the accumulation of eosinophils are under 
control of the Th2 cytokines IL-4 and IL-5, 
respectively. Other TH2 cytokines such as IL-9 
and IL-13 contribute to airway hypersensitivity 
in asthma9.
In hypersensitivity types II and III, the anti­
bodies involved are of non-IgE type, and these 
activate complement factors or bind to inflam­
matory cells (monocytes/macrophages and NK 
cells), which do not release histamine and other 
related substances.
Type IV hypersensitivity (delayed hypersen­
sitivity reaction) is mediated by TH1 cells. The 
antigen is processed by APCs, and following 
stimulation by cytokines from APCs the ThI is 
activated and produces cytokines that induce 
accumulation and activation of monocytes/ 
macrophages. This reaction also involves induc­




There are several endogenous ways to modulate 
the inflammatory response indirectly and 
directly or in terms of prolongation/shortening 
of the inflammation. Those that have been 
described in the context of OHSS are discussed 
below.
IL-10
A typical inflammatory response with the pro­
duction of proinflammatory cytokines such as 
IL-1, IL-2 and TNFa is followed by IL-10 pro­
duction with a latency of a few hours. The 
delayed secretion of IL-10 secures that the 
inflammatory response in time will be down- 
regulated. The isolated induction of IL-10 with­
out preceding secretion of proinflammatory 
cytokines seems to be a rare event10. A delay of 
IL-10 increase during ovarian stimulation was 
seen in patients who later developed OHSS4.
The cytokine IL-10 is a non-covalent homo­
dimer with a molecular weight of 17-18 kDa11. 
There are two different IL-10 receptors 
described that cooperate in IL-10 binding. They 
are expressed on most hemopoietic cells. IL-10 
is produced by CD4+ and CD8+ T cells, 
macrophages, B cells, dendritic cells11’12 and 
keratinocytes11. The action of IL-10 includes a 
broad repertoire with multiple effects on many 
different cell types to induce an overall anti­
inflammatory effect.
Inhibitory effects of IL-10 on APCs13-16 occur 
by a decrease of the expression of costimulatory 
molecules17,18. Cytokine production (IL-la and 
-(3, IL-6, IL-10, IL-12, IL-18, granulocyte colony- 
stimulating factor (G-CSF), macrophage (M)- 
CSF, GM-CSF and TNFa) from activated mono­
cytes/macrophages is inhibited by IL-1011, 
which also inhibits the production of 
chemokines, reducing the recruitment of leuko­
cytes19-22. The IL-10 effect on T cells is that IL- 
10 partially inhibits the production of cytokines 
such as IFNy, TNFa and IL-4. This results in 
decreased activation of ThI and Th2 cells. An 
important effect is the reduction of cyclo-oxyge­
nase (COX)-2 expression and thereby 
prostaglandin production by a suppressive 
effect on nuclear factor kappa B (NFkB)23.
In the human it is proposed that IL-10 is 
important to control autoimmune disease24-26. 
The net effect of lack of IL-10 function can be 
seen in mice with deletion of IL-10, typically
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with increased ThI response and increased 
clearance of infections27. Interestingly, the mice 
develop exaggerated allergic and asthmatic 
responses and will develop enterocolitis compa­
rable to Crohn’s disease.
The increase in coagulation capacity during 
any inflammation depends on the increased pro­
duction of acute-phase proteins including coag­
ulation factors such as activated factor VII and 
tissue factor. IL-10 reduces the amount of tissue 
factor produced by monocytes, thereby reducing 
the procoagulatory activity28.
Vascular endothelial growth factor (VEGF) is 
the most potent inducer of vascular leakage29, 
and has been proposed as a major factor 
involved in the development of OHSS30, and in 
angiogenesis in the corpus luteum31. Nitric 
oxide (NO), also a vascular leakage factor, 
increases in the systemic blood circulation dur­
ing gonadotropin stimulation32, and is also up- 
regulated by the expression of inducible NO 
synthetase (iNOS) enzyme abundant in mono- 
cytes/macrophages. Both VEGF and iNOS are 
down-regulated by IL-1033,34, and IL-10 has the 
capacity to regulate the vascular leakage compo­
nent induced by these factors.
Regulatory T cells and IL-2
Regulatory T cells (TR), a subset of TH cells35, 
can be subdivided into T regulatory cells (Treg) 
and Trl. Treg cells (CD4+CD25+) are unique 
owing to their expression of the a subunit CD25, 
which is an essential subunit of the high-affinity 
IL-2 receptor. The tf FOXP3 is a key regulator in 
Treg function since it induces the expression of 
high-affinity IL-2 receptor. The expression of 
this high-affinity IL-2 receptor makes Treg 
responsive at low IL-2 concentrations, and func­
tional early in an inflammatory event. Treg 
works through direct cell contact as opposed to 
common immune cell interactions, which work 
mostly through intercellular communication by 
cytokine production.
The Trl cells that produce IL-10 are impor­
tant for the Treg to gain control of autoreactive 
and hyperreactive reactions36. The Trl cells can 
by their production of IL-10 modulate the 
inflammatory response in TrI, Tr2 and APCs36. 
The central role of Trl and IL-2 (Treg) in inflam­
mation makes them likely candidates as patho­
physiological factors in OHSS.
The above indicates a role for T cell regula­
tion, as CD8+ T cells exist in the ovary37 and 
need surveillance. A pronounced cytotoxic 
response can be controlled by the production of 
IL-10 from macrophages and Trl cells. An OHSS 
patient with low production of IL-10 could react 
with increased inflammatory response due to a 
late increase to the concentration of IL-10 nec­
essary to control the inflammatory response.
Glucocorticoids
Glucocorticoids are well-known anti-inflamma­
tory factors with multiple effects on cells. Glu­
cocorticoids affect the ovary by direct action on 
glucocorticoid receptors38. Cortisol and cortisol- 
binding protein are present in human follicular 
fluid39, and an effect on granulosa cells has been 
suggested40. The follicle by itself regulates glu­
cocorticoid activity by the action of 11(3- 
hydroxysteroid dehydrogenase (11|3HSD) type 
2, which converts the biologically active cortisol 
into inactive cortisone and lipHSD type 1, 
which in turn converts cortisone into corti­
sol40.The mid-cycle luteinizing hormone (LH) 
surge, or human chorionic gonadotropin (hCG) 
as in IVF cycles, changes the expression to a 
marked increase in 11|3HSD type l 41, so that 
more local ovarian anti-inflammatory action is 
seen due to increased intrafollicular cortisol lev­
els. A key regulator in this seems to be IL-1, 
which increases the mRNA levels of 11|3HSD 
type 1 more than 30-fold42 in ovarian surface 
epithelial cells.
We propose that defects in the ovarian 
induction of lipHSD type 1 at ovulation may 
decrease the local ovarian anti-inflammatory
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mechanisms and lead to OHSS development. As 
one effect of glucocorticoids is the induction of 
IL-10 in macrophages43, an impaired glucocorti­
coid response may result in decreased IL-10 reg­
ulation, which could be an important factor in 
the development of OHSS.
Inflammation in PCOS
Polycystic ovarian syndrome (PCOS) affects 
approximately 6-10% of reproductive-aged 
women44, and the syndrome is one of the most 
established risk factors for OHSS development 
during gonadotropin stimulation45-47. One of 
the characteristics of PCOS is abdominal obe­
sity, and this group of obese PCOS women has a 
risk of about 40%44 to develop the metabolic 
syndrome, i.e. dyslipidemia, glucose intolerance 
or diabetes mellitus type 2 and hypertension48.
Excess adipose tissue located at the 
abdomen seems to play a role in the pathophys­
iology of the metabolic syndrome49. An 
increased amount of white fat tissue results in 
increased production of proinflammatory 
cytokines such as TNFa, IL-6 and also IL-10, 
cytokines produced by monocytes/macro- 
phages. In the white fat tissue of lean people, 
macrophages constitute < 10% of the cells, 
whereas in obese people they constitute up to 
40% of the cells50. The increase in these 
cytokines in obese women is reduced with 
changes in lifestyle (increased physical activity, 
reduced body weight), which in turn reduces 
the prevalence of the metabolic syndrome51.
Interestingly, macrophages have the capacity 
to induce iNOS to produce huge amounts of NO, 
which together with TNFa and other proinflam­
matory cytokines is instrumental in the devel­
opment of dyslipidemia and type 2 diabetes52. 
PCOS per se may not increase the risk of devel­
oping type 2 diabetes, but the obesity often seen 
in PCOS may be the key factor for this develop­
ment53, since a relationship was seen between 
increased body mass index (BMI), IL-6 and C- 
reactive protein (CRP).
High IL-10 concentrations seem to protect 
against development of the metabolic syndrome 
both in obese and non-obese women, whereas a 
low IL-10 predisposes both groups to develop­
ment of the metabolic syndrome51. In summary, 
a low IL-10 seems to be involved the develop­
ment of the metabolic syndrome, which is more 
often seen in PCOS patients. Women with PCOS 
and low IL-10 production with or without obe­
sity may be in a state of increased inflammation 
and thereby in a high-risk group to develop 
severe OHSS.
Inflammation in folliculogenesis
During folliculogenesis, an altered immune 
response due to differences in IL-10 concentra­
tion may be a factor in OHSS development4. The 
total numbers of T cells are low in the sur­
rounding stroma and in the theca layer of grow­
ing follicles, but the cytotoxic (CD8+) subtype is 
present37. Taking into account reactions that are 
dependent on T helper cells type 1 (Tr I), Tr 2 
lymphocytes and the balancing Tr cells, the sit­
uation during normal folliculogenesis can be 
considered as a balance between these cell 
types. This notion is based on studies that show 
the presence of TH1 cytokines (IFNy, IL-2), Tr 2 
cytokines (IL-4, IL-5) and the down-regulatory 
cytokine IL-10 (mostly produced in Trl cells 
and monocytes/macrophages) in follicular 
fluid54. During OHSS, there seems to be an 
extremely pronounced Tnl-like response, with 
high levels of IL-1, IL-2 and IL-6.
In our study of IVF patients, we found that 
the patients who later developed OHSS had 
lower IL-10 levels at the start of gonadotropin 
stimulation4. Low IL-10 production could 
permit an inflammatory response to an increase 
in T r I  cytokine production, allowing an 
enhanced inflammatory response during follicu­
lar development.
Immune mechanisms in the ovary may also 
regulate angiogenesis during folliculogenesis 
and affect the development of OHSS. Relative
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hypoxia during rapid growth of the follicle or 
during inflammatory reactions may be instru­
mental in angiogenesis in the ovary. Hypoxia 
induces the expression of growth factors, of 
which VEGF is the most potent in relation to 
angiogenesis. IL-10 is also involved in angio­
genesis as it down-regulates VEGF production55.
Inflammation in 
ovulation/luteinization
The ovulatory cascade involves local alterations 
in and around the preovulatory follicle, which 
occur from onset of the LH surge until rupture of 
the follicle. In controlled gonadotropin stimula­
tion for IVF, hCG is used as a substitute for LH. 
The triggering of the ovulatory cascade by hCG 
is obligatory for the development of OHSS, 
since OHSS will not develop without hCG/LH 
stimulation.
The cooperative actions of inflammatory 
mediators, such as plasminogen activator (PA) 
and plasmin, along with matrix metallopro- 
teinases (MMPs), degrade the collagen fibers at 
the apex of the follicle and this results in 
decreased tensility. Simultaneously, vascular 
leakage and blood flow in the vasculature of the 
follicle are augmented. Inflammatory mediators 
such as prostaglandins56 and leukotrienes57 are 
involved in these vascular changes.
Inflammatory cells are also important in 
ovulation, and several reports have demon­
strated that the abundance of various subsets of 
leukocytes increases in the ovulating follicle. 
Mast cells are located in the central medullary 
portion of the ovary58, and in the thecal layer59. 
A preovulatory increase in histamine content 
has been observed in the human ovary60.
The density of neutrophils in the ovary 
increases after the preovulatory LH surge, 
clearly described in rats37, sheep61 and pigs62. In 
the human these cells accumulate specifically 
in the tunica albuginea and theca layer of the 
preovulatory follicle63. Several lines of evidence 
suggest that macrophages are the most promi­
nent leukocyte subtype in the follicle, and that 
activation of these cells is central for ovulation 
to occur. Macrophage numbers increase consid­
erably in the human follicle wall at ovulation63 
by transmigration, involving leukocyte- 
endothelial cell recognition by specific adhesion 
molecules on endothelial cells of the ovary and 
adhesion receptors on leukocytes64. Macro­
phages carry the nuclear as well as membrane 
estrogen receptors, suggesting that they may 
respond directly to this steroid65.
Instrumental in this follicular leukocyte 
extravasation are chemokines, a group of factors 
of great importance in both ovulation and 
OHSS. Human theca cells of large antral folli­
cles produce the neutrophil-specific chemokine 
IL-866, and elevated IL-8 levels are seen in fol­
licular fluids of IVF patients and of naturally 
cycling women after the spontaneous LH surge. 
The macrophage-specific chemokine monocyte 
chemotactic protein (MCP)-l is found in high 
levels in human follicular fluid67. Decreased 
ovulation was observed when neutrophils were 
depleted from the peripheral blood of rats dur­
ing ovulation68 and when macrophages were 
depleted from mouse ovaries68. Changes in phe­
notype and secretory activity of some leukocytes 
to a more proinflammatory, promigratory pro­
file70,71 are other events in ovulation.
Several cytokines are produced at high lev­
els in the ovary by invading leukocytes or by the 
theca and granulosa cells. A higher concentra­
tion of GM-CSF exists in follicular fluids of 
hyperstimulated women compared with natu­
rally cycling women, and the receptor as well as 
the ligand is present in human granulosa-lutein 
cells72. Macrophage colony-stimulating factor 
(M-CSF) and its receptor (cFMS) are found in 
high concentrations in the human ovary73.
Ovarian IL-1 induces ovulation and ampli­
fies the LH-induced ovulatory response in ex 
vivo perfused rat ovaries74, and the IL-1 receptor 
antagonist decreases LH-supported ovulation in 
vivo71. The effects of IL-1 in facilitating ovula­
tion may be related to its stimulatory function of
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prostaglandins, MMPs, plasminogen activator 
activity and nitric oxide production, as well as 
IL-1875.
Human granulose-lutein cells secrete IL-276, 
and an effect of IL-2 on the lutenization process 
has been proposed because of its ability to 
regulate progesterone production in human 
granulosa. The IL-2 production could also result 
in activation of Treg cells and thereby reduce 
inflammation. As macrophages seem to domi­
nate the cellular response in ovulation/ 
luteinization a regulatory effect of locally pro­
duced IL-10 should be taken into consideration.
Inflammation in hyperreactivity
We demonstrated an almost doubled prevalence 
of hypersensitivity (allergy) in patients with 
OHSS (36%) in comparison with controls 
(21%)3. Allergy was defined as the presence of 
documented type I- or type IV-mediated hyper­
sensitivity (see below). The result suggested for 
the first time that systemic immunological 
mechanisms could be involved in OHSS devel­
opment. In the same study we were unable to 
identify the increased presence of infection or 
intercurrent autoimmune disease in the OHSS 
group. We also showed lower levels of IL-10 at 
the start of gonadotropin stimulation in the 
OHSS group4.
The amount of IL-10 produced is controlled 
to 50-75% by genes52,77,78, and there also exists 
an intraindividual variation of about 20%79. 
Eleven promotor and two microsatellite varia­
tions have been described77,78 in the IL-10 
genome, together forming 13 common IL-10 
haplotypes. Four of these haplotypes dominate, 
and are found in 75% of the population80.
The expression of IL-10 increases during the 
early stages of a healthy pregnancy, whereas 
reduced amounts are described in the 
endometrium and placental tissues of women 
with recurrent spontaneous abortions and pre­
eclampsia27, and, in infertility, low IL-10 pro­
duction has been described81.
Reactivity against potential allergy-inducing 
antigens can be a normal step in the body, but in 
patients without overt hypersensitivity this 
reaction is rapidly down-regulated by Treg 
cells82, whereas in the allergic patient this reac­
tion dominates the process.
In hypersensitivity patients, the induction of 
tolerance by increasing concentrations of the 
antigen has recently been shown to induce IL- 
10-producing regulatory T cells9,83-85.
Earlier studies demonstrated a shift from 
Th2 to ThI immune response towards the aller­
gen86,87, with an increase in IgG antibodies and 
a decrease in the IgE-mediated response88. As 
IL-10 can induce a shift toward the production 
of IgG4, this may have an effect on reducing 
hypersensitivity, which could persist for at least 
3-4 years89.
Other ways to induce hyposensibility 
include the use of topical or systemic corticos­
teroids, resulting in the inhibition of T cell acti­
vation and Th2 cytokine expression as well as 
an increased production of IL-10 by 
macrophages43. In vitro studies of the immune 
response toward allergens shows that vitamin 
D3 together with corticosteroids can induce Tr 
phenotypes, producing IL-10, in turn suppress­
ing the Tr2 response9,90. Although clinically 
effective, corticosteroid therapy does not seems 
to alter the initial sensitization, as the reaction 
returns after cancellation of the medication.
In summary, IL-10 is central in regulation of 
the immune response, and a genetically con­
trolled low production of IL-10 may have a cen­
tral role in the control of hypersensibility, and 
control of the inflammatory response as seen in 
situations such as pregnancy and infectious 
disease.
CONCLUSION
Based on the restricted knowledge concerning 
the pathophysiology of OHSS we have today, we 
propose a simplified working hypothesis of the
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dysregulated immune functions that contribute 
to the development of OHSS.
In the normal situation of controlled 
gonadotropin stimulation, where IL-10 levels 
are within normal ranges, IL-10 controls and 
restricts the ovary-related inflammatory 
response (Figure 1). In contrast, with an inher­
ently low IL-10 production, the ovary-related 
inflammatory response will escalate and con­
tribute to the development of OHSS (Figure 2).
In this review, several immunological factors 
in the development of OHSS have been dis­
cussed. We acknowledge that the proposed 
hypothesis is still only a basic description of the 
complex immune mechanisms in the ovaries of 
OHSS patients. Rapid expansion of the 
immunology field, together with growing 
knowledge about intraovarian regulation of fol­
licular development/ovulation, provides a new 
and complex research field concerning
Normal IL-10 production
Figure 1 Controlled follicular development/ovulation and avoidance of OHSS due to normal inter­
leukin-10 (IL-10) levels. IL-10 reduces the activation of antigen-presenting cells (APCs) and T helper 
(Tr) cells and induces a general reduction of vascular endothelial growth factor (VEGF), cyclo- 
oxygenase-2 (COX-2), inducible NO synthetase (iNOS), chemokines and tissue factor. T regulatory 
cells type 1 (Trl) control ThI and Th2 and thereby diminish hypersensitivity through the production 
of IL-10. A normal function of ll(3-hydroxysteroid dehydrogenase (11(3HSD) type 1 increases the 
potent anti-inflammatory cortisol, which induces IL-10 in macrophages. Normal IL-10 levels reduce 
polycystic ovarian syndrome (PCOS)-related inflammation. Tc, T cytotoxic cells
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Figure 2 Development of OHSS due to low IL-10 levels (see Figure 1 for definitions). Low IL-10 lev­
els increase the activity of APCs and TH cells and induce a general increase of VEGF, COX-2, iNOS, 
chemokines and tissue factor. These changes result in increased proinflammatory activity, cytokines, 
allergy, thrombotic events and vascular leakage. Trl cells cannot control TH1 and TH2 cells and 
increase the possibility of hypersensibility. Increased function of llpHSD type 2 decreases the potent 
anti-inflammatory cortisol and increases the amount of fairly inactive cortisone. The net effect is low 
IL-10 and increased PCOS-related inflammation. During uncontrolled follicular development/ovula- 
tion, the intraovarian inflammatory reaction is greatly enhanced. IVF, in vitro fertilization
immunology and OHSS. To be able to solve 
many of the problems concerning the identifica­
tion of patients at risk for OHSS and its treat­
ment, it is of importance not only to utilize mod­
ern molecular biology techniques (for example, 
gene expression profiling), but also to use mate­
rial from OHSS patients identified in prospec­
tive studies with well-defined OHSS criteria. 
The significance of all results obtained should 
be challenged in prospective randomized stud­
ies testing different factors that are proposed to 
interfere in OHSS pathophysiology.
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CHAPTER 13
Genetic aspects of 
ovarian hyperstimuiation syndrome
Anne Delbaere, Lucia Montanelli, Guillaume Smits, 
Sabine Costagliola and Gilbert Vassart
While nearly all cases of ovarian hyperstimuia­
tion (OHSS) arise as a complication of ovulation 
induction therapies, spontaneous forms of the 
syndrome have been reported in rare instances 
during pregnancy1-8. Several cases were 
reported during multiple pregnancies7 or hyda- 
tidiform moles, known to be associated with 
supraphysiological production of human chori­
onic gonadotropin (hCG)5. Other cases were 
associated with hypothyroidism, and it was pro­
posed that the high levels of thyroid-stimulating 
hormone (TSH) could stimulate the ovaries6. 
Some cases were recurrent, with development 
of the syndrome observed in 2-6 consecutive 
pregnancies1-4.
MUTATIONS IN THE FOLLICLE 
STIMULATING HORMONE RECEPTOR 
GENE IN SPONTANEOUS OHSS
It is in the last category of patients, with recur­
rent OHSS, that four different mutations were 
recently identified in exon 10 of the follicle 
stimulating hormone (FSH) receptor gene 
(Figure l)9-12.
Smits et a l 9 identified a heterozygous muta­
tion in the FSH receptor of a patient presenting 
with spontaneous OHSS during each of her four
pregnancies2. The mutation consisted of the 
substitution of an adenine for a guanine at the 
first base of codon 567 of the FSH receptor gene, 
resulting in the replacement of an aspartic acid 
with an asparagine at the cytoplasmic end of 
transmembrane helix VI in the serpentine 
domain (mutation D567N) (Figure 1). Vasseur et 
al.10 identified another heterozygous mutation 
in a patient who developed OHSS during all of 
her four pregnancies that went on beyond 6 
weeks of gestation. The mutation was also found 
in the DNA of two of the patient’s sisters, who 
similarly presented with spontaneous OHSS 
during their pregnancies, but not in that of a 
third, unaffected sister. It consisted of the 
substitution of a thymidine for a cytosine at the 
second base of codon 449, resulting in the sub­
stitution of isoleucine for threonine at the upper 
part of the third transmembrane domain of the 
receptor (mutation T449I) (Figure 1). More 
recently, Montanelli et al.11 described a distinct 
heterozygous mutation in a patient who pre­
sented with spontaneous OHSS during each of 
her two pregnancies. The mutation was also 
found in the DNA of her sister who developed 
OHSS during her unique pregnancy4. As for the 
mutation described by Vasseur et al., it also 
involved codon 449, but at its first base, with 
substitution of a guanine for an adenine, 
causing a different amino acid replacement of a
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Figure 1 Schematic representation of the follicle stimulating hormone (FSH) receptor with locations 
of the D567N/G and T449I/A mutations (gray circles) identified in patients presenting spontaneous 
OHSS. The locations of polymorphisms T307A and N680S of the FSH receptor are represented by 
black triangles
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threonine with an alanine (mutation T449A)11 
(Figure 1). A fourth mutation was identified in a 
patient diagnosed as having a hyperreactio 
luteinalis8. This clinical condition appears to be 
similar to spontaneous OHSS when it develops 
in the first trimester of pregnancy, which was 
the case in this patient. Similarly to the muta­
tion described by Smits et a l.,9 the mutation 
implicated codon 567 of the FSH receptor gene 
but at its second base, consisting of the substi­
tution of a guanine for an adenine, which 
induced the replacement of an aspartic acid 
with a glycine at the cytoplasmic end of trans­
membrane helix VI in the serpentine domain 
(mutation D567G)12 (Figure 1). This last muta­
tion had been previously reported in a hypophy- 
sectomized man, who, despite undetectable 
serum gonadotropin levels had normal testis 
volume and semen parameters13. It was the first- 
described activating mutation of the FSH 
receptor which autonomously sustained sper­
matogenesis in the absence of gonadotropins13. 
The functional characterization of the mutant 
FSH receptors in transfection experiments 
revealed that their sensitivity to FSH was mini­
mally affected, but they all displayed an abnor­
mally high sensitivity to hCG (Figure 2)9"11’14. In 
addition, all mutant receptors also displayed 
constitutive activity together with an increased 
sensitivity to TSH9-11,14. In the initial report, the 
T449I mutant receptor appeared to produce sim­
ilar basal levels of cyclic adenosine monophos­
phate (cAMP) as the wild-type receptor, and 
could not be activated by TSH10. However, in 
contrast to the original description, further site- 
directed mutagenesis and functional experi­
ments demonstrated that the T449I mutant FSH 
receptor also showed constitutive activity and 
an abnormal responsiveness to TSH14. Unex­
pectedly, the four mutations reported so far 
affected the serpentine portion of the FSH recep­
tor rather than the hormone-binding ecto- 
domain of the protein, which is known to be 
responsible for recognition specificity in glyco­
protein hormone receptors15,16. This observation 
led to the hypothesis that the emergence of
chorionic gonadotropin (CG) during the evolu­
tion of primates has been accompanied by the 
development of an intramolecular barrier to 
activation, within the serpentine domain of the 
FSH receptor, preventing its promiscuous acti­
vation by CG17. Indeed, study of the phenotype 
of spontaneous FSH receptor mutants and addi­
tional site-directed mutagenesis experiments 
established a clear relationship between consti­
tutive activity and lowering of specificity in FSH 
receptor mutants14. The increase in sensitivity 
to hCG is accompanied by a very modest 
increase in binding affinity. This is consistent 
with the suggestion that the gain of sensitivity of 
the mutants to hCG would be due to lowering of 
an intramolecular barrier to activation rather 
than to an increase in binding affinity17, with 
the consequence that a physiological concentra­
tion of hCG would become an effective FSH 
receptor stimulus during early pregnancy. 
Interestingly, it seems that protection of the 
TSH receptor against stimulation by hCG has 
evolved differently, relying on the hormone­
binding ectodomain to avoid pregnancy 
hyperthyroidism15,18.
RELATIONSHIP BETWEEN MUTANT 
FSH RECEPTORS AND SPONTANEOUS 
OHSS
The abnormal functionality of the mutant FSH 
receptors in vitro provides a rational explanation 
for their implication in the development of 
spontaneous OHSS in vivo. During pregnancy, 
the expression of FSH receptors decreases dras­
tically in the corpus luteum, but remains con­
stant in granulosa cells of developing follicles19. 
These receptors are usually not or very weakly 
stimulated during pregnancy, as pituitary 
gonadotropins fall to very low or undetectable 
levels in the serum. In the presence of a 
mutation rendering them abnormally sensitive 
to hCG, these receptors are stimulated under the 
action of pregnancy-derived hCG, resulting in 
the recruitment and growth of a follicular
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Figure 2 Functional characteristics of the four follicle stimulating hormone (FSH) mutant receptors 
identified in patients presenting spontaneous OHSS. Levels of cyclic adenosine monophosphate 
(cAMP) observed using COS-7 cells transfected with wild-type human FSH receptor (wt hFSHr), 
D567N, D567G mutants (a) and T449I, T449A mutants (b) after stimulation with recombinant human 
(rh) FSH (lOIU/ml) and increasing concentrations of recombinant human chorionic gonadotropin 
(rhCG) (100-300 IU/ml). Each graph represents the mean ± SEM of at least two separate experiments
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cohort. Accordingly, the follicles enlarge and 
acquire LH receptors on granulosa cells which 
are further stimulated by hCG, inducing follicu­
lar luteinization together with the secretion of 
vasoactive molecules responsible for develop­
ment of the syndrome.
The stimulation of the mutated FSH recep­
tors most likely occurs at a threshold level of 
hCG which could vary according to the type of 
mutation, as suggested by in vitro site-directed 
mutagenesis experiments14. hCG usually peaks 
between 8 and 10 weeks of pregnancy and 
declines thereafter. In the same way, the symp­
tomatology of most spontaneous cases of OHSS 
develops as of 8 weeks’ amenorrhea, culminat­
ing at the end of the first trimester of pregnancy. 
From these findings, it appears that the 
development of spontaneous OHSS is the result 
of a non-physiological interaction between 
pregnancy-derived hCG and the ovarian FSH 
receptor, either in the presence of normal levels 
of hCG with a mutated FSH receptor, or in the 
presence of abnormally high levels of hCG as 
found in molar or multiple pregnancies, with a 
presumably normal FSH receptor20. Indeed, it 
has been shown recently that hCG was able to 
stimulate the FSH receptor in conditions that 
mimic a high ligand concentration15’21. This 
interaction between hCG and the FSH receptor 
is likely to be a prerequisite in the development 
of spontaneous OHSS, and could explain why 
symptoms in spontaneous cases of OHSS appear 
later than in iatrogenic OHSS, in which follicu­
lar recruitment and enlargement occur during 
ovarian stimulation with exogenous FSH20 
(Figure 3). Hence, spontaneous forms of OHSS 
generally occur between 8 and 14 weeks’ amen­
orrhea, differing from iatrogenic OHSS starting 
usually between 3 and 5 weeks’ amenorrhea.
FROM SPONTANEOUS TO 
IATROGENIC OHSS
Although differing by the timing of their occur­
rence, spontaneous and iatrogenic OHSS share
similar pathophysiological sequences: massive 
recruitment and growth of ovarian follicles, 
extensive luteinization provoked by hCG and 
oversecretion of vasogenic molecules by 
luteinized corpora lutea (Figure 3). FSH receptor 
mutations being directly implicated in the 
development of spontaneous OHSS, it was 
tempting to consider the possibility that such 
mutations or polymorphisms in the FSH recep­
tor gene could constitute risk factors in the 
development of the much more frequent iatro­
genic OHSS.
In contrast to naturally occurring mutations 
which appear to be rather rare, the FSH receptor 
and its promoter display some very common 
single-nucleotide polymorphisms. Two non- 
synonymous polymorphisms have been desc­
ribed in exon 10 of the FSH receptor22. The first 
is located at nucleotide position 919, occupied 
either by adenine or by guanine, leading to 
either threonine or alanine at position 307 of the 
receptor (T307A), just before the beginning of 
the first transmembrane helix (Figure l)22. The 
second is located at nucleotide position 2039 
occupied either by adenine or guanine, leading 
to either asparagine or serine at position 680 of 
the receptor (N680S), located intracellularly at 
the end of its C-terminal tail (Figure 1). In the 
Caucasian population, the two FSH polymor­
phisms in exon 10 almost invariably occur in 
two haplotypes, leading to two allelic variants: 
threonine307-asparagine680 (allele TN) and 
alanine307-serine680 (allele AS)23. Recent 
reports suggest that the FSH receptor genotype 
could play a role in vivo in the ovarian response 
to FSH stimulation. Analysis of the FSH recep­
tor polymorphism at position 680 showed that 
patients homozygous for serine in position 680 
(SS) displayed a slightly higher basal FSH 
level24-26. In addition, higher requirements of 
exogenous FSH were necessary to achieve suc­
cessful ovarian stimulation for in vitro fertiliza­
tion (IVF) in patients with the SS680 genotype 
compared with patients with the NS680 or 
NN680 genotype24. In another retrospective
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Figure 3 Pathophysiological sequences of iatrogenic and spontaneous OHSS. In the iatrogenic form, 
follicular recruitment and enlargement occur during ovarian stimulation with exogenous follicle 
stimulating hormone (FSH). In the spontaneous form, follicular recruitment and enlargement occur 
later through promiscuous stimulation, by pregnancy-derived human chorionic gonadotropin (hCG), 
of a mutated FSH receptor (abnormally sensitive to hCG) or a wild-type receptor (in the presence of 
abnormally high levels of hCG). In both forms, massive luteinization of enlarged stimulated ovaries 
ensues, inducing the release of vasoactive mediators, leading to development of the symptoms. CG, 
chorionic gonadotropin; LH, luteinizing hormone; r, receptor. From reference 20 ©European Society 
of Human Reproduction and Embryology. Reproduced by permission of Oxford University 
Press/Human Reproduction
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study, the presence of serine in position 680 was 
associated with poor responses to gonadotropin 
stimulation in IVF, suggesting that individuals 
with the SS680 genotype could be associated 
with decreased FSH sensitivity27. However, a 
study conducted among normogonadotropic 
anovulatory patients resistant to clomiphene cit­
rate could not establish associations between 
FSH receptor genotype and ovarian sensitivity 
during ovulation induction with exogenous 
FSH26. It is possible that these discrepancies are 
related to differences in the ovarian stimulation 
protocols: in anovulatory patients, the treatment 
aims at monofollicular development, while for 
IVF, it aims at multifollicular development. The 
supraphysiological doses of FSH used during 
IVF stimulation protocols could therefore reveal 
differences in ovarian response according to 
FSH receptor genotype, which could not be 
manifest in more physiological conditions.
Analysis of the FSH receptor polymorphism 
was recently performed among patients who 
developed iatrogenic OHSS28. This pilot study 
involved 37 Caucasian patients who developed 
OHSS after an IVF cycle compared with a con­
trol IVF population (130 patients who did not 
develop OHSS after an IVF cycle) and with a 
Caucasian control population (99 patients)28. 
The OHSS population, as well as the control IVF 
population, displayed higher allelic frequencies 
of S680 in the FSH receptor gene than those 
observed in the Caucasian control population. 
Although not fully explained, this difference 
could be related to the inclusion of patients pre­
senting ovulatory disorders in the IVF control 
population and in the OHSS group25,26. No sig­
nificant difference could be established for the 
S680N polymorphism of the FSH receptor 
between the OHSS group and the IVF control 
population28. However, a significant enrichment 
in the N680 allele was observed as the severity 
of the syndrome increased28. This difference 
persisted when the analysis was performed 
between mild, moderate and severe OHSS 
patients who were pregnant. Bearing in mind
the limitations of the small number of patients 
studied, which could introduce potential sam­
ple biases, these data suggested that the FSH 
receptor genotype could not predict iatrogenic 
OHSS, but that the N680 allele of the FSH recep­
tor could be a predictor of severity of symptoms 
among OHSS patients28.
More clinical data are required to determine 
further the exact relationship between FSH 
receptor genotypes and the severity of OHSS 
symptoms after ovarian stimulation. In addition, 
further experimental data are necessary to 
understand the in vivo association of FSH 
receptor alleles and the response to ovarian 
stimulation. So far, the in vitro functional char­
acterization of the two FSH receptor variants 
(alleles TN and AS) in transfection experiments 
could not show significant differences in bind­
ing affinity, either in the production of cAMP or 
inositol phosphate after stimulation with 
FSH23,25. Several hypotheses have been pro­
posed, such as different expression of the vari­
ants at the cell surface, differences in their 
turnover or in their down-regulation rate, or dif­
ferent affinity for various FSH isoforms24. On 
the other hand, the S680N polymorphism of the 
FSH receptor could play no direct functional 
role in the development of OHSS, but instead be 
in linkage disequilibrium with other polymor­
phisms in the same or neighboring gene(s).
CONCLUSIONS AND PERSPECTIVES
The identification of mutations in the FSH 
receptor of patients presenting spontaneous 
OHSS provides for the first time a molecular 
basis for the physiopathology of spontaneous 
forms of the syndrome, and opens new perspec­
tives to understand the development of iatro­
genic OHSS. Being able to predict the individual 
ovarian response to exogenous FSH remains a 
challenge for IVF teams. While a mutation in the 
FSH receptor gene should be sought in the pres­
ence of recurrent or familial spontaneous OHSS,
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future work should aim to identify susceptibility 
genes in the development of iatrogenic OHSS. 
The individual response to controlled ovarian 
hyperstimulation is most likely a polygenic trait, 
as recently suggested by de Castro et al., who 
provided evidence of genetic interactions 
between the FSH receptor and estrogen 
receptors a  and (3 genes in relation to controlled 
ovarian hyperstimulation outcome29. The 
genetic background of the patient probably also 
plays a role in susceptibility to the increase of 
vascular permeability. Two clinical entities have 
been described in iatrogenic OHSS: early forms 
occurring 3-7 days after triggering of ovulation 
by hCG, and late forms developing 12-17 days 
after ovulation in close association with an ini­
tiated pregnancy30,31. The early pattern is 
related to an excessive response to gonadotropin 
stimulation, while the late pattern is more likely 
to be severe and is induced by endogenous hCG 
in conception cycles. Although the clinical 
sequences of the syndrome are very similar in 
both forms, it is possible that susceptibility to 
one or the other form differs between both pat­
terns: in the early form, the genetic background 
of the patient could influence the ovarian hyper- 
response to exogenous FSH, while in the late 
form, it would be more implicated in stimula­
tion of the corpora lutea by hCG. OHSS can 
indeed be viewed as a tremendous exaggeration 
of the local inflammatory-like reactions which 
accompany angiogenesis during corpus luteum 
formation in a normal menstrual cycle, with a 
massive release of vasoactive molecules such as 
vascular endothelial growth factor32,33, 
angiotensin II34>35 and various interleukins36. As 
the release of these molecules reaches a thresh­
old, physiological control mechanisms can be 
overstretched, leading to development of the 
symptoms of the syndrome. The respective 
genes of these vasoactive molecules could also 
constitute candidate susceptibility genes in the 
development of iatrogenic OHSS. These associ­
ation studies will require large series of patients, 
which will most probably only be obtained
through multicentric studies. The identification 
of patients susceptible to elicit a hyperresponse 
to standard stimulation treatments would allow 
adaptation of their treatment and avoidance, if 
not completely at least to a large extent, of 
OHSS, which remains a frequent and poten­
tially life-threatening complication of IVF.
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Potential new treatment implications derived 
from recent molecular developments in 
ovarian hyperstimulation syndrome
Raul Gomez, Ralf Zimmermann, Juan A Garcia-Velasco,
Jose Remohi, Carlos Simon and Antonio Pellicer
INTRODUCTION: THE VASCULAR 
ENDOTHELIAL GROWTH FACTOR 
SYSTEM IN OVARIAN 
HYPERSTIMULATION SYNDROME
It is known that common symptoms of ovarian 
hyperstimulation syndrome (OHSS) such as 
ascites and anasarca are a consequence of the 
extravasation of fluid from leaky vessels into 
body cavities, where it accumulates. Due to this 
extravasation a deficit in circulating volume 
develops, which can lead to hemoconcentration 
and/or prerenal failure. It is clear that increased 
vascular permeability (iVP) after gonadotropin 
administration is the main factor causing OHSS, 
but as human chorionic gonadotropin (hCG) 
itself has no vasoactive properties, its actions 
must be mediated by other specific vasoactive 
factors. It is likely that hCG induces the release 
of one or several ovarian substances that have 
potent and direct systemic effects on the vascu­
lar system, and is therefore responsible for the 
pathophysiology and its clinical presentations1.
It is likely that these mediators are of ovarian 
origin, produced in excess during induction of 
ovulation, because the syndrome resolves 
quickly in OHSS patients after oophorectomy or 
does not develop at all when the formation of an 
active corpus luteum is prevented (or does not
occur). This is very interesting, as it implies that 
hCG + ovary is an absolute requirement for the 
development of OHSS. Both oophorectomy and 
withholding hCG to prevent ovulation are effec­
tive, but not specific, approaches to prevent the 
formation of OHSS. Most efforts regarding 
OHSS research have been focused on trying to 
identify the ovarian vasoactive substance(s) 
induced by the effect of hCG.
Over the years, many substances involved in 
the regulation of vascular permeability have 
been implicated in causing OHSS. Some of them 
are still under investigation, the list of potential 
mediators including: estradiol2, histamines3, 
prostaglandins4, the ovarian renin-angiotensin 
system5, interleukin (IL)-6, IL-2 and IL-86, angio- 
genin7, insulin8 and the ovarian kinin-kallikrein 
system9 among others.
However, vascular endothelial growth factor 
(VEGF) has emerged as the main angiogenic fac­
tor responsible for increased vascular perme­
ability (iVP), leading to the extravasation of 
protein-rich fluid and, subsequently, the full 
appearance of OHSS. Both its vasoactive prop­
erties and its increased ovarian expression dur­
ing the development of OHSS suggest that VEGF 




VEGF was originally described as a tumor- 
secreted protein which caused substantial vas­
cular leakage10. It is a homodimer of relative 
molecular mass (Mr) ~  46 000 which is pro­
duced by many cell types11, including a variety 
of tumors, folliculostellate cells, macrophages, 
possibly podocytes, capsular epithelial cells in 
the renal glomeruli and granulosa cells12, among 
others. VEGF (vascular permeability factor 
(VPF) is a potent enhancer of endothelial per­
meability, being 50 000 times more potent than 
histamine13. VEGF increases capillary and venu- 
lar leakage, as a result of opening intercellular 
junctions between neighboring endothelial 
cells, as well as other morphological modifica­
tions that can rapidly occur 10 min after topical 
application, such as the induction of fenestrae 
in venular and capillary endothelia which nor­
mally are not fenestrated14.
There are several findings which support the 
role of VEGF in the development of OHSS. 
Serum VEGF levels increase after hCG adminis­
tration in superovulated women at risk of devel­
oping OHSS15. In fact, a rise in serum VEGF 
levels has been used as a marker for subsequent 
development of OHSS16. Moreover, VEGF 
plasma levels correlate with the clinical picture 
of OHSS17, and changes of VEGF levels in 
ascites have been correlated with the clinical 
course of OHSS18.
In women who develop OHSS, VEGF is over­
expressed and produced by granulosa-lutein 
cells19-23 and released into the follicular fluid in 
response to hCG24, inducing increased capillary 
permeability24-26. Similarly, we have shown that 
hCG stimulates the release of VEGF in human 
endothelial cells which, in turn, acts in an 
autocrine manner, increasing vascular perme­
ability27. Thus, both the granulosa and endothe­
lial cells may be involved in the production and 
release of VEGF in women treated with 
gonadotropins who develop OHSS. If the 
endothelium is certainly involved in the pro­
duction of VEGF, we still do not know whether 
only the vessels of the ovary, or the entire vas­
cular tree, participates in the production of 
VEGF, leading to OHSS.
The human VEGF gene has been mapped to 
chromosome 6pl228 and is made up of eight 
exons. Exons 1-5 and 8 are always present in 
VEGF mRNA, while the expression of exons 6 
and 7 is regulated by alternative splicing. This 
process allows the formation of various VEGF 
isoforms differing in length, all VEGF products 
having a common region. In humans, five differ­
ent VEGF mRNAs have been detected encoding 
the isoforms VEGF12i , VEGFi45, VEGFi65, 
VEGFigg and VEGF20629- Isoforms VEGFa2i and 
VEGFies appear to be mainly involved in the 
process of angiogenesis30, and are in fact the 
only ones that the ovary is able to secrete25.
The VEGF gene shows the same exonic 
structure in rodents and humans26. Murine- 
expressed VEGF isoforms VEGFi20, VEGFi44, 
VEGFi64, VEGFibs and VEGF20s are only one 
amino acid less in length when compared with 
human VEGF isoforms, and there is 95% protein 
homology between these two31. Similar to the 
human19-24,27, hybridization studies in the rat 
ovary have demonstrated significant VEGF 
mRNA expression seen mostly after the luteiniz­
ing hormone (LH) surge32.
Receptors for VEGF are present on the 
endothelial cell surface and belong to the tyro­
sine kinase receptor family33. They are also 
present in the inner theca of human folli­
cles12’23. Two specific endothelial cell mem­
brane receptors for VEGF have been identified: 
VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR)33,34. 
The receptor Flk-l/KDR appears to be mainly 
involved in regulating vascular permeability, 
angiogenesis and vasculogenesis35,36. Targeting 
the Flk-l/KDR receptor has been a goal for 
researchers working in gynecological oncology. 
Different specific VEGFR-2 blockers have been 
used in animal models which reduce tumor 
growth and ascites37’38. Although the mecha­
nism of ascites formation may be different in 
neoplasms and OHSS39, nobody had tried so far 
to reverse ascites formation in OHSS, targeting
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the VEGF system. This has been our main goal 
during the past few years.
Based on the above information, we basi­
cally describe in this chapter:
(1) The development of an OHSS animal 
model in order to demonstrate function­
ally the increased signaling through the 
VEGF/VEGFR-2 pathway as a key factor in 
the development o f OHSS and how inacti­
vation of this pathway by a variety of 
means can specifically and effectively 
block the iVP which underlies develop­
ment of the syndrome;
(2) How new clinical strategies may effec­
tively treat OHSS by targeting the VEGF 
system;
(3) Recent findings identifying women at 
increased risk and finally developing 
OHSS based on the up-regulation and 
bioavailability o f  VEGF.
UP-REGULATION OF VEGF PATHWAY 
AS KEY TO DEVELOPMENT OF 
INCREASED VASCULAR PERMEABILITY 
IN OHSS
Development of OHSS in an animal 
model
Our goal was to understand the pathophysiology 
of OHSS in order to expand treatment options 
beyond expectant management by directly 
influencing the VEGF/VEGFR-2 pathway.
We developed an in vivo rodent model which 
allows induction of OHSS, consistently includ­
ing the two main characteristics: ovarian 
enlargement and increased vascular permeabil­
ity leading to ascites. In immature rats, the 
hypothalamic-pituitary axis is inactive; there­
fore, follicle development is nearly inactive as 
these animals lack endogenous LH production, 
but it can be induced by the exogenous admin­
istration of gonadotropins. Follicle development 
was induced with pregnant mare’s serum 
gonadotropin (PMSG), 10IU, during 4 consecu­
tive days. On the 5th day these animals were 
injected with hCG, 30 IU, in order to trigger ovu­
lation. In agreement with previous results from 
Ujioka et a l 40, OHSS manifestations developed, 
including ascites and iVP, in these animals. The 
quantification of vascular permeability in such 
an animal model can be carried out objectively 
with the measurement of extravasation of a pre­
viously injected dye. Time-course experiments 
were performed to analyze vascular permeabil­
ity by injecting Evans blue dye into the femoral 
vein, and quantifying the amount of dye recov­
ered after irrigating the abdominal cavity with a 
fixed volume of saline 30 min later41. The results 
of these experiments (Figure 1) validated the 
animal model employed, because iVP values 
during the time course were observed in ani­
mals superovulated with PMSG if hCG was 
administered to trigger ovulation. No OHSS was 
observed in animals which received PMSG 
without hCG. This first experiment also pro­
vided useful information for later functional 
experiments showing maximal iVP at 48 h after 
hCG in all the PMSG -I- hCG-treated animals.
Increased permeability correlates with 
overexpression of VEGF and VEGFR-2
In addition to the vascular permeability experi­
ments, the expression of whole VEGF mRNA in 
the mesentery and ovaries employing the 
reverse transcriptase polymerase chain reaction 
(RT-PCR) was also measured to determine the 
tissue source(s) of VEGF. The reason for select­
ing the ovary or mesentery to measure VEGF 
expression was related to the possible ovarian or 
systemic origin of the syndrome, based on the 
presence of hCG receptors in both the ovary and 
endothelial cells. Hence, the ovary and the 
mesentery, as highly vascularized tissue, were 
selected as representative of an ovarian or sys­
temic origin of the syndrome, respectively. The
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Figure 1 Vascular permeability in three groups of animals injected with saline during 5 consecutive 
days (control group), 10IU pregnant mare’s serum gonadotropin (PMSG group) or PMSG and 10IU 
human chorionic gonadotropin (hCG) (OHSS group). EB, Evans blue
results of these experiments showed that in nar­
row correlation to vascular permeability (Figure 
1), ovarian mRNA VEGF expression increased 
during the time course, reaching peak values 
after 48 h, whereas no significant change in 
expression was observed in the mesentery (Fig­
ure 2). To demonstrate further the ovarian origin 
of VEGF, we showed that vascular permeability 
was not altered when ovariectomized rats were 
treated with PMSG + hCG41.
In addition, we also analyzed which of the 
VEGF isoforms were expressed by the ovaries of 
hyperstimulated animals with specific primers 
for conventional RT-PCR. The ovary expressed 
VEGF120 and VEGF164 isoforms. We showed that 
there was also an increase of VEGFR-2  expres­
sion in the ovaries, coincidental in time with
maximal vascular permeability42, demonstrating 
the involvement of the VEGF/VEGFR-2 system 
in OHSS. Immunohistochemistry showed VEGF 
in granulosa and in the zona pellucida of 
preovulatory and atretric follicles, and in 
granulosa-lutein and endothelial cells of whole 
corpus luteum41,42.
In summary, these experiments showed that 
the VEGF system (ligand and receptor 2) is up- 
regulated in the ovaries of hyperstimulated ani­
mals, coincidental in time with maximal 
vascular permeability, clearly suggesting a cru­
cial role for locally (ovary)-produced VEGF in 
OHSS. Although VEGF measurements in the 
serum/plasma of these animals would have 
provided us with more evidence to confirm the 
role of VEGF in OHSS, unfortunately VEGF
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Figure 2 Vascular endothelial growth factor (VEGF) mRNA expression in ovary and mesentery of 
OHSS animals. Adapted from reference 41. hCG, human chorionic gonadotropin
measurements in the serum of these animals 
were (are) in all cases below the limit of detec­
tion of the most sensitive enzyme-linked 
immunosorbent assay (ELISA) kits used.
Prevention of development of OHSS 
by interference with VEGF pathway
After the role of VEGF in establishing vascular 
permeability was demonstrated, a series of 
blocking experiments was designed through the 
administration of SU5416, a VEGFR-2 inhibitor, 
as a new strategy to prevent and treat OHSS by 
inhibiting an increase of vascular permeability. 
Since this was a totally new concept, primarily 
designed to be employed as an antiangiogenic 
approach in cancer patients, we attempted sev­
eral protocols of SU5416 administration in order
to block iVP in our OHSS animal models. We 
found that SU5416 should be administered after 
hCG, with a single injection of hCG being as 
effective as multiple injections41 (Figure 3). The 
reasons for this behavior can be found in the 
observation that the syndrome develops only 
during corpus luteum formation after the ovula­
tion process.
In any case, the ability to reverse hCG action 
on vascular permeability by targeting the 
VEGFR-2 employing SU5416 not only con­
firmed the key role of VEGF in OHSS, but also 
provided new insights into the development of 
strategies to prevent and treat the syndrome 
based on its pathophysiological mechanism, 
rather than using empirical approaches as we do 
today. In fact, tumor growth, neoangiogenesis
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Figure 3 Reversal of increased vascular permeability employing SU5416 (48 h after human chorionic 
gonadotropin (hCG) administration). Adapted from reference 41. EB, Evans blue; q24, injection of 
SU5416 every 24 h; q48, injection of SU5416 every 48 h; hCG, injection of SU5416 just after hCG 
administration
and ascites formation have been prevented in 
animals with different ovarian neoplasms by 
targeting the VEGF system43’44, and specifically 
the Flk-1 receptor with SU541645. Herein, we 
present evidence that the same approach can be 
used in the OHSS model.
Gene expression in hyperstimulated 
ovaries
In the previous experiments, we showed that 
inhibition of VEGF action was accompanied by 
reduced vascular permeability. However, the use 
of such strategies employing antiangiogenic 
drugs (in cancer patients) has been abandoned 
in women due to side-effects of these com­
pounds46-48. Aiming to find a specific non-toxic 
treatment for OHSS, we reverted to our hypoth­
esis utilizing microarray technology in order to 
investigate all the genes potentially involved in
the development of OHSS. We looked at the 
expression of gene products regulated under 
OHSS conditions. This approach resulted in the 
development of new approaches to block the 
onset of the syndrome by employing dopamine 
agonists.
Microarray technology has become one of 
the most powerful techniques to check, in a sin­
gle experiment, all the possible genes which are 
up- or down-regulated under the effects of 
administration of one or several compounds. We 
compared ovarian gene expression in animals 
subjected to different regimens of gonado­
tropins, including control animals and stimu­
lated rats developing OHSS49. Forty-eight hours 
after hCG, vascular permeability was measured, 
and mRNA from ovaries extracted to perform 
gene expression profiles in microarray filters 
containing 14 000 genes. In the microarray
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technology, RNA was reverse transcribed and 
transferred to nylon membrane filters under 
radioactive conditions. Clusters of 5 x 5 spot sig­
nals were analyzed using specific software, and 
the expression paired with other groups after 
background signal substraction. Only genes 
with a three-fold up- or down-regulation were 
considered to be significantly regulated. The 
hybridization results were confirmed by quanti­
tative fluorescence (QF)-PCR employing the 
same RNA in an ABI PRISM® 7700 thermocycler 
to amplify three up-regulated and three down- 
regulated genes. Also, immunostaining and 
cluster analysis were done. Gene expression 
showed 80 up-regulated and seven down-regu­
lated genes in OHSS as compared with mild 
stimulation and controls. Up-regulated genes 
were grouped into five families: cholesterol syn­
thesis, VEGF signal transduction, prostaglandin 
synthesis, oxidative stress process and cell cycle 
regulation. The down-regulation of tyrosine 
hydroxylase (TH, enzyme responsible for 
dopamine synthesis) was considered a charac­
teristic of OHSS as well.
Dopamine agonists to block OHSS
Taking together the results described above, it 
was realized that targeting the up-regulated 
genes could compromise basic cellular or phys­
iological processes, such as estradiol and prog­
esterone production, and ovulation. Hence, we 
focused on the down-regulated genes, hypothe­
sizing that they could act as natural inhibitors of 
the angiogenic processes which then needed to 
be enhanced or up-regulated.
Tyrosine hydroxylase, the key enzyme 
responsible for dopamine synthesis, was down- 
regulated, suggesting that perhaps dopamine 
could act as an antiangiogenic factor in the 
ovary; a deficit in its production after 
PMSG +  hCG administration in the OHSS ani­
mal model could be involved in iVP which char­
acterizes the syndrome. In fact, several reports 
showed that dopamine administration could
decrease vascular permeability in in vitro50 and 
in vivo51 cancer models by decreasing VEGFR-2 
phosphorylation, which is the first step in VEGF 
downstream signaling leading to iVP after VEGF 
binding to this receptor52. Although the mecha­
nism by which dopamine is able to decrease 
VEGFR-2 phosphorylation still remains 
unknown, we wondered whether the adminis­
tration of dopamine to experimental OHSS rats 
could be as effective for inhibiting iVP.
Thus, we performed a second series of exper­
iments in which the dopamine agonist 
bromocriptine (Br2) was employed in OHSS 
animals in order to study its effects on vascular 
permeability. Different doses of Br2 (0.1, 0.5, 1, 
5, 10 and 25mg/kg) were administered on the 
day of hCG injection in the form of pellets that 
continuously released the product. Vascular per­
meability was measured 48 h after hCG. In 
OHSS animals it was significantly reduced 
when 10 and 25 mg Br2 were employed (Figure 
4), demonstrating the efficacy of this approach.
Thus, we concluded that OHSS is associated 
with the up- and down-regulation of several 
families of genes in the ovaries. In addition to 
VEGF, the finding of up- and down-regulation of 
genes encoding for prolactin and dopamine 
expression encouraged the successful use of Br2 
to prevent increased vascular permeability49. 
Bearing in mind the few toxic and absent terato­
genic effects associated with dopamine agonist 
administration, these experiments provide the 
rationale to test Br2 as a safe and possible effec­
tive medication in the prevention/treatment of 
OHSS.
Several main questions remain unanswered 
after these experiments. One is whether 
dopamine really affects VEGFR-2 phosphoryla­
tion, because commercial antiangiogenic drugs 
with this kind of property have been shown to 
have very serious side-effects46-48, not observed 
after dopamine agonist49 administration. One 
possible explanation would be that VEGFR-2 
inhibition is not toxic per se, and side-effects 
observed with commercial drugs are due to the
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Figure 4 Reversal of increased vascular permeability with bromocriptine (Br2) in rat OHSS model. 
EB, Evans blue
chemical nature of these drugs and not to the 
molecular mechanism. Levels of VEGFR-2 phos­
phorylation in the ovaries of OHSS animals 
before and after the administration of dopamine 
agonists are currently being studied. If 
dopamine agonists are really able to block 
VEGFR-2 phosphorylation, the next question 
would be: what is their molecular mechanism of 
action? We do not know whether dopamine ago­
nists block iVP by competing with VEGF for 
VEGFR-2 binding, if they directly affect VEGFR- 
2 conformation or whether these effects are 
mediated through binding to their own 
dopamine receptors. As this is a new area of 
research, more studies are needed in order to 
elucidate this question.
THE ROLE OF VEGF IN OTHER 
STRATEGIES USED TO REDUCE OHSS 
INCIDENCE
Although based on an empirical approach, some 
clinical strategies developed to reduce the inci­
dence of OHSS, e.g. using different hormones to 
trigger ovulation, or coasting, have been suc­
cessful in achieving this purpose. Here, we 
focus on recent data providing evidence that the 
effectiveness of both of these approaches is at 
least partially related to targeting the VEGF sys­
tem. The rationale for using LH as a trigger for 
ovulation by reducing VEGF levels and, hence, 
OHSS is provided by studies performed on 
OHSS in animal models. Findings regarding the 
role of VEGF in coasting were made in OHSS 
patients.
Using hormones other than hCG to 
trigger ovulation: studies in an animal 
model
In many mammalian species, including 
humans, the mid-cycle surge of luteinizing hor­
mone (LH] initiates a series of events included 
under the term ovulation, comprising oocyte 
maturation, follicular rupture and luteinization 
of granulosa and theca cells. The LH surge is 
accompanied by a follicle stimulating hormone
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(FSH) surge which could be relevant to these 
processes as well. Because of the inconsistency 
of spontaneous LH surges and the wide use of 
gonadotropin-releasing hormone (GnRH) 
analogs, hCG has been clinically employed pref­
erentially. As already mentioned, the clinical 
use of hCG is associated with some undesirable 
effects such as OHSS. Whether LH and FSH 
induce the same phenomenon is not known. 
Thus, we aimed to study the biological activity 
of hCG, recombinant LH (rLH) and rFSH in an 
attempt to find out the minimum effective dose 
to induce ovulation and prevent OHSS in the rat 
model.
Immature female rats were treated with 
10IU PMSG for 4 days, and ovulation was trig­
gered with saline, 10 IU hCG, 10 IU FSH, 10 IU 
LH or 60 IU LH53. The number of ovulated 
oocytes entering the tubes 17-20 h after hCG, as 
well as vascular permeability and mRNA VEGF 
expression 48 h after hCG, were evaluated and 
compared. All the hormones employed to trigger 
ovulation were equally effective as compared 
with control rats, in which none was employed. 
The use of 10 IU LH was associated with a sig­
nificant reduction in vascular permeability and 
VEGF expression when compared with the 
groups treated with 10 IU hCG, 10 IU FSH or 
60 IU LH (Figure 5). It was concluded that FSH 
and hCG, as well as a six-fold dosage of LH, have 
similar biological activities, including increased 
vascular permeability due to excessive VEGF 
expression. The use of lower LH doses resulted 
in similar rates of ovulation while preventing 
the undesired changes in permeability and 
VEGF expression (Figure 5).
Initial multicentric studies in humans have 
shown that a single dose of 15 000 IU rLH, com­
parable to 5000 IU hCG, is necessary to achieve 
optimal oocyte maturation in in vitro fertiliza­
tion (IVF) and is more efficient than 5000 IU 
rLH54. These studies showed a reduced inci­
dence of OHSS when 15 000-30 000 IU rLH was 
employed, as compared with hCG. A more 
recent publication, however, obtained the same
number of mature oocytes and similar implanta­
tion rates in embryos derived from women 
treated with 5000 IU hCG or rLH55, suggesting 
that the dose of rLH necessary to trigger oocyte 
maturation and avoid OHSS might be lower 
than initially expected. Moreover, the same 
authors showed that the hemodynamic changes 
associated with controlled ovarian stimulation 
in IVF are less pronounced when rLH is 
employed, and that the overall incidence of 
OHSS is reduced55.
These animal experiments and the still con­
flicting observations in humans should encour­
age clinicians to find the optimal dose of LH to 
be employed in women to trigger ovulation and 
simultaneously avoid the risk of OHSS, since 
the medication employed in the experiments is 
commercially available.
The role of VEGF in coasting
A novel approach to avoid OHSS is to withhold 
gonadotropin adminstration during ovarian 
stimulation while continuing pituitary desensi­
tization with GnRH analogs (coasting) until the 
serum estradiol level drops.56 The clinical bene­
fit of this approach to reduce the incidence of 
OHSS without hampering oocyte and/or embryo 
quality has been shown by our group and oth­
er^ 7-6  ̂Qf aq die different options to reduce the 
incidence of OHSS, coasting is the first choice 
among physicians, as shown in a recent sur­
vey65. However, there are no experimental data 
offering a plausible biological explanation why 
coasting could be effective. Probably, mature fol­
licles will survive for a few days without exoge­
nous FSH/human menopausal gonadotropin 
(hMG) while smaller follicles will enter apopto- 
sis/necrosis, reducing the potential granulosa 
cell population that will release vascular media­
tors after hCG administration.
The aims of the study we review were:
(1) To evaluate the outcome of IVF in coasted 
cycles as well as the clinical usefulness of 
the coasting procedure in preventing
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Figure 5 Number of oocytes recovered, vascular permeability and VEGF expression after using dif­
ferent hormones to trigger ovulation. EB, Evans blue; hCG, human chorionic gonadotropin; PMSG, 
pregnant mare’s serum gonadotropin; FSH, follicle stimulating hormone; LH-10, 10IU luteinizing 
hormone; LH-60, 60 IU LH
OHSS in women undergoing controlled 
ovarian stimulation (COS);
(2) To investigate the mechanism by which 
coasting may act, hypothesizing the 
possibility that coasting acts through 
VEGF regulation;
(3) To determine which follicle population is 
more likely to be affected by coasting.
A total of 160 women (patients and oocyte 
donors) undergoing coasting and 116 controls 
were included in the study. Serum, follicular 
fluid and granulosa cells were collected on the 
day of oocyte retrieval. VEGF concentrations 
were determined using ELISA. Real-time PCR 
was performed to evaluate VEGF gene expres­
sion in granulosa cells. Cell death was studied 
by flow cytometry66.
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Follicular cells aspirated from coasted 
patients showed a ratio in favor of apoptosis, 
especially in smaller follicles (48 vs. 26%, 
p  <  0.05). Follicular fluid determinations
confirmed that coasting reduces VEGF protein 
secretion (1413 vs. 3538pg/ml, p  < 0.001) and 
gene expression (two-fold decrease) in granu­
losa cells (Figure 6). Follicular fluid VEGF
Figure 6 The vascular endothelial growth factor/glyceraldehyde-3-phosphate dehydrogenase 
(VEGF/GAPDH) ratio was used to compare VEGF expression between coasted and non-coasted 
patients, (a) Typical logarithmic curve observed during PCR amplification. At the beginning of the 
reaction increases in cDNA expression are linear (log-linear phase), so quantification is performed 
during this phase. When the reaction becomes saturated, quantification cannot be performed accu­
rately (non-log-linear phase) as products are overexpressed, (b) Temperature of melting (TM) for the 
GAPDH and VEGF cDNA PCR products in the fusion curve. As the temperature increases, double 
DNA strings separate and the dye intercalated between them can be measured. The maximum dye 
expression coincides with TM which is characteristic for each PCR product. As observed a single 
peak means that only the one expected product was amplified, (c) VEGF levels are expressed as the 
VEGF/GAPDH ratio, where GAPDH expression is used to normalize results, so VEGF expression could 
be compared at the same level. *p < 0.05
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protein levels correlated positively with follicu­
lar size (r=  0.594, p  =  0.001) and estradiol pro­
duction (r=  0.558, p  =  0.038). Women who 
underwent coasting showed a comparable IVF 
cycle outcome66. The conclusion seems to be 
that coasting affected all follicles through apop­
tosis, especially immature follicles, without 
affecting oocyte/endometrial quality. The signif­
icant decrease found in VEGF expression and 
secretion explained why coasting is clinically 
effective in reducing the incidence and severity 
of OHSS.
VEGF-RELATED PERMEABILITY 
CHANGES DEPEND ON ITS SYSTEMIC 
BIOAVAILABILITY
The correlation between VEGF and OHSS has 
been clearly demonstrated in the animal 
model41,42,53, and, similarly, such a relationship 
seems to hold in humans as well. Although 
studies trying to find differences in circulating 
VEGF blood levels between women developing 
OHSS and those who do not have usually failed 
to do so, there are several reasons that may 
explain why such a relationship was not 
detected.
In many studies, serum VEGF levels were 
measured to detect the onset of OHSS. As 
platelets and leukocytes contain VEGF and 
release this angiogenic factor during blood clot­
ting67, serum VEGF measurements do not reflect 
biologically available VEGF in the blood. This 
also explains why serum concentrations of 
VEGF are 8-10-fold higher than plasma levels, 
secondary to the release of VEGF from activated 
cellular components68.
The second reason is based on the observa­
tion that 90% of the secreted VEGF isoforms 
remain inactive in the circulation because of 
binding to the soluble VEGFR-1 (also called sFlt- 
1). The extracellular domain of VEGFR-1, 
released by endothelial cells to the circulation, 
binds VEGF and then inactivates it as well as
a 2-macroglobulin (A2M). In fact, higher or 
lower levels of either A2M69 or sFlt-170 in 
women at risk for OHSS have been proposed as 
a reason to explain why some develop OHSS 
while others do not. Variations in the ‘free’ and 
not the ‘total’ VEGF levels would hence account 
for differences between patients who develop 
the syndrome and those who do not. Differences 
in the expression and activity of the natural 
inhibitors could be the reason for differences in 
VEGF biodisponibility. Based on this hypothesis 
we performed a series of experiments to investi­
gate the implication of systemic total VEGF, free 
VEGF, sFlt-1 and A2M on the onset of OHSS. In 
this prospective study, women undergoing ovar­
ian stimulation for IVF were divided according 
to their risk of developing OHSS into three 
groups: without risk (n =  11), with risk but not 
developing (n =  18) and with risk and develop­
ing OHSS (n =  8). Factors for risk were: the pres­
ence of > 2 5  follicles at the time of oocyte 
retrieval, a previous history of OHSS or poly­
cystic ovaries. Blood was drawn from the day of 
oocyte retrieval each 72 h during the complete 
luteal phase until day 14. ELISA was used to 
measure total VEGF, free VEGF and sFlt-1 in 
plasma, while A2M was measured in serum 
using nepholometry71. We observed that total 
VEGF levels were similar during the study 
period in all groups analyzed and, interestingly, 
free VEGF levels were statistically higher at day 
6 after oocyte retrieval in the group who devel­
oped OHSS. Free VEGF/A2M and free VEGF/ 
total VEGF ratios were significantly increased in 
the OHSS risk group at day 6, when compared 
with the non-risk group and with the group not 
developing OHSS (Figure 7). It could be con­
cluded that it is likely that free VEGF and not 
total VEGF in blood is involved in causing vas­
cular permeability, and that the amount of 
VEGF-binding protein present in blood might 
influence whether a person will develop OHSS 
or not.
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Figure 7 Measurements of free vascular endothelial growth factor (VEGF) and ratios of free VEGF/a2- 
macroglobulin (A2M) and free VEGF/total VEGF in non-risk, risk without and risk with OHSS during 
the time course, 0, 3, 6, 10 and 14 (pregnancy test) days after oocyte retrieval. *p <  0.05
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Clinical management, ascites management 
and obstetrical outcome in patients with 
ovarian hyperstimulation syndrome
Raphael Ron-EI, Shevach Friedler, Morey Schachter and Arieh Raziel
INTRODUCTION
Severe ovarian hyperstimulation syndrome 
(OHSS) is defined as a serious and potentially 
life-threatening physiological complication clas­
sically encountered in patients who undergo 
controlled ovarian hyperstimulation (COH). It is 
typically associated with regimens of exogenous 
gonadotropins and rarely during the administra­
tion of clomiphene citrate.
Severe OHSS in in vitro fertilization with 
(IVF) may appear with different timing, early or 
late1. In early-onset OHSS, it occurs within 8 
days of initial human chorionic gonadotropin 
(hCG) exposure relating to ‘excessive’ preovula­
tory response to stimulation. In late OHSS it 
appears after 14-16 days of hCG administration, 
and depends on the occurrence of pregnancy, 
where endogenous hCG plays the role. Late 
OHSS is more likely to be severe, and is only 
poorly related to preovulatory events.
Much effort has been invested to prevent 
severe OHSS, as is well reflected by the gradual 
decline in the incidence of hospitalization for 
OHSS in our patients, reported over time, from 
6.4% in 1994 to 1.5% in the years 1997-99 and 
less than 1% in 2003-04. Previous studies have 
reported an incidence of severe OHSS after IVF 
of approximately 1%, which might be even
higher, because of the tendency to under­
report2. The last European IVF Monitoring 
Report recorded 1586 OHSS cases in 146 000 
assisted reproductive technologies (ART) cycles 
(1.1%)3. Severe OHSS occurred in 0.22% of the 
ART-treated patients. This gradual reduction 
reflects a change in our concepts regarding the 
use of less aggressive protocols for COH, and the 
change to use of progestogens instead of hCG for 
luteal support.
PRINCIPLES OF MANAGEMENT
A mild form of OHSS occurs in almost every 
cycle of COH. In its severe presentation it is 
characterized by increased vascular permeabil­
ity, and thus the shift of fluids from the blood 
vessels to extravascular space. Ninety-five per 
cent of severe OHSS patients have a hematocrit 
level of >  45%, 99% are with ascites, 92% are 
dyspneic, 30% oliguric, 19% with massive pleu­
ral effusion, 28% with peripheral edema, 2% 
with thromboembolic phenomena and 1% of 
patients have acute renal failure4. As such, it 
often requires hospitalization, and in its critical 




Admission to hospital should not be in 
doubt once the patient is dyspneic or complains 
of vomiting or diarrhea. Normally, such clinical 
manifestations will be already accompanied by 
hemoconcentration, with a hematocrit of 
>  45%. In OHSS patients of whom the degree of 
clinical severity is unclear, a hematocrit of 
^ 42% is an indication for active monitoring and 
treatment of the patient, which can only be done 
under continuous observation. A possible 
scheme for the management of hospitalized 
patients with severe OHSS is presented in 
Figure 1.
The following steps should be performed on 
admission: recording of vital signs: pulse, blood
pressure, number of breaths per minute and 
fluid balance; measurement of body weight and 
abdominal circumference; physical examination 
with emphasis on palpation of the abdomen and 
lung auscultation; and sonographic examination 
can be done using abdominal or vaginal ultra­
sound. Abdominal sonography is preferable for 
the patient’s convenience. It includes measure­
ment of the size of the ovaries and estimation of 
the quantity of ascitic fluid.
Laboratory tests on admission are: red and 
white blood count, electrolytes, renal and liver 
function tests (mainly albumin and total pro­
tein) and coagulation tests.
Figure 1 The management of hospitalized patients with severe OHSS
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CLINICAL MANAGEMENT OF PATIENTS WITH OHSS
Fluid administration
Principles of treatment are to continue intravas­
cular hydration in order to maintain diuresis, 
intravascular colloid pressure and electrolyte 
balance. Intravenous administration includes 
2500-3000 ml sodium chloride 0.9% (saline), as 
the starting dose. Over the next few days the 
amount of fluid administered should be deter­
mined according to the urinary output of the 
previous day. A combination of saline and dex­
trose 5% solution by intravenous administration 
should be given. Fluids should be restricted 
either when the patient is overloaded with flu­
ids, namely hemoglobin and hematocrit levels 
are low, or when the patient is in her polyuric 
phase.
Plasma expanders
The plasma expanders available are dextran and 
hydroxyethyl starch 6% solution (HES) in iso­
tonic sodium chloride solution (Fresenlus Kabi 
Deutschland). The maximum daily dose of HES 
is 33ml/kg or 250-500 ml per day. It should be 
used in dropwise and a slow rhythm, to avoid 
lung congestion.
Albumin administration
Albumin administration should be reserved for 
a later stage, once hypoalbuminemia is proven, 
because of: high cost, excessive albumin over­
load, renal function impairment and risk of viral 
contamination in general, and viral hepatitis in 
particular. The administration of albumin is 
mainly important during drainage of ascites that 
contains large amounts of proteins. The daily 
dose is between 25 and 75 g (100-300 ml) per 
day, according to the severity of hypoalbumine­
mia and the amount of drained ascitic fluid. The 
total albumin quantity in the body is measured 
by multiplying the serum albumin concentra­
tion of 30g/1000ml by 5000 ml or 51 of serum,
i.e. 150 g. By determining the shortfall between 
the present albumin value and the anticipated
value, the amount needed for intravenous use 
can be obtained. For example, if the current 
value of serum albumin is 24g/1000ml and the 
anticipated value is 30 g/1000 ml, then the short­
fall of 6 g/1000 ml multiplied by 5000 ml or 5l 
defines the need for 30 g albumin. A bottle of 
50 ml albumin 25% contains 12.5 g. To achieve 
30 g albumin, 120 ml of the above should be 
administered to the patient (practically two and 
a half bottles).
Albumin administration is done in equally 
divided doses during 24 h to increase its effect 
on urine production in a slow fashion, in order 
to prevent lung congestion.
A recent comparative study evaluated the 
effectiveness of 10% dextran 40 infusion 
(500ml/day) versus 25% human albumin 
(lOOml/day). Both infusions were continued for 
1-3 days after recovery of hemoconcentration. 
The recovery from hemoconcentration was 
much faster in the dextran group compared with 
the albumin group. Since the occurrence of 
thromboembolic phenomena of OHSS has been 
related to the rapid body-fluid shift, leading to 
hemoconcentration and increased blood viscos­
ity, faster recovery is probably an advantage of 
dextran use over that of albumin6.
Anticoagulant administration
We use anticoagulants (such as heparin or low- 
molecular-weight heparin: Clexan®) when clini­
cal evidence exists of thromboembolic 
phenomena, in the presence of congenital/ 
acquired thrombophilia and in view of a history 
of hypercoagulability or thromboembolic 
events. Anticoagulant use is also considered 
when the patient is extremely obese or non- 
mobile. Some clinicians administer anticoagu­
lants on a routine basis. Because of the danger of 
active bleeding this should be considered with 
special care while ascitic fluid is drained. Low- 
dose aspirin (such as pediatric aspirin) use is 
also an option for the prevention of thromboem­
bolic complications in patients who are scarcely
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mobile because of obesity or a long immobiliza­
tion time.
Anti prostag land in administration
Antiprostaglandin synthetase use (for example, 
indomethacin) has been suggested in the past to 
decrease vascular permeability. Although effec­
tive in rabbits, its employment in humans has 
never been effective, and therefore it is of no use 
today.
Dual renin-angiotensin blockage 
therapy
Ando et al. recently reported the first successful 
combined use of the angiotensin-converting 
enzyme (ACE) alacepril 12.5 mg and angiotensin 
II receptor blocker (ARB) cilexitil 8 mg, with 
routine cryopreservation, for the prevention of 
OHSS in four high-risk women for the syn­
drome7. We adopt their final conclusion that 
dual renin-angiotensin blockage therapy ‘would 
be worth exploring further in a study with more 
patients and prospective randomized design’.
ASCITES AND PARACENTESIS
Since ascites is very common and is the major 
reason for discomfort and dyspnea in severe 
OHSS, its drainage is an integral part of treat­
ment. The decision to drain is sometimes urgent 
according to the patient’s current condition. 
Drainage of ascitic fluid is mandatory in three 
conditions: when the patient is dyspneic, when 
extreme abdominal distension causes great dis­
comfort to the patient and when oliguria is pres­
ent despite a massive load of fluids and plasma 
expanders.
Levin et al. depicted the advantage of 
drainage of ascites in OHSS patients8. It may 
cause immediate patient relief by increased 
venous return to the right heart and increased 
cardiac output, which leads to renal function 
improvement caused by increased urinary out­
put, increased creatinine clearance rate and 
decreased blood urea nitrogen levels.
Padilla et al. showed better ventilation of the 
lower lobes of the lungs and a decrease in pul- 
satility index (PI)9 of the uterine artery after 
drainage of ascites. A shortening of hospitaliza­
tion duration has been shown by several 
clinicians10-12.
Drainage of the ascitic fluid has been 
described in several publications10-12. Ultra- 
sonographic-guided transabdominal drainage is 
frequently performed9. In rare cases, such as in 
extremely obese patients, the transvaginal route 
is preferable with the usual ovum pick-up nee­
dle13, or with the insertion of a pigtail catheter 
as suggested by Raziel et al.14.
Since the factor responsible for increased 
vascular permeability remains, the ascitic fluid 
is quickly replaced with new quantities from the 
vascular bed after paracentesis. Rizk and Aboul- 
ghar considered the reaccumulation time to be 
between 3 and 5 days. Therefore, they drained 
between 900 and 1400 ml of fluid in one session 
and, if necessary, repeated the drainage proce­
dure10. In our experience, the reaccumulation 
time of ascitic fluid can be very short, so that the 
patient becomes dyspneic again within 12-24 h 
after fluid aspiration. The refilling interval 
depends on the severity of the case and phase of 
the disease.
We believe that continuous drainage of 
ascitic fluid is preferable to intermittent 
catheterizations. The catheter is introduced 
through the abdominal wall under ultrasound 
guidance and remains until drainage stops, or 
48-72 h after its insertion. Several types of 
indwelling catheters have been described. One 
is a central venous pressure (CVP) catheter 
(Intracath, short type), as used by our group. A 
suprapubic bladder drainage catheter (Cystofix; 
Braun Melsungen, Germany) is easy for use, but 
seems traumatic when inserted. A closed- 
system Dawson-Mueller catheter (Cook, USA) 
has been used by Al-Ramahi15. A pigtail catheter
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(Boston Scientific, USA) anchored to the skin 
with a 2-0 silk suture has also been used14.
The ascitic fluid should be removed in a 
gradual manner. With too rapid drainage of the 
fluid the patient may feel extreme weakness and 
exhaustion. Normally, we drain not more than 
41 within 12 h. When 41 are already drained, we 
close the catheter while leaving it in situ.
The risk associated with abdominal drainage 
of ascitic fluid is minimal. The risk of punctur­
ing the ovaries is negligible when it is done 
under ultrasonographic guidance12,15. Loss of 
proteins is of great concern. With the drainage of 
large amounts of ascitic fluid there is a huge loss 
of plasma proteins. A peritoneovenous shunt for 
the continuous autotransfusion system of 
ascites (CATSA) was developed in order to over­
come the need for massive protein supplemen­
tation. CATSA includes a transabdominal 16 g 
Teflon catheter connected via a peristaltic pump 
and microfilter to an 18 g Teflon catheter 
inserted in the antecubital vein. The treatment 
is performed once a day for 5 h16.
Another side-effect of drainage is the devel­
opment of vulvar edema due to either massive 
drainage of ascitic fluid with inadequate albu­
min replacement or the creation of fistulous 
tracts between the peritoneal cavity and the sub­
cutaneous tissues in a lower-abdominal para­
centesis. Cellulitis at the area of insertion of the 
catheter may rarely be encountered.
In rare cases, on the grounds of a deteriorat­
ing clinical picture, after failure of the above 
‘conservative treatments’, transvaginal ultra- 
sonographic-guided aspiration of multiple cor­
pora lutea has been reported17. Bilateral partial 
oophorectomy has been offered as an effective 
approach, due not only to emptying of the con­
tents of the corpora lutea, but also to total exci­
sion of the walls of ovarian cysts which 
incorporate the granulosa cells that are probably 
the origin of most vasoactive mediators18.
Although the pathophysiology of OHSS is 
not clear, appearance of the symptoms is closely 
related to hCG production. Therefore, in
extremely rare cases of critical OHSS, reduction 
of endogenous hCG by pregnancy termination is 
the last choice18.
The clinical courses of two patients hospital­
ized for severe OHSS are illustrated in Figures 2 
and 3.
OBSTETRICAL OUTCOME IN OHSS 
PATIENTS
Since severe OHSS is a potentially life-threaten­
ing, iatrogenic complication in a basically 
healthy young woman desiring fertility, much 
effort is made to prevent it2*4’19’20. Naturally, in 
such an acute situation, the endangering syn­
drome is focused upon and the anticipated 
pregnancy is of secondary importance.
Since women with severe OHSS are in a 
lower age group (28.4 ±4.5 years) than the aver­
age age of IVF patients (35.2 ±4.5 years) and 
with a higher number of aspirated oocytes per 
cycle, it is logical that the pregnancy rate in this 
specific group will be much higher than in the 
general IVF program. Indeed, the clinical preg­
nancy rate among 104 severe OHSS patients in 
our study reached 58%, compared with 23% in 
our general IVF program19, or 73% vs. 14% 
among 142 severe OHSS patients of a multicen­
ter study21. These results were in concordance 
with a Swedish study published by Enskog et 
al., which included 428 IVF patients who 
received controlled ovarian hyperstimulation 
during a 6-month follow-up period22.
The multiple pregnancy rates among the 
patients with OHSS were higher than found in 
the general ART population. The multiple preg­
nancy rate in the above-mentioned multicenter 
study was 58%, 39% twins and 17% triplets21. 
However, the study was conducted during the 
years 1987-96. Nowadays, such a high multiple 
pregnancy rate would not be acceptable.
The miscarriage rate was significantly higher 
among severe OHSS cases than that found in 
non-OHSS IVF patients (38% vs. 15%,
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Figure 2 The management and clinical course of a polycystic ovarian disease (PCOD) patient post­
ovulation induction, presenting with late onset of severe OHSS. y, years; hMG, human menopausal 
gonadotropin; hCG, human chorionic gonadotropin; d, days; Hb, hemoglobin; HT, hematocrit; w, 
weeks
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D.H., 27 y; Male factor o)
IVF-ICSI treatment |
Admission 10 d after embryo 
transfer 
On admission:
Hb 16.9 g/dl; HT 49% 
Pregnancy-miscarriage, 8w
Figure 3 The management and clinical course of a patient who underwent in vitro fertilization- 
intracytoplasmic sperm injection (IVF-ICSI) treatment and was admitted with early onset of OHSS. 




p  <  0.001)19. The vast majority of these abor­
tions (83%) were early. The only characteristic 
of the aborters which differed from the ongoing 
pregnancy group was the longer hospitalization 
period of 10.5 ± 9.6 days compared with 5.9 ± 3.2 
days; p  <  0.02. All other parameters, including 
estradiol levels on hCG administration day, 
number of oocytes retrieved and number of 
embryos transferred, were comparable between 
the severe OHSS patients who aborted and 
those who delivered19.
Higher rates of miscarriage were observed 
also by Abramov et al., in a large study of 142 
patients who underwent embryo transfer21. 
They found a total clinical miscarriage rate of 
29.8%, of which 25% were early and 4.8% late. 
Preclinical pregnancies were not included as an 
outcome measure. Historical controls of patients 
with no OHSS, from the literature, were used for 
comparison.
Papanikolaou et al. were the first to make the 
distinction between preclinical and clinical 
abortions in IVF OHSS patients23. They found a 
rate of 91.8% clinical and 88.3% ongoing preg­
nancies in their late-OHSS group. In the early- 
OHSS group, they observed a biochemical 
pregnancy rate of 41.5% per cycle. Their clinical 
pregnancy rate was reduced to 28.3% per cycle 
due to a 31.8% preclinical pregnancy loss, com­
pared with only 14.4% pregnancy loss in the 
non-OHSS patients. There was no difference 
between the incidence of miscarriage between 
their early- and late-OHSS patients (5.8% and 
5.3%, respectively). These results of low miscar­
riage rate in OHSS patients compared with non- 
OHSS IVF patients were also found in a British 
study24. Mathur and Jenkins noted a total 12.2% 
miscarriage rate among OHSS pregnancies com­
pared with 16.8% in the control non-OHSS 
patients. The study was small in sample size, 
and also did not report on preclinical abortion 
rates.
The discrepancy between the two pairs of 
studies (references 19, 21 and 23, 24) can be 
explained by different types of patients.
Abramov and Raziel included severe and criti­
cal OHSS patients in their studies, in contrast to 
the inclusion of patients with a milder clinical 
course in the other two studies. The metabolic 
derangement in more severe OHSS cases might 
potentially directly affect the developing 
pregnancy.
It is unclear how any derangement occurring 
in OHSS may affect the early pregnancy. Is it 
because of higher estradiol levels, which were 
not proven in our study20, abnormal cytokine 
levels25 or excessive renin-angiotensin activa­
tion26’27? Or can it be attributed to intravas­
cular volume depletion, hemoconcentration or 
hypoxemia?
As for the progress of pregnancies, maternal 
and neonatal complications during pregnancy 
and delivery among the severe OHSS patients 
were as frequent as the above in the general 
pregnant population when related to singleton 
and multiple pregnancies separately21. This was 
confirmed in a recent follow-up study beyond 
the second trimester of pregnancies complicated 
by OHSS28.
SUMMARY
Although severe OHSS tends to occur less fre­
quently than in the past, it is still a serious iatro­
genic complication which demands active 
management to prevent further complications. 
Treatment should be directed toward replace­
ment of the depleted vascular bed, and drainage 
of the ascitic fluid if discomfort and dyspnea are 
present. Since the miscarriage rate in OHSS is 
high, shortening of the unstable status of the 
patient may reduce it. Recently, some authors 
tried to maintain patients with severe OHSS in 
an out-patient regimen where close follow-up 
was performed, paracentesis was done if needed 
and albumin replacement was occasionally 
used20,29,30. Whether this is an adequately safe 
management has still to be tested. There is no 
doubt that the physician confronting patients
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with severe OHSS should be experienced 
enough to provide an efficacious treatment and 
to prevent complications and inconvenience for 
the patients.
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ovarian hyperstimulation syndrome 
from an American perspective
Randy Morris
INTRODUCTION
Since ovarian hyperstimulation syndrome 
(OHSS) is a relatively uncommon complication, 
there is a paucity of data on methods to prevent 
or treat this complicated syndrome. The data 
that do exist are hampered by small numbers 
and lack of adequate control groups. This situa­
tion has led to a difference in methods of man­
agement between centers. In the United States, 
there are two primary methods for management 
of established OHSS. This chapter discusses 
these two methods and their underlying ratio­
nales. Methods to prevent or reduce the inci­
dence of OHSS are also discussed.
It is described fully, elsewhere in this book, 
that the underlying pathophysiology of OHSS is 
increased capillary permeability with resultant 
third-space fluid accumulation. The third-space 
accumulation of fluid has been reported in the 
abdominal cavity1, pleural cavity2 and pericar­
dial sac3. The presence of abnormal amounts of 
fluid in these cavities is responsible for specific 
problems. Many of the therapeutic modalities 
for OHSS have been directed toward reducing 
fluid in these locations in order to treat specific 
symptoms or, in some cases, induce remission 
of the syndrome entirely.
ABDOMINAL CAVITY FLUID (ASCITES)
The most common location for significant fluid 
accumulation is the abdominal cavity. Ascites 
causes the patient to have the physical sensa­
tions of abdominal distension, bloating, cramp­
ing and sometimes frank abdominal pain. From 
a physiological point of view, this fluid is sus­
pected to be a cause of increased abdominal 
pressure, the net effect of which is compression 
of the vena cava resulting in decreased venous 
return to the heart. This, in turn, decreases car­
diac output4, reduces renal perfusion and 
causes further worsening of OHSS-associated 
oliguria5. Increased intra-abdominal pressure, in 
combination with enlarged ovaries, causes ele­
vation of the diaphragm and restricts diaphrag­
matic movement, making inspiration more 
difficult and causing the patient to feel respira­
tory distress6. The supine position exacerbates 
this problem. The presence of ascitic fluid also 
poses a risk for secondary bacterial peritonitis7.
PREVENTION OF ASCITES AND OHSS
Albumin prophylaxis
A small initial case series pointed to the possi­
bility that intravenous infusion of salt-poor
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albumin might, through oncotic effect, prevent 
OHSS by causing the fluid to remain in the 
intravascular space8. However, this analysis was 
flawed. It has been reported that albumin, when 
administered intravenously, has a circulation 
half-life of approximately 19 days9. However, 
under circumstances of volume depletion such 
as that seen in OHSS, the oncotic actions of 
albumin last less than 36 h10. Thereafter, albu­
min leaves the intravascular space and resides 
in the insterstitium, where it can then act to 
draw fluid out of the intravascular space poten­
tially worsening the course of OHSS. After the 
initial report, several small randomized con­
trolled trials produced mixed results as to the 
efficacy of prophylactic albumin11,12. A 2002 
Cochrane review of five randomized trials total­
ing 463 cases concluded that there was a mild 
beneficial effect, with an absolute risk reduction 
of 5.5%, with one case of OHSS prevented for 
every 18 women at risk of severe OHSS13. How­
ever, a subsequent randomized trial involving 
976 women concluded that there was no benefi­
cial effect14. At the current time, use of albumin 
for the prevention of OHSS or ascites cannot be 
recommended.
Cycle cancellation/avoidance of 
human chorionic gonadotropin
Since the first reports of OHSS, it is clear that 
the occurrence of pregnancy is a key risk factor 
in the development of OHSS. Patients who 
become pregnant are more likely to develop 
severe OHSS. Egg donors, for instance, have a 
very low risk for severe OHSS despite equiva­
lent or greater levels of stimulation15. Patients 
with severe OHSS after in vitro fertilization are 
much more likely to be pregnant than in vitro 
fertilization patients who do not have OHSS. 
They are also much more likely to have a multi­
ple pregnancy16. Furthermore, multiple preg­
nancies have a longer and more severe course 
than do singletons17. It is likely that the levels of 
human chorionic gonadotropin (hCG) exposure
have a significant impact on the natural course 
of the syndrome.
Complete avoidance of pregnancy and hCG, 
therefore, are important methods to reduce the 
likelihood of development of (severe) OHSS. 
Withholding the hCG trigger injection has been 
offered as a means to reduce the incidence of 
(severe) OHSS. This method, while mostly 
effective, can still fail if the patient achieves 
pregnancy from a spontaneous luteinizing hor­
mone surge18.
In addition, most patients do not find this an 
acceptable option since it requires cancellation 
of the treatment cycle. This is seen as an ineffi­
cient route, which is costly from the standpoint 
of medication usage without a legitimate 
attempt at pregnancy.
Patients who use gonadotropins for ovula­
tion induction or superovulation can have their 
cycles converted to an in vitro fertilization 
cycle19. Aspiration of the follicle load during egg 
retrieval has a protective effect on the develop­
ment of OHSS20.
Cryopreservation of all embryos
If an in vitro fertilization patient is thought to be 
at high risk, elective cryopreservation of all 
embryos can be performed. Several studies have 
indicated that elective cryopreservation of all 
embryos can reduce the incidence and severity 
of OHSS without compromising the chance for 
pregnancy in subsequent embryo thaw 
cycles21,22. However, a 2002 Cochrane database 
review did not find a benefit in terms of a 
reduced incidence of OHSS with elective cryo­
preservation when compared with either fresh 
transfer alone or fresh transfer and prophylactic 
albumin administration23.
Modification of stimulation
‘Coasting’ is described as withholding or signifi­
cantly reducing the dose of gonadotropins in 
patients thought to be at high risk for the devel­
opment of severe OHSS. Coasting was first
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reported in 1995 in a small group of in vitro fer­
tilization patients. In that report, no cycles were 
canceled, none of the patients developed severe 
OHSS and pregnancy rates were reported as 
high24. Other centers had similar experiences 
and did not find an adverse effect on in vitro fer­
tilization cycle parameters25.
Lee et al., however, in a much larger study, 
did not find equivalent results26. Four out of 20 
women treated by coasting still developed 
OHSS. Multiple regression analysis determined 
that other factors were more likely to be respon­
sible for the better outcomes in those patients 
who did not develop OHSS.
One problem with these studies is the lack of 
uniformity in how coasting was performed. The 
time point in the cycle at which coasting was to 
be started and the duration of coasting varied 
significantly. A Cochrane review concluded that 
insufficient evidence existed to permit the rec­
ommendation of coasting as a valid means to 
reduce the risk of OHSS27. The most recent data 
also suggest that coasting is associated with a 
significant incidence of premature luteinization 
and, if needed for more than 4 days, that the 
implantation rate is reduced28.
TREATMENT BY OVER-HYDRATION 
AND ASPIRATION
A number of authors have advocated the use of 
extensive fluid hydration combined with para­
centesis for the treatment of OHSS and ascites. 
There are two underlying theories for the use of 
over-hydration. The first recognizes the fact that 
thromboembolic phenomena have been respon­
sible for the majority of fatal complications of 
OHSS, and can be responsible for significant 
morbidity such as stroke or pulmonary embo­
lus29. By hydrating the patient, it is hoped that 
this will maintain intravascular volume, reduce 
hemoconcentration and therefore lessen the 
chance for thrombosis. In addition, mainte­
nance of intravascular volume may improve 
renal perfusion and assist with natural diuresis.
However, due to the increased vascular per­
meability, a significant amount of the fluid given 
for hydration will leave the intravascular space 
and worsen the ascites, thus necessitating para­
centesis. Aspiration of the ascitic fluid by para­
centesis provides some immediate relief to the 
patient. It is also hoped that decreasing the 
intra-abdominal pressure will increase venous 
return to the heart and improve renal perfusion 
and ultimately speed the resolution process.
Rabau et al. were the first to propose abdom­
inal paracentesis for the treatment of OHSS30. 
Later, transvaginal ultrasound guided paracente­
sis was found to be an acceptable alternative31.
Protocol for management of OHSS 
with over-hydration and 
paracentesis32
(1) Patients are advised to maintain a fluid 
intake of 1000-1500 ml daily;
(2) Patients are instructed to contact the nurs­
ing staff if they experience an increase in 
abdominal girth of more than 1-2 cm, 
weight gain of >  1 kg in 24 h, shortness of 
breath, nausea, vomiting, diarrhea or a 
subjective decrease in urine output;
(3) Patients reporting these signs or symptoms 
undergo blood evaluations and are 
instructed to increase fluid by 500 ml/day 
if hemoconcentration is observed;
(4) The patients then undergo transvaginal 
u ltrasou nd -gu ided  p aracen tesis  w ith  
drainage of ascites fluid.
A typical hydration/aspiration protocol of the 
type used by many American infertility 
programs is given above. Many authors have 
published case series with various modifica­
tions of this protocol. In addition to vigorous 
oral hydration, Aboulghar et al. advocated 
intensive intravenous hydration to reduce
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hemoconcentration33. It was soon discovered 
that under this form of management many 
patients required repeat paracenteses due to 
reaccumulation of ascitic fluid34. Reports in the 
literature exist of patients having paracentesis 
five times35. Al-Ramahi and colleagues used an 
indwelling peritoneal catheter to decrease the 
need for repeated paracentesis36. Under ultra­
sound guidance a closed-system 
Dawson-Mueller catheter with ‘simp-loc’ lock­
ing design was inserted to allow continuous 
drainage of the ascitic fluid.
Risks of treatment
Massive hydration leads to worsening of tense 
ascites. Adverse consequences include the need 
for recurrent paracentesis as noted above. Other 
issues include the development of vulvar 
edema. Cases of massive vulvar edema have 
been reported during hydration therapy with 
albumin and lactated Ringer’s solution37-38.
A far more serious problem is the risk of pul­
monary edema and/or adult respiratory distress 
syndrome (ARDS). In the multicenter study of 
Abramov et al., ARDS was reported in five 
patients (2.4%), and all cases occurred after 
massive hydration (4800-7200 ml; mean 
5780ml/24h)6. This fluid intake was signifi­
cantly higher than that recorded in uncompli­
cated cases.
Although increased fluid intake is often 
stated as necessary for the prevention of throm­
boembolic phenomena, Abramov et al. showed 
that patients who developed pulmonary throm­
boembolism received similar volumes of fluids 
to those who did not6.
Therefore, the main rationale for the use of 
this method of treatment is possibly in error.
Initially, the risks of paracentesis were 
thought to be due to the danger of puncture and 
laceration of enlarged ovarian cysts39. However, 
by using ultrasound guidance, the risk of punc­
turing a cyst seems minimal40. Damage to other
intra-abdominal organs is likewise probably low 
with ultrasound guidance, but the cumulative 
risk increases with multiple aspirations. The 
risk for infection rises with each subsequent 
needle placement.
Another potential risk of paracentesis is the 
alteration of uterine blood flow. This is an espe­
cially important point when it is considered that 
the vast majority of patients who present with 
severe or critical OHSS have a clinical gesta­
tion16. However, Chen et al. measured uterine 
blood flow with color Doppler ultrasound and 
showed that drainage of 2500 ml of ascitic fluid 
within 30 min actually increased uterine perfu­
sion in some, but not all cases. Furthermore, 
there was no significant difference in the preg­
nancy or miscarriage rate, although the numbers 
were small41.
Concern has also arisen that rapid drainage 
of ascites may in itself cause volume depletion42 
and further reduction in intravasvular oncotic 
proteins by drainage of the protein-rich ascitic 
fluid. To counteract these effects, Aboulghar et 
al. reinfused the protein-rich ascitic fluid in 
three patients with OHSS, with no apparent 
adverse consequences43. Splendiani et al. per­
formed ultrafiltration of the ascitic fluid with a 
common high-flow dialyzer (polyacrylonitrile 
membrane)44. The fluid was then reinfused 
intravenously in three patients. In all three 
patients, diuresis was initiated and subjective 
improvement was seen. Beck et al. used a con­
tinuous reinfusion system in one critically ill 
patient45.
As noted above, vulvar edema can result 
from vigorous hydration of patients with OHSS. 
Performance of a paracentesis can increase that 
risk. Luxman et al. reported that abdominal 
paracentesis through lower-quadrant puncture 
sites was associated with the development of 
ipsilateral massive vulvar edema46. A literature 
search did not reveal any such reports with the 
use of transvaginal paracentesis, however.
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CONSERVATIVE MEDICAL TREATMENT 
OF OHSS
Fluid restriction
As opposed to the hydration/aspiration method, 
another method of management is mild fluid 
restriction. In the past, a widely accepted view 
of OHSS has been that electrolyte losses into 
ascitic fluid along with increased capillary per­
meability are responsible for decreased plasma 
osmolality and lower plasma sodium levels. 
Because of this assumption, it has been believed 
that sodium and electrolyte replacement is nec­
essary to correct the deficit. However, it has 
been demonstrated that decreased plasma osmo­
lality occurs in most women undergoing super­
ovulation for in vitro fertilization by 2-4 days 
after the hCG trigger injection47. Normally, these 
alterations last for only a few days. However, in 
women who develop OHSS, the reduction of 
osmolality persists for much longer despite the 
presence of intravascular volume depletion48. If 
these abnormalities were to occur in normal 
women, they would stop production of vaso­
pressin, their thirst would decrease and they 
would initiate diuresis of dilute urine in an 
attempt to raise the serum osmolality. In 
patients with OHSS, however, these thresholds 
are altered so that the patient maintains a high 
level of thirst and does not initiate diuresis48.
In this protocol, therefore, patients are 
encouraged to drink only moderate amounts. 
Only fluids with good diuretic properties are 
consumed. This includes those beverages with 
high sugar content such as juices and sodas. 
High-sodium fluids such as sport drinks and 
free water are avoided. By limiting fluid and 
sodium intake, the third-space fluid accumula­
tion is kept to a minimum, especially in the 
abdominal compartment. Thus, the problems 
associated with increased intra-abdominal pres­
sure are reduced.
Albumin volume expansion
A second component of this protocol involves 
fluid shifting from the third space back into the 
vasculature and subsequent diuresis. As noted 
above, albumin infusion is ineffective for pre­
venting OHSS. However, it can be useful for the 
treatment of established OHSS.
Patients with established OHSS are often 
hypoproteinemic due to loss of albumin and 
other proteins into the ascitic fluid. Abramov et 
al. determined that proteins up to a molecular 
weight of 180 kDa are lost49. This lowers the 
osmotic pressure and promotes further third- 
space fluid loss. When albumin is infused intra­
venously, the osmotic pressure is increased, 
with return of some fluid into the intravascular 
space. The effect is temporary, however, as 
eventually the infused albumin will also leak 
out, drawing the fluid back into the third 
space10.
We have used albumin followed immedi­
ately by diuretics to promote diuresis in 
OHSS50. The albumin draws the fluid into the 
vasculature. Immediately upon completion of 
the albumin infusion, diuretics are given. The 
first effect of the diuretic is to promote renal 
artery dilatation. The resulting large diuresis is 
achieved by using fluid from the third space. We 
and others have found that conservative man­
agement with salt-poor albumin and diuretics is 
an acceptable form of management, with rapid 
resolution of OHSS and maintenance of 
pregnancies51.
Protocol for conservative management
Out-patient management
(1) Avoid food and beverages that are high in 
sodium;
(2) Do not force fluid intake;
(3) When drinking fluids, use those that are 
high in sugar and low in sodium;
(4) Narcotic pain medication as needed;
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(5) Anti-emetics for nausea (Zofran ODT® 
8 mg every 8 h as needed);
(6) If hemoglobin is > 15g/dl, start Lovenox® 
40 mg every day;
(7) Patient to measure input and output every 
day and phone the results to the office;
(8) Patient also to call the office if she has any 
of the following:
(a) Sudden weight gain;
(b) Shortness of breath;
(c) Pain resistant to medication;
(d) Nausea resistant to medication or 
emesis.
In-patient management
(1) Dextrose 5% in half normal saline 
(D5/0.45NS) + 10 mEq/1 KC1 to match 
urine output;
(2) 250ml of salt-poor 25% albumin intra­
venously over 2 h;
(3) Upon completion of albumin drip, admin­
ister furosemide 20 mg intravenous push;
(4) If patient has persistent oliguria, start 
renal dose dopamine (2-3 pg/kg/min);
(5) Paracentesis reserved for refractory tense 
ascites or severe dyspnea.
Hydroxyethyl starch
Hydroxyethyl starch is a highly branched amy- 
lopectin that resembles glycogen. Its molecular 
weight ranges from 200 to 1000 kDa. At that 
size, it is potentially large enough to avoid leak­
ing out of the vasculature. Abramov et al. com­
pared the use of 6% hydroxyethyl starch 
solution with use of albumin in 16 patients with 
severe OHSS52. Eighty per cent of patients in the 
albumin group required paracentesis compared 
with only 33% in the starch group. Hospital stay
averaged 3 days less in the starch group. Levin 
et al. used a 10% solution and also showed effi­
cacy53. Dextran 40 has also been used as a 
plasma expander in the treatment of OHSS. 
Compared with 25% albumin, dextran 40- 
treated patients had less time to resolution of 
hemoconcentration without affecting the preg­
nancy or miscarriage rate54. The potential 
advantages of synthetic colloid expanders in the 
treatment of OHSS include lower cost and lower 
risk for infection compared with the blood- 
derived albumin. In theory, they may be more 
effective, since their size would limit their leak­
age out of the vasculature.
Dopamine
Dopamine is also an effective treatment for 
OHSS by virtue of its ability, at low doses, to 
effect dilatation of the renal vasculature, 
improve renal blood flow and thereby promote 
diuresis. Ferrareti et al. were the first to report 
the use of intravenous dopamine for the treat­
ment of OHSS55. We also reported a series of 
patients successfully treated in this way50.
One problem with dopamine is that it must 
be given intravenously. Although low-dose 
dopamine has a vasodilatory effect in selected 
tissues, high concentrations achieved locally as 
a result of intravenous (IV) site extravasation 
can still cause severe vasoconstriction and 
ischemic tissue injury. Because of this risk, most 
hospitals restrict by protocol the use of IV 
dopamine to an intensive-care setting with a 
higher nurse/patient ratio, so that the IV sites 
can be monitored more closely. This, of course, 
dramatically increases the cost of treatment. 
Treatment consists of the administration of sub­
cutaneous phentolamine into the area of 
ischemia. Typically, dramatic resolution of 
ischemic changes rapidly follows phentolamine 
injection with no untoward effects.
Tsunoda et al. reported the use of a novel 
dopamine derivative for the treatment of 
OHSS56. Docarpamine is a synthetic, orally
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administered dopamine prodrug which is con­
verted into dopamine. Twenty-seven patients 
received 750 mg of docarpamine every 8h. 
Twenty were judged to have ‘good’ or ‘fair’ 
response based on the duration of time until 
hospital discharge. Mean daily urine output 
increased significantly by the first day of treat­
ment, and remained high through 4 days. Symp­
toms of abdominal distension and pain and 
hemoconcentration all resolved in an average of 
3-7 days.
The significant benefit of this therapy is the 
avoidance of IV administration and risk of 
extravasation, thus reducing the need for 
intensive-care monitoring. Unfortunately, this 
medication is not currently available in the 
United States.
PLEURAL EFFUSION
Increased pleural fluid can lead to decreased 
tidal volume and hypoxia6. This problem may 
be more common than is generally appreciated. 
Levin et al. found that in patients diagnosed 
with severe OHSS, 23% had evidence for pleu­
ral effusion57.
Abramov et al. found that 4% of patients 
with severe OHSS had pulmonary infections, all 
of which consisted of lobar pneumonia (most 
commonly affecting the left lower lobe)6.
Semba et al. reported a patient death from 
massive pulmonary edema during apparent 
improvement from other clinical signs of 
OHSS58.
For those patients presenting with pleural 
effusion and respiratory compromise, thoraco­
centesis is an option. Rinaldi and Spirtos 
reported the use of a chest tube placed for treat­
ment of pleural effusions59. They noted that 
placement of a chest tube corrected the pleural 
effusions and the accompanying abdominal 
ascites.
The best method to avoid pulmonary edema 
is to avoid extensive hydration. However, if it
does occur, careful diuresis in an intensive-care 
setting is mandatory.
PERICARDIAL EFFUSION
There have been no specific studies that have 
addressed the issue of pericardial effusions 
directly. Fortunately, problems associated with 
pericardial effusion are rare. Tamponade with 
decreased cardiac output is the most serious 
possibility. There are no reported cases in the 
medical literature of cardiac tamponade being 
caused by OHSS.
Pericardiocentesis should be reserved for 
those emergency cases where tamponade is 
identified.
CONCLUSIONS
There are two favored methods for the treatment 
of OHSS in the United States. One method is 
characterized by over-hydration of the patient 
with repeated or continuous drainage of the 
ascitic fluid that is produced. The most serious 
risk associated with this method is the develop­
ment of ARDS or pulmonary edema. Since it 
does not appear to reduce the risk of throm­
boembolism, additional prophylactic measures 
must not be forgotten.
Another method of treatment utilizes mild 
fluid restriction combined with medical diuresis. 
Diuresis is affected by the use of albumin or 
hydroxyethyl starch to shift fluid from the third 
space into the vasculature, followed by loop 
diuretics and/or the use of low-dose dopamine.
Unfortunately, no studies have compared 
these methods directly as to their efficacy, risks 
or pregnancy outcomes.
The most popular method to prevent the 
development of OHSS is conversion of super­
ovulation cycles to in vitro fertilization cycles. 
Although this increases the expense of treat­
ment, the pregnancy rates are expected to be
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higher, and other risks, such as multiple preg­
nancy, can be controlled. Patients at risk for 
OHSS from an in vitro fertilization cycle can be 
given the options of egg retrieval, fertilization 
and cryopreservation of all embryos. Avoidance 
of pregnancy will reduce the incidence of OHSS 
and the severity of cases that do occur.
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CHAPTER 17
Life-threatening forms of 
ovarian hyperstimulation syndrome 
and intensive care of the 
ovarian hyperstimulation syndrome patient
Zalman Levine and Daniel Navot
INTRODUCTION
Ovarian hyperstimulation syndrome (OHSS) is 
an iatrogenic disease usually resulting from 
human chorionic gonadotropin (hCG) stimula­
tion of ovarian granulosa cells in gonadotropin- 
stimulated ovaries. The syndrome exists in a 
clinical spectrum, with some patients exhibiting 
only mild disease, and other patients requiring 
intensive management. OHSS and the complica­
tions thereof have even resulted in reported 
fatalities1-5. In a widely used classification 
scheme, Navot et al. defined severe and critical 
forms of OHSS to help researchers and clini­
cians identify these serious and life-threatening 
conditions6. Clinicians managing patients with 
OHSS must be familiar with the syndrome and 
its diverse manifestations, and above all must be 
familiar with medical and surgical options in 
the treatment of the critically ill OHSS patient.
CRITICAL OHSS 
Pathophysiology
The clinical manifestations of life-threatening 
OHSS are a cascade of pathophysiological 
events resulting from a global increase in vascu­
lar permeability due to ovarian overproduction 
of vasoactive substances7. This increased vascu­
lar permeability causes a change in extracellular 
fluid equilibrium, with fluid shifting into the 
extravascular or ‘third’ space, often causing 
ascites, pleural and pericardial effusions and 
hemoconcentration. Cardiac preload falls due to 
a combination of hypovolemia caused by the 
fluid shifts, and compression of the inferior 
vena cava from the increasing intraperitoneal 
ascitic pressure. Falling cardiac preload reduces 
cardiac output, which in turn leads to a decrease 
in renal perfusion. Decreasing renal perfusion 
increases proximal tubule reabsorption of salt 
and water, leading to decreased urinary sodium 
excretion and oliguria. The proximal sodium 
reabsorption, and consequently diminished 
exposure of the distal tubule to sodium, 
impaires sodium-hydrogen/potassium exchange 
in the distal tubule, causing hyperkalemic aci­
dosis. A full prerenal azotemia can develop. 
OHSS also produces a hypercoagulable state, 
possibly due to a combination of hemoconcen­
tration and high levels of ovarian steroids.
Symptomatology
The patient usually presents with initial symp­
toms of abdominal discomfort, bloating and
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anorexia, followed soon thereafter by the onset 
of nausea, and occasionally vomiting and diar­
rhea. Rapid progression of these symptoms, par­
ticularly within 48-72 h after administration of 
the hCG triggering injection, should alert the cli­
nician to a significant risk for the development 
of severe or critical OHSS8. Enlarged ovaries, 
common in OHSS, are at risk for torsion as well, 
and acute abdominal pain must arouse suspi­
cion for adnexal torsion.
Physical findings
Physical examination of the patient with severe 
or critical OHSS will reveal weight gain because 
of an increase in total body water, increased 
abdominal girth, shifting dullness and a fluid 
wave due to ascites, dullness to percussion over 
lung fields affected by hydrothorax and signs of 
hypovolemia including hypotension and olig­
uria. The ovaries are usually, but not always, 
palpable on abdominal examination, and are 
generally tender to palpation. Dyspnea, tachyp­
nea and hypoxemia can be seen from hydrotho­
rax, adult respiratory distress syndrome (ARDS) 
or thromboembolic events9,10.
Laboratory findings
Laboratory evaluation of the patient with critical 
OHSS reveals severe hemoconcentration with a 
hematocrit greater than 55%, dramatic leuko­
cytosis greater than 25 000/mm3, serum creati­
nine at least 1.6mg/dl, creatinine clearance 
50ml/min or less, hyperkalemic acidosis and 
dilutional hyponatremia with low serum osmo­
lality. Low urinary sodium excretion can be 
measured. Liver function test abnormalities are 
often seen, including elevated transaminases 
and alkaline phosphatase, and hypoalbumine- 
mia and hypogammaglobulinemia11,12. Plasma 
levels of measurable vasoactive substances are 
elevated, including plasma renin activity, aldos­
terone, atrial natriuretic peptide and antidi­
uretic hormone, prostaglandins, angiotensin II, 
vascular endothelial growth factor (VEGF),
tumor necrosis factor-a and interleukins 1, 2 
and 6. Ascitic, pleural and pericardial fluid is 
exudative, rich in protein exuded from plasma 
through hyperpermeable capillaries.
Pulmonary findings
OHSS leads to critical respiratory issues 
because of a combination of lung restriction due 
to abdominal pressure from enlarged ovaries 
and tense ascites, hydrothorax and pericardial 
effusions, thromboembolic occurrences leading 
to pulmonary embolus, and intrapulmonary 
increases in capillary permeability leading, in 
the extreme, to ARDS. Pleural effusions are 
almost universal in critical OHSS, and are usu­
ally but not always bilateral13-15.
Renal findings
Because of the intravascular hypovolemia, renal 
blood flow and glomerular filtration are 
reduced, causing severe oliguria or anuria. A 
prerenal azotemia develops, with decreased cre­
atinine clearance and elevated serum creatinine. 
Critical OHSS can feature the stigmata of acute 
renal failure, including hyperkalemia and meta­
bolic acidosis occasionally necessitating dialy­
sis. Volume overload, common in renal failure 
in other clinical settings, generally does not 
develop in OHSS because of the capillary hyper- 
permeability and consequent intravascular 
hypovolemia. Patients with critical OHSS often 
demonstrate an initial hypernatremia due to 
intravascular dehydration, but dilutional 
hyponatremia frequently develops as the 
syndrome begins to resolve and massive vol­
umes of extravascular fluids are returned to the 
circulation.
Thromboembolic events
Thromboembolic disease is a known and poten­
tially fatal feature of OHSS16, thought to be 
caused by a combination of hemoconcentration, 
ovarian steroid oversecretion and intravascular
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hypovolemia. Intrinsic changes in blood clotting 
mechanisms may also occur in OHSS, as some 
have noted the presence of thrombocytosis as 
well as elevated coagulation factors and endoge­
nous antifibrinolytics17’18. Patients developing 
OHSS who have other underlying coagulation 
abnormalities due to, for example, hereditary or 
autoimmune factors are at increased risk for the 
occurrence of thrombotic events. Such underly­
ing coagulation abnormalities can coexist with 
OHSS, but do not seem to increase the risk of 
developing OHSS19. Most thrombotic events 
due to OHSS are venous, and most venous 
thromboses occur in the head, neck and upper 
limbs. Arterial thromboses, accounting for 25% 
of OHSS-associated thrombotic events, have 
been reported in carotid, subclavian, ulnar, iliac, 
mesenteric, femoral, popliteal, retinal and 
intracerebral arteries, as well as in the aorta 
itself.
Sepsis
Patients with critical OHSS have been found to 
have plasma deficiencies of immunoglobulins, 
particularly IgG and IgA; immunoglobulin levels 
in ascitic fluids are high, suggesting that the eti­
ology of the plasma deficiency is transcapillary 
exudation of these proteins into the third 
space12,20. Presumably related to this immuno­
deficiency, febrile morbidity in patients with 
critical OHSS is high. The incidence of infec­
tions in such patients has been reported to be as 
high as 82%21, and includes urinary tract infec­
tions, pneumonia and upper respiratory 
infections.
TREATMENT OF THE OHSS PATIENT 
Medical approach
There are two possible approaches to the treat­
ment of OHSS, one pathogenesis-oriented and 
one supportive. The former approach utilizes 
agents which specifically negate the putative
causative factor(s) of OHSS. Indomethacin was 
hypothesized to be such an agent when 
prostaglandins were believed to play a role in 
OHSS. Angiotensin-converting enzyme (ACE) 
inhibitors are another group of specific pharma­
cological agents which were thought to have 
potential use in the treatment of OHSS because 
they inhibit the production of angiotensin II, a 
probable pathogenic factor for the syndrome. 
Unfortunately, indomethacin did not benefit the 
syndrome, and ACE inhibitors are teratogenic 
and thus contraindicated whenever a pregnancy 
is contemplated. Just as antagonists to VEGF 
may become useful for the prevention of OHSS, 
similar cytokine inhibitors are being studied for 
treatment of the syndrome. To date, such thera­
pies remain investigational, largely preclinical 
and not yet compelling. One recent study found 
pentoxifylline, an inhibitor of the synthesis of 
tumor necrosis factor-a, to be ineffective in lim­
iting ascites formation in an OHSS rabbit model, 
although it did decrease ovarian weight com­
pared with controls22. However, until such 
interventions are validated in human trials, the 
treatment of OHSS remains largely supportive 
in nature, aiming to mitigate the potentially fatal 
threat of critical OHSS until the condition 
resolves on its own.
Individual treatment will depend on the 
severity of the syndrome. Mild forms of OHSS 
require little more than reassurance, since it is 
well established that mild symptoms usually 
resolve, in the absence of pregnancy, within 2 
weeks after receiving hCG. If a pregnancy 
ensues, mild symptoms may progress, but rarely 
more than one degree in severity. In patients 
with moderate ascites and mild hemoconcentra- 
tion (hematocrit <  45%), bedrest and abundant 
liquid intake should be prescribed. The ten­
dency for intravascular volume depletion and 
hyponatremia may be treated with oral isotonic 
salt solutions; sports drinks, popular among ath­
letes, are particularly suitable because they are 
engineered for optimal rehydration. The patient 
should be vigilant in noting any decreases in
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urine output, significant weight gain or abdomi­
nal bloating as self-assessed by daily abdominal 
girth measurement. These findings, if present, 
may be the first warning signals of accumula­
tion of ascitic fluid and worsening hemoconcen- 
tration. A hematocrit >  45%, or 30% increased 
over baseline, indicates that the condition has 
entered the category of severe OHSS and that 
hospitalization is required.
Dramatic clinical deterioration is most likely 
to manifest 9-10 days after hCG administration, 
when endogenous, pregnancy-derived hCG 
becomes perceptible and the late form of OHSS 
sets in. Figure 1 outlines an algorithm for the 
management of the critically ill hospitalized 
OHSS patient. All fluid and electrolyte manage­
ment of such a patient ought to be performed 
through frequent physical examinations, includ­
ing vital signs and pulse oximetry, blood tests at 
least daily, abdominal ultrasound and chest 
radiographs. Strict monitoring of fluid intake 
and output should be performed through an 
indwelling transurethral urinary catheter and 
through large-bore intravenous lines, preferably 
a central venous line to measure central venous 
pressure.
The single most important variable that indi­
cates the severity of the OHSS is hemoconcen- 
tration as reflected in the hematocrit. Because 
the hematocrit is actually the ratio between red 
cell volume and total blood volume where total 
blood volume =  red cell volume + plasma vol­
ume, the change in plasma volume must always 
be larger than the change reflected by the hema­
tocrit23. Thus, a change of 2 percentage points in 
the hematocrit from 42 to 44% is four times 
smaller than the actual 8% drop in plasma vol­
ume. This is extremely important to remember 
when managing patients with OHSS. Any 
increase in the hematocrit as it approaches 45% 
underestimates the magnitude of plasma vol­
ume depletion and thus the seriousness of the 
patient’s condition. One should therefore not be 
lulled into a false sense of security when only a 
small incremental rise in hematocrit between 40
and 45% is observed. Similarly, in the face of 
hemoconcentration, small reductions in hemat­
ocrit may represent a significant improvement 
in plasma volume6.
An additional measure of hemoconcentra­
tion is the magnitude of leukocytosis; white 
blood cell (WBC) counts higher than 
25 000/mm3, largely reflecting a granulocytosis, 
may be seen. This massive neutrophilia may be 
attributed to hemoconcentration and a general­
ized stress reaction. When oral isotonic fluid 
intake is insufficient to maintain plasma vol­
ume, intravenous fluid therapy becomes manda­
tory. Crystalloids alone, although seldom 
sufficient in restoring homeostasis because of 
massive protein loss through hyperpermeable 
capillaries, still remain the mainstay of inten­
sive treatment of OHSS. Because of the ten­
dency for hyponatremia, sodium chloride with 
or without glucose is the crystalloid of choice, 
and potassium-containing fluid should be 
avoided. The daily volume infused may vary 
from 1.51 to greater than 3.01. Although some 
authors advocate fluid restriction to minimize 
the accumulation of ascites, one should rather 
deal with the discomfort of ascites than face the 
consequences of hypovolemia and hemoconcen­
tration with the attendant risks of thromboem­
bolism and renal shutdown. In order to 
maintain fluid balance, the patient’s urine out­
put, oral and intravenous fluid intake, body 
weight, abdominal girth, hematocrit and serum 
electrolytes must be monitored. In addition, 
coagulation parameters and liver enzymes 
should be periodically assessed. Intravenous 
volume replacement should aim to improve 
renal perfusion before fluid escapes into the 
peritoneal and/or pleural cavities; this transient 
hemodilution is achieved at the expense of 
increased third-spacing and increased total 
body water. Whenever adequate fluid balance 
cannot be restored by crystalloids alone, plasma 
expanders should be utilized. Since albumin is 
the main protein lost in OHSS, human albumin 
is physiological and thus the colloid of choice.
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Figure 1 Algorithm for intensive care of the patient with critical OHSS. DVT, deep vein thrombosis; 




Albumin at doses of 50-100 g at 25% concentra­
tion should be administered intravenously and 
repeated every 2-12 h until the hematocrit falls 
below 45% and urine output increases. Other 
colloids, such as hetastarch, can be used as well.
At a relatively advanced stage of OHSS, dur­
ing treatment with crystalloids and colloids, 
gradual hemodilution is obtained at the expense 
of a tightening abdominal wall with the rapid 
accumulation of ascitic fluid. At this stage of 
restored intravascular volume and improved 
renal perfusion, there may occur a sudden, par­
adoxical onset of oliguria, increasing serum 
creatinine and rapidly falling creatinine clear­
ance24. This sudden deterioration in fluid bal­
ance is probably the result of a significant rise in 
intra-abdominal pressure produced by tense 
ascites. Increased intra-abdominal pressure may 
in turn impede renal venous outflow, causing 
congestion, renal edema and a decrease in renal 
function. Such tense ascites is best treated sur­
gically via therapeutic paracentesis, although 
diuretics may also be effective. When oliguria 
persists despite evidence of adequate hemodilu­
tion, intravenous furosemide at a 10-20-mg dose 
is often beneficial. In practice, an albumin- 
furosemide chase protocol seems to yield the 
best results. Two units of albumin, 50 g each, fol­
lowed immediately by intravenous furosemide, 
will often result in diuresis. In states of volume 
contraction, hemoconcentration and hypoten­
sion, furosemide should be strictly avoided. In 
this precarious stage of OHSS, with impending 
renal failure, renal dose dopamine drip should 
be used for renal rescue to increase renal blood 
flow and glomerular filtration.
In addressing the hypercoagulable state of 
OHSS, most authors reserve anticoagulation for 
special circumstances in which thromboem­
bolic events are suspected or have already 
occurred, or in the setting of a hereditary coagu­
lopathy. Although prophylactic treatment with 
unfractionated or low-molecular-weight heparin 
is of some theoretical value and perhaps should 
be routine in all patients with critical OHSS25,
rapid alleviation of the patient’s hemoconcen­
tration is far more important.
Because of the risk of febrile morbidity and 
infection, patients with critical OHSS must be 
treated as immunocompromised, and must be 
observed carefully for any symptoms or signs of 
developing infection. Prophylactic antibiotics 
are not indicated, but immediate antimicrobial 
therapy should be initiated with the earliest sus­
picion of evolving infection. The specific type of 
antimicrobial should be targeted to the affected 
organ system and likely pathogen. Avecillas et 
al.26 have suggested that the administration of 
exogenous immunoglobulins might be benefi­
cial in OHSS, just as it has been shown to be 
beneficial in other diseases featuring protein 
loss such as the nephrotic syndrome27, but this 
intervention for OHSS needs experimental vali­
dation prior to consideration for full-scale clini­
cal use.
If pulmonary symptoms worsen despite con­
servative approaches, thoracocentesis should be 
considered. If ARDS develops, mechanical ven­
tilation may be indicated. As with any non- 
OHSS patient with ARDS, lower tidal volumes 
and lower plateau pressures may protect the 
lung and decrease mortality28. Fluid manage­
ment for OHSS patients with ARDS requires 
maintenance of intravascular volume at the low­
est possible level that will still maintain ade­
quate systemic perfusion, as measured by 
electrolytes and renal function26. Glucocorti­
coids may be helpful in critical OHSS compli­
cated by ARDS9.
Rarely, as a last resort, when the critical 
stage of OHSS is complicated by renal failure, 
thromboembolism, ARDS and multiorgan fail­
ure, there may be no choice but to perform a 
potentially life-saving termination of pregnancy.
Paracentesis
The single most important treatment modality 
for life-threatening OHSS unresponsive to med­
ical therapy is paracentesis. Rabau et al. first
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proposed the use of paracentesis in the treat­
ment of severe OHSS29. Paracentesis was tem­
porarily discredited, but later regained 
popularity. Many investigators have promoted 
paracentesis as safe and exceptionally benefi­
cial24’30’31. Dramatic improvements in the clini­
cal symptoms of severe OHSS, with almost 
instantaneous diuresis, were reported. In a 
series of seven patients in whom paracentesis 
was performed, urine output rose from 
780 ±  407 ml to 1670 ±  208 ml (p <  0.05), creati­
nine clearance rose from 75.4 ±  16ml/min to 
101 ±  15ml/min (p < 0.05), hematocrit decreased 
from 46.3 ± 2.2% to 37.1 ± 2.5% (p < 0.05), and 
a mean weight loss of 5.3 kg was observed32. In 
the study by Forman et al., 371 of ascitic fluid 
with a protein content of 46-53 g/1 (1.85 kg pro­
tein loss) was removed from a single patient, 
underscoring both the high protein content of 
ascitic fluid and the safety of the procedure31.
The indications for paracentesis include the 
need for symptomatic relief, tense ascites, olig­
uria, rising creatinine or falling creatinine clear­
ance and hemoconcentration unresponsive to 
medical treatment. Paracentesis should be per­
formed aseptically under ultrasound guidance. 
Careful monitoring of hemodynamic stability is 
also mandatory. Rizk and Aboulghar advocated 
transvaginal ultrasonically guided aspiration of 
ascitic fluid as an effective and equally safe 
method32, but a transabdominal approach can 
be used easily as well. Up to 41 may be removed 
either by slow drainage to gravity30 or with neg­
ative pressure using large evacuated containers. 
Paracentesis is contraindicated in patients who 
are hemodynamically unstable, or in the pres­
ence of suspected hemoperitoneum.
A new and innovative treatment for severe 
OHSS was suggested by Koike et al.33. These 
authors describe continuous peritoneovenous 
shunting in 18 patients with severe OHSS. This 
study group was compared with 36 control 
patients who had received intravenous albumin 
at a dose of 37.5g/day. Recirculation of ascites 
fluid rich in proteins is not a novel idea34; how­
ever, the reliance on a continuous shunt from 
the peritoneal cavity into the antecubital vein is 
a logical way to replenish the vascular tree with 
the fluids, proteins and electrolytes that were 
lost from the vasculature. The study reports 
faster hemodilution, shorter hospital stay and 
prompt improvement in symptoms in the 
shunted patients due to diuresis and reduction 
in the amount of ascites. There are, however, 
some problems with the study, beside the com­
plexity of the set-up. First, the reinfused ascites 
may contain the very substances which might 
be responsible for the profound hyperperme­
ability of OHSS, and thus may exacerbate the 
syndrome. Second, the group advocates fluid 
restriction, which may aggravate hemoconcen­
tration and thus contribute to renal failure and 
thromboembolic phenomena.
Surgery
Because of the ovarian enlargement frequently 
present in OHSS, patients may present with 
ovarian cyst rupture or hemorrhage, or with 
ovarian torsion. Cyst rupture or hemorrhage can 
often be managed conservatively, but adnexal 
torsion is a surgical emergency in OHSS as it is 
in any other context. Successful laparoscopic 
detorsion for OHSS patients has been 
reported35.
CONCLUSIONS
OHSS can present in a wide clinical spectrum, 
with some patients requiring nothing more than 
observation at home and others requiring inten­
sive management. Critical OHSS is a life- 
threatening syndrome with multiorgan 
consequences. Familiarity with the pathophysi­
ology of OHSS and with the manifestations of its 
critical form leads to a rational, supportive 
management scheme which can prevent further 
deterioration. With an understanding of the 
disease and with careful attention to fluid and
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electrolyte management, respiratory support, 
infection control and thromboembolism pro­
phylaxis, clinicians can effectively protect the 
threatened lives of these critically ill patients.
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Ovarian hyperstimulation syndrome (OHSS) is 
potentially the most serious complication of 
exogenous gonadotropin administration. Vari­
ous preventive measures have been proposed, as 
described in Chapters 19-24, yet none are com­
pletely effective. Thus, while prevention of the 
syndrome is intrinsically more desirable than 
treatment, unfortunately this goal has remained 
elusive.
In the absence of universally effective pre­
vention strategies, many clinicians have sought 
methods to reduce the impact of OHSS. We pre­
viously developed a protocol for the proactive 
out-patient management of women with OHSS, 
aimed at avoiding hospitalization and minimiz­
ing the progression and complications of 
OHSS1. Traditional management of OHSS has 
involved bedrest and supportive measures at 
home until the clinical picture deteriorates suf­
ficiently to require hospitalization. Once acutely 
ill and hospitalized, however, patients require 
intensive fluid and electrolyte management, 
often accompanied by colloid and/or diuretic 
administration, anticoagulation and paracente­
sis or thoracocentesis. In contrast, the out­
patient management protocol utilizes vigilant 
fluid management at home, early out-patient
paracentesis and judicious colloid replacement 
aimed at attenuating the course of the illness.
We have now used this out-patient protocol 
to monitor more than 4300 in vitro fertilization 
(IVF) cycles and manage 59 cases requiring 
paracentesis or thoracocentesis over the past 7 
years. That approach for out-patient luteal 
phase management of OHSS is the focus of this 
chapter. Ultimately, however, the choice of out­
patient versus in-patient management is best 
determined by the patient, her physician, the 
severity of the condition and the availability of 
facilities.
LUTEAL PHASE MONITORING
Although OHSS has a broad spectrum of clinical 
manifestations, the progression of symptoms 
often follows a predictable pattern through the 
luteal phase, affording the opportunity for close 
monitoring and early out-patient intervention. 
Various clinical risk factors can also be used to 
identify high-risk women who may benefit from 
more intensive monitoring (Chapters 2 and 3).
In our center, all patients are given written 
and verbal instructions about OHSS at the time 
of oocyte retrieval. High-risk patients receive 
similar instructions following human chorionic
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gonadotropin (hCG) administration in super­
ovulation cycles. However, superovulation 
cycles that result in five or more preovulatory 
follicles are either canceled or converted to IVF 
in our center, so we rarely see the development 
of OHSS in this circumstance.
A patient hand-out describes the progression 
from mild to severe OHSS, instructions for mon­
itoring and symptom relief at each stage, and a 
description of worsening signs and symptoms 
that necessitate contact with the clinic. Women 
are advised to limit their physical activities and 
to record their first-morning weight and abdom­
inal girth at the umbilicus in order to obtain one 
or two baseline measurements in the early luteal 
phase. All women are encouraged to maintain 
an oral intake of at least 1000 ml daily. However, 
high-risk patients are also advised not to exceed 
an intake of 1500 ml per day during the luteal 
phase, based on the results of one small ran­
domized trial2.
Some programs advocate the use of prophy­
lactic albumin infusions for high-risk patients at 
the time of oocyte retrieval. A meta-analysis of 
five randomized controlled trials initially indi­
cated a small benefit from the prophylactic 
administration of human albumin at the time of 
oocyte retrieval in high-risk cases (odds ratio
0.28, 95% confidence interval 0.11-0.73)3. How­
ever, a subsequent single-center trial with a 
larger sample size than the entire meta-analysis 
revealed no effect4. In addition, controversy 
exists surrounding the effectiveness and safety 
of albumin administration in general, so the pro­
tocol has not achieved widespread support5.
PROGRESSIVE SYMPTOMS
Women who experience progressive symptoms 
are instructed to contact the clinic if they expe­
rience a weight gain of s* 1 kg in 24 h, an increase 
in abdominal girth of more than 1-2 cm, short­
ness of breath, nausea, vomiting, diarrhea or a 
subjective decrease in urine output. Develop­
ment of these symptoms prompts a standardized 
nursing-initiated assessment in which patients 
are advised to stay home from work (if applica­
ble) and begin more intensive monitoring (Table 
1), including baseline bloodwork within 24 h of 
symptom escalation and initiation of 24-h fluid 
intake and urine output measurements1. Daily 
contact with patients is summarized via key 
parameters recorded on an OHSS flow-sheet 
placed on the front of the chart (Figure 1).
OUT-PATIENT TREATMENT OF OHSS
The treatment for OHSS is generally conserva­
tive and supportive, dictated by the severity of 
the condition (Table 1). The syndrome is self­
limited, although it may persist for several 
weeks, particularly in conception cycles6,7. In 
addition to medical interventions, substantial 
emotional support is also required to cope with 
the acute onset of distressing physical symp­
toms and the accompanying fears about the 
well-being of the woman and her early 
pregnancy.
Mild symptoms of ovarian hyperstimulation 
are a predictable consequence of hCG adminis­
tration following stimulation with exogenous 
gonadotropins. Mild OHSS presents with bloat­
ing and weight gain; it responds to supportive 
measures including rest and analgesia.
The progression to moderate or severe OHSS 
involves the development of ascites, associated 
with hemoconcentration, increased thirst, mar­
ginal renal perfusion, oliguria and a tendency 
toward thromboembolic events8. Clinically, this 
is heralded by the triad of increasing symptoms: 
evidence of dehydration or hemoconcentration 
and low or declining serum albumin concentra­
tions (Table 2). This constellation of signs and 
symptoms mandates assessment in the clinic 
and more intensive monitoring and/or therapy 
(Table 1).
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Table 1 Out-patient management guidelines for progressive ovarian hyperstimulation syndrome 
(OHSS)
Mild-moderate OHSS Moderate-severe OHSS
Advise bedrest at home Continue bedrest, analgesics and antiemetics
Record daily weight and abdominal 
girth
Record daily 24-h fluid intake and 
urine output
Provide analgesics and antiemetics as 
needed (e.g. acetaminophen and 
diphenhydramine)
Order baseline bloodwork (Hb, Hct, 
sodium, potassium, BUN, creatinine, 
PT, PTT, serum albumin and 
quantitative p-hCG)
Reinforce fluid intake of 
1000-1500 ml daily
Encourage intake of fluids rich in 
proteins, calories or electrolytes (e.g. 
fruit juices, soups, Popsicle®, Gator- 
Aid®, Ensure®, Boost®)
Continue daily monitoring of weight, abdominal girth and 
24-h fluid intake/urine output
Repeat baseline bloodwork every 1-3 days, or as clinically 
indicated:
-  Hb, Hct, sodium, potassium, serum albumin
-  as indicated: PT, PTT, BUN, creatinine and serial 
quantitative |3-hCG
Arrange transvaginal ultrasound to assess ascitic volume
Ensure appropriate rehydration and/or fluid resuscitation:
-  oral fluids or IV crystalloids, depending on severity
-  normalize hematocrit and electrolytes within 24 h, if 
possible
-  maintain urine output s* 20-25 ml/h in 24 h
Consider paracentesis if:
-  ascitic fluid pocket ^ 5-6 cm
-  abdominal distension increases daily
-  nausea and vomiting worsen daily
-  weight increases ^ 1 kg/day
-  abdominal girth increases z> 1-2 cm/day
-  urine output drops below 20-25 ml/h in 24 h despite 
adequate rehydration
-  serum albumin falls below lower limit of normal
Consider colloid replacement if:
-  urine output < 20-25 ml/h despite adequate crystalloid 
replacement
-  paracentesis is required
-  clinical edema develops
Consider hospitalization if:
-  clinical condition does not stabilize quickly
-  patient cannot return rapidly for reassessment
-  symptoms are not manageable at home
-  fluid or electrolyte disturbances persist despite 
rehydration (e.g. Hb > 145 g/1, Hct >  45%)
-  other complications develop
Consider heparinization if:
-  hospitalized and immobilized
-  coagulation parameters abnormal
Hb, hemoglobin; Hct, hematocrit; BUN, blood urea nitrogen; PT, prothrombin time; PTT, partial thromboplastin 
time; hCG, human chorionic gonadotropin
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Figure 1 Ovarian hyperstimulation syndrome (OHSS) out-patient monitoring flow-sheet
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Date Date Date Date
Patient data Weight 59.5 k # 5 7 .5 k # 5 8 * # -
Abdominal girth 79 c m 84 cm 81 c m 81 cm
24-h fluid intake « 1 0 0 0  m l 1500 m l 1800 m l 1450 m l
24-h urine output 450 m l 750 m l 725 m l
Hourly output 19 ml/h/ 31 m l/h 30 m l/h
Symptom summary Bloated, 
nauseated/, 
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Lab/clinic data Hematocrit (%) 48 41
Albumin (35-50 g/l) 31 29
p-hCG (IU/1) 204 498
Paracentesis 1900 m l
IV fluids 500 m l HES,
250 m lK in g er ’y
Rx Vo- B/W. 




firs t  parcccentests
DOB, date of birth; Rx, treatment; hCG, human chorionic gonadotropin; IV, intravenous; B/W, blood work; 
HES, hydroxyethyl starch
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Table 2 Clinical triad heralding onset of ascites
1. Increasing symptoms
-  abdominal distension
-  shortness of breath
-  nausea, vomiting
-  diarrhea
2. Hemoconcentration
-  decreasing urine output (< 20ml/h over 
24 h)
-  elevated hematocrit
-  thirst
3. Subnormal serum albumin concentrations
Rehydration
Appropriate fluid management is the key initial 
intervention, and is probably critical in mini­
mizing the risk of thromboembolic complica­
tions. Hemoconcentration requires prompt 
correction with oral or intravenous fluids, 
although rehydration will inevitably worsen the 
ascites because of the underlying increase in 
capillary permeability. The use of diuretics is 
generally counterproductive in this circum­
stance since it may aggravate the underlying 
hypovolemia without improving the extensive 
third-space losses.
In our experience, if promptly recognized, 
hemoconcentration can usually be rapidly cor­
rected by increasing oral intake over a 24-h 
period. If oral intake is marginal secondary to 
nausea and abdominal distension, patients are 
reminded to consume frequent small amounts of 
calorie-, protein- or electrolyte-rich fluids such 
as soups, juices and commercial protein or 
sports drinks in order to achieve 1000-1500 ml 
of intake daily (Table 1). If urine output is mar­
ginal (< 20-25ml/h) or hematocrit is elevated 
despite an intake of 1000-1500 ml, women are 
prompted to consume an additional 500-1000 ml 
daily. Antiemetics are often used orally or rec­
tally to control nausea; their sedating side- 
effects may also facilitate rest.
Clinical assessment
If clinical symptoms continue to worsen over a 
24-h period, patients are brought to the clinic for 
assessment and transvaginal ultrasonography 
the following morning. Most have been appro­
priately rehydrated over the preceding 24 h in 
response to advice from the nursing staff. How­
ever, they may have had substantial worsening 
of their abdominal distension in response to the 
increased oral intake. We occasionally adminis­
ter an intravenous bolus of 500-1000 ml of 
Ringer’s lactate or 5% dextrose in normal saline 
along with an intravenous antiemetic to women 
who are particularly nauseated or dehydrated 
when they attend the clinic for assessment.
Paracentesis
If ultrasonography demonstrates pockets of 
ascitic fluid greater than 5-6 cm in mean diame­
ter, paracentesis should be considered. This is 
the single strategy that predictably produces 
clinical and biochemical improvement and has­
tens resolution of the process (Table 3)9-13. In an 
out-patient setting, our preference is for the 
transvaginal route, under paracervical block, in 
the same manner as oocyte collection. However, 
other centers have reported good success with 
abdominal paracentesis1314, and occasionally 
with an indwelling vaginal or abdominal 
catheter for ongoing drainage of large amounts 
of ascites15-17. Ultimately, the choice of paracen­
tesis technique and setting will depend on the 
individual facility and operator experience.
Our transvaginal paracentesis procedure has 
previously been described in detail1. Briefly, an 
intravenous (IV) line is established with IV 
Ringer’s lactate, the vaginal vault prepped with
0.05% chlorhexidine and a paracervical block 
inserted. Intravenous medications are given as 
needed based on clinical assessment and previ­
ous response during oocyte retrieval. These
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Table 3 Improvement following first paracentesis in 53 women with late-onset ovarian hyperstimu­
lation syndrome (OHSS) (July 1997-July 2004)
0-24 h pre-paracentesis 24-48 h post-paracentesis Change
Weight (kg) 63 ±  15 62 ±  15 -1 kg
Abdominal girth (cm) 89 ± 1 7 87.3 ±  17 -1.7 cm
Urine output (ml/h) 26 ±  15 35 ± 1 8 + 9 ml/h
Albumin (g/1) 30 ± 4 27 ± 7 -3 g/1
Hematocrit (%) 45 ±0.05 42 ±0 .1 -3%
include diphenhydramine 25 mg for nausea, 
fentanyl citrate 25-50 pig for analgesia and 
atropine 0.4 mg to minimize vasovagal reac­
tions. We do not routinely use prophylactic 
antibiotics for paracentesis or oocyte collection.
There are no clear guidelines as to the 
amount or rate of fluid removal during paracen­
tesis18. One recent report indicated that the 
majority of the reduction in intra-abdominal 
pressure and renal artery resistance occurred 
following withdrawal of the first 2000 ml of 
fluid19. In general, healthy young women with­
out underlying medical conditions are unlikely 
to have difficulty with the compensatory fluid 
shift that accompanies paracentesis, unlike 
older patients with underlying hepatic disease 
or malignancy. It has been our practice to drain 
all ascitic fluid that is visible in the posterior cul 
de sac and can be safely accessed with a single 
puncture and without undue discomfort1. 
Between 2000 and 3000 ml can be drained in 
this fashion over 30-45 min using a 16-gauge 
single-lumen oocyte collection needle. We have 
not encountered bleeding, infection or other 
adverse sequelae in more than 100 such proce­
dures. Patients report progressive resolution of 
distension, nausea and shortness of breath after 
the first 500 ml of ascitic fluid has been aspi­
rated, usually followed by subjective reports of 
thirst and hunger. Women are generally dis­
charged within 2h after the procedure to con­
tinue with rest and monitoring at home.
In our experience, between one- and two- 
thirds of the patients who undergo each para­
centesis will subsequently require another 
paracentesis (Table 4). However, both the inter­
val between procedures and the volume drained 
increase progressively as the acuity of the illness 
decreases and the abdominal wall accommo­
dates to the distension.
Pleural effusions may also occur, especially 
on the right, secondary to transfer of ascitic fluid 
through the thoracic duct. While they generally 
resolve following abdominal paracentesis, occa­
sional cases require out-patient thoracocentesis, 
either alone or in addition to paracentesis, to 
alleviate persistent respiratory symptoms.
Colloid replacement
Serum albumin levels usually drop into the sub­
normal range in response to ascitic fluid accu­
mulation, and may fall further after paracentesis 
and drainage of protein-rich ascitic fluid. Judi­
cious colloid replacement may help to maintain 
urine output and prevent peripheral edema in 
these circumstances. Traditional therapy has 
involved 5 or 25% albumin, although recent 
concerns about the cost, efficacy and safety of 
albumin have prompted the use of synthetic
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Table 4 Characteristics of repeated out-patient paracentesis in 53 women with late-onset ovarian 








First paracentesis 53 17.6 ± 3 .8  days post-hCG 1941±  709 38/53 (72%)
Second paracentesis 33 3.1 ± 1 .7  days later 2245 ±991 20/33 (61%)
Third paracentesis 11 4.2 ± 2.3 days later 2459± 1279 5/11 (45%)
Fourth or more 6 5.3 ± 2 .9  days later 3110±  745 2/6 (33%)
*250 ml of 25% albumin or 500 ml of 10% hydroxyethyl starch
colloid products5. Preliminary evidence sug­
gests that colloid alternatives such as hydrox­
yethyl starch may be equally effective20-22. 
Since late 2001, it has been our practice to 
administer 500 ml of 10% hydroxyethyl starch 
to most patients undergoing their first paracen­
tesis, and as needed for subsequent procedures 
if urine output has been marginal despite appro­
priate fluid intake (Table 4). The administration 
of more than 1500 ml hydroxyethyl starch in a 
24-h period has been associated with bleeding 
complications23.
Anticoagulation
Correction of hemoconcentration is probably 
the single most important step in reducing the 
risk of thromboembolism24. Gentle mobilization, 
leg exercises and TED (antiembolic) stockings 
are also helpful, and are easy to incorporate in 
an out-patient management routine. The throm­
boembolic risks that accompany immobility are 
intuitively much higher in hospitalized patients 
confined to bed with an intravenous line and an 
indwelling urinary catheter than they are in 
women following a regimen of rest and limited 
activities at home.
The role of subcutaneous heparin remains 
controversial; some authors use it routinely in 
hospitalized patients, while others reserve it for 
those with abnormal coagulation parameters, or
a suspicious personal or family history25. It has 
not been our practice to anticoagulate patients 
unless they have a positive history for throm­
boembolism. The sole thrombotic episode in the 
series described in Table 5 involved an axillary 
vein thrombosis more than 3 weeks after clinical 
resolution of the OHSS. The woman was subse­
quently found to have a thrombophilic disorder.
RESULTS OF OUT-PATIENT 
AAANAGEMENT OF OHSS
During a 7-year period (July 1997-July 2004) we 
performed more than 4300 IVF cycles and iden­
tified 59 patients (1.4%) who developed moder­
ate to severe OHSS and required drainage of 
ascitic fluid. Two of these 59 women were man­
aged outside our standard protocol; one woman 
required a sole thoracocentesis in a local hospi­
tal out-patient clinic, and one woman was hos­
pitalized at a distant center for albumin and 
paracentesis because it was not feasible for her 
to travel to us for management. Both were preg­
nant and delivered healthy singleton and triplet 
pregnancies, respectively.
The remaining 57 women underwent at least 
one out-patient paracentesis in our free-stand­
ing clinic and are summarized in Table 5. Of 
these, two women were hospitalized briefly to
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at 7-8 week 
ultrasound Delivery
Late OHSS 
(> 10 days 
post-hCG)
n =  53
Age =  34 ± 4 years 
Oocytes =  13 ±  5
105*
(range 1-7)







(ss 10 days 
post-hCG)
17 = 4
Age =  33 ±  4 years 
Oocytes =  22 ±  5
6
(range 1-3)
2/3+ 2 singletons 2 singletons
Total n =  57 55/56 49/55 delivered 
6/55 miscarried
including one woman who required thoracocentesis following paracentesis, and one woman hospitalized for 
unresponsive symptoms after two out-patient paracenteses; The fourth woman had elective cryopreservation of 
all embryos; ^including one dichorionic triplet pregnancy electively reduced to monozygotic twins
facilitate albumin administration in the first 
year of this protocol. All subsequent albumin or 
hydroxyethyl starch infusions were adminis­
tered in our free-standing out-patient facility or 
in a hospital ambulatory clinic. One woman 
required hospital admission to manage severe 
symptoms and fluid balance issues that could 
not be controlled following two out-patient 
paracenteses. Her case appears to be the only 
true lack of success with out-patient manage­
ment.
The most common presentation of OHSS is 
in the late luteal phase, generally 10-12 days or 
more following hCG administration. The condi­
tion is probably triggered by endogenous hCG 
concentrations, as the majority of cases are 
found to be pregnant around the time of symp­
tom escalation and there is a high incidence of 
multiple pregnancy (Table 5)1’6,26. In keeping 
with these observations, 53/57 women in the 
current series presented with late-onset OHSS 
and all were pregnant following fresh embryo 
transfer. Of these, 41/53 (77%) had a multiple 
implantation and 35/53 (66%) had an ongoing
multiple pregnancy with positive fetal hearts at
7-8 weeks’ gestation.
In contrast, severe OHSS that develops in 
the early luteal phase, within 10 or 11 days after 
hCG administration, is less common and often 
follows a shorter clinical course. It is probably 
due to an excessive preovulatory response fol­
lowed by sequelae of exogenous hCG adminis­
tration, and is not necessarily accompanied by a 
pregnancy (Table 5)6,26. Indeed, only 4/59 cases 
in the current series presented with early-onset 
symptoms, but with an average of nearly nine 
more oocytes per patient than those with late 
OHSS. Two out of three conceived following 
fresh embryo transfer; the fourth woman did not 
have a fresh transfer, but still required paracen­
tesis for early OHSS despite elective cryopreser­
vation of all her embryos.
As most women learn that they are pregnant 
at the time they present with OHSS symptoms, 
concerns over the well-being of the pregnancy 
are often foremost in their thoughts. In the cur­
rent series, only 6/55 pregnancies (10.9%) were 
lost in the first (n =  2 singletons) or second
186
OUT-PATIENT MANAGEMENT OF OHSS
[n =  3 twins and 1 singleton) trimester. Nine 
additional twin pregnancies underwent sponta­
neous loss of one fetus after documentation of a 
positive fetal heartbeat, leaving ongoing single- 
ton pregnancies.
Although follow-up data are sparse, the cur­
rent series and previous published and anec­
dotal data about the outcome of pregnancies 
following OHSS are reassuring6’8. However, 
there are at least two reports of higher miscar­
riage rates and increased obstetric complica­
tions, particularly associated with higher-order 
multiple pregnancies, prolonged hospitalization 
and significant maternal complications of 
OHSS27,28. The current data emphasize the 
potential value of early intervention with 
aggressive attempts to attenuate the course of 
the disease, suggesting that early treatment may 
have a beneficial effect on both maternal and 
fetal outcome.
SUMMARY
In the absence of universally effective preven­
tion strategies, we have developed and adhered 
to a protocol of active out-patient management 
of moderate to severe OHSS. Over the past 7 
years and approximately 4300 IVF cycles, we 
have monitored 59 consecutive cases with 
symptomatic ascites or hydrothorax. Only one 
has required hospitalization related to true lack 
of success with the out-patient management 
protocol.
Our out-patient protocol encourages early 
paracentesis aimed at minimizing the progres­
sion of the disease, in contrast to late paracente­
sis aimed at hastening the recovery of critically 
ill hospitalized patients. We use oral rehydra­
tion and judicious colloid replacement in ambu­
latory patients in an attempt to circumvent the 
need for intensive parenteral fluid management 
in hospitalized patients. While OHSS remains a 
serious and potentially life-threatening disorder, 
our data suggest that vigilant monitoring and
early out-patient intervention can serve as a safe 
and effective method of managing symptoms, 
attenuating the course of the illness and mini­
mizing complications for both the affected 
women and their pregnancies.
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Q: Will this harm my pregnancy?
A: No, in our experience with out-patient management, the miscarriage rate is no higher than in other 
women of the same age group who have not developed OHSS. However, the chance of having a mul­
tiple pregnancy is higher than usual, occurring in about two-thirds of women who develop OHSS.
Q: How long will this last?
A: It is quite variable, but most women feel well enough to discontinue daily monitoring and con­
template returning to work within 1-2 weeks after the first paracentesis1.
Q: Will I have to have another paracentesis?
A: Each time we do a paracentesis, approximately half of the women will require another procedure. 
If so, you will likely notice your symptoms becoming progressively worse over the next 3-5 days.
From other physicians
Q: I was taught during m edical school not to drain more than about 1000 ml during a paracentesis. Why 
should this situation be any different?
A: Women with OHSS are generally young and healthy, and are unlikely to suffer cardiovascular com­
promise following a larger-volume paracentesis, in contrast to older individuals with a malignancy or 
hepatic failure. That said, it is still prudent to monitor clinical status and vital signs carefully during 
the paracentesis. Drainage of > 2000 ml at a time may not produce any additional improvement in 
renal or hemodynamic parameters, but may provide additional symptomatic relief and potentially 
diminish the need for repeat procedures19.
Q: Can I use a colloid infusion to increase circulating oncotic pressure, followed by a diuretic to mobi­
lize the ascites?
A: This has generally been an inefficient method of mobilizing ascites, and may even be counterpro­
ductive if it aggravates the underlying hypovolemia and marginal renal perfusion in an acutely ill 
patient. Drainage of the third-space fluid via paracentesis provides more immediate and predictable 
relief of symptoms and improvement in renal and hematological parameters. Diuretics may have 
some merit in a stable, recovering patient who still has residual peripheral edema that has not 
responded to other forms of therapy.
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CHAPTER 19
Primary prevention of ovarian 
hyperstimulation syndrome: choice of ovulation 
induction and ovarian stimulation in IVF and 
non-IVF reproductive technologies
Juliette Guibert and Frangois Olivennes
INTRODUCTION
Ovarian hyperstimulation syndrome (OHSS) is 
not frequent, its pathophysiology remains 
unclear and there are few criteria of reliable pre­
dictive value for its occurrence. For these rea­
sons, its prevention remains an unresolved 
problem for reproductive specialists, who are 
without a sufficient scientific or clinical basis to 
develop methods to guarantee complete safety.
Nevertheless, primary prevention of OHSS 
should in principle be possible at different steps 
of the management of infertility, by recognizing 
high-risk situations and by respecting safety 
rules in choosing treatments and in conducting 
ovarian stimulation.
Before treatment, the known risk factors 
should be identified, in order to target a group of 
high-risk patients for specific preventive strate­
gies. These include systematic interrogation 
about the necessity of ovarian stimulation and 
the duration of infertility, the timeliness of the 
treatment and the development of minimal-risk 
management procedures, with consideration for 
the alternative treatments of infertility, e.g. tubal 
surgery, ovarian drilling by electrocautery or 
laser vaporization, insulin-resistance-reducing 
drugs and natural-cycle in vitro fertilization 
(IVF).
During treatment, minimal safety rules of 
stimulation should be respected for all patients, 
and especially for those with an identified high 
risk. These rules concern the choice of stimula­
tion regimen (drug, dose, protocol) and adjust­
ment of the dose of gonadotropin according to 
the ovarian response (careful monitoring of the 
cycle).
PRIMARY PREVENTION BEFORE 
TREATMENT
Identification of factors influencing the 
incidence of OHSS
Patients with polycystic ovarian syndrome 
(PCOS) or showing isolated characteristics of 
PCOS (clinical, ultrasonographic or biological) 
should be considered at high risk of developing 
OHSS1-5. It appears to be the major predisposing 
factor in many studies: the proportion of 
patients showing ultrasonically diagnosed 
PCOS in severe OHSS is significantly higher 
than in patients who do not develop OHSS4. 
This is consistent with the fact that patients 
with PCOS produce more follicles than normo- 
ovulatory patients stimulated with the same 
protocols. Finding more than ten resting
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follicles on each ovary has been shown to be 
predictive of an excessive ovarian response and 
a risk factor for OHSS6. The baseline ovarian 
volume measured by three-dimensional ultra­
sonography has also been shown to be corre­
lated with the risk of developing OHSS7. 
Furthermore, inversion of the luteinizing hor­
mone (LH)/follicle stimulating hormone (FSH) 
ratio (LH > FSH), or increased ovarian androgen 
circulating levels observed separately or in 
patients with PCOS, could disturb the androgen 
conversion pathway and enhance the risk for 
OHSS4,5. Therefore, no stimulation should be 
performed without a day-3 evaluation of the 
LH/FSH ratio and of the number of resting folli­
cles observed on ultrasound. The body mass 
index (BMI) is a paradoxical clue, since a lean 
BMI increases the risk of a high ovarian 
response and of OHSS, but a high BMI is often 
related to PCOS, which increases the risk of 
OHSS. Therefore, BMI does not appear to be a 
useful marker of increased risk of OHSS8.
Young age appears to be a risk factor, since 
patients who develop OHSS are younger than 
those who do not1,2.
It has also been reported that patients show­
ing allergic dispositions may be more likely to 
develop OHSS. Because OHSS has many 
similarities to an exaggerated inflammatory 
response, it has been hypothesized that an 
individual tendency to develop pathological 
OHSS when the ovarian response is strong may 
have something to do with immunological 
sensitivity1.
Apart from these known factors, the actual 
individual risk of developing OHSS remains 
mostly unpredictable in naive patients, who 
may show individual (hyper)sensitivity to 
gonadotropin stimulation. Previous ovarian 
response needs to be considered when available, 
as it is useful in predicting this sensitivity9. The 
previous occurrence of OHSS in a mild or severe 
form is highly predictive of a high-risk situation 
in subsequent treatment cycles4. A previous 
strong ovarian response with an estradiol level
of over 1500 pg/1 at day 8 or over 3000 pg/1 at day 
11, or with more than 15 oocytes retrieved, 
should be a warning, even though no OHSS has 
occurred1.
All of these criteria should alert physicians 
to consider a preventive strategy for avoiding 
OHSS.
Initiation of treatment
First, the severity of the medical damage caused 
by OHSS has to be weighed against the neces­
sity for ovarian stimulation. It is likely that most 
IVF procedures are initiated with good evidence 
for their medical justification. However, in 
many situations, IVF is not performed for any 
gynecological pathology. Examples are patients 
with intracytoplasmic sperm injection (ICSI) for 
male-related infertility, oocyte donors, human 
immunodeficiency virus (HlV)-serodifferent 
couples asking for virus-safe procreation, and 
those seeking prevention of transmission of 
known genetic abnormalities by preimplanta­
tion diagnosis. It is noteworthy that patients 
with these indications for treatment frequently 
undergo strong ovarian stimulation despite the 
fact that they do not show any reproductive dis­
ability. Complications following such treat­
ments are particularly undesirable, and should 
be carefully explained to the women concerned.
In non-IVF procedures, the correct moment 
to initiate treatment is not easy to determine. It 
appears that OHSS does not occur in more 
severe forms in normo-ovulatory patients8, but 
obviously the occurrence of a serious complica­
tion with no medical evidence of the necessity 
for such treatment is unjustifiable. This is par­
ticularly important for couples requiring donor 
sperm insemination if no gynecological abnor­
mality is present, and for couples requiring 
assisted reproduction treatments despite a short 
duration of infertility, e.g. because of advanced 
female age or because of recurrent miscarriage. 
In these patients, the safety rules of ovarian stim­
ulation have to be strictly followed, including
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giving information to patients about possible 
medical consequences and about the benefits of 
the particular choice of stimulation that has 
been made10.
Development of minimal-risk 
procedures
With respect to non-IVF procedures, alternative 
approaches exist for the pharmacological induc­
tion of ovulation for patients with PCOS (Figure 
1). The benefits and risks of such treatments 
have to be balanced against the risk of OHSS.
Diet and weight loss have been demon­
strated to restore ovulation in some obese 
anovulatory women with PCOS, with beneficial 
effects on the incidence of diabetes mellitus and 
on cardiovascular risk11. Insulin-sensitizing 
drugs (e.g. metformin) have been shown to be 
beneficial in facilitating normal menses and 
pregnancy, and in preventing type 2 diabetes 
mellitus12,13. Ovarian drilling (either by laparo­
scopic electrocauterization or by laser vaporiza­
tion) is also able to restore spontaneous menses 
and ovulation and induce pregnancy, with a 
very low risk of multiple pregnancy, OHSS and 
miscarriage, even though the procedure has still 
not been prospectively evaluated14,15.
Preliminary weight loss prior to both non- 
IVF and IVF procedures and the administration 
of metformin or octreotide has been shown to 
normalize the ovarian response to exogenous 
gonadotropin in women with PCOS resistant to 
clomiphene citrate (CC), with a significant 
reduction of the serum estradiol level, the num­
ber of follicles and the cancellation rate, and 
with a similar pregnancy rate16,17. A statistically 
significant effect on prevention of OHSS could 
not be demonstrated in non-IVF patients, proba­
bly because of its very low incidence16. Ovarian 
drilling before stimulation for IVF in women 
with a high risk due to PCOS or with a previous 
experience of OHSS may help to avoid severe 
complications or cancellation of the cycle, but it 
has to be balanced against the risk of the 
operation18,19.
Figure 1 Stimulation regimen in non-in vitro fertilization (IVF) procedures. hCG, human chorionic 
gonadotropin; ??, treatment options which need to be confirmed by more studies
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Figure 2 Stimulation regimen in in vitro fertilization (IVF) procedures. GnRH, gonadotropin- 
releasing hormone; OC, oral contraceptive
In high-risk patients, new approaches in IVF 
should be considered (Figure 2). The debate 
about natural IVF, conducted in a natural, non- 
stimulated cycle, has recently re-emerged, since 
the use of gonadotropin-releasing hormone 
(GnRH) antagonists permits delay of the LH 
surge while a single follicle is growing sponta­
neously or with little stimulation20. Further 
studies should be conducted to compare the 
results between several ‘natural’ IVF cycles and 
a single hyperstimulated cycle. Obviously, mul­
tiple pregnancy and OHSS rates would be 
reduced, but relatively little information is 
available regarding the pregnancy rate and the 
pregnancy outcome from this procedure21-22. 
Moreover, patients with PCOS, which is the 
major risk factor for OHSS, are unlikely to ben­
efit from this procedure, since their success in 
development of a single follicle leading to the 
retrieval of a single, good-quality oocyte during 
a spontaneous cycle remains uncertain.
Culture development of immature oocytes 
could lead to the abandonment of ovarian con­
trolled hyperstimulation and the administration 
of hCG in IVF procedures, at least in high-risk 
groups of patients, such as women with PCOS 
or with previous severe OHSS, but this proce­
dure remains to be better assessed23-27. Preg­
nancy rates remain lower than with classical 
ovarian stimulation protocols. Moreover, the 
safety of the procedure concerning the well­
being of the children conceived remains to be 
established.
PRIMARY PREVENTION WHILE 
CONDUCTING TREATMENT
The effective prevention of OHSS is also possi­
ble during treatment. Primary prevention while 
conducting treatment in women with identified 
risk factors for OHSS requires the pertinent 
choice of drug combinations for ovarian stimu­
lation and the adjustment of individualized 
low-dose step-up regimens by very careful 
monitoring.
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Choice of stimulation regimen
Clomiphene citrate
In non-IVF procedures, induction of ovulation 
by CC is rarely associated with severe OHSS28. 
Therefore, CC is the treatment of choice for 
induction of ovulation, rather than gonado­
tropins (urinary or recombinant), which 
increase the incidence of OHSS. However, in 
rare patients who have experienced OHSS after 
the use of CC, gonadotropin stimulation allows 
the modulation of therapy throughout the cycle, 
which is impossible with CC. In high-risk 
patients, the initial dose of CC must be 
increased carefully to find the ovulatory thresh­
old, and gonadotropins are recommended for 
CC-resistant patients29. CC resistance is defined 
as failure to ovulate after a dose of 150 mg of CC 
for three cycles, even though higher doses have 
been proposed with variable success.
Gonadotropins
In non-IVF procedures, high-risk patients 
should undergo low-dose step-up regimens for 
ovulation induction, which have been shown to 
decrease considerably the risk of OHSS and 
multiple pregnancy. In strictly anovulatory 
patients, these regimens start with a daily dose 
of 50 or 75IU of recombinant FSH (rFSH) or uri­
nary human menopausal gonadotropin (hMG) 
during 7-14 days, and provide dose increments 
of 37.5 IU every 5 or 7 days until follicle devel­
opment initiates. This allows the development 
of a single follicle, and reduces the occurrence 
of OHSS almost to nil30. An alternative protocol 
was proposed in which the gonadotropins were 
decreased in steps (step-down)31. A prospective 
randomized study concluded in favor of the 
step-up regimen32. A combination of step-up 
and step-down has also been proposed, and 
could warrant further study33.
In IVF, the use of a low-dose stimulation reg­
imen seems to reduce OHSS incidence34. To 
optimize the ovarian response without provok­
ing OHSS is the best compromise that should be
reached by an ideal regimen of stimulation, 
which is unfortunately still not consistently 
achievable. There is a fine balance between 
increasing oocyte recruitment to improve the 
success rate of IVF and preventing OHSS by 
promoting a small pool of granulosa cells, highly 
sensitive to the future luteinizing stimulus.
The starting dose for gonadotropin is based 
on age, body mass index (BMI) and existence of 
PCOS, as well as on previous history of OHSS or 
high response. A recent study found no reduc­
tion in the occurrence of OHSS in standard 
patients when reducing the initial dose from 
200 to 100 IU35. But in high-risk patients, halv­
ing of the initial dosage of gonadotropins 
appears to prevent OHSS36. Likewise, the use of 
limited ovarian stimulation and ovulation trig­
gering when the leading follicles reach 12 mm in 
PCOS patients with previous OHSS may reduce 
the recurrence of OHSS37.
The choice of urinary or recombinant hMG 
or FSH does not seem to influence the incidence 
of OHSS38.
More recently, Filicori et al. proposed con­
ducting the end of stimulation using a treatment 
composed of low-dose hCG. Low-dose hCG as a 
source of LH activity was associated with FSH or 
was used alone in the second part of the follicu­
lar phase39. Furthermore, LH activity is capable 
of reducing the development of small ovarian 
follicles (< 10 mm) that may predispose patients 
to developing complications such as OHSS. 
This regimen was used in a small group of 
patients exposed to OHSS40. The absence of FSH 
stimulation reduced the amount of follicles and 
the estradiol value. This novel approach should 
be evaluated in prospective randomized studies. 
An excellent review exists that presents in detail 
all the studies available and the different thera­
peutic options summarized in this chapter41.
GnRH agonists and antagonists
The use of the GnRH agonist long protocol, 
which consists of previous pituitary desensitiza­
tion before the onset of ovarian stimulation by
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gonadotropins, is associated with a higher inci­
dence of OHSS, mostly because it increases fol­
licular recruitment. There is also a peripheral 
action of the GnRH agonist per se granulosa 
cells, which can explain why OHSS is more 
likely for the equivalent follicular recruitment. 
The type of GnRH agonist to be used in patients 
at risk of OHSS has not been extensively stud­
ied. It is obvious that the short protocol should 
not be proposed, as the initial flare-up effect 
could lead to an excessive ovarian response. In 
the long protocol, depot formulation versus 
daily injection and follicular versus luteal start 
have not been compared prospectively in 
patients at risk of OHSS. An interesting 
approach has been proposed by combining the 
suppression of the estrogen-progestogen pill 
with the GnRH agonist42. No comparative stud­
ies are available, but results appear to be very 
interesting and this protocol is the GnRH- 
agonist protocol of choice in many IVF centers.
The recent introduction of GnRH antagonists 
has been claimed to reduce the risk of OHSS, for 
several physiological reasons. First, follicular 
recruitment seems to be lower, and hence the 
granulosa cell pool undergoing the luteinizing 
stimulus. On the other hand, a possible ovarian 
action of GnRH antagonist could exist.
A reduction in the incidence of OHSS is 
observed in the majority of prospective random­
ized studies using GnRH antagonists43-48. 
Patients receiving antagonist treatment have 
lower estradiol serum levels at the time of hCG 
administration, mostly because of a lower num­
ber of follicles, which could explain the lower 
incidence of OHSS49. Recent meta-analyses 
failed to find a significant reduction in OHSS in 
unselected patients50,51. However, in the phase 
II and III studies analyzed in those meta­
analyses, cancellation criteria were applied, and 
patients canceled in the agonist group intro­
duced a bias into the OHSS data45. Only two 
small prospective randomized studies compared 
GnRH agonist and antagonist regimens51,52.
They found similar IVF outcomes with reduc­
tions in lengths of treatment and estradiol lev­
els, but they did not find a reduction in the 
incidence of OHSS; the study samples were not 
adequate to analyze OHSS.
The use of GnRH antagonists could further 
decrease the incidence of OHSS in high-risk 
patients when replacing hCG by a GnRH agonist 
to trigger ovulation. Several authors53-56 have 
proposed triggering ovulation with a GnRH ago­
nist to decrease the risk of OHSS. However, this 
approach cannot be proposed in a patient previ­
ously desensitized with a GnRH agonist, but 
GnRH agonists can be used to induce an endoge­
nous LH surge during an ovarian stimulation 
cycle in which a GnRH antagonist is used to pre­
vent LH surges57. A recent study carried out in a 
limited number of patients not at risk for OHSS, 
comparing the use of hCG, leuprolide (0.2 mg) 
and triptorelin (0.1 mg) to trigger ovulation in 
IVF patients treated with ganirelix (0.25 mg), 
found similar IVF-embryo transfer (ET) results 
between the three groups of patients58. A small 
group of high responders was treated with a 
combination of a GnRH antagonist and an ago­
nist, and no OHSS was observed in this prelim­
inary report59. The results should be evaluated, 
as pregnancy rates were found to be low by 
some authors (unpublished data). A recent 
prospective study, unfortunately unpublished, 
found a lower pregnancy rate in patients in 
whom GnRH agonists were used to trigger 
ovulation, despite luteal supplementation of 
estrogen and progesterone (Devroey et al., 
unpublished). Overall, GnRH antagonists could 
offer a good alternative to current stimulation 
protocols, with a reduced incidence of 
OHSS60,61.
Monitoring the cycle
Careful adaptation of the daily dose of 
gonadotropin administered for ovarian stimula­
tion to the ovarian response results, in non-IVF
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and IVF procedures, leads to a decreased inci­
dence of OHSS62. This necessary adaptation is 
possible by monitoring of the cycle, using a 
combination of frequent estradiol measure­
ments and ultrasonographic assessments of fol­
licular growth63. Some studies report a similar 
efficacy in preventing OHSS when using ultra­
sound assessment alone64-66. Whether or not the 
combination of serum estradiol measurement 
and ultrasound provides a better assessment of 
ovarian response than ultrasound assessment of 
follicular growth alone remains controversial for 
unselected patients. In high-risk patients, it is 
likely that as many clues as possible are neces­
sary to warn physicians about the risk of OHSS: 
ultrasound can identify those at risk of early 
OHSS when a large number (more than 20) of 
follicles are present, and, moreover, are growing 
on day 8. At the least, such women with higher 
numbers of follicles are then advised to have 
serum estradiol measurement, which enables 
assessment of the size of the granulosa cell pool. 
Serum estradiol measurements have been 
shown to be positively correlated with OHSS. 
The incidence of OHSS in women with a high 
number of follicles (> 35) and high levels of 
serum estradiol (> 2500pg/ml) has been esti­
mated to be up to 80%, but the estradiol cut-off 
to distinguish those women at risk of OHSS 
from those who are not is still debatable67,68. 
The time at which a number of follicles and a 
serum level of estradiol are reached (slope of 
increment) may be more important than their 
absolute values. A recent case-control study 
showed that a serum estradiol level of 
3300pg/ml on day 11 of ovarian stimulation 
gave a sensitivity and specificity of 85% for the 
detection of women at risk for OHSS69.
Nevertheless, per se, the strict observance of 
monitoring rules does not avoid all severe forms 
of OHSS. It merely allows tracking of the bio­
logical and ultrasonographic clues which com­
pel the use of secondary preventive measures.
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Strategic considerations to limit the incidence of OHSS
Primary prevention of OHSS
• To identify the known risk factors;
• To initiate specific preventive strategies:
° Is stimulation really necessary?
° Are there alternative treatments (diet, life-style, laparoscopic surgery)?
• To respect the minimal safety rules of stimulation:
° Choice of proper stimulation regimen: drug, dose, protocol;
° Careful monitoring of the cycle: estradiol (E2) plasma level, number of follicles;
° Activation of secondary prevention measures.
Risk factors for OHSS
• Polycystic ovarian syndrome (PCOS);
• High number of resting follicles at day 3 (> 10/ovary);
• Isolated characteristics of PCOS:
° Enlarged ovary volume;
• Inversion of LH/FSH;
° Increased ovarian androgen circulating levels;
• Young age;
• Allergic dispositions;
• Previous occurrence of OHSS;
• Previous strong ovarian response to stimulation:
° E2 > 1500 pg/1 day 8;
° E2 > 3000 pg/1 day 11;
° > 1 5  oocytes retrieved.
Primary prevention during treatment
• Choice of proper stimulation regimen:
° Clomiphene citrate in first line of non-IVF procedures;
° Reducing the dose of gonadotropins in IVF;
° Use of GnRH antagonist: no previous ovarian desensitization with GnRH agonist;
• Careful monitoring of the cycle:
° E2 measurements:
■ Threshold of 2500 pg/1?
° Ultrasound assessment of number of follicles:
■ > 2 0  growing follicles on day 8?
■ > 3 5  measurable follicles?
° Combination to identify high-risk situations; •
• Activation of secondary prevention measures:




Does ovulation triggering 




Ovarian hyperstimulation syndrome (OHSS) is 
the price patients pay for our attempt to override 
nature’s delicate balances that were created to 
assure a single oocyte ovulation. Spontaneous 
OHSS does occur, as we delineate later. It is, 
however, very rare. Indeed, natural-cycle-based 
assisted reproductive technologies (ART) were 
responsible for the birth of the first IVF baby; 
however, this method was abandoned because it 
is cumbersome and, more important, yields poor 
results in terms of pregnancy rate. Therefore, 
human menopausal gonadotropin (hMG) has 
been used for decades in ovulation induction 
cycles, particularly in the context of in vitro fer­
tilization (IVF). In recent years, recombinant fol­
licle stimulating hormone (FSH) preparations 
have replaced hMG in most centers. Typically, 
in these cycles, human chorionic gonadotropin 
(hCG) is used as a surrogate to luteinizing hor­
mone (LH) for the purpose of oocyte maturation 
and induction and ovulation. Given its signifi­
cantly longer half-life (> 24 h versus 60 min for 
LH1,2), hCG administration results in a pro­
longed luteotrophic effect, characterized by the 
development of multiple corpora lutea and sup- 
raphysiological levels of estradiol (E2) and prog­
esterone (P). This sustained luteotrophic effect
may result in the development of OHSS, still the 
most frequent and severe complication of ovar­
ian stimulation treatments as described in other 
chapters of this volume. Although hCG (recom­
binant or urinary-derived in different doses) is 
used routinely, other modes of ovulation trigger 
are also available, namely, recombinant LH, 
native gonadotropin-releasing hormone (GnRH) 
and GnRH agonists. The aim of this chapter is to 
explore the association between the mode of 
trigger and the risk of OHSS. This association 
culminates in an OHSS risk-free clinical proto­
col that is available at the end of the chapter.
THE SPONTANEOUS LH/FSH SURGE: 
NATURAL-CYCLE OHSS
The mid-cycle spontaneous LH surge is charac­
terized by three phases: a rapidly ascending 
limb of 14-h duration, a plateau of 14 h and a 
descending phase of 20 h3. The parallel FSH 
surge is of lower amplitude. Serum E2 levels 
reach a peak at the time of onset of the LH surge 
and then decline rapidly. Serum levels of P 
begin to rise 12 h before the LH surge, continue 
to rise for an additional 12 h and then plateau 
until follicular rupture (36 h after the LH surge 
onset). Follicular rupture is associated with a
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second rise in P and a fall in E2, as the luteal pat­
tern of ovarian steroidogenesis is attained.
The human natural cycle is designed to 
allow the recruitment of a single dominant folli­
cle, from which a fertilizable oocyte emerges. 
Antral follicles that failed to reach dominance 
are destined to atresia, which occurs before the 
mid-cycle LH surge. This mechanism assures 
that only a single corpus luteum is formed in 
each cycle, explaining the rarity of spontaneous 
OHSS.
Spontaneous OHSS is typically associated 
with high hCG levels, i.e. multiple pregnancy or 
hydatidiform mole. Recurrent OHSS suggests a 
genetic predisposition. Indeed, an FSH receptor 
gene mutation was identified in a woman who 
developed spontaneous OHSS during each of 
her four pregnancies3.
The corpus luteum originating from the 
dominant follicle is not ‘responsible’ for the 
development of spontaneous OHSS, but rather 
secondary corpora lutea that emerge while preg­
nancy is established.
OVULATION TRIGGERING WITH hCG
hCG is routinely used to trigger ovulation in 
ovarian stimulation cycles. Given its long half- 
life and luteotrophic activity, it is blamed for the 
initiation of the OHSS process. If pregnancy is 
achieved, the endogenous hCG production 
replaces and augments the trigger dose, leading 
to enhancement of the OHSS pathology. In the 
non-IVF patient, a low-dose stimulation proto­
col, resulting in monofollicular ovulation, will 
completely prevent OHSS4 regardless of the 
hCG dose used. When multifolliculogenesis is 
required for ART, the risk of OHSS is a concern. 
Although there appears to be some degree of 
correlation with the degree of ovarian response, 
individual cases tend to be unpredictable. With­
holding the hCG trigger (e.g. aborting the cycle) 
completely prevents OHSS, if measures are 
taken to prevent spontaneous ovulation. For the
purpose of inducing ovulation and minimizing 
OHSS risk, reducing the hCG dose seems to be a 
logical step to take. While a dose of 10 000IU is 
routinely used, reducing the trigger dose may be 
beneficial in terms of reducing OHSS risk. The 
comparison of single intramuscular doses of 
2000, 5000 and 10 000IU of hCG resulted in 
poor oocyte yield with the lowest dose5. Indeed, 
most clinicians administer the lower effective 
dose of hCG (5000IU) in an effort to reduce 
OHSS risk. A retrospective review of IVF clini­
cal data regarding high responders (defined as 
E2 ^ 2500 but < 4000pg/ml on the day of hCG 
trigger) tried to confirm that hCG in a dose of 
3300 IU is sufficient to provide adequate oocyte 
maturation and fertilization. While the above 
was indeed confirmed, as the lower dose 
resulted in a similar proportion of mature eggs, 
similar fertilization rate and similar pregnancy 
rate compared with 5000 IU, reducing the dose 
did not eliminate the risk of OHSS6. Although a 
randomized controlled study that compares the 
two hCG doses has not been carried out, avail­
able data suggest that the practice of relying on 
the minimal hCG dose as a safeguard against 
OHSS should be discouraged.
Recombinant hCG (rhCG) has largely 
replaced the urinary product. Subcutaneous 
rhCG (250 (xg) is superior to urinary hCG 
(5000 IU) in terms of luteal-phase progesterone 
and serum hCG levels post-administration (Fig­
ures 1 and 2)7. However, in the context of OHSS 
it seems that there is no advantage. Although 
recombinant hCG (250 pg = 6500 IU) is as effec­
tive as 10 000IU urinary hCG in terms of trig­
gering, the rate of OHSS is similar8,9.
Any discussion about triggering ovulation 
should include the type of protocol used for 
ovarian stimulation. Currently, ovarian stimula­
tion for ART relies on GnRH analogs to prevent 
a premature LH surge. Long GnRH agonist-based 
protocols are associated with an increased inci­
dence of OHSS, reflecting the recruitment of a 
large number of follicles10. GnRH antagonist- 
based protocols may reduce the incidence of
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Figure 1 Mean progesterone levels (± SEM) before and during recombinant human follicle stimulat­
ing hormone (rhFSH) stimulation and after human chorionic gonadotropin (hCG) administration. 
Closed circles represent mean values in the group receiving recombinant rhCG 250 p,g (n =  85); open 
circles represent mean values in the group receiving urinary uhCG 5000IU (n =  92). The difference 
in values at days 5-7 after hCG administration is statistically significant (p = 0.0361; analysis of vari­
ance (ANOVA), ranked data). From reference 7, by permission of the American Society for Reproduc­
tive Medicine
OHSS11. However, conflicting publications12 
suggest that the difference, if it exists, is mini­
mal. The significant advantage of GnRH antago­
nist-based protocols, as discussed herein, lies in 
the ability to trigger ovulation with a GnRH ago­
nist, and prevent OHSS altogether.
In summary, triggering ovulation with hCG 
is always associated with some risk of OHSS, 
depending primarily on the magnitude of the 
ovarian response. When the prolonged 
luteotrophic effect of hCG merges with endoge­
nous hCG (if pregnancy is achieved), the contin­
uous overstimulation of the corpora lutea may 
give rise to OHSS.
OVULATION TRIGGERING WITH LH
The availability of recombinant LH was met 
with hopes to replace hCG as trigger. After all, it 
makes sense to imitate nature. A prospective, 
comparative, dose-finding study was conducted 
to determine the minimal effective dose of 
recombinant LH13. In a long agonist protocol, 
recombinant LH was used in doses of 5000, 
15 000 or 30 000IU, or two doses of 15 000 and 
10 000 IU 3 days apart. A control group was trig­
gered with hCG 5000 IU. Moderate OHSS was 
reported in 12.4% of patients who received hCG 
and in 12% of patients who received the
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Figure 2 Mean human chorionic gonadotropin (hCG) levels (± SEM) at and after hCG administra­
tion. Closed circles represent mean values in the group receiving recombinant rhCG 250 îg (n =  85); 
open circles represent mean values in the group receiving urinary uhCG 5000IU [n =  92). Serum hCG 
levels on days 1, 2-3 and 5-7 after hCG administration were significantly higher in the rhCG group 
(p =  0.0001 for all time points; ANOVA, ranked data). From reference 7, by permission of the Ameri­
can Society for Reproductive Medicine
recombinant LH double dose. However, no 
OHSS was reported in patients who received a 
single dose of recombinant LH (up to 30 000 IU). 
The conclusion of this study was that a single 
dose of recombinant LH results in a significant 
reduction in OHSS, compared with hCG. Unfor­
tunately, the sponsoring company, Serono Inter­
national, chose not to pursue this project 
further, and hence recombinant LH is not com­
mercially available for ovulation triggering.
OVULATION TRIGGERING WITH 
NATIVE GnRH
In an effort to mimic the endogenous LH/FSH 
surges, native GnRH was used as trigger14 in 32 
OHSS high-risk patients with polycystic ovaries 
undergoing hMG ovulation induction. Late- 
follicular E2 of >  6000 pmol/1 was chosen as 
high-risk cut-off. Ten patients became pregnant, 
of whom two experienced OHSS. Evidently,
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native GnRH lacks the luteolytic effect of GnRH 
agonist as trigger, and hence its failure to pre­
vent OHSS. Native GnRH trigger in the context 
of OHSS prevention was not pursued further to 
the above-cited study; therefore, there is no evi­
dence to recommend its use.
OVULATION TRIGGERING WITH 
GnRH AGONIST
The GnRH agonist-induced LH/FSH 
surge
A GnRH agonist (GnRH-a) elicits pituitary secre­
tion of gonadotropins, which can be utilized for 
triggering oocyte maturation and ovulation, if 
given at the right time of the cycle. Numerous 
compounds, administered in different regimens, 
have been successfully used for that pur­
pose15-22. Based on these studies, it appears that 
the single administration of a GnRH-a in a dose 
of 200-500 fxg effectively and reliably triggers 
the required gonadotropin surge21’22. However, 
the minimal effective dose of GnRH-a required 
to trigger an endogenous mid-cycle LH surge 
sufficient to induce oocyte maturation and ovu­
lation remains to be established. Preliminary 
experience23 suggests that a single dose of 50 îg 
intranasal buserelin is the minimal effective 
dose to trigger ovulation.
The pituitary and ovarian responses to mid­
cycle GnRH-a injections in stimulated cycles 
have been described previously18. The injection 
of GnRH-a results in an acute release of LH and 
FSH. Serum LH and FSH levels rise during 4 and 
12 h, respectively, and are elevated for 24-36 h. 
The amplitude of the surge is similar to that 
seen in the normal menstrual cycle, but in con­
trast with the natural cycle, the surge consists of 
only two phases: a short ascending limb (> 4h) 
and a long descending limb (> 20 h). This has 
no bearing on the ovarian hormone secretion 
pattern, which is qualitatively similar to the pat­
tern observed in a natural cycle. The LH surge is
associated with a rapid rise of P and the attain­
ment of peak E2 levels during the first 12 h after 
GnRH-a administration. This is followed by a 
transient suppression of P biosynthesis and a 
gradual decline in E2 levels during the 24 h pre­
ceding follicle aspiration. After oocyte retrieval, 
a second rapid rise in P and a continuous fall in 
E2 are observed, reflecting normal transition 
from the follicular to the luteal phase in ovarian 
steroidogenesis.
The luteal phase
While the endogenous LH surge triggered by 
GnRH-a is associated with a normal early 
follicular-luteal shift in ovarian steroidogenesis, 
serum levels of E2 and P during the luteal phase 
are lower compared with those achieved after 
hCG administration18. This may be related to 
the longer duration of plasma hCG activity com­
pared with the shorter GnRH-a-induced LH ele­
vation. Normal function of the corpus luteum is 
dependent on pituitary pulsatile LH24. It is 
possible, therefore, that the presumed down- 
regulation of pituitary GnRH receptors after a 
mid-cycle injection of GnRH-a results in 
reduced LH support for the developing corpora 
lutea, reduced steroidogenesis and early luteo- 
lysis. Based on these considerations, it is pru­
dent to support the luteal phase with P (and 
possibly E2) in patients treated with mid-cycle 
GnRH-a. Continued support during early preg­
nancy (until the luteal-placental shift) is proba­
bly required.
Prevention of OHSS
The most important benefit emerging from the 
use of GnRH-a, rather than hCG, for ovulation 
induction, is the ability of this regimen to elim­
inate completely the threat of clinically signifi­
cant OHSS. It should be emphasized that the 
clinical findings attributable to mild25 OHSS 
(e.g. ovarian enlargement, abdominal discomfort 
and excessive steroid production) are an integral 
part of most cases of ovulation induction in IVF,
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and hence are meaningless in this context. As 
mentioned above, clinical experience with mid­
cycle administration of GnRH-a in the context of 
OHSS prevention is very encouraging. Effective 
ovulation is triggered with no risk of OHSS even 
in patients with extremely high E2 levels during 
the late follicular phase20.
Previous reports described cases in which 
OHSS developed despite the use of GnRH-a to 
induce ovulation. Three cases were reported by 
van der Meer et a l 28. The clinical details of 
these cases are in line with mild to moderate 
OHSS. Severe ascites, hypovolemia or elec­
trolyte imbalance did not occur, nor were the 
patients hospitalized. Of note, the three patients 
received nasal GnRH-a preparations (buserelin; 
Suprefact®; Hoechst, Germany). In one of them, 
a very weak response to GnRH-a was noted, 
with an LH-surge peak of 15.9mIU/ml, suggest­
ing that the dose used or the route of adminis­
tration was less than optimal. The possibility of 
incomplete absorption using nasal administra­
tion cannot be ignored. In addition, the three 
patients were stimulated in preparation for 
intrauterine insemination (IU). Gerris et a l 27 
have also reported OHSS following this 
approach; however, in this case, use was made 
of native GnRH (and not GnRH-a), resulting in 
successful ovulation triggering, but without the 
critical gonadotropin suppression, which is the 
key element in preventing OHSS. Shoham et 
a l 28 reported a personal communication of two 
OHSS cases. However, the complete details of 
the treatment protocols, symptoms and signs 
leading to the diagnosis of OHSS, severity of the 
syndrome and clinical outcome were not avail­
able. Last, a group from Saudi Arabia has pre­
sented its large and impressive experience with 
this strategy29. Of 708 polycystic ovarian syn­
drome (PCOS), high-responder IVF patients 
(mean E2 on the day of ovulation triggering 
7817 pg/ml!), ovulation was effectively triggered 
with GnRH-a in 682 (96%). One patient (0.1%) 
developed severe OHSS. Significantly, this 
patient was treated with hCG-based luteal sup­
port, probably by mistake, as the protocol dic­
tated progesterone-only luteal support. Also of 
note is that in 26 patients a GnRH-a-induced LH 
surge was judged as ‘inadequate’. In 18 of these 
patients, hCG was used, resulting in 11 (61%) 
cases of severe OHSS. This last figure may 
reflect the large number of severe OHSS cases in 
this series that were prevented by this strategy. 
The reason(s) for an inadequate LH surge may 
have to do with the dose (too low) or route 
(intranasal) of GnRH-a administration. A key 
point in this strategy is the ability of an ade­
quate single dose of GnRH-a to bring about an 
effective LH surge, and subsequently to induce 
early luteal-phase relative pituitary down- 
regulation. Luteolysis could be induced by 
diminished early luteal-phase LH pulsatility, 
leading to the prevention of OHSS. Our protocol 
calls for a single subcutaneous, injection of
0.2 mg triptorelin (Decapeptyl®; Ferring, Malmo, 
Sweden). We recorded no LH surge failures with 
this protocol, and of course, no clinically signif­
icant OHSS thus far (thousands of patients, 
some of which have been published).
Benefits and limitations
As discussed above, GnRH-a is an effective 
alternative to hCG in ART, particularly when the 
threat of OHSS is imminent. In addition, it 
offers a more physiological stimulus for ovula­
tion, combining both LH and FSH surges. 
Apparently, the presence of a mid-cycle FSH 
surge is not obligatory for successful ovulation, 
given the widespread use of hCG, and hence it is 
not known whether the FSH surge associated 
with GnRH-a is of any advantage.
Although a large body of evidence supports 
the role of this approach in OHSS prevention, 
none of the published papers reports the results 
of a bone fide prospective, randomized, study 
comparing GnRH-a and hCG in terms of OHSS 
occurrence. Admittedly, without such a study, 
rapid dissemination of this approach cannot be 
anticipated. The applicability of such a study at
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this time is questionable owing to ethical con­
siderations (‘Catch 22’ situation).
A practical, major, limitation of GnRH-a- 
induced ovulation is that it would not be effec­
tive in women with a low gonadotropin reserve. 
Therefore, it is not applicable in IVF stimulation 
cycles during which pituitary down-regulation 
with a GnRH agonist is used. This protocol ren­
ders the pituitary unresponsive for induction of 
an endogenous LH surge. Since GnRH agonist- 
based protocols have been used routinely by 
most IVF programs until the year 2000, GnRH-a- 
induced ovulation for OHSS prevention has not 
gained much popularity.
GnRH antagonists: new opportunities
The introduction of GnRH antagonists in con­
trolled ovarian hyperstimulation (COH) proto­
cols22,23, has opened up opportunities for novel 
stimulation protocols. A large (730 subjects) 
prospective randomized study30 was carried out 
to compare long GnRH-a (buserelin) and GnRH 
antagonist (ganirelix; Orgalutran®) protocols. 
The results suggest that ganirelix introduces a 
new treatment option for patients undergoing 
ovarian stimulation for IVF or intracytoplasmic 
sperm injection (ICSI) which is safe, short and 
simple. The clinical outcome was good, and the 
ongoing pregnancy rate was acceptable. This 
novel protocol also introduces new opportuni­
ties in the context of OHSS prevention. One 
possibility is to prevent spontaneous LH surges 
in high-risk patients safely with a high-dose 
GnRH antagonist, waiting for follicular demise 
and ovarian quiescence31. In order to prevent 
OHSS effectively, and to rescue the cycle at the 
same time, the quick reversibility of antagonist- 
induced pituitary suppression can be of advan­
tage by allowing the use of GnRH-a for the 
purpose of ovulation triggering. This possibility 
was assessed in a randomized prospective mul­
ticenter study32. Two different GnRH agonists 
(0.2 mg triptorelin and 0.5 mg leuprorelin) were 
compared with hCG for triggering ovulation in a
GnRH antagonist-based (Orgalutran® or Anta- 
gon®) protocol for IVF. High responders (> 25 
follicles beyond 11mm) were considered drop­
outs from the study; hence, agonist trigger in the 
context of OHSS prevention was not assessed. 
Luteal support was given by daily progesterone 
administration. Both agonists kick-started a suc­
cessful LH surge (peak LH 4h post-trigger). 
Interestingly, LH dynamics post-trigger was sim­
ilar to that reported without GnRH antagonist 
pretreatment18. In other words, the routine daily 
dose of a GnRH antagonist (ganirelix 0.25 mg) 
does not blunt the effect of an agonist (given 
about 12 h apart) at the pituitary level. The three 
treatment groups (two agonists and hCG) had 
comparable numbers of oocytes retrieved, per­
centages of mature oocytes, fertilization rates 
and implantation rates. The authors summa­
rized the results stating, ‘corpus luteum forma­
tion is induced by GnRH agonists with luteal 
phase steroid level closer to the physiological 
range compared with hCG’. This statement mer­
its a deeper look. Since progesterone was given 
as luteal support, the estradiol level may repre­
sent endogenous luteal activity. Mid-luteal lev­
els of estradiol were 46pg/ml and 45pg/ml in 
the agonist trigger groups vs. 490pg/ml in the 
hCG group. These levels reflect the sum of E2 
production by all the corpora lutea, the number 
of which can be drawn from the number of 
oocytes retrieved (8.3 in the hCG group, 8.7 and 
9.8 in the agonist groups). When the estradiol 
levels are plotted against the natural cycle (Fig­
ure 3), it becomes apparent that the agonist trig­
gers resulted in extremely low mid-luteal E2 
levels that cannot be considered as ‘physiologi­
cal’. In fact, the natural-cycle mid-luteal estra­
diol levels from a single corpus luteum (around 
600pmol/l, or 160pg/ml33) is >  3-fold higher 
than the mid-luteal estradiol levels produced by
8-9 corpora lutea post-agonist triggers. These 
low levels can only be interpreted as a result of 




Figure 3 Luteal phase estradiol (E2) (reflecting total luteolysis) after triggering ovulation with 
gonadotropin-releasing hormone (GnRH) agonist. Natural-cycle luteal phase estradiol is depicted by 
gray circles (based on reference 33). Mean mid-luteal serum concentrations of E2 after triggering of 
final oocyte maturation with GnRH agonist or human chorionic gonadotropin (hCG) after ovarian 
stimulation for in vitro fertilization (IVF) (based on reference 32) are plotted against the natural-cycle 
levels. In agonist- and hCG-triggered cycles, 9 and 8 (mean) oocytes were retrieved, respectively (ref­
erence 32). LH, luteinizing hormone
Another randomized controlled study was 
performed to compare unsupplemented luteal 
phase characteristics after three different trig­
gers: recombinant hCG, recombinant LH and 
GnRH agonist34. This approach allows assess­
ment of progesterone levels to reflect luteal 
activity. Indeed, the ‘area under the curve’ prog­
esterone secretion post-agonist trigger was p rac­
tically zero. This remarkable phenomenon again 
attests for complete luteolysis post-agonist trig­
ger. The concept of luteolysis post-agonist was 
first put forward by Casper and Yen35, in 1979. 
They gave mid-luteal agonist to five normal vol­
unteers. Luteolysis occurred as indicated by a 
fall in E2 and P levels, followed by a shortened 
luteal phase.
To characterize further the presumed lute- 
olytic process induced by mid-cycle injection of 
GnRH-a, and to avoid confusion between 
endogenous biosynthesis and exogenous luteal 
support, we have measured non-steroidal luteal 
function markers, inhibin A and pro-aC36. Ago­
nist trigger caused a sharp decrease in these 
markers compared with patients who were 
treated with hCG (Figure 4). Pregnancy was not 
associated with a rise in the levels of luteal 
markers. This is the most important message 
arising from this chapter: GnRH-agonist trigger 
results in complete and dramatic luteolysis. By 
the time endogenous hCG appears (if pregnancy 
is achieved), the corpora lutea are beyond the 
point of ‘resuscitation’; therefore, endogenous
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Figure 4 Luteal-phase serum concentrations (mean ± SE) of inhibin A (a), pro-aC (b), progesterone 
(c) and estradiol (d) in two in vitro fertilization (IVF) protocols: GnRH antagonist for ovulation pre­
vention and hCG (hCG group) or GnRH-a (agonist group) for oocyte maturation triggering. Time is 
represented as days relative to oocyte maturation triggering day (day 0). Changes in levels of all four 
hormones in both groups were significant over time (p < 0.0001) (Friedman test). *p <0 .05 ; 








sex steroid production does not resume, 
together with the long list of mediators respon­
sible for OHSS. Although covered in another 
chapter in this volume, it must be emphasized 
here that OHSS is a serious and protracted dis­
ease especially if pregnancy is achieved. There­
fore, it is of utmost importance to secure a 
trigger that will ‘kill’ the corpora lutea before 
endogenous hCG appears on the scene. This is 
exactly what an agonist trigger does.
GnRH-a OVULATION TRIGGERING IN 
GnRH ANTAGONIST STIMULATION 
PROTOCOLS PREVENTS OHSS
The tremendous strength of the proposed 
approach is also its weakness in terms of 
‘evidence-based medicine’. It is very difficult to 
conduct a randomized controlled study compar­
ing hCG and agonist trigger in high responders. 
Ethics committees might find it problematic to 
administer hCG to extremely high responders. 
One can compare the situation with a study on 
the merit of using a parachute when jumping 
from an airplane37. Indeed, agonist trigger can 
be looked on as a parachute to bring high 
responders safely down to the ground without 
an OHSS crash. Consequently, such studies are 
not available, although an unpublished research 
effort is currently ongoing in the USA, the 
results of which will probably be available by 
the time this volume is published. A prelimi­
nary report38 describes the use of 0.2 mg trip- 
torelin (Decapeptyl®) to trigger ovulation in 
eight patients who underwent controlled ovar­
ian hyperstimulation with recombinant FSH 
(Puregon®) and concomitant treatment with the 
GnRH antagonist ganirelix (Orgalutran®) for the 
prevention of a premature LH surge. All patients 
were considered to have an increased risk for 
developing OHSS (at least 20 follicles ss 11 mm 
and/or serum estradiol at least 3000pg/ml). On 
the day of triggering the LH surge, the mean 
number of follicles ;> 11 mm was 25.1 ±  4.5, and
the median serum estradiol concentration was 
3675 (range 2980-7670) pg/ml. After GnRH ago­
nist injection, endogenous serum LH and FSH 
surges were observed with median peak values 
of 219 and 19IU/1, respectively, measured 4h 
after injection. The mean number of oocytes 
obtained was 23.4±15.4 , of which 83% were 
mature (metaphase II). None of the patients 
developed any signs or symptoms of OHSS. So 
far, four clinical pregnancies have been achieved 
from the embryos obtained during these cycles, 
including the first birth following this approach. 
These preliminary results underlined the effec­
tiveness of this approach in OHSS prevention.
THE QUESTION OF PREGNANCY 
RATE FOLLOWING AGONIST TRIGGER
Although not yet established as a tool to prevent 
OHSS, criticism of agonist trigger arose around 
the question of the pregnancy rate. In normal 
responders the pregnancy rate following agonist 
trigger is comparable to that following 
hCG19,21,39. The question of pregnancy rate in 
high responders was addressed in cycles during 
which hCG was used as trigger. Pellicer et al.A0 
found that the implantation rate was signifi­
cantly higher in normal (18.5%) as compared 
with high (0%) responders. These researchers 
concluded that a different endocrine milieu 
between normal and high responders is detected 
by daily steroid measurements up to the preim­
plantation period, suggesting that this difference 
could be responsible for an impaired implanta­
tion in high-responder patients undergoing IVF. 
An increase in serum E2 levels seems to be the 
cause of this difference. Simon et al.41 reached 
similar conclusions, stating that their clinical 
results demonstrate that high serum estradiol 
concentrations on the day of hCG injection in 
high- and normal-responder patients, regardless 
of the number of oocytes retrieved and the 
serum progesterone concentration, are detri­
mental to uterine receptivity without affecting
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embryo quality. These results led to an effort to 
increase uterine receptivity by decreasing estra­
diol levels in high responders with the use of a 
follicle stimulating hormone step-down regi­
men. Simon et a l 42 were successful in that 
regard, although the step-down regimen 
resulted in a 17% cancellation rate, i.e. patients 
in whom FSH support to the growing follicles 
was too low, leading to a sharp decrease in estra­
diol level. At the 2004 annual European Society 
of Human Reproduction and Embryology 
(ESHRE) meeting in Berlin, Bankowski et al.43 
presented their experience with agonist trigger 
in high responders. Apparently, they have 
adopted a routine to trigger high responders (E2 
> 3000pg/ml) with an agonist. From May 2000 
to July 2003, a total of 317 patients were trig­
gered with hCG (normal responders) while 97 
patients were triggered with an agonist (high 
responders). Peak E2 levels were 2050 vs. 
4800pg/ml, number of oocytes 10 vs. 21 and 
number of embryos 5.6 vs. 12.5, respectively. 
The pregnancy rate was 21.5% in the normal 
responders vs. 11.3% in the high responders. 
Importantly, they had three cases of severe 
OHSS, all in the hCG group. These results 
demonstrate again the tremendous efficacy of 
agonist trigger in terms of OHSS prevention. In 
addition, given the large number of oocytes and 
embryos obtained (with no risk of OHSS), the 
clinical rate per oocyte retrieval (fresh and thaw 
cycles combined) is more relevant to the patient. 
It may be argued that a decrease in fresh-cycle 
pregnancy rate is a reasonable price to pay for 
total OHSS prevention (patient safety) and a 
large number of embryos obtained (subsequent 
thaw cycles).
TAKE-HOME MESSAGES
A single mid-cycle dose of GnRH-a is able to 
trigger a preovulatory LH/FSH surge, leading to 
oocyte maturation in women undergoing ovar­
ian stimulation for IVF, or induction of ovula­
tion in vivo. The main advantage of this 
approach is the complete elimination of clini­
cally significant OHSS. The application of this 
trigger in high responders requires a responsive 
pituitary. Therefore, it is not applicable in GnRH 
agonist-based cycles during which pituitary 
down-regulation is achieved. GnRH antagonist- 
induced competitive inhibition of the pituitary 
GnRH receptors is easily reversible with a GnRH 
agonist. In fact, a major reason to use GnRH 
antagonists in ovarian stimulation is to keep the 
option of agonist trigger if needed. A clinical 
protocol for the high responder is as follows:
(1) Start stimulation with 150-225IU recom­
binant FSH.
(2) Start antagonist on day 6 of stimulation. 
Consider adding 1 ampoule of recombi­
nant LH (75 IU) daily.
(3) Ignore E2 levels! There is no need to step 
down! Give the growing follicles full FSH 
support!
(4) Trigger with 0.2 mg triptorelin or 0.5 mg 
leuprorelin (at least 12 h after the last 
antagonist injection).
(5) Start luteal support with E2 and proges­
terone on the day of oocyte retrieval.
In our experience, this protocol will eliminate 
OHSS.
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CHAPTER 21
Secondary prevention of threatening 
ovarian hyperstimulation syndrome
Annick Delvigne
Primary prevention and early recognition of 
ovarian hyperstimulation syndrome (OHSS) are 
important in order to ensure the patient’s safety. 
The first step of primary prevention is the iden­
tification of risk factors, to individualize the 
patient’s stimulation regimen. Second, it is 
mandatory to monitor the ovarian response to 
gonadotropins strictly in order to adapt the 
stimulation to this response. For this purpose, 
monitoring ovulation using ultrasound and 
serum estradiol (E2) assays constitutes the ‘gold 
standard’. Several studies have evaluated the 
impact of follow-up by either technique alone or 
in combination, and concluded that the combi­
nation of both methods provides the best 
results1. Nevertheless, while it is believed that 
both E2 and ultrasound monitoring is necessary, 
it is insufficient, as most in vitro fertilization 
(IVF) centers still report the occurrence of 
severe forms of OHSS, even though such moni­
toring is practiced2.
Strict monitoring, however, allows the appli­
cation of a number of preventive methods to 
minimize the probability and/or severity of 
OHSS for high-risk patients, defined by their 
exaggerated ovarian response.
The preventive measures that have been 
described are the following:
(1) Canceling the cycle;
(2) Coasting;
(3) Early unilateral ovarian follicular aspira­
tion (EUFA);
(4) Modifying the methods of ovulation trig­
gering;
(5) Administration of glucocorticoids;
(6) Macromolecules and progesterone;
(7) Cryopreservation of all embryos;
(8) Electrocautery or laser vaporization of one 
or both ovaries;
(9) Reduction of the number of transferred 
embryos.
CANCELING THE CYCLE
Some authors suggest canceling the cycle by not 
giving human chorionic gonadotropin (hCG) 
when several risk factors of OHSS are present, 
because hCG triggers the development of OHSS.
As early as 1970, preliminary data indicated 
that the complications of superovulation could 
be totally avoided if the ovulation trigger by
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hCG stimulus was withheld3. Others confirmed 
that canceling cycles at risk by withholding hCG 
when estrogen levels were too high prevented 
severe OHSS4,5. Spontaneous OHSS is very rare 
indeed.
In ovulation-induction cycles, when 
gonadotropin-releasing hormone (GnRH) ago­
nists (GnRH-a) or antagonists are not used, one 
should remain vigilant, since a spontaneous LH 
peak may still occur, resulting in a pregnancy 
that is sometimes associated with OHSS com­
plications induced by endogenous hCG. In a sit­
uation where natural conception is possible, the 
couple should be advised to avoid intercourse or 
to use condoms, as spontaneous ovulation may 
occur up to 11 days after discontinuing 
gonadotropin treatment.
This attitude is much more difficult to apply 
in an in vitro fertilization (IVF) program, since 
the goal here is, by definition, to increase the 
number of oocytes. Therefore, it is much more 
difficult to establish a danger threshold. Fur­
thermore, physicians may also feel more reluc­
tant to propose cancellation to patients, as IVF 
implies a great commitment on the patients’ part 
in terms of procedures, time and money. More­
over, the physicians are also under pressure to 
obtain a ‘successful’ outcome when there is no 
coverage of costs by insurance6. On the other 
hand, as luteinizing hormone (LH) surge 
inhibitors (such as GnRH-a and antagonists) are 
almost always used, canceling results in an 
absolute prevention in these much more dan­
gerous situations. It has been suggested that, 
after stopping human menopausal gonadotropin 
(hMG), the GnRH-a treatment should be contin­
ued until the ovaries recover to a normal size 
and then they are restimulated using lower 
doses of gonadotropins7. Unfortunately, such 
lower doses may lead to an inadequate ovarian 
response8-10.
The necessity to maintain the administration 
of GnRH-a, after taking the decision to cancel 
the cycle, is discussed later in the section con­
cerning embryo cryopreservation.
In the future, in vitro maturation of human 
oocytes, with and without stimulation, will be 
available and yield several oocytes, thereby 
avoiding hCG administration.
Summary
Canceling the cycle and withholding hCG is the 
only method that totally avoids the risk of OHSS 
in ovarian induction cycles or in IVF.
All other procedures usually succeed in 
decreasing either the risk or the severity of 
OHSS, rather than totally preventing it.
COASTING
This technique was first described in hyper- 
stimulated cycles11,12 and first applied in IVF 
cycles by Sher et al. in 199313. The method is 
based on the assumption that E2 levels reached 
at the time of hCG administration are predictive 
of the risk for OHSS. When a patient considered 
at risk has a high E2 level, exogenous gonado­
tropins are stopped, while GnRH-a are main­
tained. hCG administration is then postponed 
until the patient’s serum E2 level decreases to ‘a 
safer zone’, attesting to the atresia of granulosa 
cells. Coasting acts probably by apoptosis of 
granulosa cells and a reduction of their func­
tional capacity to produce vasoactive factors, 
such as vascular endothelial growth factor 
(VEGF)14,15.
In a recent survey conducted among gyne­
cologists specialized in infertility treatment, 
‘coasting’ appeared to be the most popular 
method used to prevent OHSS16. There are 
many advantages in using this technique: the 
cycle is not abandoned, it enables the transfer of 
fresh embryos and, finally, no supplementary 
procedure or medical therapy is involved. It is 
therefore not surprising that some two-thirds of 
physicians who chose to apply a preventive 
method advocated the use of coasting16.
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A systematic review, aimed at deciding 
whether there was sufficient evidence to justify 
the general acceptance o f coasting, was also per­
formed17,18. It involved 493 patients in 12 stud­
ies and showed the data to be highly 
heterogeneous in terms of characteristics and 
number of patients, stimulation schemes and 
coasting procedures. In most studies, either a 
threshold value of serum E2 was used (often a 
value of 3000pg/ml), and/or the number of folli­
cles was considered. Fertilization rates 
(36.7-71%) and pregnancy rates (20-57%) were 
acceptable in terms of IVF results, in compari­
son with those of large IVF databanks. In 16% of 
cycles, ascites was described; in 2.8%, hemo- 
concentration was recorded; and 2.5% of 
patients required hospitalization. While coast­
ing does not totally avoid the risk of OHSS, it 
certainly decreases its incidence in high-risk 
patients.
In practice, different types of coasting proto­
cols have been proposed: early coasting is initi­
ated on the basis of a large number of follicles; 
and late coasting is initiated later in the cycle 
when high E2 levels are observed19.
A relevant problem is to decide how coasting 
should be managed, to obtain the best results in 
terms of oocyte quality and IVF outcome. 
Indeed, some investigators have suggested that 
oocyte quality deteriorates when using coasting 
under certain conditions. Aboulghar et al.20 
reported a low number of good-quality oocytes 
when classical coasting was applied, and rec­
ommended using a ‘modified form of coasting’, 
by decreasing the dose of hMG before withhold­
ing it completely.
Whelan and Vlahos21 also reported poor 
oocyte quality when E2 fell, and suggested mon­
itoring daily follicle size and E2 levels and 
administering hCG when E2 levels had 
plateaued for 2-3 days.
Two retrospective studies of 207 and 157 
coasted patients, respectively, analyzed the 
implications of E2 drop and coasting duration on 
IVF outcome17,22.
According to Ulug et al.22, coasting for more 
than 3 days appeared to reduce the implantation 
and pregnancy rates, while oocyte and embryo 
qualities did not appear to be affected. This sug­
gests that endometrial receptivity may be ham­
pered. Still, in another study conducted in an 
oocyte donation program, the implantation and 
pregnancy rates of recipient patients coasted for 
more than 4 days were significantly lower, indi­
cating that oocyte quality decreases after coast­
ing23. Nevertheless, in our study, no significant 
relationship was found between the number of 
coasting days, the E2 level on the day of hCG or 
the fall in E2 and outcome, whether measured in 
terms of oocyte quality, pregnancy rate or inci­
dence of OHSS24.
According to these conflicting results, 
Egbase et a l 25 applied early coasting with a 
fixed period of 3 days in 102 obese polycystic 
ovarian syndrome (PCOS) patients in order to 
avoid a possible reduction of quality. These 
authors obtained a clinical pregnancy rate of 
45.1% without the occurrence of severe OHSS.
The discrepancy between studies may be 
due to the heterogeneous criteria for initiating 
and ending the coasting process. For example, in 
early coasting, starting when the follicles are 
still small, the E2 drop could have a greater 
impact on oocyte quality, whereas coasting 
beginning later in the cycle when larger follicles 
and higher E2 already exist could have less 
implication for oocyte quality. Furthermore, in 
these latter conditions, the length of coasting 
may have a more pronounced effect on endome­
trial receptivity.
Reviewing ten relevant studies, Levinsohn- 
Tavor et a l 26 recommended stopping gonado­
tropins only when the leading follicles reached 
15 mm, and administering hCG only when E2 
fell below 3000pg/ml, to ensure effective pre­
vention of OHSS. The authors underlined the 
lack of prospective randomized studies which 




Coasting is a popular and effective method for 
reducing OHSS rates, but it does not totally 
eliminate the condition. The procedure seems to 
be associated with a reduced oocyte collection 
rate and especially so when the coasting period 
is prolonged. The quality of oocytes after coast­
ing is still the subject of debate, as is endome­
trial receptivity after E2 lowering. Available data 
are reassuring in terms of pregnancy rates.
EARLY UNILATERAL OVARIAN 
FOLLICULAR ASPIRATION
Gonen et al.27 observed that follicular aspiration 
induces intrafollicular hemorrhage which has a 
negative impact on corpus luteum function. It 
has therefore been suggested that growing folli­
cles be punctured, with the hope that the with­
drawal of follicular contents may significantly 
interfere with follicular maturation and modify 
the intraovarian mechanisms responsible for 
OHSS.
Contradictory results have been reported for 
the protective effect against OHSS of follicular 
aspiration during oocyte pick-up28,29.
The timing of the trigger dose of hCG in rela­
tion to the expected protective effect of follicu­
lar aspiration may be of importance for 
preventing OHSS.
In 1995, early unilateral ovarian follicular 
aspiration (EUFA) was first applied to 17 
patients at risk of OHSS (excessive E2 values, 
multiple follicles) 12 h after hCG administration, 
followed by regular oocyte retrieval 36 h later30. 
The method of post-hCG aspiration in one ovary 
was effective, leading to the withdrawal of all 
signs of OHSS within 6 days after the second 
aspiration post-hCG. For these authors, this is a 
quick, simple and effective method that pre­
vents the development of OHSS and allows 
pregnancy in the treated cycles.
In 1997, a prospective randomized study 
was performed to evaluate unilateral ovarian 
aspiration 6-8 h before hCG administration31. In 
an IVF program, 31 patients at risk (E2 lev­
els >  3269 pg/ml and > 1 2  follicles of 12 mm 
size per ovary) were randomized between EUFA 
[n =  16) or no pretreatment [n =  15). Fewer 
oocytes were recovered in the pretreated group, 
but fertilization, embryonic cleavage and preg­
nancy rates were similar. OHSS was recorded in 
25% of the EUFA group and in 33.3% of the con­
trol group (12.5% and 6.6% of severe forms, 
respectively). The authors concluded that uni­
lateral ovarian aspiration before hCG adminis­
tration failed to prevent or diminish the 
occurrence of severe OHSS.
Two years later, the same group performed a 
prospective randomized study comparing EUFA 
10-12 h after hCG administration with the coast­
ing method for high-risk patients (defined as an 
E2 level >6000  pg/ml and > 1 5  follicles of 
>  18 mm per ovary). Oocyte retrieval was car­
ried out in the contralateral ovary at 35-36h 
after hCG administration. Fewer oocytes were 
recovered in the coasted group, but fertilization, 
embryonic cleavage and pregnancy rates were 
similar. Neither method completely prevented 
the occurrence of severe OHSS, as 26.6% in the 
EUFA group and 20.0% in the coasted group 
developed the severe condition. This may be 
explained by the rather loose criteria used to 
identify high risk32.
More recently, EUFA before hCG was tested 
again by Schroder et a l 33, who performed uni­
lateral follicular aspiration at variable times 
before hCG administration according to the 
degree of follicular maturation. EUFA was pro­
grammed for five high-risk patients when :>15 
follicles of 12-15 mm in each ovary with 
;> 2500 pg/ml E2 was reached. In vitro maturation 
of this first cohort of oocytes was carried out and 
these embryos were cryopreserved. Regular 
oocyte retrieval was performed for the contra­
lateral ovary, 36 h after the administration of 
hCG. No pregnancy was obtained in this study,
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while the rate of severe OHSS remained high 
(80%).
Summary
It was expected that intraovarian bleeding 
induced by aspiration of granulosa cells from 
one ovary would limit the production of ovarian 
mediators of OHSS and thus reduce the risk of 
developing severe OHSS. Clinical data are, how­
ever, contradictory, with only one out of four 
studies in favor of EUFA. The number of cases is 
insufficient to establish the efficacy of this 
method. Moreover, the invasive nature of the 
method, necessitating two oocyte retrievals 
(sometimes under anesthesia), explains why it 
has been attempted less often than coasting.
MODIFICATION OF METHODS TO 
TRIGGER OVULATION
In most stimulation schemes for fertility treat­
ment, ovulation is induced using hCG of urinary 
origin, and this has been chosen for its LH-like 
effect. hCG is a well-known promoter of OHSS. 
hCG seems to initiate the complex cascade that 
leads to the development of symptomatic hyper­
stimulation, whereas an endogenous LH surge 
rarely causes OHSS.
Reduction of the hCG dose or triggering ovu­
lation with recombinant human (rh)LH or an 
endogenously induced LH surge are different 
approaches to reduce the OHSS incidence. This 
approach is treated in more depth in the pre­
ceding chapter.
hCG is characterized by a longer half-life 
than that of LH (> 24 h versus 60 min for LH), a 
higher receptor affinity and a longer duration of 
intracellular effect, compared with endogenous 
LH. Consequently, the duration of hCG activity 
lasts for up to 6 days. Urinary hCG is not only 
able to separate the cumulus-oophorus complex 
from the follicular wall and induce final matu­
ration of the oocytes, but it also has a certain
FSH-like effect which contributes to ovarian 
stimulation, as demonstrated by Gerris et a/.34.
The regularly used dose ofhCG  is 10 000IU, 
but the pregnancy rate seems not to vary for 
doses above 5000IU35. Schenker and Weinstein4 
reported, in an uncontrolled study, fewer cases 
of OHSS when using 1000-5000 IU. Hence, it 
has been suggested that a dose of 5000 IU, rather 
than 10 000IU, be used in the presence of risk 
factors for OHSS21. In high-responder patients, 
3300 IU versus 5000 IU was tested (and ana­
lyzed retrospectively), and no difference was 
observed in terms of oocyte maturation36. There 
is a need for a large prospective study to evalu­
ate the efficacy of a reduced dose of hCG in pre­
venting OHSS.
Some alternatives to hCG have been sug­
gested. As LH activity is characterized by a 
shorter duration compared with hCG, LH 
administration may reduce stimulation of the 
luteal ovary. Some authors have proposed using 
the flare-up effect o f the GnRH-a to produce ovu­
lation. Indeed, the rise of LH and follicle stimu­
lating hormone (FSH) lasts for only 34 h 
following a GnRH-a flare-up (200-500 p-g). This 
combination of initial gonadotropin ‘flare-up’ 
followed by pituitary down-regulation with 
complete luteolysis offers a unique advantage to 
minimize the risk of OHSS37-42.
This alternative can be applied when no 
down-regulation is used for stimulation. The 
recent development of giving a GnRH antagonist 
to avoid a spontaneous LH surge also permits 
the use of a GnRH-a to induce the LH peak.
GnRH-a flare-up to trigger ovulation of 
women with extremely high levels of E2 
(> 4000pg/ml) was tested, and no patients 
developed OHSS18. Imoedemhe et al.43 used this 
approach in a large group (n =  682) of very-high- 
risk patients (PCOS with mean E2 = 7817 pg/ml) 
and observed a prevalence of only 0.1% of 
severe OHSS. Among OHSS cases that still 
occurred using this method of ovulation induc­
tion, none developed severe ascites, whereas
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luteal supplementation was indeed performed 
with hCG40.
Finally, an adequate dose and route of 
GnRH-a administration has to be defined. The 
dosage that is necessary to induce ovulation 
(triptorelin 0.1 mg) seems to be lower than that 
necessary to prevent OHSS (triptorelin 0.5 mg), 
and the nasal route seems to be less efficient in 
inducing ovulation. Kol44 recommended using 
subcutaneous triptorelin (0.2 mg).
In all cases, luteal supplementation with 
exogenous progesterone and probably estradiol 
is necessary to compensate the complete luteol- 
ysis induced by GnRH-a. Unfortunately, insuffi­
cient controlled studies have been carried out to 
validate this practice, and a small controlled 
series did not permit any definitive conclusions 
to be made38. Nevertheless, the physiological 
basis and preliminary clinical applications are 
promising.
Native GnRH also constitutes an alternative, 
but its efficiency in reducing OHSS incidence 
still needs to be assessed. Gerris et a7.34 observed 
one case of OHSS after the use of native GnRH 
(500 pig) in a controlled study. These results can 
be interpreted as a consequence of successful 
ovulation triggering, without critical gonado­
tropin suppression and luteolysis, which is one 
of the elements that prevents OHSS by the use 
of GnRH-a.
Finally, a recent European prospective, ran­
domized, double-blind (n =  259) multicenter 
study assessed the safety and the minimal 
effective dose of rhLH in patients undergoing 
IVF, in comparison with 5000IU of urinary hCG. 
This study concluded that single doses of 
5000-15 000 IU of rhLH induced significantly 
fewer moderate cases of OHSS and ascites as 
compared with a 5000-IU dose of hCG (respec­
tively, 18% and 21% vs. 45%)18.
Summary
Alternatives to hCG have a strong theoretical 
basis and initial clinical experience, but further
clinical studies are needed to establish the value 
of these approaches. Moreover, efforts have been 




The use of steroids in patients at high risk of 
OHSS has been evaluated in two studies. The 
first randomized study discredited the use of 
corticoids45. More recently, a retrospective con­
trolled study has brought renewed attention to 
the use of corticosteroids46. Tan et al.45 random­
ized high-risk patients, of whom 17 were receiv­
ing corticoids and 14 were controls. Treatment 
began with 100 mg intravenous hydrocortisone 
immediately after oocyte recovery, followed by 
decreasing oral doses of prednisolone from the 
day of oocyte recovery for 5 days. Ovarian 
response was similar in both groups: 41.2% of 
treated patients developed OHSS compared 
with 42.9% in the control group. Even when 
considering only the moderate or severe forms, 
the incidence of OHSS remained high in all 
groups (11% and 6% in the corticoid-treated 
group and 7% and 7% for the control group, 
respectively). The authors concluded that gluco­
corticoids did not reduce the incidence of 
OHSS.
In contrast, oral methylprednisolone admin­
istration (16mg/day) from day 6 of stimulation 
to the first pregnancy test appeared to reduce 
the risk of OHSS from 43.9 to 10.0% in a retro­
spective, clinical, controlled study of 91 high- 
risk patients46.
However, the preventive protocols, identifi­
cation of at risk patients and design and number 
of patients tested were largely different in the 
two studies, and therefore definitive conclu­
sions cannot be drawn based on these studies.
Nevertheless, recent theories suggesting an 
inflammatory etiopathology of OHSS will bring
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about a reconsideration of the use of cortico­
steroids and other anti-inflammatory drugs in 
this context.
Summary
There is insufficient proof to consider glucocor­
ticoids as a useful treatment for the prevention 
of OHSS, but future trials are warranted.
MACROMOLECULES AND  
PROGESTERONE
Albumin
Albumin is thought to prevent the development 
of OHSS by increasing plasma oncotic pressure 
and binding of OHSS mediators of ovarian ori­
gin. In contrast, however, because capillary per­
meability is compromised, the duration of the 
oncotic effect would be insufficient to prevent 
OHSS.
A pilot study was performed in rabbits, with 
and without bovine serum albumin (BSA) pre- 
treatment. Despite an increase in serum protein 
levels, the BSA-treated group showed a compa­
rable increase in body weight and degree of 
ascites formation. The authors concluded that 
albumin did not prevent severe OHSS, despite 
its oncotic or carrier protein properties, in this 
model47.
Doldi et a7.48 evaluated the possible effect of 
albumin on vascular endothelial growth factor 
(VEGF), one of the etiological factors of OHSS. 
These authors reported that in cultured human 
luteinizing granulosa cells, VEGF mRNA expres­
sion was increased after human albumin admin­
istration, with maximal expression being 
observed in cultured cells from patients with 
high E2.
A series of clinical studies have evaluated 
the efficacy of albumin in preventing OHSS. 
The dose varied from 10 to 125 g in one or five 
administrations, also with a variable duration
from 1 day before until 5 days after oocyte pick­
up. For these reasons, it is impossible to pool all 
results, although the principal observations of 
these studies are summarized in Tables 1 and 2.
Studies have also been limited by the low 
sensitivities and predictive values of the criteria 
used to define high-risk patients.
Because most cases of severe OHSS, after 
albumin treatment, seem to be associated with 
pregnancy, it is possible that intravenous albu­
min might be more effective in preventing the 
occurrence of early OHSS than of late OHSS.
In two studies, the pregnancy rate was sig­
nificantly lower after intravenous (IV) albumin 
infusions, although this may be the conse­
quence of prolonged infusion49,50. Indeed, albu­
min administration close to the implantation 
period may have bound some factors necessary 
for implantation.
When considering data from prospective 
randomized studies and a single retrospective 
study which included a control group, a total of 
39 OHSS cases have been recorded among 468 
high-risk treated patients (8.3%) and 89 OHSS 
cases in a control group comprising a total of 
611 high-risk patients (14.6%)17,18. An extensive 
statistical analysis cannot be achieved because 
of the disparity of protocols mentioned earlier.
Nevertheless, the Cochrane review by 
Aboulghar et al.67 shows that the administration 
of IV albumin at the time of oocyte retrieval has 
a beneficial preventive effect in high-risk cases 
of severe OHSS.
Finally, according to a more recent and large 
(n = 988) single-center randomized controlled 
study, there is no use in administering albumin 
on the day of oocyte retrieval68. Indeed, after the 
administration of 40 mg of albumin immediately 
after the retrieval of more than 20 oocytes, the 
incidence of moderate-severe and severe-only 
OHSS was not statistically different from that in 
the control group (6.8% vs. 4.7%).
The possible adverse effects of albumin 
should not be underestimated:
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(1) Albumin may leave blood vessels and 
enter the interstitium, whereby it may 
draw fluid from the intravascular space;
(2] Albumin is a human product, and the 
transmission of infections by blood-borne 
viruses can never be entirely excluded.
Other side-effects include nausea, vomiting, 
febrile reactions and allergic reactions.
Summary
Current published clinical studies, as well as 
fundamental and animal studies, do not support 
a role for albumin in preventing late-severe 
OHSS. At most, albumin may improve, but not 
eliminate, early-severe OHSS in certain types of 
protocols. The large prospective randomized 
study of Bellver et a7.68 seems to bring to an end 
the controversy concerning the inefficiency of 
albumin administered on the day of oocyte 
retrieval.
Prophylactic infusion of hydroxyethyl 
starch solution
In view of the potential transmission of infective 
viruses when administering human albumin, 
some groups have tested a safe non-biological 
substitute with comparable physical properties, 
namely hydroxyethyl starch solution (HES). 
HES has a molecular weight of 200-1000 kDa, 
and significantly increases intravascular vol­
ume, therefore raising osmotic pressure. HAES 
has a serum half-life of 10 h, and also inhibits 
platelet aggregation.
One prospective study investigated the effect 
of HES, involving 100 high-risk patients (E2 lev­
els >3000pg/ml and/or > 2 0  oocytes)69. These 
patients received 1000 ml of 6% HES at the time 
of oocyte retrieval and 500 ml 48 h later. A his­
torical control group of 82 high-risk patients 
who had not been treated with HES was 
included. A significantly lower rate of moderate 
OHSS using HES was seen, but there was no 
reduction in severe OHSS.
Another group evaluated a regimen of 
1000 ml of 6% HES given shortly after embryo 
transfer, in a prospective, randomized, placebo- 
controlled study, involving a total of 101 high- 
risk patients (E2 > 1500 pg/ml or > 1 0  
follicles)70. One case of moderate OHSS devel­
oped in the HES group, whereas one severe and 
six moderate cases occurred in the placebo 
group [p =  0.031).
Subsequently, others performed a prospec­
tive randomized study to compare the efficacy 
of 500 ml of 6% HES (n =  85), and of 50 ml of 
20% human albumin (n = 85) or placebo 
[n =  83) in at-risk patients (E2 > 3000 pg/ml or 
> 20 follicles)66. All treatments were adminis­
tered during oocyte retrieval. No severe OHSS 
case was observed in the albumin and HES 
groups, while four were seen in the placebo 
group. Moderate OHSS was encountered in four 
and five patients in the albumin and HES 
groups, respectively, and in 12 patients receiv­
ing placebo [p <  0.05).
The authors recommended preventing 
OHSS by using HES, since it is as efficient as 
but safer and cheaper than human albumin.
These three studies provide concordant 
results, thereby suggesting a beneficial effect of 
HES in decreasing OHSS incidence. Although 
the patient cohort was too small to draw defini­
tive conclusions, these preliminary results sug­
gested that HES rather than albumin should be 
further evaluated.
Summary
Although the trials are small, existing results 
seem to warrant further clinical research with 
the use of HES.
High doses of intramuscular 
progesterone
Three different mechanisms of action of the pro­




(1) A general antiestrogenic effect of proges­
terone mediated by the down-regulation of 
estrogen receptors, for example on the vas­
cular endothelium;
(2) A direct inhibition of ovarian hormone 
secretion, such as prorenin;
(3) An antagonistic effect toward aldosterone.
In a prospective randomized controlled study50, 
the effectiveness of intramuscular progesterone 
was compared with IV albumin in preventing 
OHSS. High-risk patients (E2 > 2452 pg/ml and 
> 2 0  follicles) received either 200 mg proges­
terone per day (n =  54), intramuscularly, for 14 
days starting immediately after oocyte retrieval, 
or 100 ml of a 20% albumin suspension, intra­
venously (n =  42).
Progesterone prevention was significantly 
more efficient, with fewer moderate OHSS cases 
(0% vs. 5%). No severe forms were observed in 
these two groups, but a higher pregnancy rate 
was observed in the progesterone group (68% 
vs. 52.3%). This isolated and limited study has 
to be confirmed.
However, progesterone is the best choice for 
luteal supplementation, because it is associated 
with a lower incidence of OHSS71.
CRYOPRESERVATION OF ALL 
EMBRYOS
Instead of canceling the cycle, it is possible to 
administer hCG, retrieve the oocytes and then 
cryopreserve all embryos. Using this preventive 
strategy, patients are still exposed to exogenous 
hCG, and early OHSS is not totally avoided. 
Nevertheless, the risk of secondary exacerbation 
of early OHSS is avoided as well as late OHSS, 
since this is induced by endogenous hCG72-74.
Moreover, endometrial biopsies were per­
formed during the luteal phase of such canceled 
cycles in 33 patients who presented biological 
risk signs of OHSS (E2 =  4722 ±  1190 pg/ml)74.
Half of these biopsies showed glandular stromal 
asynchrony, suggesting that patients who have 
very high E2 levels may have a reduced chance 
of conception, and therefore reinforcing the 
idea that cryopreservation constitutes a valid 
alternative.
This treatment has the advantage of main­
taining many of the benefits of the IVF cycle, 
since it is hoped that in a later cycle, thawed 
embryos may be successfully replaced75.
Pattinson et al.76 recorded in these condi­
tions a pregnancy rate significantly higher than 
that obtained with ‘normal’ frozen transfer, and 
equivalent to that following fresh transfer in the 
same center, also encouraging cryopreservation. 
On the other hand, Awonuga et al.77 were the 
only ones to observe a decrease in pregnancy 
rate after cryopreservation as compared with 
controls, while OHSS incidence was similar in 
both groups. A review summarizing the several 
studies and reporting their conflicting results is 
presented in Table 318.
Among these studies, only Ferraretti et al.78 
conducted a prospective randomized study, 
although the selection criteria in this group of 
58 patients in whom cryopreservation was 
undertaken were much more loose than those 
generally applied. Women with E2 levels 
> 1500 pg/ml and > 1 5  oocytes were selected. 
The control group comprised 67 patients who 
presented the same criteria and in whom fresh 
embryos were transferred. The pregnancy rates 
were comparable (46.3% vs. 48.3%); no cases of 
OHSS occurred in the 58 cycles with cryo­
preservation, but four cycles were complicated 
by OHSS in the control group (0% vs. 6%).
The Cochrane review by D’Angelo and 
Amso67 has shown that there is insufficient evi­
dence to support routine cryopreservation.
These controversies may be explained by the 
different criteria that were used to define 
patients at risk, the different freezing proce­
dures adopted and the lack, for ethical reasons, 
of a prospective randomized study in two very- 
high-risk groups.
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One question that remains to be solved is 
whether GnRH-a should be continued when 
embryos are cryopreserved, in order to reduce 
the risk of OHSS. One group showed that LH 
levels remained low for at least 14 days during 
the luteal phase after pituitary suppression with 
GnRH-a administration and ovarian stimulation 
with hMG, even though GnRH-a was discontin­
ued on the day of hCG administration83. Others 
confirmed this observation by comparing the 
rate of ovarian quiescence, by the weekly fall in 
serum E2 concentration, following stimulation 
with or without continuing GnRH-a after the 
administration of 10 000IU of hCG. There was 
no difference between the two groups in terms 
of ovarian quiescence, and serum LH concentra­
tion remained low in all women, irrespective of 
the group73. According to these preliminary 
data, the majority of authors stopped GnRH-a 
after hCG administration.
Nevertheless, Endo et a l 84 assessed the 
efficacy of the continuous administration of 
GnRH-a for 1 week after the administration of 
5000IU of hCG and elective embryo cryopreser- 
vation to prevent early OHSS. In this prospec­
tive, randomized, controlled trial (rz =  138), no 
high-risk patients treated with continued GnRH- 
a developed severe OHSS, compared with 10% 
in the control group with embryo cryopreserva- 
tion alone. In addition to the luteolytic effect of 
continuous GnRH-a, the authors underline its 
possible local effect on the ovary in humans 
with a probable reduction of VEGF expression.
Summary
At present, there is insufficient evidence to sup­
port routine cryopreservation for the prevention 
of severe OHSS. It has not been established 
whether the elective freezing of all embryos 
completely eliminates the risk of OHSS. Early 
OHSS is not avoided, but late OHSS is avoided, 
or at least its duration and severity are reduced 
in high-risk patients. This is due to the absence 
of endogenous hCG, produced by the trophoblast.
A recent study using GnRH-a administration 
during the luteal phase after elective cryopreser­
vation decreased the incidence of early OHSS. 
In all but one report, the pregnancy rate after 
frozen-thawed embryo replacement was as high 
as when using fresh embryos.
ELECTROCAUTERY OR LASER 
VAPORIZATION OF ONE OR BOTH 
OVARIES
PCOS is the major risk factor for OHSS. The 
results of preventive methods for OHSS in these 
patients are unpredictable in terms of ovarian 
response and OHSS prevention. OHSS was 
observed despite using a low step-up regimen 
with gradual increase of the dose of gonado­
tropins. Moreover, the ovarian response may be 
unsatisfactory when decreased doses of 
gonadotropins are given after a previous experi­
ence of OHSS8’10.
One of the possible treatments of PCOS is 
destruction of follicles at the surface of the 
ovary, by wedge resection or by multiple punc­
ture using laparoscopic ovarian electrocauteri­
zation. The endocrine effects associated with 
this treatment include a reduction in serum LH 
and serum androgens, with corresponding ovu­
lation improvement and conception. A reduc­
tion of multiple pregnancy, OHSS and probably 
miscarriage rates is also observed.
A number of authors have suggested treating 
patients suffering from PCOS by using these 
destructive techniques before starting to stimu­
late them for IVF85-88. This treatment can be 
performed on one or two ovaries with electro­
cautery or laser vaporization. The main undesir­
able side-effect of these methods is the 
development of postoperative adhesions.
Fukaya et a l 85 reported preliminary encour­
aging results after ovarian laser therapy in 
patients who suffered from PCOS and had 
developed OHSS in the past.
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Only one prospective randomized study, 
involving 50 patients, affected by PCOS has 
been carried out86. PCOS patients who failed to 
become pregnant during a previous trial, or 
whose cycle had been canceled for high OHSS 
risk, were randomized between classical IVF 
treatment versus electrocautery of one ovary, 1 
week before ovarian stimulation. The pregnancy 
and miscarriage rates were identical, but the 
rate of canceling for risk of OHSS was signifi­
cantly lower in the cauterized group. There was 
no advantage in terms of miscarriage rate, which 
remained high in both groups.
Finally, a retrospective comparison was 
made of 15 women with clomiphene-resistant 
PCOS, treated by laparoscopic ovarian 
diathermy before IVF, and 16 PCOS patients 
who did not receive surgical pretreatment88. In 
this study there was only a trend toward a lower 
risk of miscarriage (28.6% vs. 66.7%) and OHSS 
(0% vs. 4.2%), and higher chances of pregnancy 
(29.4% vs. 10.5%) in the group which had been 
surgically pretreated, but these differences were 
not statistically significant.
Minimal ovarian destruction is necessary to 
sensitize PCOS to exogenous gonadotropins. 
However, in order to avoid OHSS, a consider­
able amount of healthy ovarian destruction is 
required, with the drawback that, under these 
conditions, the ovarian reserve may be 
hampered.
Summary
Since only preliminary data are available and in 
view of the possible side-effects (adhesions and 
loss of ovarian tissue) and its invasive character, 
this approach should be restricted to rebel cases 
of OHSS in patients suffering from PCOS, and 
applied only as a last resort.
REDUCTION OF THE NUMBER OF 
TRANSFERRED EMBRYOS
Late-onset OHSS may be induced or aggravated 
by the rising hCG produced by early pregnancy.
As hCG secretion is higher in multiple pregnan­
cies, it can be postulated that by reducing the 
number of conceptuses the incidence or severity 
of OHSS will decrease. In these conditions, a 
reduction of the number of transferred embryos 
could be an efficient preventive method for 
high-risk patients.
Koike et a l 89 observed, in a retrospective 
study, a higher number of days of hospital stay 
in relation to the number of conceptuses.
De Neubourg et a l 90 evaluated the incidence 
of single-embryo transfer (SET) and its subse­
quent decline in twin pregnancies. The authors 
evaluated the possible consequence of decreas­
ing multiple pregnancy on OHSS incidence. 
Over a 5-year period, SET increased from 13 to 
46%, which was associated with a decrease in 
multiple pregnancies from 33.6 to 11.7%. Dur­
ing this period, the incidence of OHSS did not 
decrease (0.5-2.4%). Moreover, the proportions 
of OHSS among singleton (3.32%) and twin 
(3.73%) conception cycles were similar. It seems 
clear from this study that the late form of OHSS 
is related more to the presence of hCG than to its 
level.
In a recent Belgian study91, multiple preg­
nancies were equally high among early- and 
late-OHSS cases (40.0% and 45.5%, respec­
tively), but only in the group of late-OHSS cases 
was significance compared with the non-OHSS 
population reached (45.5% vs. 29.1%). This late 
form, closely associated with multiple pregnan­
cies, is more likely to be severe.
According to these three preliminary stud­
ies, it is more the severity than the incidence of 
OHSS that is dependent on the level of hCG, 
resulting from multiple pregnancy
CONCLUSIONS
In the prevention of any disease, it should be 
emphasized that the possibility of primary pre­
vention depends on two main requirements: 
first, the etiology of the disease must be known,
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while causal and predisposing factors should be 
identified; and second, it must be feasible to 
avoid or manipulate such factors as part of a 
preventive strategy.
Secondary prevention requires knowledge of 
the pathophysiological mechanisms of the dis­
ease, availability of early detection methods, 
and means to intervene and correct the patho­
physiological changes46.
There is disagreement regarding the sensitiv­
ity and predictive values of the various patient 
characteristics which may be used to predict 
OHSS. The greater severity of late OHSS and its 
poor correlation with conventional ovarian 
response parameters is a major problem in clin­
ical practice. None of the predictive data for late 
OHSS are ever available before oocyte retrieval.
Late OHSS is related to hCG levels and prob­
ably to the number of ovarian cells capable of 
producing the causal ‘unidentified ovarian 
mediator’ under the influence of hCG. It may be 
useful, therefore, to act at two levels: first, to 
attempt to limit the dose or concentration of 
hCG (level 1); and second, to find a way to 
induce luteolysis (level 2) without inducing a 
detrimental effect on endometrial and oocyte 
quality.
Intervening at level 1 can theoretically be 
achieved by decreasing the hCG dose for ovula­
tion induction, by cryopreservation, by SET and 
by using progesterone instead of hCG supple­
mentation in the luteal phase. Finally, interven­
ing at level 2 may consist of enhancing 
luteolysis, as in EUFA, coasting and electro- 
cautery of one or both ovaries. Albumin and 
HES constitute secondary prevention methods.
Finally, apart from canceling, none of these 
approaches is totally efficient, although most of 
the above-mentioned methods decrease the inci­
dence in patients at high risk of OHSS.
The effect of combining methods which act 
at two different levels (1 and 2) should be 
assessed92.
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CHAPTER 22
The role of coasting in the prevention of 
threatening ovarian hyperstimulation 
syndrome: a European perspective
Marc Dhont
INTRODUCTION
Several strategies to prevent ovarian hyperstim­
ulation syndrome (OHSS) have been tried, and 
their rationale and efficacy are dealt with in 
other chapters of this book. Coasting in in vitro 
fertilization (IVF) was introduced in 19931, and 
has since been applied by many infertility cen­
ters, although the ultimate proof of its efficacy 
remains to be provided by a prospective ran­
domized trial. In this chapter, I consider a num­
ber of questions and try to give the currently 
available and generally accepted answers.
DEFINITION OF COASTING AND  
MECHANISM OF ACTION
The word coasting is a nautical term, and means 
slowing down the speed of a vessel when 
approaching the coast. In IVF, the word was 
introduced to describe the process of diminish­
ing or stopping gonadotropin therapy for a vari­
able number of days before administering 
human chorionic gonadotropin (hCG)1. It was 
suggested that this approach prevents severe 
OHSS by removing the follicle stimulating hor­
mone (FSH) stimulation of granulosa cells, 
thereby inhibiting their proliferation and reduc­
ing the number of granulosa cells available for 
luteinization2. This would allow continued fol­
licular growth and maturation while reducing 
the risk of OHSS. In addition, Tortoriello et a l 3 
suggested that the falling FSH concentration 
induces increased apoptosis of granulosa cells, 
which results in a reduction of chemical media­
tors or precursors that augment fluid extravasa­
tion. It has also been postulated that follicles of 
varying size have a different threshold to 
gonadotropins, and smaller follicles appear to 
be more susceptible to gonadotropin depriva­
tion than are larger follicles4.
Enhanced production of vascular endothe­
lial growth factor (VEGF) plays a central role in 
the pathogenesis of OHSS. The concentration of 
VEGF is increased in follicular fluid, ascites and 
plasma of patients with OHSS5-7. The expres­
sion and secretion of VEGF by human luteinized 
granulosa cells has been shown to be hCG- 
dependent8,9. It has also been demonstrated that 
there are differences in follicular fluid VEGF 
concentrations between coasted and non- 
coasted patients, which indicates that coasting 
may alter the capacity of the granulosa cells to 
produce VEGF and/or their response to hCG10. 
The same authors also demonstrated that coast­
ing alters the functional capacity of granulosa 
cells cultured in vitro11. By coasting, VEGF
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expression seems to be down-regulated12. There 
are thus a number of plausible mechanisms 
which underpin the probability of coasting 
being effective in reducing the incidence of 
OHSS.
CRITERIA FOR COASTING
Although the occurrence and severity of OHSS 
cannot be reliably predicted, there are some pre­
dictive factors that can be taken into account for 
deciding when to consider coasting. Some 
patient characteristics are helpful in deciding 
particularly which patients to coast. There cer­
tainly is also a relationship between the number 
of growing follicles and/or the serum estradiol 
level and the risk of OHSS. In susceptible 
patients, however, OHSS can occur, after trig­
gering ovulation with hCG, with fewer than ten 
mature follicles, while other patients with 30 
mature follicles can sustain the same procedure 
with only minor discomfort. Cut-off levels for 
the number of follicles and/or the estradiol level, 
therefore, are arbitrary, and will differ according 
to various authors and the perceived risk of the 
individual patient. Criteria for coasting used by 
different authors are given in Table 1. Another 
factor that cannot be computed is the choice of 
the individual patient, and the well-reasoned 
risk that she is willing to sustain after having 
been informed about the size of the risk and 
equally well about the potential hazards of 
severe ovarian stimulation and the conse­
quences of preventive procedures, from cancel­
lation of the cycle to other measures that could 
reduce her chance for pregnancy.
Patient characteristics
Patients with typical polycystic ovaries are at 
increased risk for developing OHSS and, hence, 
ovarian stimulation should be adapted from the 
outset to the anticipated number of follicles that 
will develop upon full stimulation. Lean
patients in particular are prone to OHSS, and 
coasting should be considered more readily in 
these patients.
Estradiol levels
Most authors have used a cut-off level for serum 
estradiol of between 2500 and 3000pg/ml for 
coasting. There are, however, some limitations 
in the use of estradiol levels as a criterion for 
coasting. The estradiol level does not suffi­
ciently take into account the number of smaller 
follicles, which also contribute to the develop­
ment of OHSS. With pure FSH, estradiol levels 
tend to be lower than with human menopausal 
gonadotropin (hMG), and a useful cut-off level 
for serum estradiol in these cases has not yet 
been established. Finally, this parameter does 
not take into account the presence of numerous 
follicles in only one ovary. Although it seems 
logical that the total number of follicles is the 
most important factor in the risk assessment of 
OHSS, it cannot be excluded that the number of 
follicles in a single ovary independently con­
tributes to this risk. It seems, therefore, that 
estradiol is not an absolute variable for deciding 
to coast, but it keeps its place for monitoring the 
duration of the coasting process.
Number of follicles
Although there is no linear relationship between 
the number of growing follicles and the risk of 
severity of hyperstimulation, common sense 
indicates that this is certainly the most reliable 
parameter to be taken into account, provided 
that all follicles ^13 mm are included in the 
count. Because OHSS can occur in patients with 
a single ovary, and it is not yet clear whether the 
risk of OHSS is determined by the total number 
of follicles or by the number of follicles per 
ovary, I would therefore propose considering 
coasting when the total number of follicles in 
both ovaries exceeds 30, or when more than 20 
growing follicles are present in a single ovary.
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Table 1 Criteria for coasting
Authors








E2 at hCG 
a dministra ti on 
(pg/ml)






Sher et al. (1995)2 Retrospective 51 > 3000 <3000 6.1 (3-11) >  29 follicles, 30% of 
follicles >15 mm
Benadiva et al. (1997)15 Retrospective 22 > 3000 <3000 1.9 ± 0 .9
Tortoriello et al. (1998)3 Retrospective 22 > 3000 <3000 2.6 ±0 .3 ^ 5 follicles > 1 6  mm and 
2 follicles >  19 mm
Dhont et al. (1998)16 Retrospective
case-control
120 > 2500 <2500 1.9 ±0 .8 st 20 follicles
Lee et al. (1998)17 Retrospective 20 > 2724 Decreasing 2.8 ± 1.3 Many immature follicles 
but < 3 follicles >  18 mm
Egbase et al. (1999)13 Retrospective
randomized
15 >6000 < 3000 4.9 ± 1 .6
Waldenstrom et al. (1999)18 Retrospective 65 Variable < 2724 4.3 (3-6) > 2 5  large follicles, 3 
follicles > 1 7  mm
Fluker et al. (1999)4 Retrospective 63 > 3000 25% decline 3.4 ±0 .1
Al-Shawaf et al. (2001)19 Retrospective 50 > 3595 < 2724 3.4 ±1 .6 > 20 follicles, 25% of 
follicles >  15 mm
Ulug et al. (2002)14 Retrospective 207 >4000 <4000 2.9 ±0 .1 > 20 follicles, 30% of 
follicles >  15 mm












Coasting should not be initiated too early 
because follicular development could come to a 
complete standstill. When less than 30% of fol­
licles have attained a mean diameter of 15 mm, 
an abrupt arrest in follicular development and a 
rapid decline in plasma estradiol usually com­
promises the oocyte quality. It has been shown 
that when the leading follicle reaches ^ 15 mm, 
follicular growth continues after the withdrawal 
of gonadotropins13. On the other hand, if most 
follicles are > 15 mm in mean diameter when 
coasting is started, large cystic follicles are com­
monly encountered, and the quality of oocytes 
is also compromised5. It seems, therefore, that 
coasting should start when at least half the folli­
cles have reached a mature size and have 
become independent of further gonadotropin 
stimulation for their final growth. The optimal 
threshold, both for estradiol and for follicular 
size, to start coasting remains to be determined. 
It is possible, but has not yet been firmly estab­
lished, that the higher is the estradiol level at 
the beginning of coasting, the less effective is 
coasting in preventing OHSS irrespective of the 
length of the coasting period.
DURATION OF COASTING
Most authors agree that coasting should be 
maintained until the estradiol concentration 
drops below 3000pg/ml (Table 1). After with­
holding gonadotropins, there is a further rise of 
serum estradiol for 1 or 2 days. Hence, the dura­
tion of coasting is dependent on the serum 
estradiol level at the time coasting starts; higher 
levels will require a longer coasting period. 
There is circumstantial evidence that the dura­
tion of coasting may impact on the success rate 
of IVF either by affecting oocyte and embryo 
quality or by altering endometrial receptivity. 
Ulug et al.14 found that coasting for 2>4 days 
reduced pregnancy rates, although oocyte qual­
ity was not affected. Using the oocyte donation 
model, whereby endometrial receptivity is kept 
under control by the administration of estrogens 
followed by estrogens and progesterone in an 
artificial cycle, Isaza et al.20 found that coasting 
for more than 4 days reduced pregnancy rates in 
the recipients, indicating that oocyte quality 
was affected by the duration of coasting. Alter­
ation of endometrial receptivity can be an alter­
native or concomitant factor in the inverse 
relationship between the duration of coasting 
and pregnancy rate. The prolonged drop in 
estradiol level may compromise endometrial 
integrity and even induce estrogen-withdrawal 
bleeding. A rise of progesterone before the 
administration of hCG has been shown to occur 
more frequently in the coasted patient, which 
might affect the implantation window21. There 
is a consensus that coasting should not be 
extended beyond 4 days, but the optimal dura­
tion of coasting in terms of both prevention of 
OHSS and maintaining a normal pregnancy rate 
remains to be determined.
EFFICACY OF COASTING
There are no large-scale randomized controlled 
trials to establish firmly the effectiveness of 
coasting in preventing OHSS. There is only one 
randomized controlled trial in which coasting 
was compared with early unilateral follicular 
aspiration (EUFA) for the prevention of 
moderate and severe OHSS13. Thirty women 
undergoing superovulation for IVF/intra- 
cytoplasmic sperm injection (ICSI) treatment 
with gonadotropin-releasing hormone agonist 
(GnRH-a) down-regulation and gonadotropin 
stimulation were included in the study. The 
women were considered to be at risk of hyper­
stimulation when the estradiol concentration 
was >6000pg/ml and > 1 5  follicles in each 
ovary with at least two follicles >18m m  in 
diameter were present. The number of oocytes 
retrieved was significantly lower in the coasting
242
ROLE OF COASTING: EUROPEAN PERSPECTIVE
group (9.6) than in the EUFA group (15.4), but 
the clinical pregnancy rates were comparable. 
The incidence of moderate and severe OHSS 
(3/15 in the coasting group) was not different 
between the two groups [n =  30; odds ratio (OR)
0.76, 95% confidence interval (Cl) 0.18-3.24).
We performed a case-control study in which 
we matched every case with ‘non-coasted’ IVF 
patients having comparable risk factors16. Out­
comes were compared with those from 120 
matched patients in whom serum estradiol lev­
els and number of follicles at the time of hCG 
administration were comparable to those at the 
beginning of coasting (control group). The con­
trol group was selected from patients who had 
been stimulated for IVF before coasting had 
been introduced between 1989 and 1993 
{n =  120). The main difference in the treatment 
protocol of the control group was that, in most 
of the patients, stimulation was performed using 
a long protocol (goserelin; Zeneca, Belgium), 
starting with 4 ampoules/day after complete 
pituitary desensitization was obtained. The case 
group consisted of 120 women undergoing ovar­
ian stimulation for IVF who were considered to 
be at risk for ovarian hyperstimulation (serum 
estradiol levels > 2500pg/ml or more than 20 
follicles at the time of hCG administration). 
Gonadotropin administration was withheld 
when serum estradiol exceeded 2500pg/ml, and 
hCG administration was delayed until estradiol 
levels dropped below 2500pg/ml. The luteal 
phase was supported by progesterone intramus­
cularly (50 mg per day) in all cases and control 
patients. The incidence of moderate and severe 
OHSS, number of oocytes retrieved and preg­
nancy rate were compared in both groups. The 
incidence of moderate and severe OHSS was 
5.8% in the coasting group versus 18.3% in the 
control group (p < 0.005; OR 0.27, 95% Cl
0.11-0.67). The odds ratio of severe OHSS in the 
coasting group was 0.11 (95% Cl 0.01-0.86). In 
fact, only one case with severe OHSS had to be 
hospitalized, in contrast with nine cases in the 
control group (p < 0.01), bringing the overall
incidence of severe OHSS in our IVF program 
down to less than 0.1% since coasting was intro­
duced. There was no significant difference in 
oocyte maturity (93.6% of retrieved oocytes in 
the coasting group were mature versus 93.2% in 
the control group), nor in fertilization rate. 
Although the number of oocytes was signifi­
cantly lower in the coasting group (19.7 ± 0.6 vs. 
22.1 ±0.6), coasting did not affect the preg­
nancy rate (37.5% vs. 36.7%).
Second-hand evidence for the efficacy of 
coasting to prevent OHSS comes from retro­
spective observational studies (Table 2). In most 
of these studies, the incidence of severe OHSS 
after coasting was less than 2%. Differences in 
study design and the lack of standardized crite­
ria for coasting and for the definition of severe 
OHSS are unfortunate limitations for estimating 
the real impact of coasting on the incidence of 
OHSS. Nevertheless, most studies agree that 
severe OHSS can be reduced to an incidence of 
lower than 2% in patients at risk. Two studies 
report much higher figures, but the criteria for 
starting coasting were less stringent, and only 15 
and 20 patients were studied13,17, respectively.
CONCLUSION
Coasting is one of the methods which is thought 
to be useful in preventing ovarian hyperstimula­
tion syndrome. It involves withholding gonado­
tropin stimulation when estradiol levels exceed 
a certain threshold and waiting to give hCG 
until estradiol levels start dropping. There are a 
number of case-control and retrospective obser­
vational studies to support this strategy. How­
ever, there is a lack of prospective randomized 
trials to estimate the efficacy of coasting 
compared with placebo or other preventive 
measures.
Criteria for the initiation of coasting and its 
timing and duration are not yet uniformly estab­
lished, but based on the literature, the following 
consensus can be proposed: coasting will be
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Table 2 Comparison of outcome of coasting in terms of severe ovarian hyperstimulation syndrome 
and pregnancy rate
Authors










Sher et al. (1995)2 51 0 69 10 41
Benadiva et al. (1997)15 22 0 64 — 64
Tortoriello et al. (1998)3 22 0 61 19 57
Dhont et al. (1998)16 120 0.8 — 20 38
Lee et al. (1998)17 20 20 63 — 40*
Egbase et al. (1999)13 15 20 — — 33
Waldenstrom et al. (1999)18 65 1.5 61 31 42
Fluker et al. (1999)4 63 0 71 14 37
Al-Shawaf et al. (2001)19 50 0.2 55 26 40
Ulug et al. (2002)14 207 1.9 71 19 51*
* Pregnancy rate expressed per embryo transfer
considered when > 2 0  follicles are developing; 
it should be initiated when the serum estradiol 
concentration exceeds 3500pg/ml and when the 
largest follicle has reached a diameter of 18 mm. 
The administration of hCG should be delayed 
until the estradiol level drops below 3000 pg/ml, 
but the duration of coasting should be limited to 
£4 days because both the number of oocytes 
and the pregnancy rate drop considerably after a 
longer interval. By following these guidelines, 
the incidence of severe OHSS can be reduced 
to < 2% while the pregnancy rate will be 
unaffected.
Further studies are also needed to establish 
the most optimal timing and duration of coast­
ing. Because with careful stimulation severe 
OHSS is rare, it seems unlikely that statistically 
solid proof of efficacy and data relating to timing 
and duration of stimulation will be forthcoming 
in the near future. For the time being, each IVF 
center should identify its own cut-off limit of 
serum estradiol and/or number of follicles
and/or follicle size for the onset of coasting and 
for the timing of hCG administration.
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CHAPTER 23
The role of coasting in the prevention of 
threatening ovarian hyperstimulation 
syndrome: an American perspective
Botros Rizk
INTRODUCTION
Coasting is the most popular method among 
physicians to prevent ovarian hyperstimulation 
syndrome (OHSS)1. This is absolutely true 
whether the patient is undergoing in vitro fertil­
ization (IVF) in the United States or in Europe. 
Withholding gonadotropins and delaying the 
administration of human chorionic gonado­
tropin (hCG) have been employed in ovulation 
induction since the late 1980s and early 
1990s2-5. Shortly afterwards, coasting was used 
to prevent severe OHSS in IVF cycles6. More 
than 15 studies (Tables 1-3) have been pub­
lished, and several reviews have critically eval­
uated the effect of coasting on OHSS1’7-9. In this 
chapter, the advantages and the mechanism of 
action of coasting are discussed in detail. The 
impact of the points of initiation and termina­
tion of coasting as well as the duration are ana­
lyzed for the various publications based on our 
previous reviews and critical analyses10,11.
PHILOSOPHY OF COASTING
Serum estradiol levels at the time of ovulation 
triggering are considered to be a clinical predic­
tor of the risk of developing OHSS12. It has 
therefore been proposed to postpone hCG 
administration to allow the serum estradiol lev­
els to drop below a certain threshold. This has 
been coined ‘coasting’ or ‘controlled drift 
period’.
ADVANTAGES OF COASTING
The advantages of coasting are obvious for three 
reasons10,11. The first advantage of coasting is 
that the cycle is rescued and not canceled. The 
second advantage is that the embryos that are 
generated during the treatment cycle will be 
transferred, and hence there is no need for cry- 
opreservation. The third advantage is that there 
is no need for gonadotropins or other medica­
tions nor for any supplementary procedures.
HOW DOES COASTING WORK?
The association between OHSS and high estra­
diol levels is very well established12. This cer­
tainly does not mean that the high estradiol 
levels per se result in the manifestations of 
increased permeability associated with 
OHSS8,9,13.
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Mean age (years) 
±  SD (range)




Sher et al.25, 1995 (51) 37.3 (28-42) E2 > 3000, follicle number >  29 and 
30% follicles s> 15 mm
Descriptive/NA
Benadiva et al.27, 1997 (22) 34.5 ± 3 .6 E2 a 3000 Retrospective/cryopreserved patients
Tortoriello et al 29, 1998 (44) 32.6 ± 0 .7 E2 > 3000 and five or more follicles 
;> 16 mm and two follicles st 19 mm
Retrospective/subgroup of coasted 
versus two control groups
Dhont et a l.13, 1998 (120) NA E2 > 2500 and follicle number s> 20 Retrospective/historical cohort
Lee et a l 28, 1998 (20) NA E2 > 2777 and many immature follicles 
>  18 mm
Fluker et al.5, 1999 (63) 32.2 ±NA E2 rose rapidly and generally > 3000 Descriptive/NA
Waldenstrom et al.15, 1999 (65) 31.5 (23-39) ‘Very high E2’ and > 2 5  ‘large follicles’ 
of which the three largest ;> 17 mm
Descriptive/NA
Egbase et al.43, 1999 (15) 33.5 ±2 .8 E2 > 6000 and > 1 5  follicles/ovary and 
two or more > 1 8
Prospective randomized early 
follicular aspiration
Dechaud et al.46, 2000 (14) NA E2 s> 5000 and/or > 20 follicles of which 
three or more follicles ;> 18 mm without 
abdominal pain
Descriptive/NA
Ohata et al.32, 2000 (5) 32 (25-37) ^ 30% follicles ;> 16 mm and severe 
OHSS in previous cycle
Descriptive/NA
Aboulghar et al.31, 2000 (24) 29.9 ± 4 .6 E2 >  3000 and > 2 0  follicles with a 
dominant follicle ^ 16 mm
Retrospective/historical group
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Coasting may diminish the functional gran u- 
losa cell cohort, resulting in a gradual decline in 
circulating estradiol levels, but more important, 
reduction of the chemical mediators that aug­
ment capillary permeability and fluid retention. 
Al-Shawaf et al. in 200114 postulated that coast­
ing may reduce the incidence of severe OHSS in 
several ways. Follicle stimulating hormone 
(FSH) is known to induce luteinizing hormone 
(LH) receptors on granulosa cells; withholding 
gonadotropin will result in a decrease in FSH 
concentration and down-regulation of the LH 
receptors14,15. Through this mechanism, the 
number of granulosa cells available for 
luteinization will become less and the vaso­
active substances responsible for the manifesta­
tions of OHSS will become less concentrated. 
Follicles of varying sizes may have different 
thresholds to gonadotropins10. Smaller follicles 
have a higher threshold than do larger follicles5. 
Withholding gonadotropins may therefore cause 
apoptosis of the granulosa cells and atresia of a 
large number of small follicles. Longer periods 
of coasting will cause a further reduction in FSH 
concentration followed by atresia of medium­
sized follicles. When the FSH concentration 
falls further, it is possible that mature follicles 
>  15 mm will also undergo atresia, resulting in 
large follicular cysts with poor-quality and 
lower number of oocytes14.
During coasting, estradiol levels initially 
increase because dominant follicles may con­
tinue their growth (Figure 1), despite the lack of 
hormonal stimulus, whereas intermediate folli­
cles may undergo atresia10. Presumably, this is 
one mechanism of the efficacy of coasting in 
preventing OHSS.
The characteristics o f granulosa cells in the 
follicles of women undergoing coasting in con­
trolled ovarian stimulation for IVF have recently 
been described16. The effect of withholding 
gonadotropins during controlled ovarian stimu­
lation in women at risk of developing OHSS was 
recently evaluated17. Individual follicles of vari­
able sizes were assessed in relation to the gran­
ulosa cell number, oocytes retrieved, fertiliza­
tion and embryo quality. The authors acknowl­
edged that the ideal control group of women 
would be those identified to be at risk of devel­
oping OHSS, but not coasted. However, this was 
not ethically possible, since coasting has been 
successfully used to prevent severe OHSS in 
their unit for several years14. The control group 
was selected from optimally responsive women, 
excluding all poor and hyper-responders. The 
authors observed wide variations of follicular 
fluid levels of vascular endothelial growth factor 
(VEGF) in follicles of the same size, both in dif­
ferent patients and in the same patient, which 
reflects the unique and individual composition 
of each follicular environment. Despite these 
wide variations, VEGF levels in follicular fluid 
in the coasted group were constantly lower than 
the VEGF follicular fluid levels in the control 
group.
VEGF concentration in follicular fluid may 
depend on the quality and number of granulosa 
cells18,19. Tozer et al.17 observed a negative cor­
relation between follicular fluid VEGF and gran­
ulosa cell number, which was independent of 
follicle size. Greater granulosa cell numbers 
have been associated with more competent folli­
cles20, and lower follicular fluid VEGF levels 
with more oocytes21 and better embryo qual­
ity22. Tozer et al.17 suggested that this correla­
tion, which was more significant in the coasted 
group, may be due to the differential effect of 
gonadotropin withdrawal on individual follicles 
in favor of those follicles with a greater number 
of granulosa cells/more competent follicles. The 
study did not confirm or refute VEGF as the cor­
nerstone of OHSS pathophysiology, but estab­
lished that VEGF follicular fluid concentrations 
in highly responsive women who had under­
gone coasting were significantly lower than in 
the control group of women studied.
Garcia-Velasco et al., in 2 0 0 423, suggested 
that coasting acts through down-regulation of 
VEGF gene expression and protein secretion. 
The fact that medium and small follicles are
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Table 2 In vitro fertilization (IVF) data for the coasted cycle: estradiol (E2) data are in pg/ml, means (ranges) or ±  SD are given. Repro­
duced with permission from reference 7
E2 day E2 day Coasting
o f hCG duration








3802 ±  731 2206 ±932 1597 1.9 ±0 .9
Tortoriello 
et a l ,  1998
4015 ± 112 2407± 130 2475 2.6 ±0 .3
Dhont 
et al., 1998
3834 ±872 2348 ±472.2 1486 1.94 ± 0 .8
Lee
et al., 1999
NA NA NA 2.8 ± 1.3
Fluker 
et al., 1999












10 055 ±965 1410 ± 246 NA 4.9 ± 1 .6
Patients Patients with
Fertilization Pregnancy with hemo-
Oocytes rate rate ascites concentration
In) (%) (%) In) (n)
21 69 41+ 12 0
15 ± 6 .5 62.2 63.6+ NA NA
15.8 ±  1.2 59.8 44.45+ 6 (5 clinically 
and 1 at 
ultrasound)
3
19.7 ± 0 .6 NA 37.5* NA 1
NA 63 40* 4 (2
paracentesis)
NA
10.8 ± 0 .5 71 36.5* 1 1
10 (3-21) 61 42* < 300-800 ml: 3/61
300-800 ml: 3/61
> 800 ml: 2/61







































et a l., 2000
5761 3596 NA 1.6 (1-3) 15 36.7 30+ NA 0/10
Ohata 
et a l., 2000
NA 1242.6
(425-1800)
NA 4 (3-6) 9.2 (6-15) NA 20* 5 0
Aboulghar 
et al., 2000
7150± 1050 4640± 1100 NA 2.92 ±0 .92 16 ±3 .5 59 35+ 4 0
Al-Shawaf NA NA NA 3.4 ±  1.6 11.0 ±  5.5 55.1 40* 1/50 NA
et al., 2001 (0-22)


















Sher et al., 1995 (51) 12 0
Benadiva et al., 1997 (22) NA NA 1 moderate OHSS/classification non-precise
Tortoriello et al., 1998 (44) 6 (5 clinically and 
1 at ultrasound)
3
Dhont et al., 1998 (120) NA 1 5.8% of moderate (involves ascites) and severe OHSS
Lee et al., 1998 (20) 4 (2 paracentesis) NA 4 severe OHSS (distress with ovarian enlargement 
and ascites)
Fluker et al., 1999 (63) i 1 Cumulated results of 2 groups (classical and 
modified coasting n =  93); 9/93 had nausea and 
vomiting; 2 had ascites
Waldenstrom et al., 1999 (65) < 300 ml: 6/61 
300-800 ml: 3/61 
> 800 ml: 2/61
2/61 1 paracentesis
Egbase et al., 1999 (15) 3 NA 3 additional cases of moderate OHSS when 
considering the classification of Schenker
Dechaud et al., 2000 (14) NA 0/10 Refers only to severe forms of OHSS
Ohata et al., 2000 (5) 5 0 Ascites at ultrasound
Aboulghar et al., 2000 (24) 4 0 Ascites at ultrasound (moderate according to the 
classification of Goland)
Al-Shawaf et al., 2001 (50) l*/50 NA 2 moderate OHSS according to the classification of Navot
Total 46/283 (16.3%) 7/378 (2.8%)
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Figure 1 Mean ± SE estradiol and luteinizing hormone (LH) concentrations before and during the 
coasting period in superovulation cycles. Mean LH levels rose spontaneously just before the coasting 
period, coinciding with the rapid rise in estradiol concentrations. The line with open circles repre­
sents LH concentrations, whereas the line with solid circles represents estradiol concentrations. hMG, 
human menopausal gonadotropin; hCG, human chorionic gonadotropin. Reproduced with permis­
sion from reference 5
more sensitive to undergoing atretic changes is 
of crucial relevance in both steroid and vasoac­
tive mediator secretion. They also observed that 
a significantly higher percentage of granulosa 
lutein cells become apoptotic after coasting. 
This difference is even greater for immature 
follicles.
PHYSICIAN ATTITUDES TOWARDS 
COASTING
Physicians’ practice in infertility has been more 
of an art and is now developing into science. 
Physicians’ attitudes are still more on the artis­
tic side than the scientific side. Delvigne and 
Rozenberg1 assessed whether physicians would 
modify the preventive attitude in relation to 
clinical factors and the estradiol response. They 
constructed case scenarios with three levels of 
risk factors for OHSS. At random, three of the 12 
artificially constructed case scenarios were sent 
to 573 physicians who are members of the Euro­
pean Society for Human Reproduction and 
Embryology (ESHRE). Among the selected pre­
ventive measures, coasting was by far the most 
popular choice (60%), followed by the use of 
intravenous albumin or hydroxyethyl starch 




COASTING IN NON-IVF CYCLES
The concept of withholding gonadotropins to 
prevent an overresponse has survived two 
decades (1987-2005). Several authors have 
reported a successful reduction in severe OHSS 
by delaying hCG or ‘coasting’. Rabinovici et al., 
in 19872, were the first to report their experience 
with the rescue of 12 gonadotropin-induced 
cycles that were liable to develop hyperstimula­
tion. Treatment with human menopausal 
gonadotropin (hMG) was stopped in 12 patients 
who either had overt biochemical overstimula­
tion or were at an increased risk of hyperstimu­
lation. The duration of the pause in treatment 
ranged from 2-10 days. In nine patients, includ­
ing the six who were overstimulated, the plasma 
estradiol levels declined, despite the continuing 
growth of most follicles. None of these patients 
conceived following hCG. Pregnancies occurred 
in three patients whose estradiol levels contin­
ued to rise until the day of hCG. They therefore 
concluded that, although rescue of the over- 
stimulated cycles is sometimes possible, the 
resulting conceptions seem to be associated 
with a continuing rise of estradiol during the 
period of treatment pause.
Urman et a l.3 studied 40 cycles in 32 
patients with polycystic ovarian syndrome 
(PCOS). The authors withheld gonadotropins 
and continued to monitor by daily assay for 
estradiol and frequent ultrasound examination. 
They used the term ‘controlled drift period’ to 
explain coasting. The mean duration of coasting 
was 2.8 days. The clinical pregnancy rate per 
cycle was 25% (10/40). OHSS occurred in 2.5% 
(1/40). The authors did not share the same con­
clusion about the relationship between preg­
nancy and the rise of estradiol as suggested by 
Rabinovici et al.2.
Fluker et al.5 also used coasting in 51 women 
undergoing superovulation who had estradiol 
levels of >3000 pg/ml. In four of the 51 women, 
excessive follicular diameter was observed by 
the presence of 8-10 follicles 18 mm [n =  2) or
>  30 follicles of >  10 mm [n =  2). For religious 
reasons, none of the four women would con­
sider converting to IVF. The cycles were can­
celed, and hCG administration was withheld. 
Among the remaining 47 women who indeed 
received hCG, serum estradiol levels continued 
to rise for at least 1 day after the onset of the 
coasting period, then gradually reached a 
plateau on the second day and began to fall pre­
cipitously on the third day (Figure 1). Human 
gonadotropin was administered on the evening 
of the third to the fifth day (mean 3.4 days). The 
fall from peak estradiol levels of 2824 pg/ml to 
final levels of 1246 pg/ml on the day of hCG 
administration represents a mean reduction in 
serum estradiol concentrations of 56%. Mean 
LH levels rose near the onset of the coasting 
period and decreased spontaneously while fol­
licular growth continued. Moderate OHSS 
occurred in three (6%) of the 47 women to 
whom hCG was administered. A small amount 
of ascites was noted sonographically, and 
ovaries were enlarged to 6-10 cm. This was not 
accompanied by significant abnormalities in 
renal function or hematological parameters. 
Spontaneous resolution occurred with bedrest 
at home. Eleven pregnancies occurred among 
the 47 women (23.4%), including eight single- 




HORMONE AGONIST IVF CYCLES
Between 1993 and 2005, more than 15 studies 
were published on coasting10. The long 
gonadotropin-releasing hormone (GnRH) ago­
nist protocol was used in almost all cycles, and 
the short protocol was used in only one study13. 
This is not surprising, because GnRH agonist 
(GnRH-a) protocols were the most widely used 
for IVF stimulation during that period, and they
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are also associated with the highest probability 
of OHSS development4,24.
Sher et al.6 suggested that prolonged coast­
ing in GnRH-a/hMG/FSH cycles could prevent 
life-endangering complications of OHSS. They 
withheld gonadotropins in 17 patients whose 
serum estradiol exceeded 6000pg/ml, and con­
tinued daily GnRH-a until estradiol levels had 
fallen below 3000pg/ml. hCG (10 000IU) was 
administered to trigger ovulation. The estradiol 
levels continued to rise rapidly in the 48 h fol­
lowing initiation of the coasting period, then 
plateaued and began to fall 96-168 h after 
gonadotropins were stopped. The coasting 
period lasted between 4 and 9 days, and the day 
of hCG administration fell on cycle days 12-16. 
Six of the 17 cycles (35%) produced viable preg­
nancies. All 17 patients developed signs of grade 
2 or 3 OHSS, but none developed severe OHSS. 
In 1995, the same authors treated 51 women at 
risk of developing OHSS by coasting, and also 
waited until the estradiol level dropped to 
below 3000pg/ml25. The clinical pregnancy rate 
was 41% per oocyte retrieval (21/51). None of 
the patients developed severe OHSS; however, 
the mean number of embryos transferred was 
5.4, which was extremely high.
Ben-Nun et al., in 199 326, conducted a pilot 
study of 66 patients at risk of developing OHSS. 
These patients were coasted, and hCG was given 
when the estradiol level reached 2500pg/ml. 
Four of the 66 patients developed OHSS.
Benadiva et al., in 199727, compared coast­
ing with cryopreservation. Gonadotropins were 
withheld in 22 patients at risk of OHSS. hCG 
was administered when the estradiol levels 
dropped to ^ 3000 pg/ml. The control group con­
sisted of 26 patients in whom no fresh embryo 
transfer was performed, and all the embryos 
were cryopreserved and transferred during a 
subsequent unstimulated cycle. Fertilization 
and delivery rates were not significantly differ­
ent between the two groups, and Benadiva et al. 
concluded that coasting could produce high
pregnancy rates without the need for multiple 
frozen/thawed cycles.
Dhont et al.13 published one of the largest 
retrospective studies of 120 women undergoing 
IVF between 1994 and 1996 at risk of OHSS. 
This large study is discussed in detail by the 
above author in Chapter 22 of this book. Briefly, 
patients were coasted when the estradiol levels 
exceeded 2500 pg/ml, and hCG was withheld, 
and then administered when the estradiol levels 
dropped below 2500 pg/ml. The authors com­
pared the outcome with those of 120 matched 
OHSS high-risk patients who did not undergo 
coasting. Coasting significantly decreased the 
incidence of moderate and severe OHSS with an 
odds ratio of 0.11 and confidence interval (Cl)
0.01-0.89.
Lee et al., in 199 828, carried out a pilot study 
of coasting in 20 patients at risk of OHSS. The 
mean duration of coasting was 3 days. hCG was 
administered on the day that the serum estradiol 
levels began to fall, and four of the 20 patients 
developed severe OHSS despite coasting. The 
authors observed more severe OHSS cases 
(20%) within the group of coasted women than 
in the general reference population (1%). The 
general population presented no risk factors for 
OHSS. They concluded that hCG administration 
was too early to prevent OHSS.
Tortoriello et al. performed a very interesting 
study29. The authors investigated three groups 
of patients. The first group consisted of highly 
responsive coasted patients. The second group 
consisted of equally responsive patients who 
did not undergo coasting. The third group was a 
control group consisting of age-matched nor­
mally responsive patients. The rates of moderate 
and severe OHSS did not differ statistically 
among the three groups. No patient in group 
three developed OHSS. Moderate OHSS was 
diagnosed in one patient from group one on the 
basis of sonographically demonstrable minimal 
ascites. One patient in group two obtained a sin­
gleton pregnancy and developed critical OHSS 
with severe hemoconcentration, oliguria and a
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large pleural effusion that required 7 days of 
hospitalization.
Two subsets of coasted patients were also 
compared, to assess the effect of estradiol levels 
at the time they met the criteria for hCG (Table 
4). Subset one was identical to group one, con­
sisting of those 22 coasted patients who 
achieved an estradiol level between 3000 and 
3999pg/ml at the time they met the criteria. 
Subset two consisted of the remaining 22 
coasted patients excluded from the comparison 
analysis who achieved estradiol levels of 
>  4000 pg/ml at the time they met the criteria. 
The two subsets did not differ regarding age, 
FSH level, prevalence of polycystic ovaries, 
number of oocytes retrieved or oocyte maturity, 
fertilization and cleavage. These patients on 
average coasted approximately 1 day longer 
than the less responsive subset (p =  0.0463). 
The authors observed a significantly higher
implantation rate, and the trends suggested a 
higher clinical and multiple pregnancy rate in 
subset one. There were no significant differ­
ences in severe or moderate OHSS between the 
two subsets. However, all three patients who 
developed severe OHSS were in subset two, and 
two of them were hospitalized for 2 days29.
The estradiol and progesterone levels in all 
44 coasted patients were significantly reduced 
by the end of coasting periods lasting longer 
than 2 days. Linear regression analysis demon­
strated a statistically significant positive rela­
tionship between the duration of coasting and 
peak estradiol level achieved (p <  0.0001), as 
well as a significant negative relationship 
between coasting duration and the total number 
of mature oocytes retrieved (p =  0.036). Logistic 
regression analysis of coasting interval duration 
also suggested an inverse relationship to the 
clinical pregnancy rate (p =  0.09).
Table 4 Outcome parameters for ‘coaster’ subsets depending on estradiol (E2) levels and maturity of 
follicles at time of initiation of coasting. Reproduced with permission from reference 29
Variable
Coasted group
E2 level o f  
3000-3999pg/ml 
(n =  22)
E2 level o f 
4000pg/ml 
(n =  22) p Value
Mean (± SEM) number of oocytes retrieved 15.9 ±  1.2 15.6 ± 1.2 NS
Maturity rate (%) 80.4 78.9 NS
Fertilization rate (%) 60.9 58.8 NS
Cleavage rate (%) 85.2 93.1 NS
Mean (± SEM) number of embryos transferred 4.6 ±0 .3 5.2 ±0 .3 NS
Mean (± SEM) number of embryos frozen 3.1 ±0 .8 2.8 ± 0 .8 NS
Clinical pregnancy rate (%) 57.1 31.8 NS
Implantation rate (%) 19.0 6.7 0.04*
Multiple pregnancy rate (%) 41.6 28.6 NS
Severe OHSS rate (%) 0 13.6 NS
* Significance determined by Kruskal-Wallis test; NS, not significant
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Tortoriello et a l.30 also observed severe 
OHSS, despite coasting, as gonadotropins were 
withheld when serum estradiol levels were 
14 700pmol/l. An important finding was that 
there was a higher than expected incidence of 
severe OHSS (33%) when coasting was started 
with serum estradiol levels > 2 9  000 pmol/1, and 
a large number of follicles with diameter larger 
than 18 mm.
Waldenstrom et al. performed a multicenter 
trial of coasting in 65 IVF cycles considered to 
be severely hyperstimulated. hCG was given 
when the estradiol levels fell below 
10 000 pmol/1. The mean duration of coasting 
was 4.3 days, and four cycles were canceled. 
The pregnancy rate was 42% and the implanta­
tion rate was 31%, and only one patient devel­
oped severe OHSS15.
Fluker et al.5 studied two groups of IVF 
patients undergoing coasting, with mature and 
immature follicles. In the first group (n =  63), 
the estradiol concentration rose rapidly and 
exceeded 3000pg/ml. Exogenous gonadotropins 
were withheld to allow estradiol concentrations 
to decrease by at least 25% before hCG adminis­
tration. Each subject met the follicular criteria 
for hCG administration and oocyte retrieval, ^ 3 
follicles of ^ 18 mm before or during the coasting 
period. Oocyte retrieval was performed 34 h 
later. The luteal phase was supported with 
micronized progesterone at a dosage of 200 mg 
twice daily. In the second group [n =  30), estra­
diol concentrations rose rapidly in the presence 
of numerous intermediate-size follicles. In 
anticipation of overstimulation, the hMG dosage 
was reduced. This was followed by an abrupt 
and inadvertent decline in estradiol concentra­
tions before the attainment of appropriate follic­
ular maturity. Gonadotropin treatment was then 
reinstituted to restimulate follicular growth. 
Then 10 000IU of hCG was administered once 
three or more follicles 2 : 1 8  mm were achieved. 
Oocyte retrieval was performed as per the rou­
tine protocol. The mean age, etiology and dura­
tion of infertility were similar between the two
groups. The average duration of rise was longer 
in the first group, 3.3 days, than in the second 
group, 1.37 days (Figure 2), in keeping with the 
larger follicles and more established steroid 
oogenesis5. Clinical pregnancies occurred in 23 
of 63 cycles (36.5%) and in 12 of 30 cycles 
(40%), and the implantation rate per embryo 
was 14.3% and 17.8%, respectively. Eleven 
women (12%) had evidence of moderate OHSS, 
which was managed conservatively at home. 
One woman (1.1%) from the second group was 
hospitalized with severe OHSS that required 
treatment with paracentesis and intravenous 
albumin. The authors noted that their implanta­
tion rates compared favorably with those of Sher 
et al.6, 15.4% vs. 9.5%, respectively, as did the 
clinical pregnancy rates, 37.5% vs. 41%, respec­
tively, despite the difference in the number of 
embryos transferred, 2.9 vs. 5.4, respectively. 
The authors suggested that IVF cycles do not 
have to be markedly overstimulated to have 
enough reserve to withstand the coasting 
period. Rather, a limited period of coasting 
before the administration of hCG may improve 
the margin of safety and still be well tolerated, 
even in cycles in which the response is only 
slightly increased. The approach in TVF cycles 
in the study by Fluker et al.5, was different from 
that in those studied by Sher et al.6,25. An 
aggressive stimulation was used in the studies 
by Sher et al.: the estradiol levels were 
>  6000pg/ml, or patients had > 30 follicles and 
received hCG after their estradiol levels 
decreased to <  3000pg/ml. In contrast, the more 
conservative approach to stimulation in the 
study by Fluker et al. resulted in lower peak 
estradiol levels and a less precipitous decline in 
estradiol concentration. As a result, only 18 of 
93 patients undergoing IVF in their study had 
estradiol levels of >  6000pg/ml and 28 received 
hCG, even though their estradiol levels 
remained > 3000 pg/ml. Fluker et al. highlighted 
that the only woman in whom severe OHSS 
developed in their study had an estradiol level 
of 2762 pg/ml, which is below the limit sug-
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Figure 2 Characteristics of representative in vitro fertilization-embryo transfer (IVF-ET) cycles in 
which coasting was used to restrain rapidly rising estradiol levels in two patient subgroups: (a) after 
the attainment of follicular maturity (group 2A) and (b) before reaching follicular maturity (group 2B). 
Conception occurred in both cycles. hMG, human menopausal gonadotropin; hCG, human chorionic 
gonadotropin. Reproduced with permission from reference 5
gested by most investigators as a safe point to 
give hCG and have success with coasting.
Aboulghar et al. performed a prospective 
randomized study to evaluate the incidence of 
OHSS in 49 high-risk patients, using a reduced 
hMG dose in one arm and continuation of the 
same dose in the other arm before coasting.
There were no cases of severe OHSS in either 
group after coasting; however, the duration of 
coasting was significantly reduced when the 
dose of hMG was reduced. The authors used a 
historical control group as reference for the two 
subsets of coasted patients. The incidence of 
severe OHSS in the historical group with high
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estradiol levels (mean 7200pg/ml) was 25% 
(eight cases out of 32), as compared with 17% 
(four cases out of 24) in the coasted group31.
Ohata et a l 32 performed coasting in five 
patients with PCOS who had developed severe 
OHSS in a previous cycle. Coasting was effec­
tive in preventing OHSS in these patients.
Grochowski et a l 33 performed a coasting 
study in 112 hyperstimulated IVF patients when 
the estradiol level was over 3000pg/ml and the 
leading follicle’s diameter was ^18 mm. Fertil­
ization failed in six patients. All the embryos 
were frozen in another ten patients. The preg­
nancy rate was 30.4% and the implantation rate 
was 18.1%. Moderate OHSS occurred in six 
patients and severe OHSS occurred in another 
two patients.
Al-Shawaf et a l.14 performed a modified 
coasting protocol in patients at risk of severe 
OHSS based on ultrasound monitoring. Serum 
estradiol levels were measured only in patients 
with > 2 0  follicles on ultrasound. Moderate 
OHSS occurred in three patients (0.7%) and 
severe OHSS in one patient (0.2%). Pregnancy 
rates were 39.6% and 40% in cycles where the 
gonadotropin dose was reduced or withheld, 
respectively.
Al-Shawaf et a l., in 200234, determined that 
measuring serum FSH in addition to estradiol 
levels during coasting could assist in predicting 
the point at which the serum estradiol level had 
declined to a sufficiently safe point for hCG 
administration.
The time of initiation of coasting has always 
been considered to be a crucial point. Tortoriello 
et a l 30 suggested that if coasting was initiated at 
very high estradiol levels, severe OHSS may 
occur in one out of three patients. Egbase et a l 35 
therefore performed a pilot study to determine 
the impact of withholding gonadotropins at an 
earlier stage in patients at risk of developing 
OHSS. The authors concluded that early with­
holding of gonadotropins is also associated with 
a good outcome.
Ulug et a l 36 carried out a retrospective study 
to define the optimal interval of coasting in 
patients at high risk of developing OHSS. In 
their study, patients were characterized accord­
ing to the number of days between the cessation 
of gonadotropins and hCG administration. 
Patients in whom coasting lasted s>4 days had 
significantly reduced implantation, compared 
with patients with a shorter coasting interval.
COASTING IN
GONADOTROPIN-RELEASING 
HORMONE ANTAGONIST IVF CYCLES
Delvigne et a l 37 reported two cases in which 
coasting was used in a stimulation regimen that 
included a GnRH antagonist and gonadotropins. 
The first case had an estradiol level of 
7851pg/ml on day 16 of the cycle, and the sec­
ond patient, a level of 6701pg/ml on day 13 of 
her cycle. The first patient increased her level of 
estradiol on the first day after coasting and then 
had a rapid and clinically significant 83% 
decrease in the level of estradiol. The second 
patient experienced a more progressive decrease 
of estradiol, but her estradiol level did not 
increase after hMG administration was stopped. 
Neither patient developed OHSS. The authors 
suggested that coasting could be used when stim­
ulation involves hMG and a GnRH antagonist.
WHEN TO INITIATE COASTING?
Levins ohn-Tavor et a l 38 appraised the three fac­
tors that should be considered for the initiation 
of coasting:
(1) Plasma estradiol concentration, which 
reflects the total functional granulosa cell 
population;
(2) The number of ovarian follicles, which 
predicts the potential for further granulosa 
cell population and estradiol rise;
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(3) The diameter of the leading follicles.
Most publications addressing coasting reflect that 
an estradiol concentration of 2500-3000 pg/ml 
was the value most commonly chosen by clini- 
cians5’6’13,14,27-29. The relatively low threshold 
for coasting has been shown to reduce the inci­
dence of OHSS effectively without compromis­
ing the cycle outcome38. High cut-off levels of 
around 6000 pg/ml are associated with a higher 
incidence of OHSS and the need for longer peri­
ods of coasting15.
Since the first study by Rabinovici et al.2, it 
has been demonstrated that even after with­
holding gonadotropins there is an additional 
subsequent rise in serum estradiol for 1 or more 
days5’6-35 (Figures 1 and 2). When coasting was 
initiated at a plasma estradiol value of over 
3000 pg/ml, the plasma estradiol increased to 
over 6000 pg/ml during the coasting period.
WHEN TO ADMINISTER hCG AND  
WHEN TO END COASTING?
Administration of hCG when the estradiol level 
drops below 2500-3000 pg/ml has been termed 
to be effective in lowering the risk of 
OHSS5’13’14,27,29. Dhont et a l.13 compared a 
coasting group with a matched control group. 
Both had a similar maximum estradiol level 
(3830 pg/ml) and number of follicles [n =  24). 
On the day of hCG administration, estradiol lev­
els were 2348 pg/ml in the coasted group com­
pared with 3833 pg/ml in the control group. 
Only one patient in the coasted group developed 
severe OHSS, compared with nine patients in 
the control group.
Levinsohn-Tavor et a l 38 advised that when 
an appropriate threshold for administering hCG 
is attained, the serum estradiol should be fol­
lowed and not allowed to fall too low below this 
level. We fully agree with this excellent clinical
remark. However, the greatest difficulty that we 
have encountered is the significant drop in 
estradiol level that could occur in 1 day. Rizk et 
al. encountered two patients whose estradiol 
level was above 4000 pg/ml during coasting and 
dropped to below 1000 pg/ml over a 24-h period, 
with a detrimental effect on the quality of 
oocytes and pregnancy outcome11. Waldenstrom 
et al. reported two cases in which they delayed 
hCG for an additional 2 days after the serum 
estradiol level had dropped below the threshold 
level of 2724 pg/ml, which led to bleeding and 
cycle cancellation. In three other cases, serum 
estradiol was allowed to fall below the threshold 
value, resulting in the retrieval of 1-3 oocytes of 
poor quality15.
DURATION OF COASTING
The number of recorded days of coasting has 
varied between 1 and 11 (Table 2). The effect of 
duration of coasting has remained controversial. 
While some studies suggested that gonado­
tropins could be withheld for 10 or more days 
without compromise of the outcome, others 
have experienced a decrease in pregnancy rate 
when the duration has exceeded 4 days11’29,36,39. 
Ulug et al. found that coasting for 4 or more days 
reduces the implantation and pregnancy rates, 
while oocyte quality does not appear to be 
affected36.
Moreno et al., in 200440, performed a retro­
spective study of 132 patients who demon­
strated a high response to ovarian stimulation 
with estradiol >  4500 pg/ml and/or more than 20 
follicles >  17 mm and were coasted due to the 
high risk of developing OHSS. The authors 
investigated the impact of duration of coasting 
on IVF cycle outcome. In addition, serum prog­
esterone and LH were measured, to investigate 
whether premature luteinization was present in 
the cycles and whether it might be related to
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coasting duration. A significant difference in 
implantation rate was observed when coasting 
was required for more than 4 days, together with 
a trend toward a high cancellation rate. Prema­
ture luteinization was significantly elevated in 
women undergoing coasting compared with 
control women, 34% vs. 15.6% [p <  0.05). In the 
majority of patients who showed premature 
luteinization, coasting lasted 3 days. The 
authors concluded that prolonged coasting may 
affect the endometrium in relation to the 
implantation window. These findings may 
explain why some patients undergoing extended 
coasting demonstrate a lower implantation rate 
compared with controls.
HOW SUCCESSFUL IS COASTING IN 
ELIMINATING OHSS?
There is no question that coasting has made a 
tremendous impact on the clinical management 
of OHSS. Delvigne and Rozenberg, after analyz­
ing 12 studies including almost 500 coasted 
patients, reported a 2.5% incidence of severe 
OHSS, and that ascites developed in 16% of 
cases41. One of the factors of prime importance 
is the difference in classification of OHSS: 
whereas some cases will be referred to in some 
publications as moderate, others consider them 
as severe42.
Most investigators have included coasting at 
least as part of their approach to prevent OHSS. 
From an evidence-based medicine point of view, 
there are few data in terms of prospective ran­
domized trials. The reason for that is obvious: it 
would be difficult to have a randomization in 
which one of the arms would not be coasted and 
subjected to the risk of severe OHSS. Therefore, 
many investigators have included a control 
group of another modality of OHSS prevention, 
or a group of normo-responders11’13,27,43.
COCHRANE REVIEW
D’Angelo and Amso44 performed a Cochrane 
review of coasting for the prevention of OHSS. 
They identified 13 studies, but only one trial 
met the inclusion criteria. Therefore, it was con­
cluded that there was insufficient evidence 
available to determine whether coasting was an 
effective strategy in preventing the occurrence 
of OHSS. In the only one prospective study, 15 
patients were included in each study arm com­
paring coasting with unilateral follicular aspira­
tion, a technique that is seldom used. The 
Cochrane review stressed the absence of high- 
quality studies that limited to a great extent the 
conclusions that could be drawn.
IS THERE A PROBLEM WITH 
COASTING?
The greatest concern about adopting a policy of 
coasting or withholding gonadotropins is a 
decrease in the quality or number of oocytes and 
a subsequent drop in the pregnancy rate11. One 
of the studies that could be used for background 
information is the investigation by Aboulghar et 
ai.45, evaluating the quality of oocytes in 
patients with severe OHSS. They reported that 
the inferior quality and maturity of oocytes in 
OHSS reduced the fertilization rate, but did not 
affect the quality or the number of embryos 
transferred, or the pregnancy rate. The effect on 
oocyte quality was attributed to the prevalence 
of polycystic ovaries in this group of patients. 
Whether one agrees or not about the impact of 
coasting on the quality of oocytes or embryos, 
this study serves to make the point that in 
patients with OHSS there might be a negative 
impact on the quality of oocytes, even without 
coasting.
The impact of coasting on oocyte quality has 
been discussed in coasted patients compared 
with a control group10. The literature is divided 
between those who believe that coasting has
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some negative impact on oocyte quality and 
those who believe that coasting has no impact 
on the quality of oocytes11,39,46. The criteria used 
for the initiation and determination of coasting 
that have been published in the literature are 
very heterogeneous. This probably explains 
some of the differences between reports. Ulug et 
al. found that coasting for 4 days or more 
reduces the implantation and pregnancy rate, 
while oocyte quality does not appear to be 
affected36. Isaza et al. compared cycle outcome 
in recipients of oocytes from donors who under­
went coasting and donors who did not39. The 
outcome of oocyte donation from donors under­
going coasting was not impaired, with similar 
implantation and pregnancy rates. If the dura­
tion of coasting was > 4 days, a significant 
decrease in implantation and pregnancy rates 
was found. Delvigne et al. performed a retro­
spective cohort study of 157 patients compared 
with a control group of 208 IVF cycles, who had 
reached serum estradiol levels of at least 
4000pg/ml without being coasted46. In the 
group of coasted cycles, the question of whether 
indirect parameters related to coasting had an 
effect on IVF outcome was also analyzed. The 
authors observed that patients who had under­
gone coasting had higher maximum estradiol 
levels and greater numbers of large follicles 
(p <  0.001) and lower oocyte recovery rates 
{p <  0.001) than those of the control group. The 
IVF outcomes were similar between the two 
groups. The authors also observed that within 
the group of patients who had undergone coast­
ing, no significant relationship was observed 
between the number of coasting days, estradiol 
levels on the day of hCG or fallen estradiol level 
and the outcome, whether measured in terms 
of oocyte quality, pregnancy rate or OHSS 
occurrence.
Rizk et al. similarly observed a decline in the 
implantation and pregnancy rates in those who 
underwent coasting11. The decrease in implan­
tation and pregnancy rates was not statistically 
significant. However, in the subset of patients
who received a lower dose of hCG (5000IU vs. 
10 000 IU), the difference was statistically signif­
icant (p < 0.05). In the reported publications, 
ovulation was induced in three studies by 
administering 5000 units of hCG15,32,47, but 
more often with 10 000 units5,6,13,14,29,43,45. 
Therefore, the impact of combining coasting 
with reducing the dose of hCG has to be taken 
into consideration. The combination in our 
experience has led to a lower number of oocytes 
and lower quality of embryos.
CONCLUSIONS
Coasting is the most popular method for pre­
venting OHSS. Prospective randomized studies 
regarding its efficacy are limited because it is 
unacceptable to have a control group subjected 
to the risk of severe hyperstimulation syndrome. 
A large multicenter trial with selected control 
group (s) could result in a definitive answer. The 
major advantage of such a clinical trial would be 
to have the same initiation point, a consensus of 
duration and the same finish line. To design 
such a trial, we should predetermine whether 
coasting would be initiated at a certain level of 
estradiol regardless of the size or maturity of the 
follicles, or should we include only patients 
with a specific estradiol level and follicular 
size? The optimal duration of coasting should 
also be analyzed. Finally, the point at which to 
end coasting and at which to administer hCG 
could also be a determining factor. It is neces­
sary to highlight that the starting dose of 
gonadotropins used to vary between the two 
continents compared in the Appendix, but now 
the difference is less, ranging from 75 to 150 IU 
in the United States compared with Europe. 
This must be accounted for if such a trial is con­
ducted with centers in the two continents. It 
would be interesting to perform a study sepa­
rately in each continent among the authors of 
this book and perhaps with some variation of 
the defining landmarks, as the approach could
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address the same problems from a different 
angle11’13,41.
REFERENCES
1. Delvigne A, Rozenberg S. Preventive attitude of 
physicians to avoid ovarian hyperstimulation 
syndrome in IVF patients. Hum Reprod 2001; 
16: 2491-5.
2. Rabinovici J, Kushnir O, Shalev J, et al. Rescue 
of menotropin cycles prone to develop ovarian 
hyperstimulation. Br J Obstet Gynaecol 1987; 
94 :1098-102 .
3. Urman B, Pride SM, Ho Yuen B. Management of 
over-stimulated gonadotrophin cycles with a 
controlled drift period. Hum Reprod 1992; 7: 
213-17.
4. Rizk B. Ovarian hyperstimulation syndrome. In 
Brinsden PR, Rainsbury PA, eds. A Textbook of 
In Vitro Fertilization and Assisted Reproduc­
tion. Carnforth, UK: Parthenon Publishing, 
1992: 369-83.
5. Fluker MR, Hooper WM, Yuzpe AA. Withhold­
ing gonadotropins (‘coasting’) to minimize the 
risk of ovarian hyperstimulation during super­
ovulation and in-vitro fertilization-embryo 
transfer cycles. Fertil Steril 1999; 71: 294-301.
6. Sher G, Salem R, Feinman M, et al. Eliminating 
the risks of life-endangering complications fol­
lowing over-stimulation with menotropin fertil­
ity agents: a report on women undergoing 
in-vitro fertilization and embryo transfer. Obstet 
Gynecol 1993; 81: 1009-11.
7. Delvigne A, Rozenberg S. A qualitative system­
atic review of coasting, a procedure to avoid 
ovarian hyperstimulation syndrome in IVF 
patients. Hum Reprod Update 2002; 8: 291-6.
8. Aboulghar MA, Mansour RT. Ovarian hyper- 
stimulation syndrome: classifications and criti­
cal analysis of preventive measures. Hum 
Reprod Update 2003; 9: 275-89.
9. Rizk B, Aboulghar MA. Classification, patho­
physiology and management of ovarian hyper- 
stimulation syndrome. In Brinsden P, ed. A 
Textbook of In Vitro Fertilization and Assisted
Reproduction. London: Taylor & Francis, 2005: 
217-58.
10. Rizk B. Prevention of OHSS. In Rizk B, ed. Epi­
demiology, Pathophysiology, Prevention and 
Management of Ovarian Hyperstimulation Syn­
drome. Cambridge: Cambridge University Press, 
2005 :264-94 .
11. Rizk B, Grace J, Mulekhar M. Coasting is effec­
tive for abolishing the risk of OHSS but possibly 
decreases the quality of oocytes and pregnancy 
rates. Is that the price we pay? Fertil Steril 2006; 
in press.
12. Rizk B, Aboulghar M. Modern management of 
ovarian hyperstimulation syndrome. Hum 
Reprod 1991; 6: 1082-7.
13. Dhont M, Van der straiten F, De Sutter P. Pre­
vention of severe ovarian hyperstimulation by 
coasting. Fertil Steril 1998; 70: 847-50.
14. Al-Shawaf T, Zosmer A, Hussain S, et al. Pre­
vention of severe ovarian hyperstimulation syn­
drome in IVF with or without ICSI and embryo 
transfer: a modified ‘coasting’ strategy based on 
ultrasound for identification of high-risk 
patients. Hum Reprod 2001; 16: 24-30.
15. Waldenstrom U, Kahn J, Marsk L, et al. High 
pregnancy rates and successful prevention of 
severe ovarian hyperstimulation syndrome by 
‘prolonged coasting’ of very hyperstimulated 
patients: a multi-centre study. Hum Reprod 
1999; 14: 294-7.
16. Tozer AJ, lies RK, Iammarrone E, et al. Charac­
teristics of populations of granulosa cells from 
individual follicles in women undergoing 
‘coasting’ during controlled ovarian stimulation 
(COS) for IVF. Hum Reprod 2004; 19: 2561-8.
17. Tozer AJ, lies RK, Iammarrone E, et al. The 
effects of ‘coasting’ on follicular fluid concen­
trations of vascular endothelial growth factor in 
women at risk of developing ovarian hyperstim­
ulation syndrome. Hum Reprod 2004; 19: 
522-8.
18. Van Blerkom J, Antczak M, Schrader R. The 
developmental potential of the human oocyte is 
related to the dissolved oxygen content of follic­
ular fluid: association with vascular endothelial 
growth factor levels and perifollicular blood
263
OVARIAN HYPERSTIMULATION SYNDROME
flow characteristics. Hum Reprod 1997; 12: 
1047-55.
19. Rizk B, Aboulghar M, Smitz J, et al. The role of 
vascular endothelial growth factor and inter­
leukins in the pathogenesis of severe ovarian 
hyperstimulation syndrome. Hum Reprod 
Update 1997; 3: 255-66.
20. McNatty KP, Makris A, DeGrazia C, et al. The 
production of progesterone, androgens and 
estrogens by granulosa cells, thecal tissue, and 
stromal tissue from human ovaries in vitro. J 
Clin Endocrinol Metab 1979; 49: 687-99.
21. Friedman Cl, Seifer DB, Kennard EA, et al. Ele­
vated level of follicular fluid vascular endothe­
lial growth factor is a marker of diminished 
pregnancy potential. Fertil Steril 1998; 64: 
268-72.
22. Barroso G, Barrionuevo M, Rao P, et al. Vascular 
endothelial growth factor, nitric oxide, and lep- 
tin follicular fluid levels correlate negatively 
with embryo quality in IVF patients. Fertil Steril 
1999; 72: 1024-6.
23. Garcia-Velasco JA, Zuniga A, Pacheco A. Coast­
ing acts through downregulation of VEGF gene 
expression and protein secretion. Hum Reprod 
2004; 19: 1530-8.
24. Rizk B, Smitz J. Ovarian hyperstimulation syn­
drome after superovulation using GnRH ago­
nists for IVF and related procedures. Hum 
Reprod 1992; 7: 320-7.
25. Sher G, Zouves C, Feinman M, et al. Prolonged 
coasting: an effective method. Hum Reprod 
1995; 10: 3107-9.
26. Ben-Nun I, Shulman A, Ghetler Y, et al. The sig­
nificance of 17p-estradiol levels in highly 
responding women during ovulation induction 
in IVF treatment: its impact and prognostic 
value with respect to oocyte maturation and 
treatment outcome. J Assist Reprod Genet 1993; 
10: 213-15.
27. Benadiva CA, Davis O, Kligman I, et al. With­
holding gonadotropin administration is an 
effective alternative for the prevention of ovar­
ian hyperstimulation syndrome. Fertil Steril 
1997; 67: 724-7.
28. Lee C, Tummon I, Martin J, et al. Does with­
holding gonadotrophin administration prevent
severe ovarian hyperstimulation syndrome? 
Hum Reprod 1998; 13: 1157-8.
29. Tortoriello DV, McGovern PG, Colon JM, et al. 
‘Coasting’ does not adversely affect cycle out­
come in a subset of highly responsive in-vitro 
fertilization patients. Fertil Steril 1998; 69: 
454-60.
30. Tortoriello DV, McGovern PG, Colon JM, et al. 
Critical ovarian hyperstimulation syndrome in a 
coasted in-vitro fertilization patient. Hum 
Reprod 1998; 13: 3005-8.
31. Aboulghar MA, Mansour RT, Serour GI, et al. 
Reduction of human menopausal gonadotropin 
dose before coasting prevents severe ovarian 
hyperstimulation syndrome with minimal cycle 
cancellation. J Assist Reprod Genet 2000; 17: 
298-301.
32. Ohata Y, Harada T, Ito M, et al. Coasting may 
reduce the severity of the ovarian hyperstimula­
tion syndrome in patients with polycystic ovary 
syndrome. Gynecol Obstet Invest 2000; 50: 
186-8.
33. Grochowski D, Wolczynski S, Kuczynski W, et 
al. Correctly timed coasting reduces the risk of 
ovarian hyperstimulation syndrome and gives 
good cycle outcome in an in vitro fertilization 
program. Gynecol Endocrinol 2001; 15: 234-8.
34. Al-Shawaf T, Zosmer A, Tozer A, et al. Value of 
measuring serum FSH in addition to serum 
estradiol in a coasting programme to prevent 
severe OHSS. Hum Reprod 2002; 17: 1217-21.
35. Egbase PE, Al-Sharhan M, Grudzinskas JG. 
Early ‘coasting’ in patients with polycystic ovar­
ian syndrome is consistent with good clinical 
outcome. Hum Reprod 2002; 17: 1212-16.
36. Ulug U, Bahceci M, Erden HF, et al. The signifi­
cance of coasting duration during ovarian stim­
ulation for conception in assisted fertilization 
cycles. Hum Reprod 2002; 17: 310-13.
37. Delvigne A, Carlier C, Rozenberg S. Is coasting 
effective for preventing ovarian hyperstimula­
tion syndrome in patients receiving a 
gonadotropin-releasing hormone antagonist 
during an in vitro fertilization cycle? Fertil 
Steril 2001; 76: 844-6.
264
ROLE OF COASTING: AMERICAN PERSPECTIVE
38. Levinsohn-Tavor S, Friedler M, Schachter A, et 
al. Coasting -  what is the best formula? Hum 
Reprod 2003; 18: 937-40.
39. Isaza V, Garcia-Velasco JA, Aragones M, et al. 
Oocyte and embryo quality after coasting: the 
experience from oocyte donation. Hum Reprod 
2002; 17: 1737-58.
40. Moreno L, Diaz I, Pacheco A, et al. Extended 
coasting duration exerts a negative impact on 
IVF cycle outcome due to premature luteiniza- 
tion. Reprod Biomed Online. 2004; 9: 500-4.
41. Delvigne A, Rozenberg S. Epidemiology and 
prevention of ovarian hyperstimulation syn­
drome (OHSS): a review. Hum Reprod Update 
2002; 8: 559-77.
42. Rizk B. Classification of OHSS. In Rizk B, ed. 
Epidemiology, Pathophysiology, Prevention and 
Management of Ovarian Hyperstimulation Syn­
drome. Cambridge: Cambridge University Press, 
2005: 6-26.
43. Egbase PE, Sharhan MA, Grudzinskas JG. Early 
unilateral follicular aspiration compared with 
coasting for the prevention of severe ovarian 
hyperstimulation syndrome: a prospective ran­
domized study. Hum Reprod 1999; 14: 2922-3.
44. D’Angelo A, Amso N. ‘Coasting’ (withholding 
gonadotrophins) for preventing ovarian hyper- 
stimulation syndrome. Cochrane Database Syst 
Rev 2002; (3): CD002811.
45. Aboulghar MA, Mansour RT, Serour GI, et al. 
Oocyte quality in patients with severe ovarian 
hyperstimulation syndrome. Fertil Steril 1997; 
68 :1017-21 .
46. Dechaud H, Anahory T, Aligier N, et al. Coast­
ing: a response to excessive ovarian stimulation. 
Gynecol Obstet Fertil 2000; 28: 115-19.
47. Delvigne A, Manigart Y, Kostyla K, et al. Oocyte 
quality after coasting for ovarian hyperstimula­





Comparative table of differences in approach to OHSS between the USA and Europe
USA* Europe*
Starting dose of gonadotropins 
in the normal patient
225IU for most patients, 
150IU or less for PCOS 
patients
225 IU hMG or 200 IU recFSH, 
150 IU (100 IU) in patients at risk
Triggering dose of hCG usually used 10 000IU, 5000 IU for 
patients at risk
10 000IU,
5000 IU in patients at risk
Start coasting when E2 exceeds 
??? pg/ml (or pmol/ml)
3000 pg/ml 3500 pg/ml
Start coasting when number of 
follicles per ovary exceeds ???
30 follicles Total 30 follicles in both ovaries 
or > 20 follicles in a single ovary
Start coasting when >  50% of 
follicles exceed ??? mm
14 mm 18 mm
Start coasting at any of the 
following combinations of serum 
E2/sonography or other criteria
3000 pg/ml and 30 follicles The threshold criteria for 
coasting can be lowered in very 
lean patients or patients with a 
previous history of OHSS
Maximum duration of coasting No maximum, but some 
believe worse results for 
patients coasted longer 
than 4 days
4 days
Lower threshold at which hCG 
will be given
Wait until hCG drops 
below 3000 pg/ml
From 3000 pg/ml onwards
Other differences regarding 
coasting between USA and Europe
Most commonly used 
technique
Out-patient management until 
severe OHSS grade A 
(Rizk and Aboulghar, 2005)
Most patients are managed 
as out-patient with 
aspiration and rehydration 
unless there is respiratory 
difficulty, kidney problems 
or biochemical problems
Ascites, severe discomfort and 
hematocrit of >  45
*USA data provided by Botros Rizk, European data provided by Marc Dhont; hCG, human chorionic 
gonadotropin; E2, estradiol; PCOS, polycystic ovarian syndrome; hMG, human menopausal gonadotropin; recFSH, 
recombinant follicle stimulating hormone
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Health-economic reflections on 
ovarian hyperstimulation syndrome 
and the importance of registries
Petra De Sutter and Jan Gerris




Not much has been published on the costs 
induced by the occurrence of the ovarian hyper- 
stimulation syndrome (OHSS) as part of a treat­
ment with in vitro fertilization/intracytoplasmic 
sperm injection (IVF/ICSI) or as part of non-IVF 
treatments. In several of the more important 
papers on the cost-effectiveness of infertility 
treatment, no specific mention of the relative 
cost of OHSS is made1-6. In a paper by Philips et 
a l7 , IVF costs were analyzed in general and 
compared with other treatment options, and 
these authors estimated OHSS to yield an extra 
cost of 236.69 GBP (around €355) per unit, and 
the incidence of OHSS in their model was esti­
mated to be 4%. In their calculations, OHSS 
contributed 0.5% to the total cost of IVF. The 
costs they used, however, were not real costs, 
but were derived from a separate cost model.
To calculate the costs associated with OHSS, 
one has to take into account several preliminary 
and interconnected considerations.
The management of the more serious forms 
of OHSS differs from one place to another. To try
to save costs, in some countries or centers 
patients may be hospitalized only when severe 
symptoms and signs occur, whereas in others 
they may be hospitalized more readily, to avoid 
further deterioration of the patient. The stan­
dard operating procedures may be influenced by 
previous personal bad experience with OHSS 
patients. Criteria for hospitalization are not very 
strict, although there is some agreement, as 
shown by the publication of both American and 
European8-10 guidelines. Frequently, specific 
national guidelines for the diagnosis and man­
agement of OHSS are in existence as well. Dif­
ferences between American and European 
approaches are to be expected with respect to a 
technique such as coasting, but also with 
respect to indications for hospitalization. A 
hematocrit level of more than 45% is an 
absolute indication for hospitalization. If the 
hematocrit is between 42 and 45%, it is the clin­
ical situation of the patient which determines 
whether hospital admission is required in order 
to monitor the patient closely or relieve symp­
toms. Also, costs in absolute terms may be very 
different from one hospital to another. Finally, 
both direct costs and indirect costs have to be 
taken into consideration.
A specific consideration is that if a human 
life is lost because of uncontrollable events
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linked to severe OHSS, this will be considered 
as an unacceptable outcome.
Apart from costs incurred by hospitalization 
in the case of severe OHSS, which can to a cer­
tain extent be calculated on the basis of real 
costs, there are extra costs which are the conse­
quence of mild and moderate forms of OHSS not 
necessitating hospitalization. These include 
repeat visits to the center, repeat sonograms and 
blood examinations, the administration of 
symptomatic drugs and indirect costs due to 
incapacity to work.
In an attempt to construct a detailed cost 
analysis of ovarian hyperstimulation in its many 
and varied forms, including the tip of the ice­
berg called OHSS, all of these have to be taken 
into consideration.
Data analysis
To obtain an idea of the direct costs incurred by 
hospitalization of an average OHSS patient, we 
analyzed hospital bills of 77 patients who were 
hospitalized from 2001 until 2004 after IVF/ICSI 
in two Flemish centers (25 in the Middelheim 
Hospital (AZM) Antwerp and 52 in the Univer­
sity Hospital (UZ) Ghent). These 77 cases of 
OHSS occurred as complications in a total of 
6238 IVF/ICSI treatments in the same period 
(1585 in AZM Antwerp and 4653 in UZ Ghent), 
leading to an observed incidence of 
77/6238 =  1.23%, which corresponds to pub­
lished incidence data as well as to the national 
average for Belgium (142/9494 =  1.49% for 
2002). It should be noted, however, that some 
patients treated in either hospital and having 
developed OHSS, may have been subsequently 
hospitalized elsewhere and therefore were not 
included in the present analysis. This is defi­
nitely the case for patients coming from The 
Netherlands, who are often treated by microsur- 
gical epididymal sperm aspiration/testicular 
sperm extraction (MESA/TESE) plus ICSI in Bel­
gium because of differences in regulations
between the two countries, but who are subse­
quently treated in their country of origin.
The mean age of the patients was 30.7 ±  4.3 
years, which is significantly younger than the 
mean age of the total population of patients 
treated with IVF/ICSI in both centers 
(32.82 ±  4.50 in Antwerp and 34.1 ±  4.85 in 
Ghent).
Clinical data of the patients hospitalized for 
OHSS were not analyzed in detail for the pur­
pose of this study. The number of oocytes 
obtained in the patient group at the time of egg 
retrieval was 18.4 ± 10.6 (median 15.5, range 
4-53), which is, as expected, significantly 
higher than the mean number of oocytes in the 
whole population treated in both programs 
(median 10 for both hospitals ) (Figure 1).
Hospitalization lasted between 1 and 20 
days with a median of 4 days. Costs were 
divided into hospitalization cost (room cost), 
costs for drugs (the main cost driver being intra­
venous albumin), costs for medical fees and 
technical procedures (mainly sonography and 
ascites puncture) and miscellaneous other costs, 
and were found to vary between a minimum of 
€407  and a maximum of €7633 with a mean of 
€1539 ± 1247 (median €1012) (Figure 2). Table 
1 shows that of this total cost of €1539, the 
room cost was €1004 (65%), the cost for drugs 
was €138 (9%), physician’s costs were €350 
(23%) and other costs €4 8  (3%). Because all 
patients included in this study benefited from 
reimbursement by the Belgian social security 
system, they had to pay on average €320 (21% 
of the total costs), whereas €1219 (79%) was 
paid by social security.
A multivariate analysis could not identify 
any correlation between patient-related parame­
ters and either length of stay or cost parameters. 
This means that the duration and cost of the 
management of OHSS are as unpredictable as its 
occurrence in the first place. Prevention, there­
fore, once more, is the only sensible solution to 
the problem of OHSS.
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Figure 1 Frequency distribution of number of oocytes in patients hospitalized with OHSS
Exactly half of the patients hospitalized were 
pregnant and the other half were not. Neither 
the multivariate analysis nor a direct compari­
son of the groups of pregnant versus non­
pregnant women hospitalized because of severe 
OHSS showed any difference in cost between 
groups (€1299 ±  (SD) 941 versus €1445 ±  (SD) 
989 for non-pregnant versus pregnant patients, 
respectively).
Discussion
In Belgium, the total cost of one IVF/ICSI cycle, 
including gonadotropins, averages about €4000. 
When considering only treatments conducted in 
both centers as contributing to this analysis,
this means that for a total expense of 6238 
(total number of cycles) x €4000 =  €24  952 000 
needed for primary treatment over the period of 
time considered, an additional total expense of 77 
(hospitalized OHSS cases)x€l539 =  €118503 
is incurred for direct costs due to OHSS hospi­
talization. This does not include indirect costs 
due to working incapacity, and additional direct 
and indirect costs for OHSS patients who man­
age to escape hospitalization but nevertheless 
need extra consultation, sonography, blood tests 
and mostly analgesic drugs. These costs were 
not analyzed in this study, but may be estimated 
to be at least the same amount as the direct 
costs. This means that the total costs for OHSS
269
OVARIAN HYPERSTIMULATION SYNDROME
Figure 2 Frequency distribution of costs for hospitalized patients with OHSS
(about €237 000 with 1.23% severe cases) con­
stitute approximately 1% of the primary treat­
ment costs (€237 000 from € 2 4  952 000).
More than half of these patients obtained an 
ongoing pregnancy, and it is therefore not possi­
ble to say that all these cases could have been 
prevented by not administering human chori­
onic gonadotropin (hCG) as an ovulation trigger. 
However, about two-thirds of patients clearly 
had the early form of the syndrome with a short 
hospitalization period, whereas one-third had a 
pregnancy enhanced form. Therefore, it makes 
sense to consider what the effect would have 
been if another ovulation trigger, e.g. recombi­
nant luteinizing hormone (LH), had been used. 
It may be assumed that two-thirds of all OHSS
cases could have been prevented in doing so, 
resulting in a saving of at least two-thirds of 
€237 000, i.e. approximately €158 000.
In terms of prevention, the administration of 
recombinant (rec)LH could theoretically reduce 
the incidence of OHSS if compared with the use 
of hCG to induce ovulation. We tried to calcu­
late what the savings would be if recLH were to 
be used in all patients treated with IVF, or in a 
risk group. In Belgium, 1 ampoule of 5000IU of 
hCG (required to induce ovulation in a patient at 
risk of OHSS) costs €4.65. If we hypothesize 
that (at least) two-thirds of all cases of OHSS 
could be prevented by administering recLH 
instead of hCG, the dose required might cost 
€158 000/6238 =  approx. €25  as an equivalent.
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Table 1 Costs of hospitalization (in € )  of OHSS patients
Mean Median Standard deviation Minimum Maximum
Hospital stay 1003.7 471.1 1094.8 200.5 6469.4
Pharmacy 137.8 62.8 233.0 2.2 1318.7
Physician 349.6 301.8 162.4 168.8 958.8
Other 47.9 13.5 202.4 0.0 1713.9
Total 1538.9 1012.1 1246.9 407.4 7633.0
In other words, even at a price five times as high 
as that of the currently used hCG, recLH would 
be cost-effective in preventing OHSS. Unfortu­
nately, this product is not available at this price 
in the required dose, and until now the manu­
facturer has not (yet) decided to market this 
product further for this indication. However, 
whether this theoretical calculation holds is 
uncertain, because from the few data available 
to date, there seems not to be a lower incidence 
of OHSS after using recLH, although this has yet 
to be confirmed11.
Besides the use of recLH, there could be 
other measures to prevent OHSS, such as the 
administration of methylprednisolone12,13, 
coasting14, unilateral ovarian aspiration15 or 
avoiding transfer, and freezing all embryos16. 
The cost-effectiveness of these other measures 
to prevent OHSS must be computed to establish 
the most appropriate way to prevent OHSS from 
a health-economic perspective.
It is probable that even more is to be gained 
if one considers the predictive factors for the 
early form of OHSS as well as the reduction in 
morbidity in cases treated on an out-patient 
basis.
THE IMPORTANCE OF REGISTRIES
An issue that is linked to the problem of cost is 
the problem of correct registration of complica­
tions. The two most important complications of 
IVF/ICSI are multiple pregnancies and the ovar­
ian hyperstimulation syndrome. Registration of 
the former has been part of national and supra­
national IVF/ICSI registries for a number of 
years now. Although at present not the case, it 
seems likely that at some time in the future 
there will be a reliable registration of the per­
centage of singletons and twins. The relative 
occurrence of singletons and twins may even be 
part of the way of reporting quality, using the 
acronym CUSIDERA (cumulative singleton 
delivery rate) as a measure of efficiency and 
CUTWIDERA (cumulative twin delivery rate) as 
a measure of safety17.
For OHSS, the situation is more complex. 
There is a problem of definition to start with. 
What are mild, moderate and severe OHSS? 
May mild OHSS become severe OHSS? What do 
we want to register: only cases with hospitaliza­
tion because they tend to be costly, or all cases 
with a minimal clinical impact because they 
tend to give an idea of how aggressively stimu­
lations are conducted? Or, perhaps, do we want 
to register just lethal cases with the more than 
certain risk of severe underreporting?
Nevertheless, registration of OHSS makes 
sense for several reasons.
OHSS can lead to a potentially lethal 
outcome, and the symptomatology of its compli­
cations (mainly of a thromboembolic nature) 
may be masked by the other signs and symptoms
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of the syndrome. It can be hoped that the imme­
diate reasons for any death due to OHSS can be 
properly understood so that future similar cases 
might eventually be saved. We should not be 
scared by the perfidious sensationalism of the 
modern-day press, but strive towards anony­
mous registration.
This is not an easy task. If a major complica­
tion occurs, the patient will be transferred to an 
intensive-care unit and treatment will be taken 
over by other health professionals. If there is no 
good registration and/or reporting of the major 
complications or even mortality of OHSS, and if 
a major complication or mortality occurs, the 
patient will be mentioned in the registries under 
the final diagnosis (often thrombosis and/or 
embolism), but the link with the OHSS cause 
could be lost. In our opinion, it is therefore 
mandatory that IVF registries track down all 
cases of severe OHSS and record their compli­
cations and outcome. Only in this way will the 
real size of the OHSS problem be known and the 
necessity of its prevention be obvious to every­
one treating patients for infertility through 
assisted reproductive technologies (ART).
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CHAPTER 25
Intravenous hydroxyethyl starch infusion 
and albumin administration: effective 
tools as adjuvants in the prevention of 
ovarian hyperstimulation syndrome
Oya Gdkmen and A Zeki Isik
The induction of ovulation by gonadotropins 
can result in ovarian hyperstimulation syndrome 
(OHSS), which can be lethal in its severest form. 
Mild and moderate ovarian hyperstimulation 
are usually self-limited and require no further 
treatment other than observation. Severe OHSS, 
appearing in about 0.2-5% of cases undergoing 
induction of ovulation, is characterized by 
massive ovarian enlargement, ascites, pleural 
effusion, oliguria, hemoconcentration and 
thromboembolic phenomena1-4. Accumulation 
of extravascular protein-rich exudate in the peri­
toneum and in the pleura combined with 
intravascular volume depletion and hemocon­
centration are essential characteristics of the 
syndrome and are related to an increased capil­
lary permeability5-7.
Primary and secondary preventive measures 
have been discussed in previous chapters. In 
this chapter, the value of the intravenous admin­
istration of albumin and hydroxyethyl starch 
(HES) is discussed in more specific detail.
INTRAVENOUS ALBUMIN 
ADMINISTRATION FOR THE 
PREVENTION OF OHSS
Two of its properties make albumin worthwhile 
both in the prevention and in the treatment of
OHSS. First, albumin is the most abundant cir­
culating protein, and responsible for 70-80% of 
plasma oncotic pressure. Second, it is the prin­
cipal binding and carrier protein for a variety of 
substances including fatty acids, drugs, biliru­
bin and hormones8. Thus, albumin administra­
tion is able to prevent the fluid shift to the third 
space, and binds the above-mentioned factor or 
factors responsible for the major events in the 
development of OHSS. Human albumin also has 
an excellent record of both clinical and viral 
safety9-11. Therefore, albumin has been recog­
nized as an effective volume expander in the 
treatment of severe OHSS12,13.
The administration of intravenous (IV) albu­
min to prevent the development of severe OHSS 
was first suggested by Asch et a l,14. Although no 
case of severe OHSS developed in this series, 
the study was not controlled, it had a small sam­
ple size (n =  36) and the embryo transfer rate 
was low, 15 transfers out of 36 cycles. Other 
prospective, randomized, controlled studies 
have given support to the effectiveness of IV 
albumin in the prevention of severe OHSS15-18. 
In the study of Shoham et al., 31 cases with a 
mean serum estradiol level of 1906pg/ml were 
randomized to receive, IV, either 50 g albumin or 
saline at the time of oocyte retrieval15. No case 
of severe OHSS was recorded in the albumin
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group, whereas four cases required hospitaliza­
tion in the saline group. Shalev et al. also found 
a significantly higher number of severe OHSS 
cases (n =  4) in the control group than in the 
treatment group, who received a dose of IV albu­
min (20 g) after oocyte retrieval16. Isik et al. also 
reported a significant difference in favor of 
albumin treatment17. In another study, patients 
at risk of developing severe OHSS were ran­
domized to receive IV albumin and transfer of 
fresh embryos or cryopreservation of all 
embryos18. Severe OHSS was not observed in 
any of the patients in either group. The results 
of these studies all confirmed that human albu­
min is an effective method in the prevention of 
OHSS.
Others have postulated that IV albumin 
given to high-risk patients is only beneficial in 
cases which do not conceive or carry singleton 
pregnancies19.
In contrast, doubt was cast on the potential 
preventive effect IV administration of albumin 
on patients at risk of OHSS by Ng et al.20. In 
their cohort study, they stated that IV albumin 
does not prevent OHSS. The prospective, ran­
domized, placebo-controlled, double-blind 
study of Ben-Chetrit et al. recorded four severe 
and five moderate OHSS cases in the IV albu­
min group (n =  46)21. In the control group, 
severe OHSS developed in one case and moder­
ate OHSS in five patients. As no significant dif­
ference in the incidence of OHSS was found 
between the two groups, the authors suggested 
that albumin has no positive effect on OHSS 
rates.
Albumin as a potential preventive measure 
in OHSS was further investigated in a recent 
large randomized controlled trial22. Women 
undergoing in vitro fertilization (IVF) with > 2 0  
retrieved oocytes (n =  988) were randomized to 
receive 40 g albumin IV or no treatment. No dif­
ference was found between the two groups in 
OHSS rates. Severe OHSS was observed in 5% 
of the albumin group and 4.7% in the control 
group. Although the study group consisted of
patients considered at risk of developing moder­
ate or severe OHSS, the standard protocol for 
controlled ovarian stimulation as starting dose 
was 225IU/day of highly purified or recombi­
nant follicle stimulating hormone (FSH) plus 
75IU/day of human menopausal gonadotropin 
(hMG), which was a fairly high dose for this 
group of patients. The high incidence of severe 
OHSS and the comment of the authors that 
albumin infusion on the day of oocyte retrieval 
was not useful for preventing the development 
of OHSS could be due to this high starting dose 
of gonadotropin administration, and to the 
absence of any other preventive measure against 
OHSS in this high-risk population. On the other 
hand, they stated that they did not see any side- 
effect in the albumin group, and albumin infu­
sion did not seem to affect the IVF outcome.
A Cochrane review on the use of IV albumin 
to prevent severe OHSS enrolled 378 women 
(193 albumin-treated and 185 controls) from 
five randomized controlled trials23. The results 
of the meta-analysis pointed out a significant 
decrease in severe OHSS by albumin adminis­
tration, with an absolute risk reduction of 5.5 
(odds ratio =  0.28, 95% confidence interval
0.11-0.73). The details of the controlled studies 
using IV albumin versus placebo for the preven­
tion of OHSS are listed in Table l 24.
Isik et al. suggested a combined approach for 
the prevention of OHSS in high-risk patients by 
combining a late step-down administration of 
gonadotropins, a decreased dose of human 
chorionic gonadotropin (hCG) to trigger ovula­
tion, IV albumin adminstration and proges­
terone use for luteal support25. The authors 
reported that this approach in their hands 
proved to be effective, and it has been supported 
by others4,26. The same group obtained extended 
experience using this combined approach in the 
prevention of severe to moderate OHSS27. The 
results for 87 high-risk patients managed by this 
approach were compared with those for 274 
low-risk patients.
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Table 1 Intravenous albumin for prevention of ovarian hyperstimulation syndrome (OHSS): controlled studies versus placebo
Study Type Total





E2 level on 






Shoham et al., 1994 Prospective randomized 31 16 15 50 g 1906 0 4
Shalev et al., 1995 Prospective randomized 40 22 18 20g > 2500 0 4
Isik et al., 1996 Prospective randomized 55 27 28 10 mg *3000 0 4
Ben Chetrit et al., 2001 Prospective randomized 87 46 41 50 g 2724 4 1
Ng et al., 1995 Cohort controlled 207 49 158 50 g 2724 2 10










In summary, the results of the studies can 
still be considered inconclusive, and the role of 
albumin in preventing severe OHSS in the eyes 
of these authors needs to be further clarified by 
multicenter, randomized, prospective studies. 
The routine use of albumin in high-risk patients 
must be judged by clinicians until large ran­
domized trials give a definitive answer. When 
considering the data above, it seems that the use 
of albumin can be advocated, preferably in com­
bination with other approaches rather than on 
its own.
PROPHYLACTIC INFUSION OF 
HYDROXYETHYL STARCH SOLUTION
Hydroxyethyl starch (HES) is a synthetic 
colloid, glycogen-like polysaccharide derived 
from amylopectin. It is an effective volume 
expander. It exists in different molecular 
weights: high-molecular-weight (MW) HES of 
400 kDa; medium-MW HES of 200 kDa and low- 
MW HES of 50-100 kDa. These different HES 
molecules have different clinical properties. 
High-MW HES has a longer half-life, and it is 
associated more frequently with coagulation 
deficiencies (decrease in factor VIII, fibrinogen 
and von Willebrand factor). HES of MW 200, 
which was used in our practice, is associated 
less with such problems36,37.
HES (MW 200) is used in several clinical 
conditions, such as hypovolemia associated 
with major surgery, circulatory shock or sepsis, 
and during and after cardiac operations28. HES 
provides volume expansion comparable to that 
of human albumin, and many papers have been 
published comparing albumin with HES in var­
ious clinical conditions. These studies were 
mainly anesthesiology- or critical-care medi­
cine-related, and the authors in these series 
have concluded that HES and albumin have 
comparable efficacy37. Although it has been 
well known for a long time that HES is a cheaper 
alternative to human albumin, its use in the
prevention and treatment of OHSS was not eval­
uated until recently.
Abramov et al. suggested that hydroxyethyl 
starch might be superior to albumin as a colloid 
solution for the treatment of severe OHSS. They 
have previously shown that severe OHSS is 
characterized by the leakage of albumin (with a 
molecular weight of 69 kDa) as well as 
immunoglobulins IgG and IgA (with molecular 
weights of 150 kDa and 180 kDa, respectively) to 
the abdominal cavity. No leakage of IgM, which 
has a molecular weight of 900 kDa, has been 
observed. IgA has been shown to leak more. It 
has been concluded that molecular weight is the 
most important factor determining protein 
extravasation. Therefore, low-molecular-weight 
human albumin solution for preservation of 
intravascular oncotic pressure in severe OHSS 
remains controversial29,30.
The side-effects of HES treatment were ana­
phylactoid reactions causing pruritus and skin 
symptoms such as urticaria on the trunk, anus 
and legs31. Other reported complications related 
to high-molecular-weight HES included serum 
macroamylasemia, severe pruritus and, most 
important, bleeding complications and 
increases in prothrombin and bleeding time31. 
With the use of medium-molecular-weight HES, 
these complications are rare. The tendency 
toward bleeding in coagulation tests was found 
to be reassuring because of the state of hyperco­
agulation in controlled ovarian hyperstimula­
tion. HES is removed from the circulation by 
two major mechanisms: renal excretion and 
redistribution. Renal excretion has two distinct 
phases. The first phase occurs upon administra­
tion, and a second phase of prolonged glomeru­
lar filtration ensues as HES molecules are 
metabolized. The duration of volume expansion 
with HES is approximately 24 h, with 29-38% of 
the colloid still available after this time.
The prospective study of Graf et al. compared 
high-risk patients (estradiol > 1 1 010pmol/l and 
>  20 follicles) [n =  100), who received 1000 ml 
of 6% HES at the time of oocyte retrieval and
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500 ml 48 h later, with control-group patients 
(n =  82) who were not treated with HES32.
No reduction in severe OHSS was seen. In 
another prospective, randomized, placebo- 
controlled study by Konig et al., 1000 ml of 6% 
HES was given after embryo transfer in a total 
number of 101 high-risk patients. It showed a 
significantly lower number of OHSS cases in the 
study group {p =  0.031)33.
As HES is cheaper and carries no risk of viral 
or prion transmission of a blood product com­
pared with albumin, it has been tested in the 
prevention of OHSS by different groups.
Gokmen et al. carried out a study in a large 
series to evaluate the efficacy of the prophylac­
tic use of HES by comparing it with albumin, 
and a control group, in patients at risk of devel­
oping OHSS, in a prospective, randomized 
placebo-controlled trial34. In all 250 patients 
(cycles) considered at risk of developing OHSS 
in an IVF program were included in this trial. 
Criteria for inclusion were: serum estradiol 
value of > 3000 pg/ml or the presence of >  20 
follicles of >  14 mm on the day of hCG adminis­
tration. The characteristics of patients and treat­
ment variables for the HES, albumin and control 
groups were similar with respect to patient age, 
serum estradiol level on the day of hCG, body 
mass index (BMI), the number of oocytes 
retrieved, the number of embryos transferred
and pregnancies. The first group (n =  85) 
received 500 ml of 6% HES, the second group 
(n =  85) received 50 ml of 20% human albumin 
and the third group [n =  83) received a placebo. 
Table 2 presents the number and percentage of 
patients who developed moderate and severe 
OHSS in all patients receiving either HES 
(n =  85), albumin (n =  85) or placebo [n =  83). 
There were no severe OHSS cases in patients 
who received albumin and HES, whereas four 
patients who received a placebo developed 
severe OHSS. On the other hand, moderate 
OHSS was encountered in four patients in the 
albumin group, in five patients receiving HES 
and in 12 patients receiving placebo. The 
authors concluded that both HES and albumin 
significantly reduced the incidence of moderate 
and severe OHSS.
The same group further enlarged their study 
group and presented a randomized, prospective, 
placebo-controlled study of intravenous albu­
min versus hydroxyethyl starch for the preven­
tion of ovarian hyperstimulation in an IVF 
program. This study was designed to assess the 
effectiveness of IV administration of 6% hydrox­
yethyl starch solution or intravenous 20% albu­
min versus a placebo group in the prevention of 
moderate and severe ovarian hyperstimulation 
(OHSS). Three hundred and twenty women who 
had a serum estradiol value of >  3000 pg/ml
Table 2 Comparison of incidence of ovarian hyperstimulation syndrome (OHSS) among groups of 






(n =  85)
Control group 
(n =  83)
p  Valuen % n % n %
Moderate 5 5.9 4 4.9 12 14.5 <0 .05
Severe — — — — 4 4.8 <0.05
Overall 5 5.9 4 4.9 16 19.2 <0.01
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and/or > 20 follicles of ;>14 mm on the day of 
hCG administration were recruited and allotted 
to one of three groups: the HES group [n =  112) 
received 500 ml of 6% HES (Isohes; 
Eczacibasi/Baxter, Turkey); the albumin group 
(n = 105) received 50 ml (10 g) of 20% human 
albumin (Albumin Human; Octopharma/Berk, 
Turkey); and the placebo group (n =  103) 
received 500 ml of sodium chloride 0.9% solu­
tion, infused over a period of 30 min immedi­
ately after oocyte retrieval. The three groups 
were similar in age, serum estradiol level on the 
day of hCG, body mass index, number of 
oocytes retrieved, number of embryos trans­
ferred and duration of coasting (Table 3). Table 4
presents the number of patients who developed 
moderate, severe and overall (moderate + 
severe) OHSS in all groups. There was a statisti­
cally significant difference in the incidence of 
moderate, severe and overall OHSS among 
groups (p values <  0.05, <  0.05, <  0.01). Both 
HES and albumin significantly reduced the inci­
dence of moderate and severe and the overall 
incidence of OHSS35.
CONCLUSION
In conclusion, the combination of several effec­
tive measures of prevention of OHSS should be
Table 3 Baseline and cycle characteristics of the patients in a study of intravenous albumin versus 
hydroxyethyl starch (HES) for the prevention of OHSS35
HES group 
(n =  112)
Albumin 
(n =  105)
Control group 
(n =  103) p  Value
Age (years) 29.8 ±  4.3 30.0 ±  4.7 29.6 ±  2.8 n.s.
E2 on hCG day 4975 ± 12.0 4556 ±  10.11 4940 ±  15.71 n.s.
BMI (kg/m2) 22.1 ±  2.5 20.2 ±  2.1 2.3 ±  1.5 n.s.
No. of oocytes retrieved 15 ±  1.6 14 ±  4.7 13.2 ±  5.6 n.s.
No. of embryos transferred 3.4 ±  1.1 3.2 ±  1.1 3.0 ±  3 n.s.
No. of pregnancies 50.5% 44.1% 43.4% n.s.
(n =  136) (n =  119) (n =  117)
n.s., not significant
Table 4 Comparison of incidence of OHSS among the groups in the study35
HES group Albumin Control group
cnTv-(T-lII (n =  105) (n =  103) p Value
Moderate (n) 8 7 18 < 0 .5
Severe (n) — — 6 <0.05
Total (n) 8 7 24 <0.05
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assessed by more groups in order to reach a con­
sensus on this issue, as no single measure can 
totally prevent OHSS.
In our experience, 500 ml of 6% HES of MW 
200 kDa used during ovum pick-up is as effec­
tive as 50 ml of 20% human albumin to reduce 
the incidence of OHSS or blunt its clinical 
severity. Because its use carries no risk for infec­
tion with blood-borne agents and because it 
costs less than albumin, HES might be a more 
promising alternative to albumin for the treat­
ment of OHSS.
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CHAPTER 26
Ovarian hyperstimulation syndrome: 
summary and guidelines
Jan Gerris and Petra De Sutter
DESCRIPTION OF THE PROBLEM 
Definition
The ovarian hyperstimulation syndrome 
(OHSS) is an iatrogenic complication of the 
luteal phase and/or early pregnancy after ovula­
tion induction (provoking ovulation in anovula­
tory women) or after ovarian stimulation (in the 
context of intrauterine insemination or in vitro 
fertilization).
Essential characteristics
The essence of OHSS is cystic enlargement of 
the ovaries and a fluid shift from the intravas­
cular to the third space due to increased capil­
lary permeability and ovarian neoangiogenesis. 
Its occurrence is dependent on the administra­
tion of human chorionic gonadotropin (hCG). 
Without hCG, OHSS is extremely rare. Its 
impact on the general health of the patient may 
be very important. Fatal cases have occasionally 
been reported.
Early and late forms of OHSS
The early form of OHSS, although elicited by 
hCG, is related to an exaggerated ovarian 
response to gonadotropin stimulation, whereas
the late form is mainly related to the secretion of 
placental hCG. The most recent definition1 still 
relies on the underlying etiology, but makes a 
clear distinction between the early form (< 10 
days after the ovulation-triggering injection of 
hCG) and the late form (^ 10 days after hCG). 
Particularly those cases which are constituted 
by a combination of the early form followed by 
pregnancy are serious and long-lasting2.
ANALYSIS OF AVAILABLE 
KNOWLEDGE
Incidence
Precise figures of incidence are unknown 
because of a lack of systematic registration. Mild 
ovarian hyperstimulation probably occurs in 
8-23% of stimulated cycles, moderate forms in 
< 1-7% and severe forms in —0.5% of stimu­
lated cycles3,4. This causes severe OHSS to be 
viewed by individual gynecologists as a rela­
tively rare complication. However, the total 
annual number of cases in the world is esti­
mated to be in the thousands. The incidence has 
almost certainly increased over the years5. 
There are fatal cases, although these are never 
reported. Given the reason for treatment
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(infertility in young healthy women), each death 
is a disaster that should have been avoided.
Symptoms
Most frequent symptoms and signs
• Low-abdominal distension;
• Progressive increase in abdominal circum­
ference measured at the level of the 
umbilicus;
• Ovaries enlarged up to > 1 2  cm;
• Nausea and vomiting preventing intake of 
food and fluids;
• Dyspnea and respiratory distress due to an 
elevated diaphragm and hydrothorax;
• Diarrhea;
• Quick weight gain.
More severe signs and symptoms
• Ascites;
• Hypotension;
• Pleural effusion (more and more fre­
quently at the right side);
• Pericardial effusion;
• Adult form of respiratory distress syn­
drome;
• Oliguria and anuria;
• Multiple organ failure;
• Death (1/500 000 cycles)6.
Biological findings
• Electrolyte disorders (hyponatremia 
< 136mmol/l; hyperkalemia >  5.0mmol/l);
• Hypovolemia;
• Hemoconcentration (hematocrit > 45%);
• Leukocytosis >  15 000/mm3;
• Creatinine clearance < 50 ml/min; serum
creatinine > 1.2mg/dl;
• Elevated liver enzymes;
• Hypercoagulability;
• Hypoproteinemia and hypoalbuminemia 
(< 30g/1).
Additional complications
Ovarian torsion This causes sudden, extreme 
abdominal pain and nausea. There is an inci­
dence of 1/5000 stimulation cycles, but is more 
frequent if OHSS and pregnancy are present7.
Ovarian bleeding This is caused by ovarian 
rupture or intraovarian bleeding as a result of 
pressure or bimanual examination. It leads to 
signs of acute hemorrhage (hypotension, nau­
sea, sudden drop in hematocrit).
Thromboembolic symptoms Both venous (65.7%) 
and arterial localizations have been described; 
83% of these occur in neck, arm or head veins 
(60%); thrombosis also occurs in arteries and 
veins of the lower body8; in 4-12% pulmonary 
embolism occurs9. Embolism has been 
described in the V. humeralis, subclavia, jugu- 
laris interna and cava, and arterial cases in the 
A. subclavia, ulnaris, carotis interna and cerebri 
media and in the coronary arteries.
Primary risk factors
• Polycystic ovarian syndrome (PCOS);
• Patients with some characteristics of 
PCOS:
° High number of follicles in both
ovaries at the quiescent state before 
stimulation (s> 10 follicles of 
4 -10mm in each ovary);
0 luteinizing hormone/follicle stimu­
lating hormone (LH/FSH) ratio > 2;
° Hyperandrogenism;
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• History of OHSS;
• Young patients (less evidence);
• Lean women (less evidence);
• Allergic predisposition (less evidence).
Secondary risk factors
• Maximum serum estradiol 
>  3000-4000 pg/ml:
° No clear cut-off value;
° Relatively poor predictive power
(max. 73%);
° Estradiol itself is no mediator since 
OHSS is also possible with low 
serum estradiol values (stimulation 
with recombinant (rec)FSH);
° The slope of the estradiol rise is the 
main risk factor and is of more 
importance than the maximum level 
(positive predictive value 77%);
• Number of follicles per ovary > 20-25;
° No clear cut-off value (10-35);
° Variation dependent upon operator
and technique;
• Measurements of the absolute vascular 
endothelial growth factor (VEGF) serum 
concentration are not useful for individual 
prediction10.
Pathophysiology
The pathophysiology of OHSS is increasingly 
better understood. The crux is an equilibrium 
between proangiogenic and antiangiogenic fac­
tors present in follicular fluid. The proangio­
genic role of VEGF is beyond doubt the most 
important mediator of the syndrome1112. High 
concentrations of VEGF have been demon­
strated in follicular fluid, making the mediating
role of ovarian VEGF in the development of 
OHSS very plausible. VEGF concentrations in 
ascitic fluid, serum and plasma of OHSS 
patients were shown to be increased13-15. The 
mRNA expression of VEGF in human luteinized 
granulosa cells is time- and dose-dependent on 
hCG, further underlining the role of VEGF in the 
development of OHSS16,17. Later, it was shown 
that two VEGF receptors exist (VEGFR-1 and 
VEGFR-2), both produced by endothelial cells, 
one of which exists in a soluble form, serum 
(s)VEGFR-l, acting as a negative modulator of 
the bioactivity of VEGF.
An excess of bioactive proangiogenic VEGF 
increases the risk for OHSS; an excess of antian­
giogenic sVEGFR-1 (and other antiangiogenic 
factors) decreases the ovarian response and the 
risk for OHSS and is accompanied by a 
decreased pregnancy rate11. Absolute serum 
concentrations have no value in individual risk 
assessment because there are individual varia­
tions in the binding of VEGF to its receptors1012.
In rats, proof of concept was shown of a 
VEGFR-2 inhibitor (SU5416) to block hCG- 
dependent VEGF production (and ensuing 
neoangiogenesis)18. Also, in rats it was shown 
that ovulation triggering using LH instead of 
hCG results in lower VEGF production. This 
serves as the theoretical basis for ovulation trig­
gering utilizing recLH in clinical situations19.
The pathophysiological cascade of OHSS 
consists of: neoangiogenesis and increased cap­
illary permeability of the enlarged ovarian and 
other endothelial surfaces, fluid shift from the 
intravascular space to the extravascular space 
(abdomen, pleura, pericardium), hemoconcen- 
tration, decreased renal clearance, oliguria/ 
anuria, hyperviscosity of the blood, modifica­
tion in coagulation factors and thromboembolic 
risks. Hemoconcentration leads to an increase of 
hematocrit, and of the concentration of platelets 
and leukocytes, creatinine, urea and liver 
enzymes in the plasma, as well as to hyper­
kalemia and acidosis. Serum albumin decreases 
as a result of extravasation of fluid and ascites
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formation20. The process is self-limiting as the 
hCG effect decreases, unless fetal hCG starts to 
be secreted.
Classification
The quantitative aspects of definition of the syn­
drome cannot exactly be measured: ovarian 
dimensions can be assessed to a certain extent 
using echography, but ascites volume is difficult 
to measure. Therefore, classification is not cate­
gorical and daily weighing and fluid balance 
assessment remain key elements of the clinical 
follow-up. The most frequently used classifica­
tion system is the one proposed by Golan3 (Table 
1 ).
Subsequently, two further refinements were 
introduced: ‘critical OHSS'4 and ‘group C severe 
OHSS’21, which both describe the same life- 
threatening clinical entity: severe reduction in 
circulating volume, severe hemoconcentration,
multiple organ failure (kidney, liver, heart) 
and/or thromboembolic symptoms. Both are 
considered as grade 6 in the modern classifica­
tion of Golan.
It is essential to understand that these grades 
are not strictly separated entities and that a 
mild-grade OHSS can quickly evolve into severe 
OHSS. This should not be forgotten when decid­
ing to follow-up a patient ‘by telephone’. The 
foremost criterion of clinical seriousness imply­




Patients who have a primary risk for OHSS 
should be exposed to gonadotropins as little as 
possible. This implies that all other more safe
Table 1 Classification of OHSS according to Golan et al.3
Grade Mild Moderate Severe
1 Abdominal distension 
and discomfort
2 Criteria of grade 1 +  nausea, 
vomiting, and/or diarrhea. 
Ovaries enlarged 5-12 cm
3 Criteria of mild OHSS + 
echographic signs of ascites
4 Criteria of moderate OHSS + 
clinical signs of ascites and/or 
hydrothorax and respiratory 
distress
5 All of the above -I- changes in 
blood volume and viscosity, 
hemoconcentration, coagulation 
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treatments should have had fair trail: life-style 
changes (diet and exercise), oral ovulation 
induction, use of pulsed gonadotropin-releasing 
hormone (GnRH), laparoscopic ovarian drilling. 
This should especially be kept in mind when 
treating young women in their first assisted 
reproductive technologies (ART) treatment 
cycles, women with PCOS and women with a 
history of OHSS.
The identification of women with throm­
bophilia, those with a family history of throm­
boembolism and women with antiphospholipid 
antibodies should ideally be performed before 
starting gonadotropin treatment. When indi­
cated, the lowest possible dose of gonadotropins 
should be used and treatment adequately moni­
tored, which means frequent use of vaginal 
echography and serum estradiol measurements. 
All patients at risk should be informed verbally 
and in writing so that, at the occurrence of early 
symptoms, they should consult the gynecologist 
responsible and not an inexperienced physician.
In cases of high primary risk, prophylactic 
treatment with heparin has been proposed.
Secondary prevention
Cycle cancellation
In ovulation induction, withholding hCG pre­
vents the early form of OHSS. Avoiding hCG 
and intercourse/insemination prevents both the 
early and the late forms. This decision is often 
psychologically difficult, especially in in vitro 
fertilization (IVF), because it may entail the loss 
of considerable financial expense in countries 
without reimbursement. In very severe cases 
with poor follow-up possibilities, however, it 
may be the only method to avoid disaster.
Coasting ('soft landing')
Principle When high-risk patients rapidly reach 
high (> 3000pg/ml) serum estradiol levels with 
a large number (> 20 per ovary) of follicles dur­
ing stimulation, gonadotropin administration 
can be decreased or stopped while maintaining
GnRH agonist administration. This allows larger 
follicles to continue to grow, whereas intermedi­
ary and small follicles enter atresia. Based on 
the FSH-threshold theory, a number of follicles 
will no longer respond to the decreasing FSH 
levels, or become unresponsive to hCG22. Coast­
ing causes down-regulation of VEGF gene 
expression and protein production as a result of 
increased apoptosis in the granulosa cells of all, 
but mainly immature, follicles without influence 
on oocyte quality and endometrial receptivity23.
Although no randomized clinical trials have 
been conducted to assess its true efficiency, the 
method is very popular, and is followed by 
acceptable pregnancy rates24. It has the advan­
tage that the cycle is brought to its expected end 
with the replacement of fresh embryos and that 
no additional technical procedures are needed.
Criteria for coasting Criteria for coasting are 
based on a relationship between the number of 
growing follicles and/or the serum estradiol 
level and the risk for OHSS. There are two crite­
ria for decision: the serum estradiol level deter­
mines whether coasting is done or not; the 
echographic image determines when.
Serum estradiol levels Most authors use val­
ues between 2500 and 3000pg/ml. Continuing 
gonadotropins at a serum estradiol level o f 
> 3000pg/ml is considered not good clinical 
practice. When using recFSH, estradiol values 
tend to be lower and the above criteria do not 
hold. It has therefore been suggested that the 
estradiol value should come into play only if at 
the same time there are > 2 0  follicles per ovary.
Number of growing follicles Coasting should 
not be started too early because follicle growth 
might come to a complete standstill. When 
< 30% of all follicles have reached a mean diam­
eter of 15 mm, coasting will result in an abrupt 
stop in follicle development and rapid serum 
estradiol decrease. On the other hand, when the 
majority of follicles are > 15 mm at the start of 
coasting, a number of cystically enlarged folli­
cles with decreased oocyte quality may ensue25.
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Hence, this leads to the golden rule o f the middle 
way: coasting should start when ~  50% of the 
follicles are —15 mm in diameter and have 
become independent of further gonadotropin 
stimulation.
Duration of coasting It has been shown that a 
coasting period of s>4 days (from the first day 
that the gonadotropin dose is interrupted or 
decreased) results in decreased pregnancy 
rates26, but this remains controversial25,27. Fur­
ther clinical research is desirable to assess the 
subtleties with respect to oocyte number and 
quality and endometrial receptivity.
Modification of the ovulation-triggering 
agent
Although good data are lacking, it is not impos­
sible that lower doses of hCG than those usually 
utilized (5000 or 10 000IU) may cause sufficient 
oocyte maturation while reducing the risk for 
OHSS.
The replacement of hCG by exogenous or 
endogenous LH as ovulation trigger could have 
a considerable impact on the incidence of (the 
early form of) OHSS. An endogenous LH surge 
can be provoked by the administration of a 
short-acting GnRH agonist28. This is only possi­
ble in cycles without pituitary desensitization 
by a GnRH agonist. The combination with an 
antagonist remains a possibility. The adminis­
tration of exogenous LH (recLH) is another 
option, but for the time being there is no inter­
est from the pharcameuticals industry to com­
mercialize this (available) product for such an 
indication. Hence, it remains that the 50-year- 
old use of urinary hCG as ovulation trigger is 
much cheaper, but its impact on the incidence 
of OHSS is huge.
Administration of macromolecules
Albumin administration Prophylactic albumin 
administration is supposed to interrupt the 
development of OHSS by increasing the plasma 
oncotic pressure and binding mediators of ovar­
ian origin. This effect could be counteracted by 
increased capillary permeability. Prospective 
randomized trials and one retrospective study 
with a control group show 39 cases of OHSS in 
468 treated risk cycles (8.3%) versus 89 OHSS 
cases in 611 untreated risk cycles (14.6%)24. A 
Cochrane review also shows that intravenous 
(IV) albumin administration at the time of 
oocyte collection has a preventive effect in 
cycles with a severe risk for OHSS29. However, a 
recent prospective randomized trial of 488 cases 
in each arm of the study seems to prove the inef­
ficiency of human albumin30. Two studies show 
a decreased pregnancy rate after the use of IV 
albumin31,32. Albumin administration also has 
side-effects: viral transmission, nausea, vomit­
ing and febrile and allergic reactions, and it is 
expensive.
Hydroxyethyl starch solution (HES) Because of 
the risk of viral transmission with human albu­
min, some authors have tested the effect of a 
safer non-biological substitute with comparable 
physiological properties: HES. Three studies 
suggest a useful effect, but the cohorts are too 
small to draw definite conclusions33-35. Further 
clinical research seems warranted.
Cryopreservation of all embryos
Instead of canceling the cycle, it is also possible 
to administer hCG, to retrieve the oocytes and to 
freeze all embryos. This does not exclude the 
risk for the early form of OHSS, but it does 
exclude the late form (caused by pregnancy). 
The removal of a large number of granulosa cells 
from the follicles probably decreases the risk as 
well. A Cochrane review concludes that the 
present evidence is insufficient to consider this 
approach as the standard treatment36. It may be 
considered when coasting has not been applied 
when it should have, and when, at the time of 
oocyte retrieval, one finds oneself in a very 
high-risk situation for the early form of OHSS in 
a patient with a very good prognosis of becoming
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pregnant and, hence, who has a high risk for the 
late form of OHSS.
Summary
No method can prevent all cases of OHSS, apart 
from withholding hCG, still the ubiquitous ovu­
lation-triggering agent, although other mole­
cules exist (recLH) but are either not available or 
very expensive. In practice, in ART, coasting is 
still the most popular approach, which probably 
does have some preventive effect. The late form 
cannot be avoided altogether. Combinations of 
different preventive methods acting at different 
levels could give the opportunity to avoid OHSS 
completely37. Single embryo transfer after ART 
prevents multiple pregnancies but not OHSS38.
CLINICAL MANAGEMENT
Criteria for hospitalization
• Hematocrit >  45%;
• Any sign of severe OHSS.
Elements of out-patient follow-up
• Daily fluid balance;
• Daily weighing;
• Increase in umbilical abdominal circum­
ference;
• Instruction to contact the center at any 
sign of deterioration;
• Out-patient follow-up every 48-72 h with 
blood tests and ultrasound examination.
Elements of hospital follow-up
• Heart rate;
• Blood pressure;
• Daily fluid balance;
• Echographic assessment: ascites volume, 
ovarian dimensions;
• Radiography of thorax (if dyspneic) to 
diagnose pleural effusion;
• ECG (to exclude pericardiac effusion);
• Hematological examination: hematocrit, 
red blood cell count, white blood cell 
count, electrolytes, kidney function tests, 





• Intravenous administration of Ringer’s lac­
tate solution;
• First 24 h: 1500-3000 ml; in order to avoid 
overadministration of fluid, some centers 
restrict total fluid intake (including oral) to 
1500 ml;
• Subsequent days: fluid volume as function 
of fluid balance;
• Combination of Ringer’s lactate +  dextrose 
5% solution or NaCl 0.9% +  dextrose 5% 
(standard) solution.
Plasma expanders
• HES (hydroxyethyl starch) 6% solution in 
isotonic NaCl;
• Maximum daily dose: 33ml/kg in
250-500 ml per day, drop-wise, utilizing 
slow administration to avoid lung conges­
tion.
Albumin administration
• Is only started if hypoalbuminemia 
(<28mg/dl) is demonstrated because of 
the risk for hepatitis, overdosage with 
albumin, renal function disorders and
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high cost; should definitely be started 
when ascitic fluid is drained because this 
causes a huge loss of protein.
Anticoagulant drugs
Low-molecular-weight heparin preparations are 
preferably given primarily in all cases of severe 
OHSS with hospitalization, but certainly if:
• Clinical signs of thromboembolic compli­
cations;
• Documented thrombophilia;
• History of hypercoagulability or throm­
boembolism;
• Uncorrected hemoconcentration after 48 h 
of usual intravenous treatment.
As a prevention of thromboembolic complica­
tions, especially in patients who are immobi­
lized due to obesity or other reasons, low-dose 
aspirin administration has been suggested. 
When ascites puncture is performed, this has to 
be weighed against the risk for bleeding. If avail­
able, thromboembolic disease (TED) stockings 
may be indicated.
Ascites drainage
This can be performed both abdominally and 
vaginally39,40, but always under sonographic 
guidance. It is considered when there is severe 
abdominal discomfort and dyspnea, and results 
in rapid subjective relief for the patient. It also 
results in increased venous return and increased 
cardiac output, diuresis, creatinine clearance 
and lung ventilation. It should be performed 
gradually: a maximum of 4 l over 12 h. The 
removal of large quantities means losing huge 
amounts of protein, which must be substituted. 
One liter of ascitic fluid contains 3.0-3.5 g of 
albumin; daily administration of 30-50 g albu­
min is recommended.
Out-patient management of OHSS can only 
be performed following strict rules. When signs 
of deterioration occur, hospitalization should be
considered, preferably in an expert center. Hos­
pitalized patients must be visited frequently by 
the same physician, as the clinical picture may 
change quickly (over the period of a single day), 
and the clinician can and must recognize this. 
When critical OHSS exists, the patient must be 
admitted to an intensive-care ward. In very 
severe cases, the interruption of a beginning 
pregnancy should be considered.
Pregnancy after OHSS
The pregnancy rate in patients with OHSS is 
higher than average. This is because the patients 
are usually young women, in their first ART 
cycles, with many oocytes and good-quality 
embryos. Several authors have reported an 
increase in early pregnancy loss in OHSS 
patients2,41.
CONCLUSIONS AND  
RECOMMENDATIONS
Although theoretically known, OHSS remains 
underestimated because the perceived inci­
dence per gynecologist is low. The syndrome is 
very traumatizing for the patient and her part­
ner. Subjective discomfort is very important, 
and objective changes may be dramatic. 
Although long-term sequelae are unusual, they 
are serious (thromboembolism). Although fatal 
cases are rare, they go unreported and thus may 
be underestimated, and they are never in pro­
portion to the indication for treatment (infertil­
ity in young healthy women).
Essential recommendations, therefore, are:
(1) Gonadotropin treatment for ovulation 
induction should be considered only 
when all other options have failed after a 
sufficiently long trying time.
(2) If gonadotropin stimulation for ovulation 
induction is unavoidable, one should use 
‘friendly’ stimulation regimens aiming at
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‘SOFT’ (single ovarian follicle treatment): 
low-dose step-up regimen, step-down regi­
men, or antagonists, always utilizing blood 
and sonographic control of ovarian 
response.
(3) hCG as an ovulation trigger should be 
replaced by safer methods (recLH, endoge­
nous GnRH surge by an agonist); recLH 
exists but is not commercially available.
(4) In IVF/intracytoplasmic sperm injection 
(ICSI) the principle of obtaining ‘as many 
oocytes as possible’ should be replaced by 
softer stimulation regimens aiming at 
fewer oocytes of good quality.
(5) In risk situations, the patient should be 
informed about possibilities such as can­
celing, coasting or freezing for subsequent 
replacement.
(6) When signs of OHSS occur, the patient 
must be completely informed and hospi­
talization should be proposed at the slight­
est deterioration.
(7) These patients belong in a hospital ward 
where the clinical picture is known and 
the personnel have expertise in its treat­
ment and follow-up. Admission to an 
intensive-care unit is necessary when crit­
ical OHSS develops.
(8) Registration of all cases of severe OHSS 
and their outcome should become com­
pulsory in all ART programs, as well as 
after ovulation induction.
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